Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
33700.0 | 2017-01-24 00:00:00 UTC | Pre-Market Earnings Report for January 25, 2017 : BA, UTX, ABT, ITW, NSC, STT, TEL, FCX, NVS, PGR, APH, HES | ABT | https://www.nasdaq.com/articles/pre-market-earnings-report-january-25-2017-ba-utx-abt-itw-nsc-stt-tel-fcx-nvs-pgr-aph-hes | nan | nan | The following companies are expected to report earnings prior to market open on 01/25/2017. Visit our Earnings Calendar for a full list of expected earnings releases.
Boeing Company ( BA ) is reporting for the quarter ending December 31, 2016. The aerospace and defense company's consensus earnings per share forecast from the 10 analysts that follow the stock is $2.34. This value represents a 46.25% increase compared to the same quarter last year. BA missed the consensus earnings per share in the 1st calendar quarter of 2016 by -3.87%. Zacks Investment Research reports that the 2016 Price to Earnings ratio for BA is 22.17 vs. an industry ratio of 15.30, implying that they will have a higher earnings growth than their competitors in the same industry.
United Technologies Corporation ( UTX ) is reporting for the quarter ending December 31, 2016. The diversified operations company's consensus earnings per share forecast from the 10 analysts that follow the stock is $1.56. This value represents a 1.96% increase compared to the same quarter last year. In the past year UTX has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 4.76%. Zacks Investment Research reports that the 2016 Price to Earnings ratio for UTX is 16.72 vs. an industry ratio of 20.50.
Abbott Laboratories ( ABT ) is reporting for the quarter ending December 31, 2016. The large cap pharmaceutical company's consensus earnings per share forecast from the 10 analysts that follow the stock is $0.64. This value represents a 3.23% increase compared to the same quarter last year. In the past year ABT has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 1.72%. Zacks Investment Research reports that the 2016 Price to Earnings ratio for ABT is 18.34 vs. an industry ratio of 16.90, implying that they will have a higher earnings growth than their competitors in the same industry.
Illinois Tool Works Inc. ( ITW ) is reporting for the quarter ending December 31, 2016. The machinery company's consensus earnings per share forecast from the 9 analysts that follow the stock is $1.37. This value represents a 11.38% increase compared to the same quarter last year. In the past year ITW has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 0.67%. Zacks Investment Research reports that the 2016 Price to Earnings ratio for ITW is 22.03 vs. an industry ratio of 81.40.
Norfolk Souther Corporation ( NSC ) is reporting for the quarter ending December 31, 2016. The transportation (rail) company's consensus earnings per share forecast from the 12 analysts that follow the stock is $1.38. This value represents a 15.00% increase compared to the same quarter last year. NSC missed the consensus earnings per share in the 4th calendar quarter of 2015 by -5.51%. Zacks Investment Research reports that the 2016 Price to Earnings ratio for NSC is 20.35 vs. an industry ratio of 18.40, implying that they will have a higher earnings growth than their competitors in the same industry.
State Street Corporation ( STT ) is reporting for the quarter ending December 31, 2016. The bank company's consensus earnings per share forecast from the 7 analysts that follow the stock is $1.34. This value represents a 10.74% increase compared to the same quarter last year. In the past year STT has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 8%. Zacks Investment Research reports that the 2016 Price to Earnings ratio for STT is 15.37 vs. an industry ratio of 14.60, implying that they will have a higher earnings growth than their competitors in the same industry.
TE Connectivity Ltd. ( TEL ) is reporting for the quarter ending December 31, 2016. The electrical instrument company's consensus earnings per share forecast from the 5 analysts that follow the stock is $1.00. This value represents a 19.05% increase compared to the same quarter last year. In the past year TEL has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 6.72%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for TEL is 16.21 vs. an industry ratio of 17.50.
Freeport-McMoran, Inc. ( FCX ) is reporting for the quarter ending December 31, 2016. The mining company's consensus earnings per share forecast from the 9 analysts that follow the stock is $0.32. This value represents a 1700.00% increase compared to the same quarter last year. The last two quarters FCX had negative earnings surprises; the latest report they missed by -31.58%. Zacks Investment Research reports that the 2016 Price to Earnings ratio for FCX is 58.22 vs. an industry ratio of 3.90, implying that they will have a higher earnings growth than their competitors in the same industry.
Novartis AG ( NVS ) is reporting for the quarter ending December 31, 2016. The large cap pharmaceutical company's consensus earnings per share forecast from the 4 analysts that follow the stock is $1.09. This value represents a 1.80% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2016 Price to Earnings ratio for NVS is 14.89 vs. an industry ratio of 16.90.
Progressive Corporation ( PGR ) is reporting for the quarter ending December 31, 2016. The insurance (property & casualty) company's consensus earnings per share forecast from the 9 analysts that follow the stock is $0.51. This value represents a 5.56% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2016 Price to Earnings ratio for PGR is 23.21 vs. an industry ratio of 4.20, implying that they will have a higher earnings growth than their competitors in the same industry.
Amphenol Corporation ( APH ) is reporting for the quarter ending December 31, 2016. The electrical connectors company's consensus earnings per share forecast from the 5 analysts that follow the stock is $0.72. This value represents a 14.29% increase compared to the same quarter last year. In the past year APH has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 7.35%. Zacks Investment Research reports that the 2016 Price to Earnings ratio for APH is 25.18 vs. an industry ratio of 13.30, implying that they will have a higher earnings growth than their competitors in the same industry.
Hess Corporation ( HES ) is reporting for the quarter ending December 31, 2016. The oil company's consensus earnings per share forecast from the 8 analysts that follow the stock is $-1.09. This value represents a 22.14% increase compared to the same quarter last year. HES missed the consensus earnings per share in the 4th calendar quarter of 2015 by -2.94%. Zacks Investment Research reports that the 2016 Price to Earnings ratio for HES is -11.38 vs. an industry ratio of -16.50, implying that they will have a higher earnings growth than their competitors in the same industry.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is reporting for the quarter ending December 31, 2016. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2016 Price to Earnings ratio for ABT is 18.34 vs. an industry ratio of 16.90, implying that they will have a higher earnings growth than their competitors in the same industry. | Abbott Laboratories ( ABT ) is reporting for the quarter ending December 31, 2016. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2016 Price to Earnings ratio for ABT is 18.34 vs. an industry ratio of 16.90, implying that they will have a higher earnings growth than their competitors in the same industry. | Zacks Investment Research reports that the 2016 Price to Earnings ratio for ABT is 18.34 vs. an industry ratio of 16.90, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories ( ABT ) is reporting for the quarter ending December 31, 2016. In the past year ABT has beat the expectations every quarter. | Abbott Laboratories ( ABT ) is reporting for the quarter ending December 31, 2016. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2016 Price to Earnings ratio for ABT is 18.34 vs. an industry ratio of 16.90, implying that they will have a higher earnings growth than their competitors in the same industry. |
33701.0 | 2017-01-20 00:00:00 UTC | IHI, MDT, ABT, TMO: ETF Inflow Alert | ABT | https://www.nasdaq.com/articles/ihi-mdt-abt-tmo-etf-inflow-alert-2017-01-20 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $139.1 million dollar inflow -- that's a 13.9% increase week over week in outstanding units (from 7,200,000 to 8,200,000). Among the largest underlying components of IHI, in trading today Medtronic PLC (Symbol: MDT) is trading flat, Abbott Laboratories (Symbol: ABT) is up about 0.5%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 0.1%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average:
Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $146.91 as the 52 week high point - that compares with a last trade of $139.04. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IHI, in trading today Medtronic PLC (Symbol: MDT) is trading flat, Abbott Laboratories (Symbol: ABT) is up about 0.5%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 0.1%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $146.91 as the 52 week high point - that compares with a last trade of $139.04. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IHI, in trading today Medtronic PLC (Symbol: MDT) is trading flat, Abbott Laboratories (Symbol: ABT) is up about 0.5%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 0.1%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $146.91 as the 52 week high point - that compares with a last trade of $139.04. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IHI, in trading today Medtronic PLC (Symbol: MDT) is trading flat, Abbott Laboratories (Symbol: ABT) is up about 0.5%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $139.1 million dollar inflow -- that's a 13.9% increase week over week in outstanding units (from 7,200,000 to 8,200,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $146.91 as the 52 week high point - that compares with a last trade of $139.04. | Among the largest underlying components of IHI, in trading today Medtronic PLC (Symbol: MDT) is trading flat, Abbott Laboratories (Symbol: ABT) is up about 0.5%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $139.1 million dollar inflow -- that's a 13.9% increase week over week in outstanding units (from 7,200,000 to 8,200,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $146.91 as the 52 week high point - that compares with a last trade of $139.04. |
33702.0 | 2017-01-20 00:00:00 UTC | What's in Store for Abbott Labs (ABT) This Earnings Season? | ABT | https://www.nasdaq.com/articles/whats-in-store-for-abbott-labs-abt-this-earnings-season-2017-01-20 | nan | nan | Abbott LaboratoriesABT is scheduled to report fourth-quarter and full year 2016 results before the opening bell on Jan 25.
Shares of Abbott Labs have outperformed the Zacks classified Large Cap Pharmaceuticals industry in the last 12 months. In fact, the stock improved 1.1% during this period, compared to an inch up of 0.3% for the industry.
Last quarter, Abbott Labs delivered a positive earnings surprise of 1.72%. Let's see how things are shaping up for this quarter.
Factors at Play
Abbott Labs operates under four segments - Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition.Abbott has a strong position in both developed and emerging markets. Continued outperformance at the Medical Devices and Established Pharmaceuticals division is likely to drive sales in the quarter.
The Diagnostics segment is expected to see persistent above-market performance in Core Laboratory and Point of Care Diagnostics. The launch of AlinIQ should also add to the company's top line. Segment sales are anticipated to grow in the mid-single digits in the fourth quarter.
The soft performance in pediatric nutrition business in China has impacted the third-quarter results of the company. Further it is expected to persist in the near term. The business environment in China has also been impacted by rapid channel shifts and new safety regulations which are driving an oversupply of product in the market and huge discounts.
At EPD, sales are expected to grow in high single digits in the fourth quarter. Realignment of the division through acquisitions in Latin America and Russia, along with business divestitures in developed markets, has placed the company advantageously for the coming quarters. The company has a leading position in India, Russia and Latin America
At Medical Devices, Vascular is expected to grow in the mid-single digits in the fourth quarter driven by growth from MitraClip and Supera, while Diabetes care sales are expected to increase in the double-digits band, driven by continued consumer uptake of FreeStyle Libre system in Europe. During the third quarter, the company obtained FDA approval for Absorb, the only fully dissolving vascular stent. In Sep 2016, the FDA also approved FreeStyle Libre Pro system in the U.S. which should boost diabetes-care sales.
The recent acquisition of St. Jude Medical has augmented the company's position in cardiovascular devices market. Medical Optics is forecasted to grow in low to mid single-digit sales. Meanwhile, Abbott Labs announced to sell its medical optical business to Johnson & Johnson JNJ in Sep 2016 in order to focus on its cardiovascular devices business.
Concurrent with the third-quarter results, Abbott Labs narrowed its 2016 earning guidance to $2.19 to $2.21 from the previous range of $2.14 to $2.24 per share. The company continues to expect sales growth in the mid-single digits (on an operational basis) for 2016. Unfavorable movements in foreign exchange rates should negatively impact sales by 2% resulting in reported sales growth in the low-single digits for 2016.
For the fourth quarter, the company expects earnings per share in the range of 64 cents-66 cents. On an operational basis, sales are expected to grow in mid-single digits.
During the quarterly call, investors focus should remain on the company's performance, sales ramp-up of the newly launched products and recent developments.
Surprise History
Abbott Labs has an impressive track record. The company surpassed estimates in each of the trailing four quarters with an average earnings surprise of 3.07%.
What Our Model Indicates
Our proven model does not conclusively show that Abbott Labs is likely to beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to beat earnings. However, that is not the case here, as you will see below.
Zacks ESP : The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at 64 cents. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank : Abbott Labs has a Zacks Rank #3 which in turn increases the predictive power of ESP. However, we need to have a positive ESP to be confident about an earnings beat.
As it is we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Abbott Laboratories Price and Consensus
Abbott Laboratories Price and Consensus | Abbott Laboratories Quote
Stocks to Consider
Here are some other health care stocks that you may want to consider, as our model shows that they too have the right combination of elements to post an earnings beat this quarter.
AbbVie, Inc. ABBV has an Earnings ESP of +0.83% and a Zacks Rank #3. The company is expected to release results on Jan 27. You can see the complete list of today's Zacks #1 Rank stocks here .
Eli Lilly and Company LLY has an Earnings ESP of +3.06% and a Zacks Rank #3. The company is scheduled to release results on Jan 31.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks - absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Eli Lilly and Co. (LLY): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT is scheduled to report fourth-quarter and full year 2016 results before the opening bell on Jan 25. Click to get this free report Eli Lilly and Co. (LLY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Factors at Play Abbott Labs operates under four segments - Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition.Abbott has a strong position in both developed and emerging markets. | Click to get this free report Eli Lilly and Co. (LLY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is scheduled to report fourth-quarter and full year 2016 results before the opening bell on Jan 25. Factors at Play Abbott Labs operates under four segments - Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition.Abbott has a strong position in both developed and emerging markets. | Click to get this free report Eli Lilly and Co. (LLY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is scheduled to report fourth-quarter and full year 2016 results before the opening bell on Jan 25. The company has a leading position in India, Russia and Latin America At Medical Devices, Vascular is expected to grow in the mid-single digits in the fourth quarter driven by growth from MitraClip and Supera, while Diabetes care sales are expected to increase in the double-digits band, driven by continued consumer uptake of FreeStyle Libre system in Europe. | Abbott LaboratoriesABT is scheduled to report fourth-quarter and full year 2016 results before the opening bell on Jan 25. Click to get this free report Eli Lilly and Co. (LLY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Last quarter, Abbott Labs delivered a positive earnings surprise of 1.72%. |
33703.0 | 2017-01-19 00:00:00 UTC | Insiders Buy the Holdings of XHE ETF | ABT | https://www.nasdaq.com/articles/insiders-buy-holdings-xhe-etf-2017-01-19 | nan | nan | A look at the weighted underlying holdings of the SPDR S&P Health Care Equipment ETF ( XHE ) shows an impressive 11.8% of holdings on a weighted basis have experienced insider buying within the past six months.
Abbott Laboratories (Symbol: ABT), which makes up 1.78% of the SPDR S&P Health Care Equipment ETF ( XHE ), has seen 4 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $1,387,294 worth of ABT, making it the #25 largest holding. The table below details the recent insider buying activity observed at ABT:
ABT - last trade: $40.76 - Recent Insider Buys:
And Endologix Inc. (Symbol: ELGX), the #43 largest holding among components of the SPDR S&P Health Care Equipment ETF ( XHE ), shows 4 directors and officers as recently filing Form 4's indicating purchases. The ETF holds $1,234,325 worth of ELGX, which represents approximately 1.58% of the ETF's total assets at last check. The recent insider buying activity observed at ELGX is detailed in the table below:
ELGX - last trade: $6.40 - Recent Insider Buys:
10 ETFs With Stocks That Insiders Are Buying »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (Symbol: ABT), which makes up 1.78% of the SPDR S&P Health Care Equipment ETF ( XHE ), has seen 4 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at ABT: ABT - last trade: $40.76 - Recent Insider Buys: And Endologix Inc. (Symbol: ELGX), the #43 largest holding among components of the SPDR S&P Health Care Equipment ETF ( XHE ), shows 4 directors and officers as recently filing Form 4's indicating purchases. The ETF holds a total of $1,387,294 worth of ABT, making it the #25 largest holding. | Abbott Laboratories (Symbol: ABT), which makes up 1.78% of the SPDR S&P Health Care Equipment ETF ( XHE ), has seen 4 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at ABT: ABT - last trade: $40.76 - Recent Insider Buys: And Endologix Inc. (Symbol: ELGX), the #43 largest holding among components of the SPDR S&P Health Care Equipment ETF ( XHE ), shows 4 directors and officers as recently filing Form 4's indicating purchases. The ETF holds a total of $1,387,294 worth of ABT, making it the #25 largest holding. | The table below details the recent insider buying activity observed at ABT: ABT - last trade: $40.76 - Recent Insider Buys: And Endologix Inc. (Symbol: ELGX), the #43 largest holding among components of the SPDR S&P Health Care Equipment ETF ( XHE ), shows 4 directors and officers as recently filing Form 4's indicating purchases. Abbott Laboratories (Symbol: ABT), which makes up 1.78% of the SPDR S&P Health Care Equipment ETF ( XHE ), has seen 4 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $1,387,294 worth of ABT, making it the #25 largest holding. | Abbott Laboratories (Symbol: ABT), which makes up 1.78% of the SPDR S&P Health Care Equipment ETF ( XHE ), has seen 4 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $1,387,294 worth of ABT, making it the #25 largest holding. The table below details the recent insider buying activity observed at ABT: ABT - last trade: $40.76 - Recent Insider Buys: And Endologix Inc. (Symbol: ELGX), the #43 largest holding among components of the SPDR S&P Health Care Equipment ETF ( XHE ), shows 4 directors and officers as recently filing Form 4's indicating purchases. |
33704.0 | 2017-01-18 00:00:00 UTC | After Hours Most Active for Jan 18, 2017 : DHT, NFLX, SQ, NVDA, F, GE, V, ABT, HBAN, MSFT, QQQ, INTC | ABT | https://www.nasdaq.com/articles/after-hours-most-active-jan-18-2017-dht-nflx-sq-nvda-f-ge-v-abt-hban-msft-qqq-intc-2017-01 | nan | nan | The NASDAQ 100 After Hours Indicator is up 9.66 to 5,065.51. The total After hours volume is currently 45,767,258 shares traded.
The following are the most active stocks for the after hours session :
DHT Holdings, Inc. ( DHT ) is -0.0661 at $4.16, with 6,507,500 shares traded. DHT's current last sale is 75.71% of the target price of $5.5.
Netflix, Inc. ( NFLX ) is +10.91 at $144.17, with 3,325,301 shares traded. Seeking Alpha Reports: Jerry Seinfeld's Agreement With Netflix Isn't About Nothing
Square, Inc. ( SQ ) is unchanged at $14.64, with 3,215,070 shares traded. As reported by Zacks, the current mean recommendation for SQ is in the "buy range".
NVIDIA Corporation ( NVDA ) is +0.15 at $103.10, with 2,747,985 shares traded. As reported by Zacks, the current mean recommendation for NVDA is in the "buy range".
Ford Motor Company ( F ) is +0.01 at $12.42, with 1,902,011 shares traded. F's current last sale is 95.54% of the target price of $13.
General Electric Company ( GE ) is unchanged at $31.23, with 1,547,598 shares traded.GE is scheduled to provide an earnings report on 1/20/2017, for the fiscal quarter ending Dec2016. The consensus earnings per share forecast is 0.46 per share, which represents a 52 percent increase over the EPS one Year Ago
Visa Inc. ( V ) is unchanged at $81.59, with 1,464,663 shares traded. As reported by Zacks, the current mean recommendation for V is in the "buy range".
Abbott Laboratories ( ABT ) is unchanged at $40.76, with 1,426,317 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2017. The consensus EPS forecast is $0.48. ABT is scheduled to provide an earnings report on 1/25/2017, for the fiscal quarter ending Dec2016. The consensus earnings per share forecast is 0.64 per share, which represents a 62 percent increase over the EPS one Year Ago
Huntington Bancshares Incorporated ( HBAN ) is unchanged at $13.15, with 1,411,122 shares traded.HBAN is scheduled to provide an earnings report on 1/25/2017, for the fiscal quarter ending Dec2016. The consensus earnings per share forecast is 0.22 per share, which represents a 22 percent increase over the EPS one Year Ago
Microsoft Corporation ( MSFT ) is +0.05 at $62.55, with 1,270,622 shares traded. As reported by Zacks, the current mean recommendation for MSFT is in the "buy range".
PowerShares QQQ Trust, Series 1 ( QQQ ) is +0.11 at $123.15, with 1,232,047 shares traded. This represents a 29.85% increase from its 52 Week Low.
Intel Corporation ( INTC ) is +0.07 at $36.83, with 1,053,720 shares traded. As reported by Zacks, the current mean recommendation for INTC is in the "buy range".
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT is scheduled to provide an earnings report on 1/25/2017, for the fiscal quarter ending Dec2016. Abbott Laboratories ( ABT ) is unchanged at $40.76, with 1,426,317 shares traded. Seeking Alpha Reports: Jerry Seinfeld's Agreement With Netflix Isn't About Nothing Square, Inc. ( SQ ) is unchanged at $14.64, with 3,215,070 shares traded. | Abbott Laboratories ( ABT ) is unchanged at $40.76, with 1,426,317 shares traded. ABT is scheduled to provide an earnings report on 1/25/2017, for the fiscal quarter ending Dec2016. The consensus earnings per share forecast is 0.46 per share, which represents a 52 percent increase over the EPS one Year Ago Visa Inc. ( V ) is unchanged at $81.59, with 1,464,663 shares traded. | Abbott Laboratories ( ABT ) is unchanged at $40.76, with 1,426,317 shares traded. ABT is scheduled to provide an earnings report on 1/25/2017, for the fiscal quarter ending Dec2016. The consensus earnings per share forecast is 0.46 per share, which represents a 52 percent increase over the EPS one Year Ago Visa Inc. ( V ) is unchanged at $81.59, with 1,464,663 shares traded. | Abbott Laboratories ( ABT ) is unchanged at $40.76, with 1,426,317 shares traded. ABT is scheduled to provide an earnings report on 1/25/2017, for the fiscal quarter ending Dec2016. The NASDAQ 100 After Hours Indicator is up 9.66 to 5,065.51. |
33705.0 | 2017-01-11 00:00:00 UTC | Analyst Reports for Facebook, Bank of America & ConocoPhillips | ABT | https://www.nasdaq.com/articles/analyst-reports-facebook-bank-america-conocophillips-2017-01-11 | nan | nan | Wednesday, January 11 2017
Today's Research Daily features new research reports on 16 major stocks, including Bank of America (BAC), Facebook (FB) and ConocoPhillips (COP).
Bank of America shares have been one of the biggest beneficiaries of the changed macro backdrop following the election, which includes expectations of faster economic growth and overhaul of the country's tax and regulatory systems. The resulting uptrend in interest rates promises to give bank stocks in general and Bank of America in particular a big boost. No doubt, Bank of America shares have been strong performers since the election - up +34.9% since November 8th vs. +21.8% gain for the Zacks Major Banks industry in that time period, but the analyst still | Wednesday, January 11 2017 Today's Research Daily features new research reports on 16 major stocks, including Bank of America (BAC), Facebook (FB) and ConocoPhillips (COP). Bank of America shares have been one of the biggest beneficiaries of the changed macro backdrop following the election, which includes expectations of faster economic growth and overhaul of the country's tax and regulatory systems. No doubt, Bank of America shares have been strong performers since the election - up +34.9% since November 8th vs. +21.8% gain for the Zacks Major Banks industry in that time period, but the analyst still | Wednesday, January 11 2017 Today's Research Daily features new research reports on 16 major stocks, including Bank of America (BAC), Facebook (FB) and ConocoPhillips (COP). Bank of America shares have been one of the biggest beneficiaries of the changed macro backdrop following the election, which includes expectations of faster economic growth and overhaul of the country's tax and regulatory systems. No doubt, Bank of America shares have been strong performers since the election - up +34.9% since November 8th vs. +21.8% gain for the Zacks Major Banks industry in that time period, but the analyst still | Wednesday, January 11 2017 Today's Research Daily features new research reports on 16 major stocks, including Bank of America (BAC), Facebook (FB) and ConocoPhillips (COP). Bank of America shares have been one of the biggest beneficiaries of the changed macro backdrop following the election, which includes expectations of faster economic growth and overhaul of the country's tax and regulatory systems. No doubt, Bank of America shares have been strong performers since the election - up +34.9% since November 8th vs. +21.8% gain for the Zacks Major Banks industry in that time period, but the analyst still | Wednesday, January 11 2017 Today's Research Daily features new research reports on 16 major stocks, including Bank of America (BAC), Facebook (FB) and ConocoPhillips (COP). Bank of America shares have been one of the biggest beneficiaries of the changed macro backdrop following the election, which includes expectations of faster economic growth and overhaul of the country's tax and regulatory systems. The resulting uptrend in interest rates promises to give bank stocks in general and Bank of America in particular a big boost. |
33706.0 | 2017-01-10 00:00:00 UTC | Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for January 11, 2017 | ABT | https://www.nasdaq.com/articles/abbott-laboratories-abt-ex-dividend-date-scheduled-january-11-2017-2017-01-10 | nan | nan | Abbott Laboratories ( ABT ) will begin trading ex-dividend on January 11, 2017. A cash dividend payment of $0.265 per share is scheduled to be paid on February 15, 2017. Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 1.92% increase over prior dividend payment.
The previous trading day's last sale of ABT was $40.74, representing a -11.03% decrease from the 52 week high of $45.79 and a 13.17% increase over the 52 week low of $36.
ABT is a part of the Health Care sector, which includes companies such as Johnson & Johnson ( JNJ ) and Pfizer, Inc. ( PFE ). ABT's current earnings per share, an indicator of a company's profitability, is $.91. Zacks Investment Research reports ABT's forecasted earnings growth in 2016 as 2.4%, compared to an industry average of 4.5%.
For more information on the declaration, record and payment dates, visit the ABT Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to ABT through an Exchange Traded Fund [ETF]?
The following ETF(s) have ABT as a top-10 holding:
iShares U.S. Medical Devices ETF ( IHI )
PowerShares Russell Top 200 Pure Value Portfolio ( PXLV ).
The top-performing ETF of this group is PXLV with an increase of 11.19% over the last 100 days. IHI has the highest percent weighting of ABT at 9.14%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports ABT's forecasted earnings growth in 2016 as 2.4%, compared to an industry average of 4.5%. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott Laboratories ( ABT ) will begin trading ex-dividend on January 11, 2017. Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. The previous trading day's last sale of ABT was $40.74, representing a -11.03% decrease from the 52 week high of $45.79 and a 13.17% increase over the 52 week low of $36. The following ETF(s) have ABT as a top-10 holding: iShares U.S. Medical Devices ETF ( IHI ) PowerShares Russell Top 200 Pure Value Portfolio ( PXLV ). | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. The following ETF(s) have ABT as a top-10 holding: iShares U.S. Medical Devices ETF ( IHI ) PowerShares Russell Top 200 Pure Value Portfolio ( PXLV ). Abbott Laboratories ( ABT ) will begin trading ex-dividend on January 11, 2017. |
33707.0 | 2017-01-10 00:00:00 UTC | Health Care Sector Update for 01/10/2017: IMNP, VRX, JNJ, PFE, ABT, MRK, AMGN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-01102017-imnp-vrx-jnj-pfe-abt-mrk-amgn-2017-01-10 | nan | nan | Top Health Care stocks:
JNJ: flat
PFE: +1.1%
ABT: flat
MRK: flat
AMGN: flat
Health care shares were mostly unchanged in pre-market trade Tuesday.
In health care stocks news, Immune Pharmaceuticals ( IMNP ) was up 9.8% after it said late Monday it intends to request a hearing before a Nasdaq listing panel to appeal a notification that Immune's securities are subject to delisting. The company will present its plan at the upcoming hearing to regain compliance with the minimum bid price requirement, it said in a statement. The stock will continue to be listed pending a resolution of the appeal.
And, Valeant Pharmaceuticals International ( VRX ) was up 12% after the company struck $2.12 billion in asset sales. The company agreed to sell its CeraVe, AcneFree and AMBI skincare brands to France-based L'Oreal for $1.3 billion in cash as well all of its outstanding equity interests in Dendreon Pharmaceuticals to China-based Sanpower Group Co., Ltd. for $819.9 million in cash.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat MRK: flat AMGN: flat Health care shares were mostly unchanged in pre-market trade Tuesday. The company will present its plan at the upcoming hearing to regain compliance with the minimum bid price requirement, it said in a statement. And, Valeant Pharmaceuticals International ( VRX ) was up 12% after the company struck $2.12 billion in asset sales. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ABT: flat MRK: flat AMGN: flat Health care shares were mostly unchanged in pre-market trade Tuesday. In health care stocks news, Immune Pharmaceuticals ( IMNP ) was up 9.8% after it said late Monday it intends to request a hearing before a Nasdaq listing panel to appeal a notification that Immune's securities are subject to delisting. | ABT: flat MRK: flat AMGN: flat Health care shares were mostly unchanged in pre-market trade Tuesday. In health care stocks news, Immune Pharmaceuticals ( IMNP ) was up 9.8% after it said late Monday it intends to request a hearing before a Nasdaq listing panel to appeal a notification that Immune's securities are subject to delisting. The company agreed to sell its CeraVe, AcneFree and AMBI skincare brands to France-based L'Oreal for $1.3 billion in cash as well all of its outstanding equity interests in Dendreon Pharmaceuticals to China-based Sanpower Group Co., Ltd. for $819.9 million in cash. | ABT: flat MRK: flat AMGN: flat Health care shares were mostly unchanged in pre-market trade Tuesday. Top Health Care stocks: JNJ: flat In health care stocks news, Immune Pharmaceuticals ( IMNP ) was up 9.8% after it said late Monday it intends to request a hearing before a Nasdaq listing panel to appeal a notification that Immune's securities are subject to delisting. |
33708.0 | 2017-01-09 00:00:00 UTC | Health Care Sector Update for 01/09/2017: ARWR, EXAS, JNJ, PFE, ABT, MRK, AMGN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-01092017-arwr-exas-jnj-pfe-abt-mrk-amgn-2017-01-09 | nan | nan | Top Health Care stocks:
JNJ: +0.1%
PFE: -0.1%
ABT: -0.1%
MRK: +0.4%
AMGN: +0.5%
Health care shares were mostly higher in pre-market trade Monday.
In health care stocks news, Exact Sciences ( EXAS ) was up 16.6% after the company said Sunday it expects to report revenues between $34.9 million and $35.4 million in Q4, up 142% year-over-year and above the $30.1 million consensus estimate from analysts polled by Capital IQ. For the year the company expects to report revenues between $99.0 million and $99.5 million, up 150% from a year ago and higher than the $94.2 million consensus. The maker of a colon-cancer screening test said 244,000 Cologuard tests were completed in 2016, a 134% increase. Exact said insurance coverage expanded by 67% during 2016.
And, Arrowhead Research ( ARWR ) was up 7.7% as the company said there has been no discussions about a potential transaction with London-listed Silence Therapeutics, which Monday said it has acquired an 8.4% stake in Arrowhead. The company said it plans to develop its RNAi-based drug candidates ARO-HBV, ARO-AAT, ARO-F12, ARO-HIF2, ARO-LPA, ARO-AMG1, and other undisclosed programs, are unchanged and unaffected by the announcement, while saying it will "continue to seek partnerships and collaborations that maximize the value of its assets, as such opportunities may arise in the future."
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Health care shares were mostly higher in pre-market trade Monday. And, Arrowhead Research ( ARWR ) was up 7.7% as the company said there has been no discussions about a potential transaction with London-listed Silence Therapeutics, which Monday said it has acquired an 8.4% stake in Arrowhead. The company said it plans to develop its RNAi-based drug candidates ARO-HBV, ARO-AAT, ARO-F12, ARO-HIF2, ARO-LPA, ARO-AMG1, and other undisclosed programs, are unchanged and unaffected by the announcement, while saying it will "continue to seek partnerships and collaborations that maximize the value of its assets, as such opportunities may arise in the future." | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. For the year the company expects to report revenues between $99.0 million and $99.5 million, up 150% from a year ago and higher than the $94.2 million consensus. | In health care stocks news, Exact Sciences ( EXAS ) was up 16.6% after the company said Sunday it expects to report revenues between $34.9 million and $35.4 million in Q4, up 142% year-over-year and above the $30.1 million consensus estimate from analysts polled by Capital IQ. For the year the company expects to report revenues between $99.0 million and $99.5 million, up 150% from a year ago and higher than the $94.2 million consensus. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health Care stocks: In health care stocks news, Exact Sciences ( EXAS ) was up 16.6% after the company said Sunday it expects to report revenues between $34.9 million and $35.4 million in Q4, up 142% year-over-year and above the $30.1 million consensus estimate from analysts polled by Capital IQ. The maker of a colon-cancer screening test said 244,000 Cologuard tests were completed in 2016, a 134% increase. |
33709.0 | 2017-01-09 00:00:00 UTC | Oil Sinks Dow Jones Industrial Average as Nasdaq Scores Another High | ABT | https://www.nasdaq.com/articles/oil-sinks-dow-jones-industrial-average-nasdaq-scores-another-high-2017-01-09 | nan | nan | After coming within a fraction of a point from the 20,000 level on Friday, the Dow Jones Industrial Average (DJIA) explored a relatively narrow range today, but failed to find its way into positive territory, as falling crude oil prices weighed on stocks. Still, the Nasdaq Composite (COMP) managed to outperform, thanks to strength in the biotech sector, snagging new record highs on both an intraday and closing basis.
It was a relatively quiet day for data, leaving traders to digest the latest, and somewhat mixed, comments from Federal Reserve officials. After Boston Fed President Eric Rosengren's rather hawkish comments this morning, Atlanta Fed President Dennis Lockhart -- who is due to retire from his post next month -- said he believes the Fed may only need to raise interest rates twice in 2017.
Continue reading for more on today's market, including:
What the first 5 days of trading signal for 2017 .
The CEO of this Chinese firm just had a "great" meeting with Donald Trump .
Behind a $1.5 million options bet on Facebook Inc ( FB ) record highs.
Plus ... 3 healthcare stocks on the move, the biotech ETF on a hot streak, and 2 bank stocks in the options spotlight.
The Dow Jones Industrial Average (DJIA- 19,887.38) slid 76.4 points, or 0.4%, with energy stock Exxon Mobil Corporation ( XOM ) leading 22 of the 30 blue chips lower on a 1.6% drop. Drugmaker Merck & Co., Inc. ( MRK ) led the eight gainers, adding 1.4%.
The S&P 500 Index (SPX - 2,268.90) slid 8.1 points, or 0.4%, but the Nasdaq Composite (COMP - 5,531.82) bucked the bearish trend, tacking on 10.8 points, or 0.2%, for its highest finish on record. Earlier, the COMP hit an all-time peak of 5,541.07.
The CBOE Volatility Index (VIX - 11.56) added 0.2 point, or 2.1%, for the day.
5 Items on Our Radar Today
With questions still looming regarding how closely connected President-elect Donald Trump will remain to his personal businesses, Democratic Senator Elizabeth Warren joined her fellow party members in introducing a bill that would force the incoming president to "divest all interests that create financial conflicts of interest placing those assets in a true blind trust." Trump is expected to give a press conference regarding just such issues later this week. ( CNBC )
Abbott Laboratories ( ABT ) reported today that it has begun releasing updates for its recently acquired St. Jude heart devices, providing extra cybersecurity measures , and allowing doctors to track the performance of devices. The updates come five months after the U.S. government began investigating claims these devices could be vulnerable to cyber hacks that put patients at risk. ( Reuters )
The news sending these 3 healthcare stocks sharply higher.
Option bulls bombarded SPDR S&P Biotech (ETF) ( XBI ) as the ETF finished its fifth straight day in the black.
How pre-earnings options traders have been lining up on 2 booming bank stocks .
Data courtesy ofTrade-Alert
Commodities:
Crude oil spent the session sliding, as traders digested reports that output from Iraq's southern Basra ports hit a record high in December, reigniting worries that the country may not be complying with agreed-upon production cuts. Crude for February delivery dropped $2.03, or 3.8%, to settle at $51.96 per barrel -- a three-week low.
Gold prices stair-stepped higher throughout the day, as the strength of the U.S. dollar steadied. Tempered expectations ahead of President-elect Trump's upcoming inauguration later this month also helped boost the commodity, with February gold futures tacking on $11.50, or 1%, to finish the day at a nearly six-week high of $1,184.90 an ounce.
Stay on top of overnight news & big morning movers. Sign up now for Schaeffer's Opening View.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ( CNBC ) Abbott Laboratories ( ABT ) reported today that it has begun releasing updates for its recently acquired St. Jude heart devices, providing extra cybersecurity measures , and allowing doctors to track the performance of devices. After coming within a fraction of a point from the 20,000 level on Friday, the Dow Jones Industrial Average (DJIA) explored a relatively narrow range today, but failed to find its way into positive territory, as falling crude oil prices weighed on stocks. Data courtesy ofTrade-Alert Commodities: Crude oil spent the session sliding, as traders digested reports that output from Iraq's southern Basra ports hit a record high in December, reigniting worries that the country may not be complying with agreed-upon production cuts. | ( CNBC ) Abbott Laboratories ( ABT ) reported today that it has begun releasing updates for its recently acquired St. Jude heart devices, providing extra cybersecurity measures , and allowing doctors to track the performance of devices. After coming within a fraction of a point from the 20,000 level on Friday, the Dow Jones Industrial Average (DJIA) explored a relatively narrow range today, but failed to find its way into positive territory, as falling crude oil prices weighed on stocks. The Dow Jones Industrial Average (DJIA- 19,887.38) slid 76.4 points, or 0.4%, with energy stock Exxon Mobil Corporation ( XOM ) leading 22 of the 30 blue chips lower on a 1.6% drop. | ( CNBC ) Abbott Laboratories ( ABT ) reported today that it has begun releasing updates for its recently acquired St. Jude heart devices, providing extra cybersecurity measures , and allowing doctors to track the performance of devices. After coming within a fraction of a point from the 20,000 level on Friday, the Dow Jones Industrial Average (DJIA) explored a relatively narrow range today, but failed to find its way into positive territory, as falling crude oil prices weighed on stocks. 5 Items on Our Radar Today With questions still looming regarding how closely connected President-elect Donald Trump will remain to his personal businesses, Democratic Senator Elizabeth Warren joined her fellow party members in introducing a bill that would force the incoming president to "divest all interests that create financial conflicts of interest placing those assets in a true blind trust." | ( CNBC ) Abbott Laboratories ( ABT ) reported today that it has begun releasing updates for its recently acquired St. Jude heart devices, providing extra cybersecurity measures , and allowing doctors to track the performance of devices. Plus ... 3 healthcare stocks on the move, the biotech ETF on a hot streak, and 2 bank stocks in the options spotlight. The S&P 500 Index (SPX - 2,268.90) slid 8.1 points, or 0.4%, but the Nasdaq Composite (COMP - 5,531.82) bucked the bearish trend, tacking on 10.8 points, or 0.2%, for its highest finish on record. |
33710.0 | 2017-01-08 00:00:00 UTC | Will Johnson & Johnson Shock Investors with a Spin-off in 2017? | ABT | https://www.nasdaq.com/articles/will-johnson-johnson-shock-investors-spin-2017-2017-01-08 | nan | nan | Every new year brings the possibility of surprise.
Who would have thought that the Chicago Cubs would win the World Series at the beginning of 2016? Maybe something even more surprising could happen this year, like Kim Kardashian forsaking all publicity. On second thought, maybe not. There is one potential surprise, though, that I think has at least a tiny possibility of actually happening this year. Here's why Johnson & Johnson (NYSE: JNJ) could shock the investing world with a spin-off in 2017.
Image source: Getty Images.
Two sluggish segments and one that's solid
When you think of Johnson & Johnson, what first comes to mind? There are many possible answers, from Band-Aids and baby shampoo to Xarelto and Zytiga. J&J's scope is so broad that it's basically multiple companies under one umbrella.
Band-Aids, baby shampoo, and dozens of other products fall into Johnson & Johnson's consumer business segment. While this segment might have the most well-known products, sales aren't doing so well. J&J's consumer segment reported a year-over-year drop in sales of 3.1% during the first three quarters of 2016.
Another business segment is also struggling somewhat: medical devices. During the first three quarters of 2016, J&J's medical device sales slipped 0.2% from the prior year period. However, the segment generated revenue during the period of $18.7 billion -- a lot more than the roughly $10.2 billion made by the company's consumer business.
Xarelto, Zytiga, and a host of other drugs belong to J&J's pharmaceuticals segment. Unlike the company's other two segments, pharmaceuticals sales are growing solidly -- up 8% year over year in the first three quarters of 2016. It's also by far the most profitable business segment for Johnson & Johnson.
A relevant precedent
This big gap in performance among different business segments isn't unusual. However, such gaps have also played an important role in cases made by other companies for spinning off segments to unlock shareholder value.
Probably the most relevant precedent for J&J is Abbott Laboratories '(NYSE: ABT) decision in 2011 to spin off its pharmaceuticals business into a new company. Abbott's premise was that its parts were worth more separate than combined. The spin-off was completed by early 2013, with the new AbbVie (NYSE: ABBV) focusing on innovative drugs and Abbott focusing on diagnostics and medical devices.
Abbott arguably had less of a case for a spin-off in 2011 than J&J does right now. Sales for its proprietary pharmaceuticals business were up 8% from the prior year -- the same as J&J's pharmaceuticals segment's 2016 performance. Unlike J&J, though, Abbott's diagnostics and medical device sales were also growing.
Did Abbott's spin-off of AbbVie unlock value for shareholders? Abbott's stock increased by just 17% in the five years prior to AbbVie's launch. Over the next four years, Abbott's stock rose nearly 24%, while AbbVie's share price soared over 80%.
That's a slam dunk case for spinning off, right? Not necessarily. The initial five-year period included the huge market plunge in 2008 and 2009. Still, though, I doubt very many people who owned Abbott stock back in 2011 and 2012 are disappointed now that the company spun off AbbVie.
What to spin off?
If Johnson & Johnson did opt to spin off a business segment as a separate entity, which segments would stay and which would go? The least likely choice would be to create three separate companies for each business segment. I'd say that alternative has roughly the same chances as the Chicago Cubs winning another world championship -- in hockey.
Another option would be for J&J to keep its consumer and medical device segments and spin off pharmaceuticals as its own entity. This would be similar to what Abbott did with AbbVie.
Perhaps the next best choice would be for the company to spin off its medical device segment. That would leave J&J with its higher-growth pharmaceuticals business and all of its beloved brands for which the company is best known.
Why not just sell the medical device segment instead? Taxes. Spin-offs can be done in a way that doesn't generate hundreds of millions of dollars in tax payments that would be required with a sale to another company.
Don't be surprised
Could Johnson & Johnson stun investors by announcing a spin-off this year? It's certainly within the realm of possibility. Don't be surprised, though, if J&J doesn't make any big moves in 2017.
The odds of a spin-off are really low. While many healthcare stocks languished last year, J&J's stock price gained nearly 15%. Also, even though sales for J&J's consumer and medical device segments aren't growing right now, the businesses are both quite profitable.
My view is that the more likely shock from the healthcare giant this year will be the opposite of a spin-off -- a major acquisition. Then again, considering J&J's history, that probably wouldn't be shocking at all.
10 stocks we like better than Johnson and Johnson
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Johnson and Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of January 4, 2017
Keith Speights has no position in any stocks mentioned. The Motley Fool recommends Johnson and Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Probably the most relevant precedent for J&J is Abbott Laboratories '(NYSE: ABT) decision in 2011 to spin off its pharmaceuticals business into a new company. However, such gaps have also played an important role in cases made by other companies for spinning off segments to unlock shareholder value. Spin-offs can be done in a way that doesn't generate hundreds of millions of dollars in tax payments that would be required with a sale to another company. | Probably the most relevant precedent for J&J is Abbott Laboratories '(NYSE: ABT) decision in 2011 to spin off its pharmaceuticals business into a new company. Unlike the company's other two segments, pharmaceuticals sales are growing solidly -- up 8% year over year in the first three quarters of 2016. A relevant precedent This big gap in performance among different business segments isn't unusual. | Probably the most relevant precedent for J&J is Abbott Laboratories '(NYSE: ABT) decision in 2011 to spin off its pharmaceuticals business into a new company. Unlike the company's other two segments, pharmaceuticals sales are growing solidly -- up 8% year over year in the first three quarters of 2016. If Johnson & Johnson did opt to spin off a business segment as a separate entity, which segments would stay and which would go? | Probably the most relevant precedent for J&J is Abbott Laboratories '(NYSE: ABT) decision in 2011 to spin off its pharmaceuticals business into a new company. Here's why Johnson & Johnson (NYSE: JNJ) could shock the investing world with a spin-off in 2017. Unlike the company's other two segments, pharmaceuticals sales are growing solidly -- up 8% year over year in the first three quarters of 2016. |
33711.0 | 2017-01-06 00:00:00 UTC | Abbott Laboratories (ABT) Shares Cross Above 200 DMA | ABT | https://www.nasdaq.com/articles/abbott-laboratories-abt-shares-cross-above-200-dma-2017-01-06 | nan | nan | In trading on Friday, shares of Abbott Laboratories (Symbol: ABT) crossed above their 200 day moving average of $40.78, changing hands as high as $40.99 per share. Abbott Laboratories shares are currently trading up about 2.5% on the day. The chart below shows the one year performance of ABT shares, versus its 200 day moving average:
Looking at the chart above, ABT's low point in its 52 week range is $36.00 per share, with $45.79 as the 52 week high point - that compares with a last trade of $40.77.
According to the ETF Finder at ETF Channel, ABT makes up 7.98% of the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH) which is trading up by about 0.5% on the day Friday.
Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Friday, shares of Abbott Laboratories (Symbol: ABT) crossed above their 200 day moving average of $40.78, changing hands as high as $40.99 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $36.00 per share, with $45.79 as the 52 week high point - that compares with a last trade of $40.77. According to the ETF Finder at ETF Channel, ABT makes up 7.98% of the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH) which is trading up by about 0.5% on the day Friday. | In trading on Friday, shares of Abbott Laboratories (Symbol: ABT) crossed above their 200 day moving average of $40.78, changing hands as high as $40.99 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $36.00 per share, with $45.79 as the 52 week high point - that compares with a last trade of $40.77. According to the ETF Finder at ETF Channel, ABT makes up 7.98% of the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH) which is trading up by about 0.5% on the day Friday. | In trading on Friday, shares of Abbott Laboratories (Symbol: ABT) crossed above their 200 day moving average of $40.78, changing hands as high as $40.99 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $36.00 per share, with $45.79 as the 52 week high point - that compares with a last trade of $40.77. According to the ETF Finder at ETF Channel, ABT makes up 7.98% of the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH) which is trading up by about 0.5% on the day Friday. | In trading on Friday, shares of Abbott Laboratories (Symbol: ABT) crossed above their 200 day moving average of $40.78, changing hands as high as $40.99 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $36.00 per share, with $45.79 as the 52 week high point - that compares with a last trade of $40.77. According to the ETF Finder at ETF Channel, ABT makes up 7.98% of the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH) which is trading up by about 0.5% on the day Friday. |
33712.0 | 2017-01-06 00:00:00 UTC | Notable Friday Option Activity: GS, ABT, ULTA | ABT | https://www.nasdaq.com/articles/notable-friday-option-activity-gs-abt-ulta-2017-01-06 | nan | nan | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Goldman Sachs Group, Inc. (Symbol: GS), where a total of 30,902 contracts have traded so far, representing approximately 3.1 million underlying shares. That amounts to about 73.6% of GS's average daily trading volume over the past month of 4.2 million shares. Especially high volume was seen for the $245 strike call option expiring January 06, 2017 , with 2,470 contracts trading so far today, representing approximately 247,000 underlying shares of GS. Below is a chart showing GS's trailing twelve month trading history, with the $245 strike highlighted in orange:
Abbott Laboratories (Symbol: ABT) options are showing a volume of 48,714 contracts thus far today. That number of contracts represents approximately 4.9 million underlying shares, working out to a sizeable 51.3% of ABT's average daily trading volume over the past month, of 9.5 million shares. Particularly high volume was seen for the $40 strike put option expiring January 20, 2017 , with 10,070 contracts trading so far today, representing approximately 1.0 million underlying shares of ABT. Below is a chart showing ABT's trailing twelve month trading history, with the $40 strike highlighted in orange:
And Ulta Salon Cosmetics & Fragrance Inc. (Symbol: ULTA) options are showing a volume of 3,207 contracts thus far today. That number of contracts represents approximately 320,700 underlying shares, working out to a sizeable 47.4% of ULTA's average daily trading volume over the past month, of 676,855 shares. Especially high volume was seen for the $270 strike call option expiring January 20, 2017 , with 235 contracts trading so far today, representing approximately 23,500 underlying shares of ULTA. Below is a chart showing ULTA's trailing twelve month trading history, with the $270 strike highlighted in orange:
For the various different available expirations for GS options , ABT options , or ULTA options , visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Particularly high volume was seen for the $40 strike put option expiring January 20, 2017 , with 10,070 contracts trading so far today, representing approximately 1.0 million underlying shares of ABT. Below is a chart showing GS's trailing twelve month trading history, with the $245 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) options are showing a volume of 48,714 contracts thus far today. That number of contracts represents approximately 4.9 million underlying shares, working out to a sizeable 51.3% of ABT's average daily trading volume over the past month, of 9.5 million shares. | Below is a chart showing GS's trailing twelve month trading history, with the $245 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) options are showing a volume of 48,714 contracts thus far today. That number of contracts represents approximately 4.9 million underlying shares, working out to a sizeable 51.3% of ABT's average daily trading volume over the past month, of 9.5 million shares. Below is a chart showing ABT's trailing twelve month trading history, with the $40 strike highlighted in orange: And Ulta Salon Cosmetics & Fragrance Inc. (Symbol: ULTA) options are showing a volume of 3,207 contracts thus far today. | Particularly high volume was seen for the $40 strike put option expiring January 20, 2017 , with 10,070 contracts trading so far today, representing approximately 1.0 million underlying shares of ABT. Below is a chart showing ABT's trailing twelve month trading history, with the $40 strike highlighted in orange: And Ulta Salon Cosmetics & Fragrance Inc. (Symbol: ULTA) options are showing a volume of 3,207 contracts thus far today. Below is a chart showing GS's trailing twelve month trading history, with the $245 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) options are showing a volume of 48,714 contracts thus far today. | Particularly high volume was seen for the $40 strike put option expiring January 20, 2017 , with 10,070 contracts trading so far today, representing approximately 1.0 million underlying shares of ABT. Below is a chart showing GS's trailing twelve month trading history, with the $245 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) options are showing a volume of 48,714 contracts thus far today. That number of contracts represents approximately 4.9 million underlying shares, working out to a sizeable 51.3% of ABT's average daily trading volume over the past month, of 9.5 million shares. |
33713.0 | 2017-01-05 00:00:00 UTC | Health Care Sector Update for 01/05/2017: CTIC, HRTX, JNJ, PFE, ABT, MRK, AMGN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-01052017-ctic-hrtx-jnj-pfe-abt-mrk-amgn-2017-01-05 | nan | nan | Top Health Care stocks:
JNJ: flat
PFE: -0.3%
ABT: flat
MRK: flat
AMGN: flat
Health care shares were mostly unchanged in pre-market trade Thursday.
In health care stocks news, Heron Therapeutics ( HRTX ) was down 9.4% after providing weak outlook for sales of Sustol, its anti-nausea drug, overshadowed the company's Wednesday release of data from a phase 2 clinical trial of HTX-011 in abdominoplasty, or tummy tucks, which showed the treatment "produced statistically significant reductions in both pain intensity and need for opioids" through 96 hours post surgery. In a company outlook presentation, Heron disclosed that it anticipates Sustol sales of just $15 million to $25 million in 2017. The Street was expecting about $50 million in sales for the treatment. The stock had initially spiked as high as $15.70 in after-hours trade on the tummy tuck data, but retreated in pre-market Thursday to as low as $12.00, below the stock's 52-week low of $12.30.
And, CTI BioPharma ( CTIC ) was up 20.9% after the U.S. Food and Drug Administration removed the full clinical hold on all clinical trials conducted under the investigational new drug application for pacritinib to treat myelofibrosis. The company said its complete response submission included among others clinical study reports for both PERSIST-1 and 2 trials and a dose-exploration clinical trial protocol that the FDA requested. The company said the new trial, PAC203 plans to enroll up to approximately 105 patients with primary myelofibrosis who have failed prior ruxolitinib therapy to evaluate the safety and the dose response relationship for efficacy. It expects to start the trial in Q2 of 2017.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat MRK: flat AMGN: flat Health care shares were mostly unchanged in pre-market trade Thursday. In health care stocks news, Heron Therapeutics ( HRTX ) was down 9.4% after providing weak outlook for sales of Sustol, its anti-nausea drug, overshadowed the company's Wednesday release of data from a phase 2 clinical trial of HTX-011 in abdominoplasty, or tummy tucks, which showed the treatment "produced statistically significant reductions in both pain intensity and need for opioids" through 96 hours post surgery. And, CTI BioPharma ( CTIC ) was up 20.9% after the U.S. Food and Drug Administration removed the full clinical hold on all clinical trials conducted under the investigational new drug application for pacritinib to treat myelofibrosis. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ABT: flat MRK: flat AMGN: flat Health care shares were mostly unchanged in pre-market trade Thursday. The stock had initially spiked as high as $15.70 in after-hours trade on the tummy tuck data, but retreated in pre-market Thursday to as low as $12.00, below the stock's 52-week low of $12.30. | ABT: flat MRK: flat AMGN: flat Health care shares were mostly unchanged in pre-market trade Thursday. In health care stocks news, Heron Therapeutics ( HRTX ) was down 9.4% after providing weak outlook for sales of Sustol, its anti-nausea drug, overshadowed the company's Wednesday release of data from a phase 2 clinical trial of HTX-011 in abdominoplasty, or tummy tucks, which showed the treatment "produced statistically significant reductions in both pain intensity and need for opioids" through 96 hours post surgery. And, CTI BioPharma ( CTIC ) was up 20.9% after the U.S. Food and Drug Administration removed the full clinical hold on all clinical trials conducted under the investigational new drug application for pacritinib to treat myelofibrosis. | ABT: flat MRK: flat AMGN: flat Health care shares were mostly unchanged in pre-market trade Thursday. Top Health Care stocks: JNJ: flat In health care stocks news, Heron Therapeutics ( HRTX ) was down 9.4% after providing weak outlook for sales of Sustol, its anti-nausea drug, overshadowed the company's Wednesday release of data from a phase 2 clinical trial of HTX-011 in abdominoplasty, or tummy tucks, which showed the treatment "produced statistically significant reductions in both pain intensity and need for opioids" through 96 hours post surgery. |
33714.0 | 2017-01-04 00:00:00 UTC | Health Care Sector Update for 01/04/2017: NVLS, JNJ, PFE, ABT, MRK, AMGN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-01042017-nvls-jnj-pfe-abt-mrk-amgn-2017-01-04 | nan | nan | Top Health Care stocks:
JNJ: +0.9%
PFE: +0.5%
ABT: flat
MRK: +0.1%
AMGN: +0.3%
Health care shares were mostly higher in pre-market trade Wednesday.
In health care stocks news, Johnson & Johnson ( JNJ ) was up 0.9% following a Reuters report that said it will only have to pay about half of the more than $1 billion awarded by a jury to plaintiffs in six lawsuits who said they were injured by DePuy's Pinnacle hip implants. The report cited U.S. District Judge Ed Kinkeade in Dallas. About $500 million of punitive damages will be cut from the more than $1 billion awarded to the plaintiffs that had the implants and then experienced tissue death, bone erosion and other injuries. The report said the judge cited "constitutional considerations" that limit how much plaintiffs may recover in punitive damages but upheld the jury's findings that the implants were defectively designed and that the companies failed to warn consumers about the risks.
And, Nivalis Therapeutics ( NVLS ) was up 6.8% after it said late Tuesday that its board has formed a special committee to explore and evaluate a range of strategic alternatives for the company. The company also intends to streamline its operations to preserve its capital and cash resources, and intends to complete its ongoing SNO-7 trial of cavosonstat in patients with cystic fibrosis in Q1 2017.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat About $500 million of punitive damages will be cut from the more than $1 billion awarded to the plaintiffs that had the implants and then experienced tissue death, bone erosion and other injuries. The report said the judge cited "constitutional considerations" that limit how much plaintiffs may recover in punitive damages but upheld the jury's findings that the implants were defectively designed and that the companies failed to warn consumers about the risks. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ABT: flat In health care stocks news, Johnson & Johnson ( JNJ ) was up 0.9% following a Reuters report that said it will only have to pay about half of the more than $1 billion awarded by a jury to plaintiffs in six lawsuits who said they were injured by DePuy's Pinnacle hip implants. | ABT: flat In health care stocks news, Johnson & Johnson ( JNJ ) was up 0.9% following a Reuters report that said it will only have to pay about half of the more than $1 billion awarded by a jury to plaintiffs in six lawsuits who said they were injured by DePuy's Pinnacle hip implants. The report said the judge cited "constitutional considerations" that limit how much plaintiffs may recover in punitive damages but upheld the jury's findings that the implants were defectively designed and that the companies failed to warn consumers about the risks. | ABT: flat Top Health Care stocks: In health care stocks news, Johnson & Johnson ( JNJ ) was up 0.9% following a Reuters report that said it will only have to pay about half of the more than $1 billion awarded by a jury to plaintiffs in six lawsuits who said they were injured by DePuy's Pinnacle hip implants. |
33715.0 | 2017-01-04 00:00:00 UTC | After Hours Most Active for Jan 4, 2017 : CC, IDXX, ABT, MT, STJ, BAC, MSFT, PK, QQQ, EBAY, FOLD, INTC | ABT | https://www.nasdaq.com/articles/after-hours-most-active-jan-4-2017-cc-idxx-abt-mt-stj-bac-msft-pk-qqq-ebay-fold-intc-2017 | nan | nan | The NASDAQ 100 After Hours Indicator is down -1.61 to 4,935.6. The total After hours volume is currently 36,360,338 shares traded.
The following are the most active stocks for the after hours session :
Chemours Company (The) ( CC ) is -0.06 at $22.15, with 17,634,647 shares traded. CC's current last sale is 110.75% of the target price of $20.
IDEXX Laboratories, Inc. ( IDXX ) is -0.15 at $115.80, with 11,022,715 shares traded. IDXX's current last sale is 102.03% of the target price of $113.5.
Abbott Laboratories ( ABT ) is +0.0852 at $39.45, with 3,504,117 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2017. The consensus EPS forecast is $0.49. As reported by Zacks, the current mean recommendation for ABT is in the "buy range".
ArcelorMittal ( MT ) is +0.04 at $7.69, with 3,416,236 shares traded. MT's current last sale is 96.13% of the target price of $8.
St. Jude Medical, Inc. ( STJ ) is +0.15 at $80.97, with 2,493,800 shares traded. STJ's current last sale is 98.15% of the target price of $82.5.
Bank of America Corporation ( BAC ) is -0.02 at $22.93, with 1,455,516 shares traded. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2016. The consensus EPS forecast is $0.38. As reported by Zacks, the current mean recommendation for BAC is in the "buy range".
Microsoft Corporation ( MSFT ) is -0.09 at $62.21, with 1,447,808 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2016. The consensus EPS forecast is $0.78. As reported by Zacks, the current mean recommendation for MSFT is in the "buy range".
Park Hotels & Resorts Inc. ( PK ) is -0.37 at $29.53, with 1,253,988 shares traded.
PowerShares QQQ Trust, Series 1 ( QQQ ) is -0.02 at $120.17, with 1,079,822 shares traded. This represents a 26.71% increase from its 52 Week Low.
eBay Inc. ( EBAY ) is -0.1498 at $29.61, with 820,365 shares traded. EBAY's current last sale is 92.53% of the target price of $32.
Amicus Therapeutics, Inc. ( FOLD ) is unchanged at $5.63, with 631,061 shares traded. As reported by Zacks, the current mean recommendation for FOLD is in the "buy range".
Intel Corporation ( INTC ) is -0.05 at $36.36, with 572,029 shares traded. As reported by Zacks, the current mean recommendation for INTC is in the "buy range".
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is +0.0852 at $39.45, with 3,504,117 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range". The following are the most active stocks for the after hours session : Chemours Company (The) ( CC ) is -0.06 at $22.15, with 17,634,647 shares traded. | Abbott Laboratories ( ABT ) is +0.0852 at $39.45, with 3,504,117 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range". Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2016. | Abbott Laboratories ( ABT ) is +0.0852 at $39.45, with 3,504,117 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range". Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2017. | Abbott Laboratories ( ABT ) is +0.0852 at $39.45, with 3,504,117 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range". The NASDAQ 100 After Hours Indicator is down -1.61 to 4,935.6. |
33716.0 | 2017-01-03 00:00:00 UTC | VHT, ABT, TMO, DHR: Large Outflows Detected at ETF | ABT | https://www.nasdaq.com/articles/vht-abt-tmo-dhr-large-outflows-detected-etf-2017-01-03 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Health Care ETF (Symbol: VHT) where we have detected an approximate $19.0 million dollar outflow -- that's a 0.3% decrease week over week (from 43,234,773 to 43,084,773). Among the largest underlying components of VHT, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.7%, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 1.6%, and Danaher Corp (Symbol: DHR) is higher by about 1%. For a complete list of holdings, visit the VHT Holdings page » The chart below shows the one year price performance of VHT, versus its 200 day moving average:
Looking at the chart above, VHT's low point in its 52 week range is $113.02 per share, with $138.99 as the 52 week high point - that compares with a last trade of $128.00. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VHT, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.7%, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 1.6%, and Danaher Corp (Symbol: DHR) is higher by about 1%. For a complete list of holdings, visit the VHT Holdings page » The chart below shows the one year price performance of VHT, versus its 200 day moving average: Looking at the chart above, VHT's low point in its 52 week range is $113.02 per share, with $138.99 as the 52 week high point - that compares with a last trade of $128.00. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of VHT, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.7%, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 1.6%, and Danaher Corp (Symbol: DHR) is higher by about 1%. For a complete list of holdings, visit the VHT Holdings page » The chart below shows the one year price performance of VHT, versus its 200 day moving average: Looking at the chart above, VHT's low point in its 52 week range is $113.02 per share, with $138.99 as the 52 week high point - that compares with a last trade of $128.00. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of VHT, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.7%, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 1.6%, and Danaher Corp (Symbol: DHR) is higher by about 1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Health Care ETF (Symbol: VHT) where we have detected an approximate $19.0 million dollar outflow -- that's a 0.3% decrease week over week (from 43,234,773 to 43,084,773). For a complete list of holdings, visit the VHT Holdings page » The chart below shows the one year price performance of VHT, versus its 200 day moving average: Looking at the chart above, VHT's low point in its 52 week range is $113.02 per share, with $138.99 as the 52 week high point - that compares with a last trade of $128.00. | Among the largest underlying components of VHT, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.7%, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 1.6%, and Danaher Corp (Symbol: DHR) is higher by about 1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Health Care ETF (Symbol: VHT) where we have detected an approximate $19.0 million dollar outflow -- that's a 0.3% decrease week over week (from 43,234,773 to 43,084,773). For a complete list of holdings, visit the VHT Holdings page » The chart below shows the one year price performance of VHT, versus its 200 day moving average: Looking at the chart above, VHT's low point in its 52 week range is $113.02 per share, with $138.99 as the 52 week high point - that compares with a last trade of $128.00. |
33717.0 | 2017-01-03 00:00:00 UTC | Health Care Sector Update for 01/03/2017: AGN, ITEK, JNJ, PFE, ABT, MRK, AMGN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-01032017-agn-itek-jnj-pfe-abt-mrk-amgn-2017-01-03 | nan | nan | Top Health Care stocks:
JNJ: -0.2%
PFE: +0.5%
ABT: +2.2%
MRK: -0.03%
AMGN: +0.6%
Health care shares were mostly higher in pre-market trade Tuesday.
In health care stocks news, Inotek Pharmaceuticals ( ITEK ) were down 67.7% after the company said that top-line results of a trial of trabodenoson, the company's lead clinical candidate, did not achieve its primary endpoint. Trabodenoson is a potential new therapy for ocular hypertension (OHT) and primary open-angle glaucoma (POAG). The company said the trial did not achieve superiority in reduction of intraocular pressure (IOP) compared with a placebo.
And, Allergan ( AGN ) rose 2.6% after gaining approval from the U.S. Food and Drug Administration (FDA) to market Natrelle Inspira SoftTouch breast implants.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Trabodenoson is a potential new therapy for ocular hypertension (OHT) and primary open-angle glaucoma (POAG). The company said the trial did not achieve superiority in reduction of intraocular pressure (IOP) compared with a placebo. And, Allergan ( AGN ) rose 2.6% after gaining approval from the U.S. Food and Drug Administration (FDA) to market Natrelle Inspira SoftTouch breast implants. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Top Health Care stocks: | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In health care stocks news, Inotek Pharmaceuticals ( ITEK ) were down 67.7% after the company said that top-line results of a trial of trabodenoson, the company's lead clinical candidate, did not achieve its primary endpoint. | Top Health Care stocks: In health care stocks news, Inotek Pharmaceuticals ( ITEK ) were down 67.7% after the company said that top-line results of a trial of trabodenoson, the company's lead clinical candidate, did not achieve its primary endpoint. Trabodenoson is a potential new therapy for ocular hypertension (OHT) and primary open-angle glaucoma (POAG). |
33718.0 | 2017-01-02 00:00:00 UTC | Abbott Labs to Close St. Jude Acquisition Later this Week | ABT | https://www.nasdaq.com/articles/abbott-labs-to-close-st.-jude-acquisition-later-this-week-2017-01-02 | nan | nan | Abbott LaboratoriesABT announced that it will close the acquisition of St. Jude Medical, Inc. STJ on Jan 4, 2017.
Shares of Abbott Labs underperformed the Zacks classified Large Cap Pharmaceuticals industry in 2016. In fact, Abbott Labs lost 10.6% in 2016, compared with a drop of 4.2% for the industry.
The company has obtained all regulatory clearances necessary for closing the transaction.
The acquisition will render Abbott Labs a leading position with a strong and diverse portfolio of devices, diagnostics, nutritionals and branded generic pharmaceuticals. The merged entity would control more than 70% of the vascular closure device market.
St. Jude Medical has a dominant position in fast-growing areas such as atrial fibrillation, heart failure, structural heart and chronic pain, which will complement Abbott Labs' leading position in the coronary interventions and mitral valve disease markets.
Post acquisition, Abbott Labs will compete in nearly every field of the $30 billion cardiovascular market, and boast a strong position across large and high-growth cardiovascular device markets.
The combined portfolio will have the depth, breadth, scale and innovation to help patients restore their health, improve outcomes and deliver greater value to customers and payors with products like EnSite Precision, ConfirmRx, HeartMate 3, Portico Transcatheter Aortic Heart Valves and Proclaim DRG system.
The combined cardiovascular and neuromodulation portfolio will generate annual sales of approximately $8.7 billion.
The acquisition of St. Jude Medical is expected to be accretive to Abbott Labs' bottom line in the first full year and increase thereafter, making contributions of approximately 21 cents in 2017 and 29 cents in 2018. The acquisition will also generate annual pre-tax synergies of $500 million by 2020, including both sales and operational benefits.
Last week, Abbott Labs agreed to divest two medical device businesses to settle Federal Trade Commission (FTC) charges in relation to the St. Jude Medical acquisition. The divestment will ensure fair competition in the U.S. markets for medical devices used in cardiac and vascular catheterization. Note that the FTC had alleged that the proposed acquisition would impact the competitive scenario in the U.S. markets for vascular closure devices if the company proceeds without a remedy.
Abbott Labs currently carries a Zacks Rank #3 (Hold).
ABBOTT LABS Price and Consensus
ABBOTT LABS Price and Consensus | ABBOTT LABS Quote
Key Picks in the Sector
A couple of better-ranked stocks in the health care sector include Heska Corp. HSKA and Vanda Pharmaceuticals VNDA . Both of them sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Heska's earnings estimates increased from $1.13 to $1.35 for 2016 and from $1.38 to $1.53 for 2017 over the last 60 days. The company posted a positive earnings surprise in all of the four trailing quarters with an average beat of 301.64%. Its share price has increased 93.7% year to date.
Vanda's loss estimates for 2016 narrowed from 62 cents to 45 cents, while its earnings estimates for 2017 decreased from 13 cents to 9 cents over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 56.65%. Its share price has surged almost 77.4% year to date.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
ST JUDE MEDICAL (STJ): Free Stock Analysis Report
HESKA CORP (HSKA): Free Stock Analysis Report
VANDA PHARMACT (VNDA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT announced that it will close the acquisition of St. Jude Medical, Inc. STJ on Jan 4, 2017. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report VANDA PHARMACT (VNDA): Free Stock Analysis Report To read this article on Zacks.com click here. The acquisition will render Abbott Labs a leading position with a strong and diverse portfolio of devices, diagnostics, nutritionals and branded generic pharmaceuticals. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report VANDA PHARMACT (VNDA): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT announced that it will close the acquisition of St. Jude Medical, Inc. STJ on Jan 4, 2017. ABBOTT LABS Price and Consensus ABBOTT LABS Price and Consensus | ABBOTT LABS Quote Key Picks in the Sector A couple of better-ranked stocks in the health care sector include Heska Corp. HSKA and Vanda Pharmaceuticals VNDA . | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report VANDA PHARMACT (VNDA): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT announced that it will close the acquisition of St. Jude Medical, Inc. STJ on Jan 4, 2017. Post acquisition, Abbott Labs will compete in nearly every field of the $30 billion cardiovascular market, and boast a strong position across large and high-growth cardiovascular device markets. | Abbott LaboratoriesABT announced that it will close the acquisition of St. Jude Medical, Inc. STJ on Jan 4, 2017. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report VANDA PHARMACT (VNDA): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of Abbott Labs underperformed the Zacks classified Large Cap Pharmaceuticals industry in 2016. |
33719.0 | 2016-12-30 00:00:00 UTC | Health Care Sector Update for 12/30/2016: ABT,STJ,MRNS,INNL | ABT | https://www.nasdaq.com/articles/health-care-sector-update-12302016-abtstjmrnsinnl-2016-12-30 | nan | nan | Top Health Care Stocks
JNJ -0.16%
PFE +0.02%
MRK +0.27%
ABT +0.13%
AMGN -1.03%
Health care stocks were narrowly mixed in recent trade, with the NYSE Health Care Index climbing about 0.1% while shares of health care companies in the S&P 500 were down nearly 0.2% as a group.
In company news, shares of Abbott Laboratories ( ABT ) and St. Jude Medical ( STJ ) were edging higher shortly before the closing bell late Friday after the medical device companies today said they expect to close their proposed $25 billion merger next Wednesday, Jan. 4.
The announcement follows Chinese authorities overnight signing off on the acquisition after the companies agreed to divest St. Jude's small vessel closure device business, the final regulatory hurdle remaining for the deal to move forward. The U.S. Federal Trade Commission earlier this week similarly approved the deal on anti-trust grounds.
Abbott is expecting the transaction will increase non-GAAP earnings by $0.21 during 2017 and by $0.29 per share in 2018. The combination also is seen producing around $500 million in yearly pre-tax synergies by 2020, including both sales and operational benefits.
ABT shares were up about 0.1% at $38.36 apiece this afternoon, giving back most of an earlier climb to $38.87 a share. STJ still was 0.3% higher at $80.09 each, previously topping out today at $80.53 a share.
In other sector news,
(+) MRNS, (+27.0%) U.S. Food and Drug Administration designates company's Ganaxolone generic medication as an orphan drug for the treatment of fragile X syndrome.
(-) INNL, (-65.5%) FDA issues refuse-to-file letter for the company's Xaracoll drug-device to treat post-surgical pain, triggering analyst downgrades to Market Perform at both FBR & Co. and JMP Securities while Janney lowers rating to Neutral from Buy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In company news, shares of Abbott Laboratories ( ABT ) and St. Jude Medical ( STJ ) were edging higher shortly before the closing bell late Friday after the medical device companies today said they expect to close their proposed $25 billion merger next Wednesday, Jan. 4. ABT shares were up about 0.1% at $38.36 apiece this afternoon, giving back most of an earlier climb to $38.87 a share. The announcement follows Chinese authorities overnight signing off on the acquisition after the companies agreed to divest St. Jude's small vessel closure device business, the final regulatory hurdle remaining for the deal to move forward. | In company news, shares of Abbott Laboratories ( ABT ) and St. Jude Medical ( STJ ) were edging higher shortly before the closing bell late Friday after the medical device companies today said they expect to close their proposed $25 billion merger next Wednesday, Jan. 4. ABT shares were up about 0.1% at $38.36 apiece this afternoon, giving back most of an earlier climb to $38.87 a share. Top Health Care Stocks | In company news, shares of Abbott Laboratories ( ABT ) and St. Jude Medical ( STJ ) were edging higher shortly before the closing bell late Friday after the medical device companies today said they expect to close their proposed $25 billion merger next Wednesday, Jan. 4. ABT shares were up about 0.1% at $38.36 apiece this afternoon, giving back most of an earlier climb to $38.87 a share. Health care stocks were narrowly mixed in recent trade, with the NYSE Health Care Index climbing about 0.1% while shares of health care companies in the S&P 500 were down nearly 0.2% as a group. | In company news, shares of Abbott Laboratories ( ABT ) and St. Jude Medical ( STJ ) were edging higher shortly before the closing bell late Friday after the medical device companies today said they expect to close their proposed $25 billion merger next Wednesday, Jan. 4. ABT shares were up about 0.1% at $38.36 apiece this afternoon, giving back most of an earlier climb to $38.87 a share. Top Health Care Stocks |
33720.0 | 2016-12-30 00:00:00 UTC | Health Care Sector Update for 12/30/2016: CO, JNJ, PFE, ABT, MRK, AMGN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-12302016-co-jnj-pfe-abt-mrk-amgn-2016-12-30 | nan | nan | Top Health-care stocks:
JNJ: flat
PFE: +0.4%
ABT: +0.1%
MRK: +0.7%
AMGN: +0.1%
Health care shares were higher in pre-market trade Friday.
In health care stocks news, Merck & Company ( MRK ) was up 0.7% after it received orphan drug designation for Keytruda as treatment of Merkel cell carcinoma from the U.S. Food and Drug Adminstration, according to the agency's website. Merkel cell carcinoma is a rare type of skin cancer, usually appearing as a flesh-colored or bluish-red nodule, often on the face, head or neck. It is also called neuroendocrine carcinoma of the skin. Keytruda or pembrolizumab is a cancer drug that works against the growth and spread of cancer cells in the body.It was previously approved by the FDA on an "accelerated" basis to treat lung cancer or head and neck cancer.
And,China Cord Blood ( CO ) was up 16% after Golden Meditech Holdings, owner of a 65.4% equity stake in the company, said it has agreed to sell its entire holding to Nanjing Yingpeng Huikang Medical Industry Investment Partnership for RMB5.76 billion ($830.4 million). Golden Meditech, an integrated healthcare firm based in China, signed a sale and purchase pact with Nanjing, a limited partnership, on Dec. 30 in relation to the disposal, which will be put to a shareholders vote for approval at an extraordinary general meeting. As part of the deal, Golden Meditech agreed to offer Nanjing a three-year performance guarantee on behalf of China Cord. In the case of an earnings shortfall, Golden Meditech will compensate Nanjing in cash an amount that will be calculated as per a formula set forth in the profit-compensation agreement.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Merkel cell carcinoma is a rare type of skin cancer, usually appearing as a flesh-colored or bluish-red nodule, often on the face, head or neck. Golden Meditech, an integrated healthcare firm based in China, signed a sale and purchase pact with Nanjing, a limited partnership, on Dec. 30 in relation to the disposal, which will be put to a shareholders vote for approval at an extraordinary general meeting. In the case of an earnings shortfall, Golden Meditech will compensate Nanjing in cash an amount that will be calculated as per a formula set forth in the profit-compensation agreement. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In health care stocks news, Merck & Company ( MRK ) was up 0.7% after it received orphan drug designation for Keytruda as treatment of Merkel cell carcinoma from the U.S. Food and Drug Adminstration, according to the agency's website. | In health care stocks news, Merck & Company ( MRK ) was up 0.7% after it received orphan drug designation for Keytruda as treatment of Merkel cell carcinoma from the U.S. Food and Drug Adminstration, according to the agency's website. Keytruda or pembrolizumab is a cancer drug that works against the growth and spread of cancer cells in the body.It was previously approved by the FDA on an "accelerated" basis to treat lung cancer or head and neck cancer. And,China Cord Blood ( CO ) was up 16% after Golden Meditech Holdings, owner of a 65.4% equity stake in the company, said it has agreed to sell its entire holding to Nanjing Yingpeng Huikang Medical Industry Investment Partnership for RMB5.76 billion ($830.4 million). | Top Health-care stocks: JNJ: flat In health care stocks news, Merck & Company ( MRK ) was up 0.7% after it received orphan drug designation for Keytruda as treatment of Merkel cell carcinoma from the U.S. Food and Drug Adminstration, according to the agency's website. Merkel cell carcinoma is a rare type of skin cancer, usually appearing as a flesh-colored or bluish-red nodule, often on the face, head or neck. |
33721.0 | 2016-12-30 00:00:00 UTC | AbbVie's Humira and Imbruvica Drive Performance in 2016 | ABT | https://www.nasdaq.com/articles/abbvies-humira-and-imbruvica-drive-performance-in-2016-2016-12-30 | nan | nan | North Chicago, IL-based AbbVie Inc.ABBV came into existence on Jan 1, 2013, after Abbott Laboratories ABT divested its pharmaceutical division. AbbVie has a presence in the rheumatoid arthritis, cancer, psoriasis, Crohn's disease, HIV, hepatitis C virus (HCV), testosterone, thyroid disease, Parkinson's disease, ulcerative colitis, and chronic kidney disease markets.
The biopharmaceutical company's share price is up 5.9% so far this year - a year fraught with challenges for the pharma/biotech sector, as it faced immense flak for steep drug prices. This compares favorably with the 6.1% fall for the Zacks categorized Large-Cap Pharma industry.
Strong Earnings Performance: AbbVie delivered positive earnings surprises in two of the three quarters of 2016, reported so far this year.
AbbVie's next year's EPS growth rate is 13.1%, while for the long term (3-5 years), its EPS growth rate is 14.54%. Next year, sales growth is expected to be 10%.
Humira Doing Well: AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, axial spondyloarthritis, pediatric Crohn's disease and chronic plaque psoriasis. Humira has been performing well and sales should be continue to be driven by growing awareness, favorable clinical data, additional indications and expansion into new markets. The company expects Humira to bring in total sales of more than $18 billion in 2020.
Imbruvica, a Key Driver: Cancer drug, Imbruvica was added to AbbVie's pipeline with the May 2015 acquisition of Pharmacyclics. AbbVie expects Imbruvica peak sales of more than $7 billion and revenues of about $5 billion in 2020. Imbruvica, currently approved for quite a few indications, has multi-billion dollar potential and AbbVie is exploring the potential to expand Imbruvica's label into solid tumors and autoimmune diseases.
Collaborations and Agreements to Strengthen Pipeline : AbbVie has been actively pursuing partnership deals and collaborations for candidates across several therapeutic areas including oncology, immunology, neuroscience, and infectious diseases. Some partners include Roche (Venclexta - oncology), Biogen Inc. BIIB (Zinbryta - multiple sclerosis), Bristol-Myers Squibb Company BMY (Empliciti - multiple myeloma), Ablynx (vobarilizumab - inflammatory diseases including rheumatoid arthritis and systemic lupus erythematosus) and Boehringer Ingelheim (risankizumab - immunology) among others.
Efforts to Strengthen Presence in Oncology and HCV: AbbVie continues to work on expanding and accelerating its presence in oncology, building upon its growing position in hematological oncology. The company acquired cancer drug maker Stemcentrx and gained a late-stage candidate, rovalpituzumab tesirine or Rova-T, which is currently in registrational studies for small cell lung cancer (SCLC). According to AbbVie, the candidate has blockbuster potential and could be launched in 2018. AbbVie intends to study the candidate for additional indications and estimates peak sales close to $5 billion.
AbbVie is also studying marketed oncology drug Venclyxto/Venclexta to expand the label to address the broader relapsed/refractory CLL patient population, expand into earlier lines of therapy, and broaden into other hematologic malignancies.
We are also positive on the company's progress with the development of interferon-free treatments for HCV.
Conclusion
Viekira faces intense pricing pressure and competition in the HCV market. Moreover, quite a few companies are working on bringing Humira biosimilars to the market. Yet, we believe AbbVie's deep pipeline and strong financial position will continue to help the company navigate tough times.
AbbVie carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Zacks' Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BRISTOL-MYERS (BMY): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
BIOGEN INC (BIIB): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | North Chicago, IL-based AbbVie Inc.ABBV came into existence on Jan 1, 2013, after Abbott Laboratories ABT divested its pharmaceutical division. Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Humira has been performing well and sales should be continue to be driven by growing awareness, favorable clinical data, additional indications and expansion into new markets. | Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. North Chicago, IL-based AbbVie Inc.ABBV came into existence on Jan 1, 2013, after Abbott Laboratories ABT divested its pharmaceutical division. Humira Doing Well: AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, axial spondyloarthritis, pediatric Crohn's disease and chronic plaque psoriasis. | Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. North Chicago, IL-based AbbVie Inc.ABBV came into existence on Jan 1, 2013, after Abbott Laboratories ABT divested its pharmaceutical division. AbbVie has a presence in the rheumatoid arthritis, cancer, psoriasis, Crohn's disease, HIV, hepatitis C virus (HCV), testosterone, thyroid disease, Parkinson's disease, ulcerative colitis, and chronic kidney disease markets. | North Chicago, IL-based AbbVie Inc.ABBV came into existence on Jan 1, 2013, after Abbott Laboratories ABT divested its pharmaceutical division. Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie intends to study the candidate for additional indications and estimates peak sales close to $5 billion. |
33722.0 | 2016-12-29 00:00:00 UTC | Abbott to Sell 2 Medical Device Businesses for St. Jude Buyout | ABT | https://www.nasdaq.com/articles/abbott-to-sell-2-medical-device-businesses-for-st.-jude-buyout-2016-12-29 | nan | nan | Abbott LaboratoriesABT has agreed to divest two medical device businesses in order to settle Federal Trade Commission (FTC) charges in relation to its proposed acquisition of St. Jude Medical STJ .
Shares of Abbott Labs underperformed the Zacks classified Large Cap Pharmaceuticals industry in the year-to-date period. In fact, the stock has lost 14.9% during this period, compared with a drop of 6.1% for the industry.
Note that the FTC had alleged that the proposed acquisition would impact the competitive scenario in the U.S. markets for vascular closure devices if the company proceeds without a remedy.
The merged entity would control more than 70% of the vascular closure device market. St. Jude has been a pioneer in the steerable sheath market for more than a decade and Abbott is looking to foray into the space. The merger would thus eliminate substantial price competition between the competitors.
Under the consent order, the companies are required to divest all rights and assets related to St. Jude's vascular closure device business and Abbott Labs' steerable sheath unit to Tokyo-based medical device maker Terumo Corporation.
Meanwhile, Abbott Labs is required to notify the FTC if it intends to acquire lesion-assessing ablation catheter assets from Advanced Cardiac Therapeutics. We note that Abbott Labs and Advanced Cardiac Therapeutics have a partnership for developing these catheters. However, following the St. Jude acquisition, if Abbott acquires the lesion-assessing ablation catheter assets from Advanced Cardiac Therapeutics, it could eliminate additional competition that would have resulted if Advanced Cardiac Therapeutics was independent.
Abbott has been facing issues related to its recent acquisitions. Earlier this month, the company filed a complaint to terminate its proposed acquisition of Alere based on a substantial deterioration in the latter's value following the merger agreement.
ABBOTT LABS Price and Consensus
ABBOTT LABS Price and Consensus | ABBOTT LABS Quote
Abbott Labs currently carries a Zacks Rank #3 (Hold).
Key Picks in the Sector
A couple of better-ranked stocks in the health care sector include Heska Corp. HSKA and Vanda Pharmaceuticals VNDA . Both of them sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Heska's earnings estimates increased from $1.13 to $1.35 for 2016 and from $1.38 to $1.53 for 2017 over the last 60 days. The company posted a positive earnings surprise in all of the four trailing quarters with an average beat of 301.64%. Its share price has increased 87.6% year to date.
Vanda's loss estimates for 2016 narrowed from 62 cents to 45 cents, while its earnings estimates for 2017 decreased from 13 cents to 9 cents over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 56.65%. Its share price has surged almost 72.4% year to date.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today's most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
ST JUDE MEDICAL (STJ): Free Stock Analysis Report
HESKA CORP (HSKA): Free Stock Analysis Report
VANDA PHARMACT (VNDA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT has agreed to divest two medical device businesses in order to settle Federal Trade Commission (FTC) charges in relation to its proposed acquisition of St. Jude Medical STJ . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report VANDA PHARMACT (VNDA): Free Stock Analysis Report To read this article on Zacks.com click here. Note that the FTC had alleged that the proposed acquisition would impact the competitive scenario in the U.S. markets for vascular closure devices if the company proceeds without a remedy. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report VANDA PHARMACT (VNDA): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT has agreed to divest two medical device businesses in order to settle Federal Trade Commission (FTC) charges in relation to its proposed acquisition of St. Jude Medical STJ . Under the consent order, the companies are required to divest all rights and assets related to St. Jude's vascular closure device business and Abbott Labs' steerable sheath unit to Tokyo-based medical device maker Terumo Corporation. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report VANDA PHARMACT (VNDA): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT has agreed to divest two medical device businesses in order to settle Federal Trade Commission (FTC) charges in relation to its proposed acquisition of St. Jude Medical STJ . Under the consent order, the companies are required to divest all rights and assets related to St. Jude's vascular closure device business and Abbott Labs' steerable sheath unit to Tokyo-based medical device maker Terumo Corporation. | Abbott LaboratoriesABT has agreed to divest two medical device businesses in order to settle Federal Trade Commission (FTC) charges in relation to its proposed acquisition of St. Jude Medical STJ . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report VANDA PHARMACT (VNDA): Free Stock Analysis Report To read this article on Zacks.com click here. Under the consent order, the companies are required to divest all rights and assets related to St. Jude's vascular closure device business and Abbott Labs' steerable sheath unit to Tokyo-based medical device maker Terumo Corporation. |
33723.0 | 2016-12-28 00:00:00 UTC | Abbott Labs to Buy St. Jude Medical for $—5 Billion | ABT | https://www.nasdaq.com/articles/abbott-labs-buy-st-jude-medical-5-billion-2016-12-28 | nan | nan | Abbott Labs ( ABT ) agreed Dec. 27 to the conditions imposed by the U.S. Federal Trade Commission for the closing of the deal that will see Abbott purchase St. Jude Medical ( STJ ) for a total consideration of $25 billion.
After Abbott Labs' agreement on the FTC's conditions, there aren't any other obstacles to Abbott's plan to purchase St. Jude Medical. Thus, the white smoke is expected anytime soon.
The conditions were imposed by the FTC in respect of certain antitrust rules. In particular, the FTC required Abbott to sell off two cardiovascular devices.
Last October the two U.S. companies agreed to sell St. Jude Medical's Angio-Seal and Femoseal, vascular closure products, and Abbott's Vado Steerable Sheath, a heart catheter, to Terumo Corp. ( TSE:4543 ) for a consideration of approximately $1.12 billion.
Once the Abbott Labs-St. Jude Medical deal is completed, the combined business will have a positive impact on both shareholders and heart patients because the new business entity will be a leader in the cardiovascular market. Thus, it will contribute more effectively to the improvement of heart patients' life quality and to the health care costs' reduction.
A positive reaction to the news from the stock market is expected in today's negotiations.
Abbott closed at $38.60 per share Dec. 27, up 18 cents, or 0.47%, from the previous trading day, with 6,633,668 shares traded on the New York Stock Exchange (NYSE) versus an average volume of 7.6 million over the last 10 trading days and an average volume of 8.6 million shares over the last three months.
The stock is more volatile than the stock market (beta = 1.48) and underperformed with 25.05% the Standard & Poor's 500 year to date.
Abbott Labs has a market capitalization of $56.83 billion and 1.47 billion shares outstanding. The percentage of shares held by insiders is 0.21% and by institutions is 70.50%.
The number of shares available for trading is 1.47 billion. The price-earnings (P/E) ratio ( TTM ) is 25.48, the EPS ( TTM ) is $1.51 per share, and the dividend yield is 2.76%.
The company has approximately $4.51 billion of cash on hand or $3.06 per share. The total debt (mrq) is $8.51 billion, and the book value per share (mrq) is $14.06.
As of today, analysts suggest buying shares of Abbott, and the average target price is $46.85 per share.
During the third quarter, First Eagle Investment ( Trades , Portfolio ), George Soros (Trades, Portfolio) and Richard Pzena (Trades, Portfolio) reduced their positions in Abbot Labs by 57.24%, 21.26% and 5.81% while Joel Greenblatt (Trades, Portfolio) sold out his position.
Ken Fisher (Trades, Portfolio) and Mario Gabelli (Trades, Portfolio) increased their positions by 0.39% and 0.07%.
Abbott is a member of the S&P 500 Dividend Aristocrats Index.
St. Jude Medical closed at $80.15 per share Dec. 27, up 32 cents or plus 0.40%, with a volume of 3,178,204 shares traded on the NYSE versus an average volume of 2.24 million traded over the last 10 trading days and an average volume of 2.41 million shares over the last three months.
As of Wednesday, 19 analysts out of a total of 20 suggest holding shares of St. Jude Medical, and the average target price is $81.96 per share.
St. Jude Medical has a market capitalization of $22.9 billion and approximately 285.72 million shares outstanding, of which 278.38 million can be traded on the NYSE, 2.43% is held by insiders, and 86.30% is held by institutions.
During the third quarter, John Rogers (Trades, Portfolio), David Dreman (Trades, Portfolio), Greenblatt and Gabelli reduced their positions in St. Jude Medical by 90.15%, 99.70%, 86.91% and 10.08%.
Leucadia National (Trades, Portfolio) and John Paulson (Trades, Portfolio) increased their positions by 166.0% and 107.69%.
Soros, Fisher and Keeley Asset Management Corp (Trades, Portfolio) sold out their positions while First Eagle Investment opened a position in St. Jude Medical and bought 545,389 shares of the company.
The company had $403 million in cash on hand and securities that can be readily converted into cash, as of the most recent quarter. The total debt amounted to $5.77 billion.
Disclosure: I have no positions in any stock mentioned in this article.
Start a free seven-day trial of Premium Membership to GuruFocus.
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ( ABT ) agreed Dec. 27 to the conditions imposed by the U.S. Federal Trade Commission for the closing of the deal that will see Abbott purchase St. Jude Medical ( STJ ) for a total consideration of $25 billion. Last October the two U.S. companies agreed to sell St. Jude Medical's Angio-Seal and Femoseal, vascular closure products, and Abbott's Vado Steerable Sheath, a heart catheter, to Terumo Corp. ( TSE:4543 ) for a consideration of approximately $1.12 billion. Thus, it will contribute more effectively to the improvement of heart patients' life quality and to the health care costs' reduction. | Abbott Labs ( ABT ) agreed Dec. 27 to the conditions imposed by the U.S. Federal Trade Commission for the closing of the deal that will see Abbott purchase St. Jude Medical ( STJ ) for a total consideration of $25 billion. During the third quarter, First Eagle Investment ( Trades , Portfolio ), George Soros (Trades, Portfolio) and Richard Pzena (Trades, Portfolio) reduced their positions in Abbot Labs by 57.24%, 21.26% and 5.81% while Joel Greenblatt (Trades, Portfolio) sold out his position. St. Jude Medical closed at $80.15 per share Dec. 27, up 32 cents or plus 0.40%, with a volume of 3,178,204 shares traded on the NYSE versus an average volume of 2.24 million traded over the last 10 trading days and an average volume of 2.41 million shares over the last three months. | Abbott Labs ( ABT ) agreed Dec. 27 to the conditions imposed by the U.S. Federal Trade Commission for the closing of the deal that will see Abbott purchase St. Jude Medical ( STJ ) for a total consideration of $25 billion. Abbott closed at $38.60 per share Dec. 27, up 18 cents, or 0.47%, from the previous trading day, with 6,633,668 shares traded on the New York Stock Exchange (NYSE) versus an average volume of 7.6 million over the last 10 trading days and an average volume of 8.6 million shares over the last three months. During the third quarter, First Eagle Investment ( Trades , Portfolio ), George Soros (Trades, Portfolio) and Richard Pzena (Trades, Portfolio) reduced their positions in Abbot Labs by 57.24%, 21.26% and 5.81% while Joel Greenblatt (Trades, Portfolio) sold out his position. | Abbott Labs ( ABT ) agreed Dec. 27 to the conditions imposed by the U.S. Federal Trade Commission for the closing of the deal that will see Abbott purchase St. Jude Medical ( STJ ) for a total consideration of $25 billion. A positive reaction to the news from the stock market is expected in today's negotiations. The number of shares available for trading is 1.47 billion. |
33724.0 | 2016-12-28 00:00:00 UTC | ABT, STJ: Abbott Laboratories Gets OK to Buy St. Jude Medical, Inc. | ABT | https://www.nasdaq.com/articles/abt-stj%3A-abbott-laboratories-gets-ok-to-buy-st.-jude-medical-inc.-2016-12-28 | nan | nan | InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips
The Federal Trade Commission (FTC) has given its approval to Abbott Laboratories' (NYSE: ABT ) deal to acquire St. Jude Medical, Inc. (NYSE: STJ ).
The FTC has certain conditions that Abbott Laboratories must fulfill to complete its acquisition of St. Jude Medical, Inc. One of these conditions is that it divests rights and assets for certain devices to Tokyo-based Terumo Corporation .
The rights and assets that it must divests are for vascular closure devices and steerable sheaths. St. Jude Medical, Inc. is the owner of the vascular closure devices and Abbott Laboratories owns the steerable sheaths. The companies must also help Terumo Corporation establish manufacturing for the devices. This condition was put in place to keep ABT from monopolizing the market for these devices.
There's also another condition that the FTC has for Abbott Laboratories' acquisition of St. Jude Medical, Inc. This is that it must inform the organization if it plans to purchase lesion-assessing ablation catheter assets from Advanced Cardiac Therapeutics .
Advanced Cardiac Therapeutics and St. Jude Medical, Inc. currently cover the market for lesion-assessing ablation catheters in the United States. This means that if Abbott Laboratories seeks to buy the lesion-assessing ablation catheters assets from Advanced Cardiac Therapeutics, it would corner the market for them in America.
There is also still a 30-day period of time before the FTC decides if it will give the final consent order for the acquisition to Abbott Laboratories. During this time, the organization will be accepting public comments. This will have the final decision taking place on Jan. 26, 2017.
More From InvestorPlace
7 Fast-Growing Consumer Stocks to Buy
The 10 Best Fidelity Funds for 2017
3 Stocks That Could Get Pounded by Tax Loss Selling
The post ABT, STJ: Abbott Laboratories Gets OK to Buy St. Jude Medical, Inc. appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips The Federal Trade Commission (FTC) has given its approval to Abbott Laboratories' (NYSE: ABT ) deal to acquire St. Jude Medical, Inc. (NYSE: STJ ). This condition was put in place to keep ABT from monopolizing the market for these devices. More From InvestorPlace 7 Fast-Growing Consumer Stocks to Buy The 10 Best Fidelity Funds for 2017 3 Stocks That Could Get Pounded by Tax Loss Selling The post ABT, STJ: Abbott Laboratories Gets OK to Buy St. Jude Medical, Inc. appeared first on InvestorPlace . | InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips The Federal Trade Commission (FTC) has given its approval to Abbott Laboratories' (NYSE: ABT ) deal to acquire St. Jude Medical, Inc. (NYSE: STJ ). This condition was put in place to keep ABT from monopolizing the market for these devices. More From InvestorPlace 7 Fast-Growing Consumer Stocks to Buy The 10 Best Fidelity Funds for 2017 3 Stocks That Could Get Pounded by Tax Loss Selling The post ABT, STJ: Abbott Laboratories Gets OK to Buy St. Jude Medical, Inc. appeared first on InvestorPlace . | InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips The Federal Trade Commission (FTC) has given its approval to Abbott Laboratories' (NYSE: ABT ) deal to acquire St. Jude Medical, Inc. (NYSE: STJ ). More From InvestorPlace 7 Fast-Growing Consumer Stocks to Buy The 10 Best Fidelity Funds for 2017 3 Stocks That Could Get Pounded by Tax Loss Selling The post ABT, STJ: Abbott Laboratories Gets OK to Buy St. Jude Medical, Inc. appeared first on InvestorPlace . This condition was put in place to keep ABT from monopolizing the market for these devices. | InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips The Federal Trade Commission (FTC) has given its approval to Abbott Laboratories' (NYSE: ABT ) deal to acquire St. Jude Medical, Inc. (NYSE: STJ ). This condition was put in place to keep ABT from monopolizing the market for these devices. More From InvestorPlace 7 Fast-Growing Consumer Stocks to Buy The 10 Best Fidelity Funds for 2017 3 Stocks That Could Get Pounded by Tax Loss Selling The post ABT, STJ: Abbott Laboratories Gets OK to Buy St. Jude Medical, Inc. appeared first on InvestorPlace . |
33725.0 | 2016-12-27 00:00:00 UTC | Top Research Reports for 27th December, 2016 | ABT | https://www.nasdaq.com/articles/top-research-reports-27th-december-2016-2016-12-27 | nan | nan | Tuesday, December 27 2016
Today's Research Daily features new research reports on 17 major stocks, including Visa (V), Reynolds (RAI), General Motors (GM) and Abbott (ABT).
Visa shares have gained 0.8% year to date, underperforming the Zacks Financial Transaction Services sector which has gained 5.6% over the same period, reflecting concerns about high client incentives, the stronger U.S. dollar, and global economic uncertainty. These issues notwithstanding, the Zacks analyst likes Visa's strategic acquisitions and alliances, technology upgrades and effective marketing efforts. The company has reaffirmed that the acquisition of Visa Europe will be accretive in 2017. In addition, the company's efforts to enhance shareholder value are impressive. (You can read the full research report on Visa here. )
Buy rated Reynolds shares have gained 21.4% year to date, outperforming the Zacks Tobacco industry. Estimates have more or less remained unchanged for Reynolds over the past 30 days. Cigarette and moist snuff pricing coupled with strong performance across both smokeable and smokeless categories continue to help the company maintain its market share. Further, investors are curious if British American will bid higher to buy Reynolds American's remaining stake, after the rejection of initial bid (You can read the full research report on Reynolds here. )
General Motors shares have gained 4.9% year to date, outperforming the Zacks Domestic Auto Manufacturers sector which has gained 2.9% over the same period. Most of the company's estimates have increased over the last sixty days. The analyst stresses that it has a positive record of earnings surprises in recent quarters. The automaker is increasing capacity investment in emerging markets to enhance its global sales. It is also focused on investment in innovative technologies and vehicles for sustained growth. However, series of recalls, scaling down or shutting manufacturing operations in some regions and challenging South American market are headwinds for the company. (You can read the full research report on General Motors here. )
Abbott shares have lost 14.5% year to date, underperforming the beleaguered Zacks Large-Cap Pharma sector which has lost 5.6% over the same period. However, the analyst likes how Abbott has been reshaping its portfolio through strategic acquisitions/divestitures for long-term growth. The St. Jude Medical buyout will complement its cardiovascular devices business. The company recently filed a complaint to terminate its proposed acquisition of Alere, based on a substantial deterioration in the latter's value following the merger agreement. Meanwhile, weakness in the nutrition business in China and sluggish growth in the Venezuelan market is concerning. (You can read the full research report on Abbott here. )
Other noteworthy reports we are featuring today include General Dynamics (GD), Coca-Cola (KO) and American Express (AXP).
Confidential: Best Trades from Zacks Research
Would you like to see a hand-picked "all-star" selection of investment ideas from the man who heads up Zacks' trading and investing services? Steve Reitmeister knows when key trades are about to be triggered and which of our experts has the hottest hand. He is now prepared to pass them along to you. Today Steve is also opening up Zacks' 7 Best Stocks for January, 2017 free of charge. From 220 Zacks Rank #1 Strong Buys, this Special tabs 7 for immediate breakout . Click to access these private picks>>
Note: If you want an email notification each time Sheraz publishes a new article, pleaseclick here>>>
Today's Must Read
Visa's (V) Technological Upgrades to Support Profitability
Reynolds (RAI) Boosts Vapor Category; Gets Merger Proposal
General Motors (GM) Fined in China on Anti-Competitive Grounds
Abbott (ABT) Continues to Reshape Business, Cancels Alere
Featured Reports
Priceline (PCLN) Appoints Glenn Fogel as its New CEO
The Zacks analyst believes that Priceline's appointment of new CEO, strength in international markets, growth opportunities in the domestic market and strong financial position are positives.
American Express' (AXP) Efforts to Grow Revenue Commendable
Per the Zacks analyst, American Express' efforts to technologically upgrade payment system and higher late fee will lead to revenue growth. Yet, loss of major client and higher provisions are concerns
Alaska Air Group (ALK) Completes Virgin America Acquisition
The completion of the merger has expanded Alaska Air's presence significantly, particularly in the West Coast. Though positive on the deal, the Zacks analyst is cautious about the integration risks.
Autoliv (ALV) Gains from acquisitions and JVs
Autoliv' planned joint venture with Volvo should boost earnings in the long run. Apart from acquisitions and JVs, it also boosts shareholder value through capital deployment and product launches.
Corning (GLW) Acquires STRAN to Foray into New Markets
The Zacks analyst believes that the STRAN acquisition will help Corning to extend its presence in the military, aerospace, oil and gas markets.
KeyCorp (KEY) Poised For Organic Growth; Raises Prime Rate
The covering analyst thinks KeyCorp remains poised for organic growth, driven by a rise in loans and deposit balances.
Dominion Resources (D) Gains from Systematic Investments
The covering analyst believes Dominion Resources remains poised to gain from its organic and inorganic growth strategies.
New Upgrades
General Dynamics (GD) Gains from Attractive Product Mix
The Zacks analyst believes that the company's diverse customer base and an attractive product mix will help maintain a steady growth momentum and drive results in the quarters ahead.
Electronic Arts' (EA) Strong Digital Business a Big Positive
The covering analyst thinks EA's strong digital business and popular game franchises will continue to boost revenues going ahead. However hit driven nature of video game industry begets caution.
TD Ameritrade (AMTD) Well Poised for Impressive Growth
The Zacks analyst thinks TD Ameritrade 's efforts to grow through acquisitions will lead to enhanced profitability. Further, improved clients trades are expected to enhance trading revenue.
New Downgrades
Philips (PHG) Hit by Healthcare Spending Cuts & Rising Costs
The Zacks analyst thinks lackluster prospects of the healthcare markets in the near-term as well as higher restructuring expenses and rising taxes have thwarted Philips' growth significantly.
Forex Headwinds Hurt Coca-Cola (KO), Emerging Markets Volatile
Negative currency impact is a major concern for Coca-Cola. Per the Zacks Analyst, weak demand in emerging and developing markets and shift in consumer tastes could weigh on the company's performance.
GE (GE) Lowers Organic Growth Guidance on Macroeconomic Woes
Owing to a highly volatile environment and sluggish growth across the globe, General Electric recorded lower 3Q Industrial segment profit and lowered its organic revenue growth guidance for 2016.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
VISA INC-A (V): Free Stock Analysis Report
REYNOLDS AMER (RAI): Free Stock Analysis Report
GENERAL MOTORS (GM): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to access these private picks>> Note: If you want an email notification each time Sheraz publishes a new article, pleaseclick here>>> Today's Must Read Visa's (V) Technological Upgrades to Support Profitability Reynolds (RAI) Boosts Vapor Category; Gets Merger Proposal General Motors (GM) Fined in China on Anti-Competitive Grounds Abbott (ABT) Continues to Reshape Business, Cancels Alere Featured Reports Priceline (PCLN) Appoints Glenn Fogel as its New CEO The Zacks analyst believes that Priceline's appointment of new CEO, strength in international markets, growth opportunities in the domestic market and strong financial position are positives. Tuesday, December 27 2016 Today's Research Daily features new research reports on 17 major stocks, including Visa (V), Reynolds (RAI), General Motors (GM) and Abbott (ABT). Click to get this free report VISA INC-A (V): Free Stock Analysis Report REYNOLDS AMER (RAI): Free Stock Analysis Report GENERAL MOTORS (GM): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. | Tuesday, December 27 2016 Today's Research Daily features new research reports on 17 major stocks, including Visa (V), Reynolds (RAI), General Motors (GM) and Abbott (ABT). Click to access these private picks>> Note: If you want an email notification each time Sheraz publishes a new article, pleaseclick here>>> Today's Must Read Visa's (V) Technological Upgrades to Support Profitability Reynolds (RAI) Boosts Vapor Category; Gets Merger Proposal General Motors (GM) Fined in China on Anti-Competitive Grounds Abbott (ABT) Continues to Reshape Business, Cancels Alere Featured Reports Priceline (PCLN) Appoints Glenn Fogel as its New CEO The Zacks analyst believes that Priceline's appointment of new CEO, strength in international markets, growth opportunities in the domestic market and strong financial position are positives. Click to get this free report VISA INC-A (V): Free Stock Analysis Report REYNOLDS AMER (RAI): Free Stock Analysis Report GENERAL MOTORS (GM): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to access these private picks>> Note: If you want an email notification each time Sheraz publishes a new article, pleaseclick here>>> Today's Must Read Visa's (V) Technological Upgrades to Support Profitability Reynolds (RAI) Boosts Vapor Category; Gets Merger Proposal General Motors (GM) Fined in China on Anti-Competitive Grounds Abbott (ABT) Continues to Reshape Business, Cancels Alere Featured Reports Priceline (PCLN) Appoints Glenn Fogel as its New CEO The Zacks analyst believes that Priceline's appointment of new CEO, strength in international markets, growth opportunities in the domestic market and strong financial position are positives. Click to get this free report VISA INC-A (V): Free Stock Analysis Report REYNOLDS AMER (RAI): Free Stock Analysis Report GENERAL MOTORS (GM): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Tuesday, December 27 2016 Today's Research Daily features new research reports on 17 major stocks, including Visa (V), Reynolds (RAI), General Motors (GM) and Abbott (ABT). | Tuesday, December 27 2016 Today's Research Daily features new research reports on 17 major stocks, including Visa (V), Reynolds (RAI), General Motors (GM) and Abbott (ABT). Click to access these private picks>> Note: If you want an email notification each time Sheraz publishes a new article, pleaseclick here>>> Today's Must Read Visa's (V) Technological Upgrades to Support Profitability Reynolds (RAI) Boosts Vapor Category; Gets Merger Proposal General Motors (GM) Fined in China on Anti-Competitive Grounds Abbott (ABT) Continues to Reshape Business, Cancels Alere Featured Reports Priceline (PCLN) Appoints Glenn Fogel as its New CEO The Zacks analyst believes that Priceline's appointment of new CEO, strength in international markets, growth opportunities in the domestic market and strong financial position are positives. Click to get this free report VISA INC-A (V): Free Stock Analysis Report REYNOLDS AMER (RAI): Free Stock Analysis Report GENERAL MOTORS (GM): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. |
33726.0 | 2016-12-24 00:00:00 UTC | Top Insider Buys of the Week | ABT | https://www.nasdaq.com/articles/top-insider-buys-week-2016-12-24 | nan | nan | The largest insider buys during the week were for Eli Lilly and Co. ( LLY ), Abbott Laboratories ( ABT ), Regency Centers Corp. ( REG ) and TiVo Corp. ( TIVO ).
Eli Lilly and Co. ( LLY ): Director Jackson P. Tai bought -,'75 shares
Tai bought -,'75 shares of LLY stock on Dec. -6 at the average price of $7-.64 per share. The price of the stock has increased by -.46% since.
Director R. David Hoover bought 5…… shares of LLY stock on Dec. -6 at the average price of $7-.85. The price of the stock has increased by -.57% since.
Chief Accounting Officer Donald A. Zakrowski sold -,……… shares of LLY stock on Dec. -6 at the average price of $7-.-' per share. The price of the stock has increased by -.-8% since.
Warren Buffett Recent Buys
Lilly and Company is an international pharmaceutical company headquartered in the U.S. The company has offices in -7 other countries and their products are sold in more than --5 countries. Lilly and Company was the first company to mass-produce penicillin, the Salk polio vaccine and insulin. The company has a market cap of $74.54 billion, and as of Dec. -' the company traded at $7'.79.
On Nov. -', Eli Lilly announced that their experimental Alzheimer's drug, solanezumab, failed in the clinical trial phase. The drug attacks amyloid plaques, a hallmark of Alzheimer's disease. After appearing to show promise in slowing the symptoms of Alzheimer's disease in July, the large scale clinical trial disproved the earlier results.
Abbott Laboratories ( ABT ): Executive Vice President Brian J. Blaser bought -5,58… shares
Blaser bought -5,58… shares of ABT stock on Dec. -… at the average price of $'8.45 per share. The price of the stock has decreased by ….-'% since.
Abbott Laboratories is an American-based international health care company. It has more than 74,……… employees in -5… countries. Some products include pharmaceutical drugs, medical devices and nutritional products. The company has a market cap of $56.54 billion, and as of Dec. -' it traded at $'8.4-.
On Dec. 7, Abbott Laboratories sought to terminate its $5.8 billion proposed acquisition of Alere Inc. The company cited the substantial loss in Alere's value since the signing of the merger agreement on Jan. '… as the main reason. Some of the business developments that Abbott Laboratories has cited include the permanent recall of a product platform and two criminal government subpoenas.
Regency Centers Corp. ( REG ): Director Bryce Blair bought -,486 shares
Blair bought -,486 shares of REG stock on Dec. -- at the average price of $66.9- per share. The price of the stock has increased by ….76% since.
Regency Centers Corporation is an American-based real estate investment trust company. It is one of the largest operators of grocery-anchored shopping centers. Around 9…% of its shopping centers are anchored by grocery chains ranking in the top three of the American market. The company has a market cap of $7.…5 billion, and as of Dec. -' it traded at $67.45.
On Dec. -, Regency Centers announced that its board of directors declared a quarterly cash dividend of 4- cents per share on the company's series 6 preferred stock. The dividend is payable on Dec. '… to shareholders of record on Dec. -'.
TiVo Corp. ( TIVO ): Director Glenn W. Welling bought 75,……… shares
Welling bought 75,……… shares of TIVO stock on Dec. -5 at the average price of $--.'… per share. The price of the stock has decreased by 5.-6% since.
TiVo is an American-based technology company that holds over 6,……… patents. It is involved in licensing intellectual property within the consumer electronics industry, including digital rights management, electronic program guide software and metadata. The company has a market cap of $-.4- billion, and as of Dec. -' it traded at $-….-….
On Nov. -8, TiVo Corporation announced that they signed licensing agreements with Netflix that allow both companies to deliver a better and smoother entertainment experience to consumers. The product agreement calls for TiVo to continue integrating Netflix into TiVo set-top boxes that are available to consumers through a select number of pay TV providers and retail stores.
For the complete list of stocks bought by company CEOs, go to: CEO Buys.
Disclosure: I do not own stock in any of the companies mentioned in the article.
Start a free seven-day trial of Premium Membership to GuruFocus.�
Read More:
Start a free seven-day trial of Premium Membership to GuruFocus�
Charles Schwab Corp ( SCHW ) President and CEO Walter W Bettinger Sold $--.9 million of Shares
About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The largest insider buys during the week were for Eli Lilly and Co. ( LLY ), Abbott Laboratories ( ABT ), Regency Centers Corp. ( REG ) and TiVo Corp. ( TIVO ). Abbott Laboratories ( ABT ): Executive Vice President Brian J. Blaser bought -5,58… shares Blaser bought -5,58… shares of ABT stock on Dec. -… at the average price of $'8.45 per share. After appearing to show promise in slowing the symptoms of Alzheimer's disease in July, the large scale clinical trial disproved the earlier results. | The largest insider buys during the week were for Eli Lilly and Co. ( LLY ), Abbott Laboratories ( ABT ), Regency Centers Corp. ( REG ) and TiVo Corp. ( TIVO ). Abbott Laboratories ( ABT ): Executive Vice President Brian J. Blaser bought -5,58… shares Blaser bought -5,58… shares of ABT stock on Dec. -… at the average price of $'8.45 per share. Eli Lilly and Co. ( LLY ): Director Jackson P. Tai bought -,'75 shares Tai bought -,'75 shares of LLY stock on Dec. -6 at the average price of $7-.64 per share. | The largest insider buys during the week were for Eli Lilly and Co. ( LLY ), Abbott Laboratories ( ABT ), Regency Centers Corp. ( REG ) and TiVo Corp. ( TIVO ). Abbott Laboratories ( ABT ): Executive Vice President Brian J. Blaser bought -5,58… shares Blaser bought -5,58… shares of ABT stock on Dec. -… at the average price of $'8.45 per share. Eli Lilly and Co. ( LLY ): Director Jackson P. Tai bought -,'75 shares Tai bought -,'75 shares of LLY stock on Dec. -6 at the average price of $7-.64 per share. | The largest insider buys during the week were for Eli Lilly and Co. ( LLY ), Abbott Laboratories ( ABT ), Regency Centers Corp. ( REG ) and TiVo Corp. ( TIVO ). Abbott Laboratories ( ABT ): Executive Vice President Brian J. Blaser bought -5,58… shares Blaser bought -5,58… shares of ABT stock on Dec. -… at the average price of $'8.45 per share. Director R. David Hoover bought 5…… shares of LLY stock on Dec. -6 at the average price of $7-.85. |
33727.0 | 2016-12-22 00:00:00 UTC | Health Care Sector Update for 12/22/2016: STJ,ABT,TKAI,OVAS | ABT | https://www.nasdaq.com/articles/health-care-sector-update-12222016-stjabttkaiovas-2016-12-22 | nan | nan | Top Health Care Stocks
JNJ +0.15%
PFE -0.26%
MRK 0.00%
ABT +0.16%
AMGN +0.08%
Health care stocks were slightly higher in late trade, with the NYSE Health Care Index climbing about 0.1% while shares of health care companies in the S&P 500 also were up 0.1% as a group.
In company news, shares of St. Jude Medical ( STJ ) firmed this afternoon following a report earlier Thursday federal regulators are ready to approve Abbott Laboratories' ( ABT ) $25 billion proposed acquisition of the rival medical device manufacturer.
The U.S. Federal Trade Commission is poised to sign off on the deal as soon as this week or next, a pair of sources with knowledge of the matter told Reuters. It was not clear what - if any - conditions the business competition agency would require of the companies although Abbott in October said it would sell some of their device operations to Ja | In company news, shares of St. Jude Medical ( STJ ) firmed this afternoon following a report earlier Thursday federal regulators are ready to approve Abbott Laboratories' ( ABT ) $25 billion proposed acquisition of the rival medical device manufacturer. The U.S. Federal Trade Commission is poised to sign off on the deal as soon as this week or next, a pair of sources with knowledge of the matter told Reuters. It was not clear what - if any - conditions the business competition agency would require of the companies although Abbott in October said it would sell some of their device operations to Ja | In company news, shares of St. Jude Medical ( STJ ) firmed this afternoon following a report earlier Thursday federal regulators are ready to approve Abbott Laboratories' ( ABT ) $25 billion proposed acquisition of the rival medical device manufacturer. Top Health Care Stocks Health care stocks were slightly higher in late trade, with the NYSE Health Care Index climbing about 0.1% while shares of health care companies in the S&P 500 also were up 0.1% as a group. | In company news, shares of St. Jude Medical ( STJ ) firmed this afternoon following a report earlier Thursday federal regulators are ready to approve Abbott Laboratories' ( ABT ) $25 billion proposed acquisition of the rival medical device manufacturer. Health care stocks were slightly higher in late trade, with the NYSE Health Care Index climbing about 0.1% while shares of health care companies in the S&P 500 also were up 0.1% as a group. The U.S. Federal Trade Commission is poised to sign off on the deal as soon as this week or next, a pair of sources with knowledge of the matter told Reuters. | In company news, shares of St. Jude Medical ( STJ ) firmed this afternoon following a report earlier Thursday federal regulators are ready to approve Abbott Laboratories' ( ABT ) $25 billion proposed acquisition of the rival medical device manufacturer. Top Health Care Stocks Health care stocks were slightly higher in late trade, with the NYSE Health Care Index climbing about 0.1% while shares of health care companies in the S&P 500 also were up 0.1% as a group. |
33728.0 | 2016-12-20 00:00:00 UTC | iShares Russell 3000 ETF Experiences Big Inflow | ABT | https://www.nasdaq.com/articles/ishares-russell-3000-etf-experiences-big-inflow-2016-12-20 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 3000 ETF (Symbol: IWV) where we have detected an approximate $404.7 million dollar inflow -- that's a 6.0% increase week over week in outstanding units (from 49,950,000 to 52,950,000). Among the largest underlying components of IWV, in trading today Celgene Corp. (Symbol: CELG) is up about 1.9%, Abbott Laboratories (Symbol: ABT) is down about 0.8%, and Thermo Fisher Scientific Inc (Symbol: TMO) is higher by about 0.5%. For a complete list of holdings, visit the IWV Holdings page » The chart below shows the one year price performance of IWV, versus its 200 day moving average:
Looking at the chart above, IWV's low point in its 52 week range is $105.62 per share, with $135.76 as the 52 week high point - that compares with a last trade of $135.40. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IWV, in trading today Celgene Corp. (Symbol: CELG) is up about 1.9%, Abbott Laboratories (Symbol: ABT) is down about 0.8%, and Thermo Fisher Scientific Inc (Symbol: TMO) is higher by about 0.5%. For a complete list of holdings, visit the IWV Holdings page » The chart below shows the one year price performance of IWV, versus its 200 day moving average: Looking at the chart above, IWV's low point in its 52 week range is $105.62 per share, with $135.76 as the 52 week high point - that compares with a last trade of $135.40. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IWV, in trading today Celgene Corp. (Symbol: CELG) is up about 1.9%, Abbott Laboratories (Symbol: ABT) is down about 0.8%, and Thermo Fisher Scientific Inc (Symbol: TMO) is higher by about 0.5%. For a complete list of holdings, visit the IWV Holdings page » The chart below shows the one year price performance of IWV, versus its 200 day moving average: Looking at the chart above, IWV's low point in its 52 week range is $105.62 per share, with $135.76 as the 52 week high point - that compares with a last trade of $135.40. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IWV, in trading today Celgene Corp. (Symbol: CELG) is up about 1.9%, Abbott Laboratories (Symbol: ABT) is down about 0.8%, and Thermo Fisher Scientific Inc (Symbol: TMO) is higher by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 3000 ETF (Symbol: IWV) where we have detected an approximate $404.7 million dollar inflow -- that's a 6.0% increase week over week in outstanding units (from 49,950,000 to 52,950,000). For a complete list of holdings, visit the IWV Holdings page » The chart below shows the one year price performance of IWV, versus its 200 day moving average: Looking at the chart above, IWV's low point in its 52 week range is $105.62 per share, with $135.76 as the 52 week high point - that compares with a last trade of $135.40. | Among the largest underlying components of IWV, in trading today Celgene Corp. (Symbol: CELG) is up about 1.9%, Abbott Laboratories (Symbol: ABT) is down about 0.8%, and Thermo Fisher Scientific Inc (Symbol: TMO) is higher by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 3000 ETF (Symbol: IWV) where we have detected an approximate $404.7 million dollar inflow -- that's a 6.0% increase week over week in outstanding units (from 49,950,000 to 52,950,000). For a complete list of holdings, visit the IWV Holdings page » The chart below shows the one year price performance of IWV, versus its 200 day moving average: Looking at the chart above, IWV's low point in its 52 week range is $105.62 per share, with $135.76 as the 52 week high point - that compares with a last trade of $135.40. |
33729.0 | 2016-12-19 00:00:00 UTC | Health Care Sector Update for 12/19/2016: BCLI, JNJ, PFE, ABT, MRK, AMGN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-12192016-bcli-jnj-pfe-abt-mrk-amgn-2016-12-19 | nan | nan | Top Health Care stocks:
JNJ: flat
PFE: +1.2%
ABT: +1.2%
MRK: -0.9%
AMGN: flat
Health care shares were mixed in pre-market trade Monday.
In health care stocks news, Pfizer ( PFE ) rose 1% after it said Monday that Nimenrix, a treatment for infants with invasive meningococcal disease, was approved by the European Commission for an expanded indication in the European Union. The decision was made based on the company's phase 3 trial of the drug, which looked at its impact on 1,000 infants from six weeks of age. The drug was approved in a two dose primary series, with the first coming from six weeks old and an interval of two months between the dosages, with a booster at 12 months.
And, Brainstorm Cell Therapeutics ( BCLI ) was up 11.2% after it said Monday it has completed an end-of-phase 2 meeting with the U.S. Food and Drug Administration and reached an agreement with the agency to proceed to a phase 3 trial for NurOwn for the treatment of Amyotrophic lateral sclerosis, or Lou Gehrig's disease. The company said the FDA has accepted the key elements of the phase 3 program to support a biologic license application for the drug. The phase 3 trial is expected to begin enrolling patients in Q2 2017. The company also plans to submit an application in Israel for a Hospital Exemption status for NurOwn. Israel's Hospital Exemption program provides for advanced therapy medicinal products to a group of patients to be agreed upon by the Israeli Minister of Health.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | And, Brainstorm Cell Therapeutics ( BCLI ) was up 11.2% after it said Monday it has completed an end-of-phase 2 meeting with the U.S. Food and Drug Administration and reached an agreement with the agency to proceed to a phase 3 trial for NurOwn for the treatment of Amyotrophic lateral sclerosis, or Lou Gehrig's disease. The company said the FDA has accepted the key elements of the phase 3 program to support a biologic license application for the drug. Israel's Hospital Exemption program provides for advanced therapy medicinal products to a group of patients to be agreed upon by the Israeli Minister of Health. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Israel's Hospital Exemption program provides for advanced therapy medicinal products to a group of patients to be agreed upon by the Israeli Minister of Health. | In health care stocks news, Pfizer ( PFE ) rose 1% after it said Monday that Nimenrix, a treatment for infants with invasive meningococcal disease, was approved by the European Commission for an expanded indication in the European Union. The decision was made based on the company's phase 3 trial of the drug, which looked at its impact on 1,000 infants from six weeks of age. And, Brainstorm Cell Therapeutics ( BCLI ) was up 11.2% after it said Monday it has completed an end-of-phase 2 meeting with the U.S. Food and Drug Administration and reached an agreement with the agency to proceed to a phase 3 trial for NurOwn for the treatment of Amyotrophic lateral sclerosis, or Lou Gehrig's disease. | The decision was made based on the company's phase 3 trial of the drug, which looked at its impact on 1,000 infants from six weeks of age. The drug was approved in a two dose primary series, with the first coming from six weeks old and an interval of two months between the dosages, with a booster at 12 months. The company also plans to submit an application in Israel for a Hospital Exemption status for NurOwn. |
33730.0 | 2016-12-15 00:00:00 UTC | The Worst Dividend Aristocrats of 2016 | ABT | https://www.nasdaq.com/articles/worst-dividend-aristocrats-2016-2016-12-15 | nan | nan | Image source: Getty Images.
The Dividend Aristocrats list of top dividend stocks is a great starting point for investors seeking more income from their stock portfolios. However, just because a stock is a Dividend Aristocrat doesn't mean that it will produce good returns every single year. Even as the broader stock market made solid gains this year, several members of this elite group of dividend stocks lost ground. Three of the worst-performing Dividend Aristocrats were Cardinal Health (NYSE: CAH) , Abbott Laboratories (NYSE: ABT) , and VF Corp. (NYSE: VFC) . Let's take a closer look at how these three stocks did and whether they can rebound in the coming year.
CAH Total Return Price data by YCharts .
Cardinal feels a bit sick
Cardinal Health has a history of raising dividend payments that goes back for decades, and that has helped it gain a solid reputation in the healthcare industry as an income stock. The company currently pays a dividend yield of about 2.5%, and its most recent dividend increase earlier this year added about 16% to its quarterly payout, bringing it to $0.4489 per share. That growth rate has persisted for several years, leading its dividend to double since early 2012.
Cardinal Health has had to overcome some tough conditions in the wholesale drug business. With many pharmaceutical companies under pressure to keep their prices lower, Cardinal hasn't been able to count on the price increases that traditionally help it keep its own margins stronger. Businesses in various other medical devices and accessories have given Cardinal some diversification, but given the uncertainty about potential healthcare reform in the wake of the presidential election, Cardinal investors are nervous.
Abbott Labs deals with industry headwinds
Elsewhere in the healthcare space, Abbott Labs has a long history of dividend increases. But for much of its 44-year history of consecutive annual dividend raises, Abbott had its pharmaceutical division helping to support its payout boosts. With the spinoff of its pharma division, the remaining Abbott is focused on medical products. Its 2.7% yield is still healthy, although its most recent dividend increase only added $0.005 to its quarterly payment of $0.265 per share.
Abbott Labs has seen ups and downs this year. In September, the company sold off its Abbott Medical Optics business to Johnson & Johnson for $4.33 billion, helping Abbott move more strongly into specialized devices. Yet planned acquisitions of St. Jude Medical and Alere could result in massive changes to Abbott Labs' business, and controversy concerning Alere's accounting issues has led Abbott to try to terminate the merger deal. Combine that with the uncertainty in healthcare more generally, and it's easy to understand why the stock hasn't kept up with its better-performing Dividend Aristocrat peers in 2016.
VF Corp. dresses down
Finally, VF Corp. has seen modest declines as well. The apparel company behind brands like The North Face, Vans, and Timberland has fallen 8% so far in 2016. Yet for 44 straight years, VF has boosted its dividend, and its most recent increase of 14% took the quarterly payout to $0.42 per share, making for a yield of 3.1%.
The environment for retail generally in 2016 has been tough, and VF hasn't been immune to the adverse trends that have worked against the company and many of its peers. Sales growth has been tepid, and inventory management challenges have weighed on earnings. Yet the company has made some smart moves to redirect its business into its most lucrative prospects going forward. Moreover, the athletic apparel space has been doing better than some other retail sub-segments, and that could help push VF higher even if the rest of the industry doesn't necessarily follow suit. Its results will rely heavily on the current holiday season, but VF has better prospects than many give it credit for.
Not every Dividend Aristocrat has done well in 2016, and investors need to remember that even great stocks can have bad years. Once some of the adverse trends that have held these three stocks back start to wane, their history of solid returns should reassert itself.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of Nov. 7, 2016
Dan Caplinger has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Three of the worst-performing Dividend Aristocrats were Cardinal Health (NYSE: CAH) , Abbott Laboratories (NYSE: ABT) , and VF Corp. (NYSE: VFC) . Combine that with the uncertainty in healthcare more generally, and it's easy to understand why the stock hasn't kept up with its better-performing Dividend Aristocrat peers in 2016. The environment for retail generally in 2016 has been tough, and VF hasn't been immune to the adverse trends that have worked against the company and many of its peers. | Three of the worst-performing Dividend Aristocrats were Cardinal Health (NYSE: CAH) , Abbott Laboratories (NYSE: ABT) , and VF Corp. (NYSE: VFC) . Cardinal feels a bit sick Cardinal Health has a history of raising dividend payments that goes back for decades, and that has helped it gain a solid reputation in the healthcare industry as an income stock. Yet for 44 straight years, VF has boosted its dividend, and its most recent increase of 14% took the quarterly payout to $0.42 per share, making for a yield of 3.1%. | Three of the worst-performing Dividend Aristocrats were Cardinal Health (NYSE: CAH) , Abbott Laboratories (NYSE: ABT) , and VF Corp. (NYSE: VFC) . The Dividend Aristocrats list of top dividend stocks is a great starting point for investors seeking more income from their stock portfolios. Even as the broader stock market made solid gains this year, several members of this elite group of dividend stocks lost ground. | Three of the worst-performing Dividend Aristocrats were Cardinal Health (NYSE: CAH) , Abbott Laboratories (NYSE: ABT) , and VF Corp. (NYSE: VFC) . Cardinal feels a bit sick Cardinal Health has a history of raising dividend payments that goes back for decades, and that has helped it gain a solid reputation in the healthcare industry as an income stock. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market. |
33731.0 | 2016-12-14 00:00:00 UTC | First Trust Nasdaq Pharmaceuticals ETF -- Insider Buying Index Registering 10.7% | ABT | https://www.nasdaq.com/articles/first-trust-nasdaq-pharmaceuticals-etf-insider-buying-index-registering-107-2016-12-14 | nan | nan | A look at the weighted underlying holdings of the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH) shows an impressive 10.7% of holdings on a weighted basis have experienced insider buying within the past six months.
Abbott Laboratories (Symbol: ABT), which makes up 8.43% of the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $155,137 worth of ABT, making it the #4 largest holding. The table below details the recent insider buying activity observed at ABT:
ABT - last trade: $39.44 - Recent Insider Buys:
And Medicines Co (Symbol: MDCO), the #16 largest holding among components of the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH), shows 2 directors and officers as recently filing Form 4's indicating purchases. The ETF holds $41,910 worth of MDCO, which represents approximately 2.28% of the ETF's total assets at last check. The recent insider buying activity observed at MDCO is detailed in the table below:
MDCO - last trade: $36.52 - Recent Insider Buys:
10 ETFs With Stocks That Insiders Are Buying »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (Symbol: ABT), which makes up 8.43% of the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at ABT: ABT - last trade: $39.44 - Recent Insider Buys: And Medicines Co (Symbol: MDCO), the #16 largest holding among components of the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH), shows 2 directors and officers as recently filing Form 4's indicating purchases. The ETF holds a total of $155,137 worth of ABT, making it the #4 largest holding. | The table below details the recent insider buying activity observed at ABT: ABT - last trade: $39.44 - Recent Insider Buys: And Medicines Co (Symbol: MDCO), the #16 largest holding among components of the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH), shows 2 directors and officers as recently filing Form 4's indicating purchases. Abbott Laboratories (Symbol: ABT), which makes up 8.43% of the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $155,137 worth of ABT, making it the #4 largest holding. | The table below details the recent insider buying activity observed at ABT: ABT - last trade: $39.44 - Recent Insider Buys: And Medicines Co (Symbol: MDCO), the #16 largest holding among components of the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH), shows 2 directors and officers as recently filing Form 4's indicating purchases. Abbott Laboratories (Symbol: ABT), which makes up 8.43% of the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $155,137 worth of ABT, making it the #4 largest holding. | Abbott Laboratories (Symbol: ABT), which makes up 8.43% of the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $155,137 worth of ABT, making it the #4 largest holding. The table below details the recent insider buying activity observed at ABT: ABT - last trade: $39.44 - Recent Insider Buys: And Medicines Co (Symbol: MDCO), the #16 largest holding among components of the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH), shows 2 directors and officers as recently filing Form 4's indicating purchases. |
33732.0 | 2016-12-09 00:00:00 UTC | Vanguard Value ETF Experiences Big Inflow | ABT | https://www.nasdaq.com/articles/vanguard-value-etf-experiences-big-inflow-2016-12-09 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Value ETF (Symbol: VTV) where we have detected an approximate $234.2 million dollar inflow -- that's a 0.9% increase week over week in outstanding units (from 282,658,182 to 285,158,182). Among the largest underlying components of VTV, in trading today Intel Corp (Symbol: INTC) is trading flat, Eli Lilly & Co. (Symbol: LLY) is up about 0.9%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.7%. For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performance of VTV, versus its 200 day moving average:
Looking at the chart above, VTV's low point in its 52 week range is $72.48 per share, with $94.00 as the 52 week high point - that compares with a last trade of $93.78. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VTV, in trading today Intel Corp (Symbol: INTC) is trading flat, Eli Lilly & Co. (Symbol: LLY) is up about 0.9%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.7%. For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performance of VTV, versus its 200 day moving average: Looking at the chart above, VTV's low point in its 52 week range is $72.48 per share, with $94.00 as the 52 week high point - that compares with a last trade of $93.78. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of VTV, in trading today Intel Corp (Symbol: INTC) is trading flat, Eli Lilly & Co. (Symbol: LLY) is up about 0.9%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.7%. For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performance of VTV, versus its 200 day moving average: Looking at the chart above, VTV's low point in its 52 week range is $72.48 per share, with $94.00 as the 52 week high point - that compares with a last trade of $93.78. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VTV, in trading today Intel Corp (Symbol: INTC) is trading flat, Eli Lilly & Co. (Symbol: LLY) is up about 0.9%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Value ETF (Symbol: VTV) where we have detected an approximate $234.2 million dollar inflow -- that's a 0.9% increase week over week in outstanding units (from 282,658,182 to 285,158,182). For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performance of VTV, versus its 200 day moving average: Looking at the chart above, VTV's low point in its 52 week range is $72.48 per share, with $94.00 as the 52 week high point - that compares with a last trade of $93.78. | Among the largest underlying components of VTV, in trading today Intel Corp (Symbol: INTC) is trading flat, Eli Lilly & Co. (Symbol: LLY) is up about 0.9%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Value ETF (Symbol: VTV) where we have detected an approximate $234.2 million dollar inflow -- that's a 0.9% increase week over week in outstanding units (from 282,658,182 to 285,158,182). For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performance of VTV, versus its 200 day moving average: Looking at the chart above, VTV's low point in its 52 week range is $72.48 per share, with $94.00 as the 52 week high point - that compares with a last trade of $93.78. |
33733.0 | 2016-12-09 00:00:00 UTC | Daily Dividend Report: GE, BMY, ABT, ECL, EIX, VTR, CAG | ABT | https://www.nasdaq.com/articles/daily-dividend-report-ge-bmy-abt-ecl-eix-vtr-cag-2016-12-09 | nan | nan | GE ( GE ) raised the Company's quarterly dividend 4%, or $0.01 per outstanding share of the Company's common stock, to $0.24 per outstanding share of the Company's common stock. The Board declared that the dividend is payable January 25, 2017 to shareowners of record at the close of business on December 27, 2016. The ex- dividend date is December 22, 2016.
Bristol-Myers Squibb Company ( BMY ) declared an increase of 2.6% percent in the company's quarterly dividend, beginning in the first quarter of 2017. The dividend increase will result in a quarterly dividend of thirty nine cents per share on the $.10 par value Common Stock of the corporation. The next quarterly dividend will be payable on February 1, 2017, to stockholders of record at the close of business on January 6, 2017.
Abbott ( ABT ) increased the company's quarterly common dividend to 26.5 cents per share from 26 cents per share. The cash dividend is payable Feb. 15, 2017, to shareholders of record at the close of business on Jan. 13, 2017.
Ecolab declared a 6 percent increase in the company's quarterly cash dividend to $0.37 per common share, to be paid Jan. 17, 2017, to shareholders of record at the close of business on Dec. 20, 2016.
Edison International ( EIX ) declared a quarterly common stock dividend of $0.5425 per share, payable on January 31, 2017, to shareholders of record on December 30, 2016. This action increases the annual dividend by $0.25 per share for the third year in a row. The 2017 annual dividend rate will be $2.17 per share, an increase of 13 percent from the current annual dividend rate of $1.92 per share.
Ventas ( VTR ) increased the Company's fourth quarter 2016 dividend by 6 percent to $0.775 per share. The dividend is payable in cash on December 30, 2016 to stockholders of record on December 20, 2016.
Conagra Brands approved its first dividend since the completion of the spin-off of its Lamb Weston business on November 9, 2016. A dividend payment of $0.20 per share of CAG common stock will be paid on March 1, 2017, to stockholders of record as of the close of business on January 30, 2017.
VIDEO: Daily Dividend Report: GE, BMY, ABT, ECL, EIX, VTR, CAG
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott ( ABT ) increased the company's quarterly common dividend to 26.5 cents per share from 26 cents per share. VIDEO: Daily Dividend Report: GE, BMY, ABT, ECL, EIX, VTR, CAG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Ecolab declared a 6 percent increase in the company's quarterly cash dividend to $0.37 per common share, to be paid Jan. 17, 2017, to shareholders of record at the close of business on Dec. 20, 2016. | VIDEO: Daily Dividend Report: GE, BMY, ABT, ECL, EIX, VTR, CAG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott ( ABT ) increased the company's quarterly common dividend to 26.5 cents per share from 26 cents per share. GE ( GE ) raised the Company's quarterly dividend 4%, or $0.01 per outstanding share of the Company's common stock, to $0.24 per outstanding share of the Company's common stock. | Abbott ( ABT ) increased the company's quarterly common dividend to 26.5 cents per share from 26 cents per share. VIDEO: Daily Dividend Report: GE, BMY, ABT, ECL, EIX, VTR, CAG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. GE ( GE ) raised the Company's quarterly dividend 4%, or $0.01 per outstanding share of the Company's common stock, to $0.24 per outstanding share of the Company's common stock. | Abbott ( ABT ) increased the company's quarterly common dividend to 26.5 cents per share from 26 cents per share. VIDEO: Daily Dividend Report: GE, BMY, ABT, ECL, EIX, VTR, CAG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The Board declared that the dividend is payable January 25, 2017 to shareowners of record at the close of business on December 27, 2016. |
33734.0 | 2016-12-08 00:00:00 UTC | Mylan (MYL) Stock Falls on Restructuring Plans, Layoffs | ABT | https://www.nasdaq.com/articles/mylan-myl-stock-falls-on-restructuring-plans-layoffs-2016-12-08 | nan | nan | In an 8-K filing, generic drug maker Mylan N.V.MYL revealed restructuring programs in certain locations in an attempt to streamline its operations globally as it focuses on the integration of acquired businesses. The company expects to cut less than 10% of its global workforce, marking the first step in a series of actions.
The company is currently straightening out the details of the cost-saving and restructuring initiatives, and will divulge more information once these plans are finalized. We note that Mylan's global workforce comprised nearly 35,000 employees as of Dec 31, 2015. This implies that the layoff could affect up to 3,500 people.
Note that Mylan has been on an acquisition spree since 2015. In Feb | In an 8-K filing, generic drug maker Mylan N.V.MYL revealed restructuring programs in certain locations in an attempt to streamline its operations globally as it focuses on the integration of acquired businesses. The company expects to cut less than 10% of its global workforce, marking the first step in a series of actions. The company is currently straightening out the details of the cost-saving and restructuring initiatives, and will divulge more information once these plans are finalized. | In an 8-K filing, generic drug maker Mylan N.V.MYL revealed restructuring programs in certain locations in an attempt to streamline its operations globally as it focuses on the integration of acquired businesses. The company expects to cut less than 10% of its global workforce, marking the first step in a series of actions. We note that Mylan's global workforce comprised nearly 35,000 employees as of Dec 31, 2015. | In an 8-K filing, generic drug maker Mylan N.V.MYL revealed restructuring programs in certain locations in an attempt to streamline its operations globally as it focuses on the integration of acquired businesses. We note that Mylan's global workforce comprised nearly 35,000 employees as of Dec 31, 2015. This implies that the layoff could affect up to 3,500 people. | In an 8-K filing, generic drug maker Mylan N.V.MYL revealed restructuring programs in certain locations in an attempt to streamline its operations globally as it focuses on the integration of acquired businesses. The company is currently straightening out the details of the cost-saving and restructuring initiatives, and will divulge more information once these plans are finalized. We note that Mylan's global workforce comprised nearly 35,000 employees as of Dec 31, 2015. |
33735.0 | 2016-12-05 00:00:00 UTC | 3 Beaten-Down Generic Drugmakers to Buy | ABT | https://www.nasdaq.com/articles/3-beaten-down-generic-drugmakers-to-buy-2016-12-05 | nan | nan | InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips
Earlier in November, some of the largest firms in the generic drugs firm space received subpoenas from the U.S. Justice Department. The Justice Department is alleging that certain generic drugmakers may have engaged in colluding to control prices they charge to hospitals, patients and others in the healthcare system.
Source: Flickr
For prospective investors, negative news events, including somewhat significant ones such as these, can prove to be buying opportunities. The stocks of many of the largest players in the space fell between 7% and 20% following news the subpoenas were sent out.
This investigation has been going on for a couple of years now, and right now it's hard to say if any of the allegations will turn out to be true. It's also unknown who might be affected and how high any fines might be for the impacted pharma stocks.
One benefit is the political changing of the guard in Washington, D.C. This could dampen the seriousness of any charges, as well as regulation to reign in what has been seen as overly rapid price increases for branded and generic drugs. The DOJ allegations also stem from certain drugs, meaning the fines could be based off only a few product segments.
The Best Investments for 2017
Below are three beaten-down firms that make generic drugs that have decent growth prospects over the long haul. More conservative investors might want to wait until any formal DOJ charges are submitted or publicized. But overall, it's difficult to see that these firms will be ruined, though any convictions or admissions of guilt would certainly necessitate removing management teams and employees that were responsible.
Generic Drugmakers to Buy: Teva (TEVA)
Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA ) are down 46% from their 52-week high of over $66 per share. Now at around $36, they now trade at an unseemly bargain-basement forward price-to-earnings ratio of 7. This is based off the average analyst earnings projection of $5.13 for 2016. This expected to jump to $5.51 per share by the end of next year.
Teva is busy digesting the acquisition of Actavis Generics, the generics arm of pharmaceutical firm Allergan Plc (NYSE: AGN ). The purchase helped boost third-quarter sales by 15% to $5.6 billion. Management expects full-year sales will grow 9% annually through 2019 to as high as $28 billion.
Earnings could grow 14% annually over this period on the back of cost savings from folding in Actavis Generics and other organic growth. Combined with solid free cash flow generation (management expects as much as $7 per share this year), Teva offers a compelling combination of growth at a very reasonable price (namely, the low P/E ratio).
Generic Drugmakers to Buy: Mylan (MYL)
Mylan NV 's (NYSE: MYL ) stock is also beaten down and 35% below its highs for the year. The forward P/E is also low, at about 7, based off the $4.75 in earnings analysts expect this year.
In addition to the collusion worries, Mylan has gotten itself into hot water and received lots of negative press through the high and increased pricing of its EpiPen, a device that can provide a shot of epinephrine and save lives during a severe allergic reaction.
This, as well as the overall negative sentiment against the industry, have sent MYL's valuation to roughly a quarter of its five-year average P/E level of 25. Earnings are expected to jump 14% by 2017 to $5.38 per share.
Mylan is also growing through acquisitions. Last year, it acquired a portfolio of both branded and generic drugs from pharma giant Abbott Laboratories (NYSE: ABT ). The purchase helped boost third quarter sales up 13% to $3.1 billion.
The 10 Biggest Stock Market Successes of 2016
Mylan's valuation is also compelling, but it has more questionable growth prospects over the long haul. Its sales are less diversified than rivals and makes it more susceptible to lower-priced competitors. It is looking to boost branded drugs and more complex ones on patent, though.
Generic Drugmakers to Buy: Novartis (NVS)
Novartis AG (ADR) (NYSE: NVS ) is one of the largest pharmaceutical companies in the world. Housed in its corporate structure is Sandoz , the second-largest generics drug provider in the world.
Sandoz sold an estimated $10 billion in generic drugs and related products last year. By investing in Novartis, analysts also gain exposure to a pharma giant boasting in excess of $50 billion in annual sales.
Novartis' forward P/E is higher than Teva and Mylan above, but it offers less exposure to the generic space. This could prove beneficial should the collusion allegations prove more serious than they look.
It also lets investors get paid for exposure to generic pharma stocks. Novartis' dividend yield is close to 4%. Free cash flow generation is robust - Novartis recently reported around $4 in cash flow generation. This leaves ample room to support the dividend and buy back stock.
As of this writing, Ryan Fuhrmann did not hold a position in any of the aforementioned securities.
The post 3 Beaten-Down Generic Drugmakers to Buy appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Last year, it acquired a portfolio of both branded and generic drugs from pharma giant Abbott Laboratories (NYSE: ABT ). The Justice Department is alleging that certain generic drugmakers may have engaged in colluding to control prices they charge to hospitals, patients and others in the healthcare system. In addition to the collusion worries, Mylan has gotten itself into hot water and received lots of negative press through the high and increased pricing of its EpiPen, a device that can provide a shot of epinephrine and save lives during a severe allergic reaction. | Last year, it acquired a portfolio of both branded and generic drugs from pharma giant Abbott Laboratories (NYSE: ABT ). Generic Drugmakers to Buy: Teva (TEVA) Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA ) are down 46% from their 52-week high of over $66 per share. Generic Drugmakers to Buy: Mylan (MYL) Mylan NV 's (NYSE: MYL ) stock is also beaten down and 35% below its highs for the year. | Last year, it acquired a portfolio of both branded and generic drugs from pharma giant Abbott Laboratories (NYSE: ABT ). InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips Earlier in November, some of the largest firms in the generic drugs firm space received subpoenas from the U.S. Justice Department. Generic Drugmakers to Buy: Teva (TEVA) Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA ) are down 46% from their 52-week high of over $66 per share. | Last year, it acquired a portfolio of both branded and generic drugs from pharma giant Abbott Laboratories (NYSE: ABT ). Combined with solid free cash flow generation (management expects as much as $7 per share this year), Teva offers a compelling combination of growth at a very reasonable price (namely, the low P/E ratio). Generic Drugmakers to Buy: Mylan (MYL) Mylan NV 's (NYSE: MYL ) stock is also beaten down and 35% below its highs for the year. |
33736.0 | 2016-12-01 00:00:00 UTC | Health Care Sector Update for 12/01/2016: JNJ, PFE, ABT, MRK, AMGN, ARDM, HTBX | ABT | https://www.nasdaq.com/articles/health-care-sector-update-12012016-jnj-pfe-abt-mrk-amgn-ardm-htbx-2016-12-01 | nan | nan | Top Health-care stocks:
JNJ: flat
PFE: +0.6%
ABT: flat
MRK: flat
AMGN: +1.3%
Health care shares were mostly unchanged in pre-market trade Thursday.
In health care stocks news, Aradigm ( ARDM ) was 63.4% higher in pre-market trade, coming off a trading halt, after the company reported mixed top-line results from two phase 3 studies of Pulmaquin for patients with non-cystic fibrosis bronchiectasis with chronic lung infections with Pseudomonas aeruginosa. In the ORBIT-3 trial, the median time to first, mild or severe pulmonary exacerbation was 221 days in the treatment group compared to 126 in the placebo group but was not statistically significant. In the key secondary efficacy endpoint, there was a 13% reduction in the frequency of PE's over the 48-week treatment period in the Pulmaquin treatment group as compared to the placebo group.
And, Heat Biologics ( HTBX ) was down 51.9% after the company reported data from its phase 2 trial of HS-410 for the treatment of non-muscle invasive bladder cancer showed that the vaccine did not generate a statistically significant difference in the primary endpoint compared with placebo.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat MRK: flat Health care shares were mostly unchanged in pre-market trade Thursday. In health care stocks news, Aradigm ( ARDM ) was 63.4% higher in pre-market trade, coming off a trading halt, after the company reported mixed top-line results from two phase 3 studies of Pulmaquin for patients with non-cystic fibrosis bronchiectasis with chronic lung infections with Pseudomonas aeruginosa. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ABT: flat MRK: flat In the ORBIT-3 trial, the median time to first, mild or severe pulmonary exacerbation was 221 days in the treatment group compared to 126 in the placebo group but was not statistically significant. | ABT: flat MRK: flat In health care stocks news, Aradigm ( ARDM ) was 63.4% higher in pre-market trade, coming off a trading halt, after the company reported mixed top-line results from two phase 3 studies of Pulmaquin for patients with non-cystic fibrosis bronchiectasis with chronic lung infections with Pseudomonas aeruginosa. In the key secondary efficacy endpoint, there was a 13% reduction in the frequency of PE's over the 48-week treatment period in the Pulmaquin treatment group as compared to the placebo group. | ABT: flat MRK: flat Top Health-care stocks: JNJ: flat Health care shares were mostly unchanged in pre-market trade Thursday. |
33737.0 | 2016-11-29 00:00:00 UTC | The Best Obamacare Stocks of 2016 | ABT | https://www.nasdaq.com/articles/best-obamacare-stocks-2016-2016-11-29 | nan | nan | Some stocks performed well in 2016 due to Obamacare, but they did so not because of successes for the health reform legislation.
Several stocks scored solid gains this year partially as a result of Obamacare. However, those gains came in large part from expected benefits from the potential unraveling of the Affordable Care Act. Here's why HealthEquity (NASDAQ: HQY) , UnitedHealth Group (NYSE: UNH) , and St. Jude Medical (NYSE: STJ) stand out as three of the best Obamacare stocks of 2016.
A leader in health savings accounts
HealthEquity is probably the biggest Obamacare stock of the year. The company's shares soared over 70% this year, with much of those gains coming after Donald Trump won the U.S. presidential election.
Trump has been adamant that Obamacare be repealed and replaced. The good news for HealthEquity is that health savings accounts (HSAs) are a big component of a potential replacement program. HealthEquity provides a technology platform where consumers can manage their tax-advantaged healthcare savings accounts.
HealthEquity is the integrated HSA platform for 25 of the 50 largest health plans in the U.S. Through its network partners, which includes health plans and employers who are customers of its services, HealthEquity has the potential to reach roughly 39% of Americans under age 65 who are candidates for individual health insurance.
The company was doing well even before the election outcome. HealthEquity's HSA membership jumped 50% year over year in its latest quarter. With HSAs likely to become an important cornerstone of healthcare proposals from the Trump Administration and the Republican congress, HealthEquity seems likely to continue to enjoy robust growth.
Exchanging losses for profits
UnitedHealth Group lost $475 million on Obamacare plans last year and expects to lose another $500 million this year. The giant health insurer's stock, however, has climbed nearly 30% in 2016. Part of the reason for this solid performance was a decision made by UnitedHealth Group to pull out of most of the Obamacare exchanges.
At the beginning of 2016, UnitedHealth participated in the Obamacare exchanges of 34 states. In 2017, the company plans to participate "in only a few individual public exchanges." The move might reduce revenue, but it will improve the insurer's bottom line.
Thanks to its other business, that bottom line already looked pretty good in 2016. During the first nine months of the year, UnitedHealth's earnings grew 16% compared to the prior year period. The company's Optum business segment, which includes pharmacy benefits management (PBM) and technology services, played a big role in that growth.
UnitedHealth Group could also benefit from the repeal of Obamacare. Removal of minimum benefits requirements could allow the company to tailor insurance plans that are more attractive to customers and are more profitable.
Taxes not so certain after all
Benjamin Franklin once said, "In this world nothing can be said to be certain, except death and taxes." For medical device maker St. Jude Medical, the certainty of not incurring Obamacare taxes helped in 2016.
In December 2015, President Obama signed a tax and spending bill that suspended the 2.3% medical device excise tax enacted with Obamacare. This bill put the tax on hold for two years. Of course, should Obamacare be repealed, the tax could be gone forever.
The biggest news for St. Jude in 2016, though, had nothing to do with Obamacare. In April, Abbott Laboratories (NYSE: ABT) announced that it would acquire St. Jude in a $25 billion deal. This sent St. Jude's stock soaring.
Despite the removal of the medical device excise tax, St. Jude Medical made less profit in the first nine months of the year than it did in the prior year period. The decline stemmed from higher spending. Abbott expects the acquisition of St. Jude will improve its bottom line beginning in 2017.
Best chances in the New Year
HealthEquity could do well yet again in 2017. HSAs seem poised to grow in popularity regardless of what happens on the political scene. With a big push for HSAs by the Trump Administration, though, HealthEquity could reap even greater rewards.
10 stocks we like better than HealthEquity
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and HealthEquity wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 7, 2016
Keith Speights has no position in any stocks mentioned. The Motley Fool recommends UnitedHealth Group. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In April, Abbott Laboratories (NYSE: ABT) announced that it would acquire St. Jude in a $25 billion deal. The good news for HealthEquity is that health savings accounts (HSAs) are a big component of a potential replacement program. With HSAs likely to become an important cornerstone of healthcare proposals from the Trump Administration and the Republican congress, HealthEquity seems likely to continue to enjoy robust growth. | In April, Abbott Laboratories (NYSE: ABT) announced that it would acquire St. Jude in a $25 billion deal. Here's why HealthEquity (NASDAQ: HQY) , UnitedHealth Group (NYSE: UNH) , and St. Jude Medical (NYSE: STJ) stand out as three of the best Obamacare stocks of 2016. Exchanging losses for profits UnitedHealth Group lost $475 million on Obamacare plans last year and expects to lose another $500 million this year. | In April, Abbott Laboratories (NYSE: ABT) announced that it would acquire St. Jude in a $25 billion deal. Here's why HealthEquity (NASDAQ: HQY) , UnitedHealth Group (NYSE: UNH) , and St. Jude Medical (NYSE: STJ) stand out as three of the best Obamacare stocks of 2016. A leader in health savings accounts HealthEquity is probably the biggest Obamacare stock of the year. | In April, Abbott Laboratories (NYSE: ABT) announced that it would acquire St. Jude in a $25 billion deal. A leader in health savings accounts HealthEquity is probably the biggest Obamacare stock of the year. UnitedHealth Group could also benefit from the repeal of Obamacare. |
33738.0 | 2016-11-16 00:00:00 UTC | 121,456 shares bought by Abbott Chairman | ABT | https://www.nasdaq.com/articles/121456-shares-bought-abbott-chairman-2016-11-16 | nan | nan | Miles White, Chairman and Chief Executive Officer at Abbott Laboratories ( ABT ), bought 121,456 shares of the company's common stock on November 10. The shares were purchased at $40.45 for a total of $4,912,895.20
InvestorsKeyhole Trade Alert
IK-> The technicals for ABT($40.13 up $0.32) are neutral with a neutral trend. Support has been around $39.20 and resistance around $40.61 Look at the January 30/35 bull-put spread for a 20-cent credit. That's a 4.2% return and the stock has to fall 12.8% to cause a problem. [InvestorsKeyhole, Various news and data services]
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Originally published on InvestorsObserver.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Miles White, Chairman and Chief Executive Officer at Abbott Laboratories ( ABT ), bought 121,456 shares of the company's common stock on November 10. The shares were purchased at $40.45 for a total of $4,912,895.20 InvestorsKeyhole Trade Alert IK-> The technicals for ABT($40.13 up $0.32) are neutral with a neutral trend. Support has been around $39.20 and resistance around $40.61 Look at the January 30/35 bull-put spread for a 20-cent credit. | Miles White, Chairman and Chief Executive Officer at Abbott Laboratories ( ABT ), bought 121,456 shares of the company's common stock on November 10. The shares were purchased at $40.45 for a total of $4,912,895.20 InvestorsKeyhole Trade Alert IK-> The technicals for ABT($40.13 up $0.32) are neutral with a neutral trend. [InvestorsKeyhole, Various news and data services] The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Miles White, Chairman and Chief Executive Officer at Abbott Laboratories ( ABT ), bought 121,456 shares of the company's common stock on November 10. The shares were purchased at $40.45 for a total of $4,912,895.20 InvestorsKeyhole Trade Alert IK-> The technicals for ABT($40.13 up $0.32) are neutral with a neutral trend. [InvestorsKeyhole, Various news and data services] The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Miles White, Chairman and Chief Executive Officer at Abbott Laboratories ( ABT ), bought 121,456 shares of the company's common stock on November 10. The shares were purchased at $40.45 for a total of $4,912,895.20 InvestorsKeyhole Trade Alert IK-> The technicals for ABT($40.13 up $0.32) are neutral with a neutral trend. Support has been around $39.20 and resistance around $40.61 Look at the January 30/35 bull-put spread for a 20-cent credit. |
33739.0 | 2016-11-15 00:00:00 UTC | Health Care Sector Update for 11/15/2016: ABT,STJ,JNJ,JNP,AGN,TSRO | ABT | https://www.nasdaq.com/articles/health-care-sector-update-11152016-abtstjjnjjnpagntsro-2016-11-15 | nan | nan | Top Health Care Stocks
JNJ -0.35%
PFE -0.68%
MRK +1.54%
ABT +1.51%
AMGN +0.29%
Health care stocks turned narrowly higher this afternoon, reversing prior declines, with the NYSE Health Care Index adding about 0.1% while shares of health care companies in the S&P 500 were down almost 0.3% as a group.
In company news, Abbott Laboratories ( ABT ) and St. Jude Medical ( STJ ) were advancing ahead of Tuesday's closing bell after the medical device giants were said to be nearing regulatory approval in Europe for their $25 billion merger proposal.
Citing a person familiar with the matter, Reuters today reported European Union regulators were ready to grant conditional approval to the deal. The companies Oct. 31 provided undisclosed concessions to the EU.
The moves follow the sale last month of St. Jude's Angio-SealT and FemosealT vascular closure products and Abbott's Vado steerable sheath to Japan-based Terumo Corp. for about $1.12 billion. Abbott also sold its eye surgury unit to Johnson & Johnson ( JNJ ) for about $4.3 billion in September.
ABT shares gained Tuesday, recently adding about 1.5% to $39.79 apiece, easing slightly from an intra-day high of $39.94 a share. STJ shares also were higher, rising almost 2% to $79.74 each in late trade, earlier climbing to a session high of $70.53 a share.
In other sector news,
(+) JNP, Receives one-time, $11 mln payment under agreement with Allergan ( AGN ) to monetize future royalty payments for U.S. sales of its Crinone gel.
(-) TSRO, Prices $236.3 mln public offering of 1.75 mln shares of its common stock at $135.00 apiece, a 9.1% discount to Monday's closing price.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In company news, Abbott Laboratories ( ABT ) and St. Jude Medical ( STJ ) were advancing ahead of Tuesday's closing bell after the medical device giants were said to be nearing regulatory approval in Europe for their $25 billion merger proposal. ABT shares gained Tuesday, recently adding about 1.5% to $39.79 apiece, easing slightly from an intra-day high of $39.94 a share. Citing a person familiar with the matter, Reuters today reported European Union regulators were ready to grant conditional approval to the deal. | In company news, Abbott Laboratories ( ABT ) and St. Jude Medical ( STJ ) were advancing ahead of Tuesday's closing bell after the medical device giants were said to be nearing regulatory approval in Europe for their $25 billion merger proposal. ABT shares gained Tuesday, recently adding about 1.5% to $39.79 apiece, easing slightly from an intra-day high of $39.94 a share. Health care stocks turned narrowly higher this afternoon, reversing prior declines, with the NYSE Health Care Index adding about 0.1% while shares of health care companies in the S&P 500 were down almost 0.3% as a group. | In company news, Abbott Laboratories ( ABT ) and St. Jude Medical ( STJ ) were advancing ahead of Tuesday's closing bell after the medical device giants were said to be nearing regulatory approval in Europe for their $25 billion merger proposal. ABT shares gained Tuesday, recently adding about 1.5% to $39.79 apiece, easing slightly from an intra-day high of $39.94 a share. Health care stocks turned narrowly higher this afternoon, reversing prior declines, with the NYSE Health Care Index adding about 0.1% while shares of health care companies in the S&P 500 were down almost 0.3% as a group. | ABT shares gained Tuesday, recently adding about 1.5% to $39.79 apiece, easing slightly from an intra-day high of $39.94 a share. In company news, Abbott Laboratories ( ABT ) and St. Jude Medical ( STJ ) were advancing ahead of Tuesday's closing bell after the medical device giants were said to be nearing regulatory approval in Europe for their $25 billion merger proposal. Top Health Care Stocks |
33740.0 | 2016-11-14 00:00:00 UTC | IHI, TMO, ABT, DHR: Large Inflows Detected at ETF | ABT | https://www.nasdaq.com/articles/ihi-tmo-abt-dhr-large-inflows-detected-etf-2016-11-14 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $60.7 million dollar inflow -- that's a 4.9% increase week over week in outstanding units (from 9,200,000 to 9,650,000). Among the largest underlying components of IHI, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is off about 0.2%, Abbott Laboratories (Symbol: ABT) is down about 0.6%, and Danaher Corp (Symbol: DHR) is lower by about 0.4%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average:
Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $146.91 as the 52 week high point - that compares with a last trade of $134.00. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IHI, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is off about 0.2%, Abbott Laboratories (Symbol: ABT) is down about 0.6%, and Danaher Corp (Symbol: DHR) is lower by about 0.4%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $146.91 as the 52 week high point - that compares with a last trade of $134.00. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IHI, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is off about 0.2%, Abbott Laboratories (Symbol: ABT) is down about 0.6%, and Danaher Corp (Symbol: DHR) is lower by about 0.4%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $146.91 as the 52 week high point - that compares with a last trade of $134.00. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IHI, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is off about 0.2%, Abbott Laboratories (Symbol: ABT) is down about 0.6%, and Danaher Corp (Symbol: DHR) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $60.7 million dollar inflow -- that's a 4.9% increase week over week in outstanding units (from 9,200,000 to 9,650,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $146.91 as the 52 week high point - that compares with a last trade of $134.00. | Among the largest underlying components of IHI, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is off about 0.2%, Abbott Laboratories (Symbol: ABT) is down about 0.6%, and Danaher Corp (Symbol: DHR) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $60.7 million dollar inflow -- that's a 4.9% increase week over week in outstanding units (from 9,200,000 to 9,650,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $146.91 as the 52 week high point - that compares with a last trade of $134.00. |
33741.0 | 2016-11-14 00:00:00 UTC | Abbott Laboratories (ABT) Chairman and CEO Miles D White Bought $‘.6 million of Shares | ABT | https://www.nasdaq.com/articles/abbott-laboratories-abt-chairman-and-ceo-miles-d-white-bought-6-million-shares-2016-11-14 | nan | nan | Chairman and CEO of Abbott Laboratories ( ABT ) Miles D White bought 89,578 shares of ABT on --/-…/-…-6 at an average price of $4….5' a share. The total cost of this purchase was $'.6 million.
Abbott Laboratories discovers, develops, manufactures and sells health care products. Its products include branded generic pharmaceuticals manufactured internationally, marketed and sold outside the United States. Abbott Laboratories has a market cap of $56.'7 billion; its shares were traded at around $'9.6- with a P/E ratio of 4'.54 and P/S ratio of -.85. The dividend yield of Abbott Laboratories stocks is -.6-%.
CEO Recent Trades:
Chairman and CEO Miles D White bought 58,-6' shares of ABT stock on --/-…/-…-6 at the average price of $4….67. The price of the stock has decreased by -.58% since.
Chairman and CEO Miles D White bought 48,76- shares of ABT stock on --/-…/-…-6 at the average price of $4….65. The price of the stock has decreased by -.5'% since.
Chairman and CEO Miles D White bought 89,578 shares of ABT stock on --/-…/-…-6 at the average price of $4….5'. The price of the stock has decreased by -.-5% since.
Chairman and CEO Miles D White bought ---,456 shares of ABT stock on --/-…/-…-6 at the average price of $4….45. The price of the stock has decreased by -.…5% since.
Chairman and CEO Miles D White bought 5-,89- shares of ABT stock on --/-…/-…-6 at the average price of $4….54. The price of the stock has decreased by -.-7% since.
Directors and Officers Recent Trades:
Director Sally E. Blount bought 5,-…… shares of ABT stock on --/…-/-…-6 at the average price of $'9.-4. The price of the stock has increased by ….97% since.
Warren Buffett Recent Buys
For the complete insider trading history of ABT, click here
.About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Chairman and CEO Miles D White bought 48,76- shares of ABT stock on --/-…/-…-6 at the average price of $4….65. Warren Buffett Recent Buys For the complete insider trading history of ABT, click here .About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. Chairman and CEO of Abbott Laboratories ( ABT ) Miles D White bought 89,578 shares of ABT on --/-…/-…-6 at an average price of $4….5' a share. | Chairman and CEO of Abbott Laboratories ( ABT ) Miles D White bought 89,578 shares of ABT on --/-…/-…-6 at an average price of $4….5' a share. CEO Recent Trades: Chairman and CEO Miles D White bought 58,-6' shares of ABT stock on --/-…/-…-6 at the average price of $4….67. Chairman and CEO Miles D White bought 48,76- shares of ABT stock on --/-…/-…-6 at the average price of $4….65. | Chairman and CEO of Abbott Laboratories ( ABT ) Miles D White bought 89,578 shares of ABT on --/-…/-…-6 at an average price of $4….5' a share. CEO Recent Trades: Chairman and CEO Miles D White bought 58,-6' shares of ABT stock on --/-…/-…-6 at the average price of $4….67. Chairman and CEO Miles D White bought 48,76- shares of ABT stock on --/-…/-…-6 at the average price of $4….65. | Chairman and CEO of Abbott Laboratories ( ABT ) Miles D White bought 89,578 shares of ABT on --/-…/-…-6 at an average price of $4….5' a share. CEO Recent Trades: Chairman and CEO Miles D White bought 58,-6' shares of ABT stock on --/-…/-…-6 at the average price of $4….67. Chairman and CEO Miles D White bought 48,76- shares of ABT stock on --/-…/-…-6 at the average price of $4….65. |
33742.0 | 2016-11-14 00:00:00 UTC | Abbott Laboratories (ABT) Chairman and CEO Miles D White Bought $—.– million of Shares | ABT | https://www.nasdaq.com/articles/abbott-laboratories-abt-chairman-and-ceo-miles-d-white-bought-million-shares-2016-11-14 | nan | nan | Chairman and CEO of Abbott Laboratories ( ABT ) Miles D White bought 5-,89- shares of ABT on --/-…/-…-6 at an average price of $4….54 a share. The total cost of this purchase was $-.- million.
Abbott Laboratories discovers, develops, manufactures and sells health care products. Its products include branded generic pharmaceuticals manufactured internationally, marketed and sold outside the United States. Abbott Laboratories has a market cap of $56.'7 billion; its shares were traded at around $'9.6- with a P/E ratio of 4'.54 and P/S ratio of -.85. The dividend yield of Abbott Laboratories stocks is -.6-%.
CEO Recent Trades:
Chairman and CEO Miles D White bought 58,-6' shares of ABT stock on --/-…/-…-6 at the average price of $4….67. The price of the stock has decreased by -.58% since.
Chairman and CEO Miles D White bought 48,76- shares of ABT stock on --/-…/-…-6 at the average price of $4….65. The price of the stock has decreased by -.5'% since.
Chairman and CEO Miles D White bought 89,578 shares of ABT stock on --/-…/-…-6 at the average price of $4….5'. The price of the stock has decreased by -.-5% since.
Chairman and CEO Miles D White bought ---,456 shares of ABT stock on --/-…/-…-6 at the average price of $4….45. The price of the stock has decreased by -.…5% since.
Chairman and CEO Miles D White bought 5-,89- shares of ABT stock on --/-…/-…-6 at the average price of $4….54. The price of the stock has decreased by -.-7% since.
Directors and Officers Recent Trades:
Director Sally E. Blount bought 5,-…… shares of ABT stock on --/…-/-…-6 at the average price of $'9.-4. The price of the stock has increased by ….97% since.
Warren Buffett Recent Buys
For the complete insider trading history of ABT, click here
.About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Chairman and CEO Miles D White bought 48,76- shares of ABT stock on --/-…/-…-6 at the average price of $4….65. Warren Buffett Recent Buys For the complete insider trading history of ABT, click here .About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. Chairman and CEO of Abbott Laboratories ( ABT ) Miles D White bought 5-,89- shares of ABT on --/-…/-…-6 at an average price of $4….54 a share. | Chairman and CEO of Abbott Laboratories ( ABT ) Miles D White bought 5-,89- shares of ABT on --/-…/-…-6 at an average price of $4….54 a share. CEO Recent Trades: Chairman and CEO Miles D White bought 58,-6' shares of ABT stock on --/-…/-…-6 at the average price of $4….67. Chairman and CEO Miles D White bought 48,76- shares of ABT stock on --/-…/-…-6 at the average price of $4….65. | Chairman and CEO of Abbott Laboratories ( ABT ) Miles D White bought 5-,89- shares of ABT on --/-…/-…-6 at an average price of $4….54 a share. CEO Recent Trades: Chairman and CEO Miles D White bought 58,-6' shares of ABT stock on --/-…/-…-6 at the average price of $4….67. Chairman and CEO Miles D White bought 48,76- shares of ABT stock on --/-…/-…-6 at the average price of $4….65. | Chairman and CEO of Abbott Laboratories ( ABT ) Miles D White bought 5-,89- shares of ABT on --/-…/-…-6 at an average price of $4….54 a share. CEO Recent Trades: Chairman and CEO Miles D White bought 58,-6' shares of ABT stock on --/-…/-…-6 at the average price of $4….67. Chairman and CEO Miles D White bought 48,76- shares of ABT stock on --/-…/-…-6 at the average price of $4….65. |
33743.0 | 2016-11-04 00:00:00 UTC | Notable ETF Outflow Detected - IHI, TMO, ABT, DHR | ABT | https://www.nasdaq.com/articles/notable-etf-outflow-detected-ihi-tmo-abt-dhr-2016-11-04 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $59.8 million dollar outflow -- that's a 4.7% decrease week over week (from 9,650,000 to 9,200,000). Among the largest underlying components of IHI, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.3%, Abbott Laboratories (Symbol: ABT) is up about 1.6%, and Danaher Corp (Symbol: DHR) is up by about 0.3%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average:
Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $146.91 as the 52 week high point - that compares with a last trade of $134.13. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IHI, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.3%, Abbott Laboratories (Symbol: ABT) is up about 1.6%, and Danaher Corp (Symbol: DHR) is up by about 0.3%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $146.91 as the 52 week high point - that compares with a last trade of $134.13. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IHI, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.3%, Abbott Laboratories (Symbol: ABT) is up about 1.6%, and Danaher Corp (Symbol: DHR) is up by about 0.3%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $146.91 as the 52 week high point - that compares with a last trade of $134.13. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of IHI, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.3%, Abbott Laboratories (Symbol: ABT) is up about 1.6%, and Danaher Corp (Symbol: DHR) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $59.8 million dollar outflow -- that's a 4.7% decrease week over week (from 9,650,000 to 9,200,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $146.91 as the 52 week high point - that compares with a last trade of $134.13. | Among the largest underlying components of IHI, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.3%, Abbott Laboratories (Symbol: ABT) is up about 1.6%, and Danaher Corp (Symbol: DHR) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $59.8 million dollar outflow -- that's a 4.7% decrease week over week (from 9,650,000 to 9,200,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $146.91 as the 52 week high point - that compares with a last trade of $134.13. |
33744.0 | 2016-11-04 00:00:00 UTC | 10.6% of FTXH Holdings Seeing Recent Insider Buys | ABT | https://www.nasdaq.com/articles/106-ftxh-holdings-seeing-recent-insider-buys-2016-11-04 | nan | nan | A look at the weighted underlying holdings of the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH) shows an impressive 10.6% of holdings on a weighted basis have experienced insider buying within the past six months.
Abbott Laboratories (Symbol: ABT), which makes up 8.55% of the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $153,507 worth of ABT, making it the #4 largest holding. The table below details the recent insider buying activity observed at ABT:
ABT - last trade: $38.38 - Recent Insider Buys:
And Medicines Co (Symbol: MDCO), the #22 largest holding among components of the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH), shows 2 directors and officers as recently filing Form 4's indicating purchases. The ETF holds $36,796 worth of MDCO, which represents approximately 2.05% of the ETF's total assets at last check. The recent insider buying activity observed at MDCO is detailed in the table below:
MDCO - last trade: $30.88 - Recent Insider Buys:
10 ETFs With Stocks That Insiders Are Buying »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (Symbol: ABT), which makes up 8.55% of the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at ABT: ABT - last trade: $38.38 - Recent Insider Buys: And Medicines Co (Symbol: MDCO), the #22 largest holding among components of the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH), shows 2 directors and officers as recently filing Form 4's indicating purchases. The ETF holds a total of $153,507 worth of ABT, making it the #4 largest holding. | The table below details the recent insider buying activity observed at ABT: ABT - last trade: $38.38 - Recent Insider Buys: And Medicines Co (Symbol: MDCO), the #22 largest holding among components of the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH), shows 2 directors and officers as recently filing Form 4's indicating purchases. Abbott Laboratories (Symbol: ABT), which makes up 8.55% of the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $153,507 worth of ABT, making it the #4 largest holding. | The table below details the recent insider buying activity observed at ABT: ABT - last trade: $38.38 - Recent Insider Buys: And Medicines Co (Symbol: MDCO), the #22 largest holding among components of the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH), shows 2 directors and officers as recently filing Form 4's indicating purchases. Abbott Laboratories (Symbol: ABT), which makes up 8.55% of the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $153,507 worth of ABT, making it the #4 largest holding. | Abbott Laboratories (Symbol: ABT), which makes up 8.55% of the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $153,507 worth of ABT, making it the #4 largest holding. The table below details the recent insider buying activity observed at ABT: ABT - last trade: $38.38 - Recent Insider Buys: And Medicines Co (Symbol: MDCO), the #22 largest holding among components of the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH), shows 2 directors and officers as recently filing Form 4's indicating purchases. |
33745.0 | 2016-11-04 00:00:00 UTC | Alere Inc. Has Been Left for Dead, With Its Shares Down 13% | ABT | https://www.nasdaq.com/articles/alere-inc-has-been-left-dead-its-shares-down-13-2016-11-04 | nan | nan | What happened
Shares of Alere (NYSE: ALR) , a provider of diagnostic tests to the medical community for disease detection, plunged as much as 16% during Friday's trading session after releasing disappointing third-quarter earnings results, and announcing that one of its business units has had its Medicare status revoked.
So what
For the quarter, Alere reported revenue of $582 million, a 4% decline from the prior-year quarter, despite 11% growth from its infectious-disease diagnostics. Revenue for the company's cardiometabolic diagnostic tests, which are its largest platform by sales, declined 10% in Q3. Net income from operations totaled $0.46 per share on an adjusted basis, which was shy of the $0.54 consensus estimate on Wall Street, with adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) of $63.6 million. Alere has now missed Wall Street's profit expectations in four of the past five quarters.
Perhaps more worrisome was the disclosure that the Centers for Medicare and Medicaid Services had revoked the Medicare status of the company's Arriva Medical unit after claims were filed for 211 deceased patients over a five-year period. According to Alere, only 47 of those claims were specifically identified, and Alere made clear that these 211 claims are out of a pool of 5.8 million claims made over that time period. Alere also suggests that it did not receive reimbursement from the aforementioned 211 claims. Alere hopes to have its Medicare status reinstated retroactively, but there are no guarantees that'll happen.
Now what
Alere has been a mess for months. After delaying the filing of its annual report by more than four months, the company finally submitted partial results in mid-July to the Securities and Exchange Commission. The delay stemmed from improper revenue recognition that went on for a period of three years. Allegedly, the company was recognizing revenue when products were shipped to distributors, rather than when they were paid for.
Making matters even stranger, Abbott Laboratories (NYSE: ABT) agreed to acquire Alere for $5.8 billion in the weeks before this accounting mess came to a head. Abbott has seemed more than willing to back out of the deal and pay Alere an associated breakup fee, but Alere's management team has clung to Abbott's offer with a viselike grip. In fact, Alere has sued Abbott to essentially force the company to complete the merger. It's really an odd situation.
Given the company's relatively weak third-quarter report, the revoking of its Medicare status for Arriva, its internal control issues with accounting, and the ongoing brouhaha between it and its potential acquirer Abbott, I believe the only true recourse here is to stay as far away from Alere as possible.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen nameTMFUltraLong, and check him out on Twitter, where he goes by the handle@TMFUltraLong.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insights makes us better investors. The Motley Fool has adisclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Making matters even stranger, Abbott Laboratories (NYSE: ABT) agreed to acquire Alere for $5.8 billion in the weeks before this accounting mess came to a head. What happened Shares of Alere (NYSE: ALR) , a provider of diagnostic tests to the medical community for disease detection, plunged as much as 16% during Friday's trading session after releasing disappointing third-quarter earnings results, and announcing that one of its business units has had its Medicare status revoked. Given the company's relatively weak third-quarter report, the revoking of its Medicare status for Arriva, its internal control issues with accounting, and the ongoing brouhaha between it and its potential acquirer Abbott, I believe the only true recourse here is to stay as far away from Alere as possible. | Making matters even stranger, Abbott Laboratories (NYSE: ABT) agreed to acquire Alere for $5.8 billion in the weeks before this accounting mess came to a head. So what For the quarter, Alere reported revenue of $582 million, a 4% decline from the prior-year quarter, despite 11% growth from its infectious-disease diagnostics. Perhaps more worrisome was the disclosure that the Centers for Medicare and Medicaid Services had revoked the Medicare status of the company's Arriva Medical unit after claims were filed for 211 deceased patients over a five-year period. | Making matters even stranger, Abbott Laboratories (NYSE: ABT) agreed to acquire Alere for $5.8 billion in the weeks before this accounting mess came to a head. According to Alere, only 47 of those claims were specifically identified, and Alere made clear that these 211 claims are out of a pool of 5.8 million claims made over that time period. Given the company's relatively weak third-quarter report, the revoking of its Medicare status for Arriva, its internal control issues with accounting, and the ongoing brouhaha between it and its potential acquirer Abbott, I believe the only true recourse here is to stay as far away from Alere as possible. | Making matters even stranger, Abbott Laboratories (NYSE: ABT) agreed to acquire Alere for $5.8 billion in the weeks before this accounting mess came to a head. What happened Shares of Alere (NYSE: ALR) , a provider of diagnostic tests to the medical community for disease detection, plunged as much as 16% during Friday's trading session after releasing disappointing third-quarter earnings results, and announcing that one of its business units has had its Medicare status revoked. Alere has now missed Wall Street's profit expectations in four of the past five quarters. |
33746.0 | 2016-10-25 00:00:00 UTC | Drug Stock Earnings to Watch on Oct 26: BIIB, MDCO & More | ABT | https://www.nasdaq.com/articles/drug-stock-earnings-to-watch-on-oct-26%3A-biib-mdco-more-2016-10-25 | nan | nan | With Q3 earnings picking up pace, approximately 116 S&P 500 members (representing 23.2% of the index's total market capitalization) have already reported quarterly results as of Oct 21. An impressive 80.2% of these companies managed to post an earnings beat, while 62.9% recorded better-than-expected sales.
As per our Earnings Preview report, earnings at the sector will improve 3.7% year over year on 7.4% higher revenues in Q3.
How has the Medical Sector Fared So Far?
As of Oct 21, 11.3% companies in the Medical sector have reported results, recording a blended beat of 50% (the percentage of companies that have beaten both earnings and revenue estimates). Overall the sector has registered 15.9% earnings growth on 8.8% higher revenues.
Healthcare giant and industry bellwether, Johnson & Johnson JNJ reported strong third-quarter results with both its earnings and revenues beating estimates. The company also raised the low end of its earnings outlook for the full year. (Read More: J&J Outshines in Q3 Earnings on Strong Pharma Sales ). A couple of other companies that released earnings last week included - Abbott Laboratories ABT and Roche Holding AG RHHBY . Abbott Labs' quarterly earnings beat the Zacks Consensus Estimate for earnings and delivered in-line revenues, while Roche's quarterly sales fell marginally short of expectations.
Let's take a sneak peek at four companies in the medical sector that are scheduled to report third-quarter results on Oct 26.
Multiple sclerosis (MS) market leader Biogen Inc.BIIB is scheduled to report results before the opening bell. Biogen has beaten expectations in all of the past four quarters, bringing the average earnings surprise to +11.39%. The company currently has an Earnings ESP of +0.20% and carries a Zacks Rank #3 (Hold), increasing its odds of beating earnings this quarter. You can see the complete list of today's Zacks #1 Rank stocks here .
The Zacks Consensus Estimate for the quarter is pegged at $4.97 per share. The first progressive multifocal leukoencephalopathy (PML)-related death of a patient using Biogen's oral MS drug, Tecfidera, brought the drug under the spotlight and during the upcomingearnings call we expect investors to focus remain on the drug's performance. (Read more: Can Biogen Keep the Earnings Streak Alive in Q3? )
Our previous article shows that Biogen was unlikely to beat earnings this quarter. However, estimates changed thereafter and we are reasonably confident about an earnings beat this season. Please check our Earnings ESP Filter that enables you find stocks that are expected to come out with earnings surprises.
BIOGEN INC Price and EPS Surprise
BIOGEN INC Price and EPS Surprise | BIOGEN INC Quote
Parsippany, NJ-based The Medicines CompanyMDCO will also be reporting before market opens. This biopharmaceutical company focuses on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. Its track record has been quite encouraging with the company delivering positive surprises thrice in the last four quarters. The average earnings surprise for the four trailing quarters is +11.16%. The combination of its Zacks Rank #3 (Hold) and Earnings ESP of +23.31 makes us reasonably positive for an earnings beat this quarter. The Zacks Consensus Estimate for the quarter is pegged at a loss of $1.33.
MEDICINES CO Price and EPS Surprise
MEDICINES CO Price and EPS Surprise | MEDICINES CO Quote
Orthopedic medicines company Anika Therapeutics Inc.ANIK is scheduled to report results after the market closes . Focused on improving the lives of patients with degenerative orthopedic diseases and traumatic conditions, the company offers innovative and differentiated therapeutic pain management solutions. Anika's track record has been impressive so far, having beaten estimates in all of the last four quarters. The company's average earnings surprise over the last four quarters is +42.19%. However, we are not sure of an earnings beat this quarter. Though the company's Zacks Rank #3 enhances the predictive power of the ESP, its 0.00% ESP makes surprise prediction difficult. The Zacks Consensus Estimate for the quarter is pegged at 47 cents. Going forward, the company's lead viscosupplementation products - Orthovisc and Monovisc - should continue acting as the main revenue drivers.
ANIKA THERAPEUT Price and EPS Surprise
ANIKA THERAPEUT Price and EPS Surprise | ANIKA THERAPEUT Quote
Molecular diagnostics company Exact Sciences Corporation 's EXAS track record has been decent so far, with the company surpassing expectations in three of the last four quarters. It has an average earnings surprise of +9.48%. The company, which specializes in cancer genetics testing and information services, currently carries a Zacks Rank #3, which when combined with its +6.98% Earnings ESP, makes us reasonably confident of a positive earnings this season. The Zacks Consensus Estimate for the quarter is pegged at a loss of 43 cents.
EXACT SCIENCES Price and EPS Surprise
EXACT SCIENCES Price and EPS Surprise | EXACT SCIENCES Quote
Confidential from Zacks
This week, Zacks researchers have named 7 other stocks that look to break out even sooner than today's Bull of the Day. You can see these time-sensitive tickers free, and access additional trades that are not available to the public. Simply click here>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
MEDICINES CO (MDCO): Free Stock Analysis Report
BIOGEN INC (BIIB): Free Stock Analysis Report
ANIKA THERAPEUT (ANIK): Free Stock Analysis Report
EXACT SCIENCES (EXAS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A couple of other companies that released earnings last week included - Abbott Laboratories ABT and Roche Holding AG RHHBY . Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MEDICINES CO (MDCO): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report EXACT SCIENCES (EXAS): Free Stock Analysis Report To read this article on Zacks.com click here. With Q3 earnings picking up pace, approximately 116 S&P 500 members (representing 23.2% of the index's total market capitalization) have already reported quarterly results as of Oct 21. | Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MEDICINES CO (MDCO): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report EXACT SCIENCES (EXAS): Free Stock Analysis Report To read this article on Zacks.com click here. A couple of other companies that released earnings last week included - Abbott Laboratories ABT and Roche Holding AG RHHBY . MEDICINES CO Price and EPS Surprise MEDICINES CO Price and EPS Surprise | MEDICINES CO Quote Orthopedic medicines company Anika Therapeutics Inc.ANIK is scheduled to report results after the market closes . | Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MEDICINES CO (MDCO): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report EXACT SCIENCES (EXAS): Free Stock Analysis Report To read this article on Zacks.com click here. A couple of other companies that released earnings last week included - Abbott Laboratories ABT and Roche Holding AG RHHBY . Abbott Labs' quarterly earnings beat the Zacks Consensus Estimate for earnings and delivered in-line revenues, while Roche's quarterly sales fell marginally short of expectations. | A couple of other companies that released earnings last week included - Abbott Laboratories ABT and Roche Holding AG RHHBY . Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MEDICINES CO (MDCO): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report EXACT SCIENCES (EXAS): Free Stock Analysis Report To read this article on Zacks.com click here. As of Oct 21, 11.3% companies in the Medical sector have reported results, recording a blended beat of 50% (the percentage of companies that have beaten both earnings and revenue estimates). |
33747.0 | 2016-10-24 00:00:00 UTC | The Zacks Analyst Blog Highlights: Abbott, Goldman Sachs, Verizon and Union Pacific | ABT | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-abbott-goldman-sachs-verizon-and-union-pacific-2016-10 | nan | nan | For Immediate Release
Chicago, IL - October 24, 2016 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Abbott (NYSE: ABT - Free Report ), Goldman Sachs (NYSE: GS - Free Report ), Verizon (NYSE: VZ - Free Report ) and Union Pacific (NYSE: UNP - Free Report ).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Friday's Analyst Blog:
Top Research Reports for Goldman Sachs, Verizon, Abbott Labs and Others
Today's Research Daily features new research reports on 16 major stocks, including Abbott (NYSE: ABT - Free Report ), Goldman Sachs (NYSE: GS - Free Report ), Verizon (NYSE: VZ - Free Report ) and Union Pacific (NYSE: UNP - Free Report ).
Goldman Sachs shares have lagged the peer group as well as the broader market, though sentiment appears to be shifting following the strong Q3 report. Estimates are going up following the Q3 strength, which has pushed the stock to Zacks Rank # 2 (Buy). The analyst likes Goldman's industry leading investment banking franchise and its approach of capitalizing on growth opportunities through strategic moves, like its new digital consumer lending platform. Further, the company is poised to benefit from its disciplined expense management and solid capital position. (You can read the full research report on Goldman Sachs here>> )
Abbott shares have struggled this year, as have most of its peers, given the political/regulatory overhang on the space. On top of the macro worries, the company is also dealing with its Chinese nutrition business that played a role in its lowered guidance for the year. In the updated research report issued today, the Zacks analyst discusses the pros & cons of investing in Abbott shares; the analyst highlights management's efforts to reshape the business portfolio through strategic acquisitions and divestitures. (You can read the full research report on Abbott here>> )
Verizon shares have lost ground lately, inline with the market's reduced interest in telecom stocks over the last couple of months; the mixed Q3 earnings report didn't help either. These issues notwithstanding, the Zacks analyst likes the manner in which Verizon is systematically diversifying its businesses into related fields. The company is set to launch super-fast 5G wireless network in 2017. Following this launch, Verizon will target the vast market opportunity of Internet of Things (IoT). (You can read the full research report on Verizon here>> )
Union Pacific shares fell sharply following the weak Q3 report and soft guidance for the current period, though the stock is still more than 15% year-to-date. Apart from coal, decreasing volumes of industrial products, automotive, chemicals and intermodal also hurt results. But the analyst likes the company's prudent cost management. The company, which achieved an operating ratio of 62.1% in the third quarter, is on track to achieve its guidance of around 60% by 2019. (You can read the full research report on Union Pacific here>> )
Confidential: Best Trades from Zacks Research
Would you like to see a hand-picked "all-star" selection of investment ideas from the man who heads up Zacks' trading and investing services? Steve Reitmeister knows when key trades are about to be triggered and which of our experts has the hottest hand. He is now prepared to pass them along to you. Today Steve is also opening up Zacks' 7 Best Stocks for October, 2016 free of charge. From 220 Zacks Rank #1 Strong Buys, this Special tabs 7 for immediate breakout. Click to access these private picks>>
You can find all of today's stock research reports here >>
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free .
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Get the full Report on ABT - FREE
Get the full Report on GS - FREE
Get the full Report on VZ - FREE
Get the full Report on UNP - FREE
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.
This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
GOLDMAN SACHS (GS): Free Stock Analysis Report
VERIZON COMM (VZ): Free Stock Analysis Report
UNION PAC CORP (UNP): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include Abbott (NYSE: ABT - Free Report ), Goldman Sachs (NYSE: GS - Free Report ), Verizon (NYSE: VZ - Free Report ) and Union Pacific (NYSE: UNP - Free Report ). Here are highlights from Friday's Analyst Blog: Top Research Reports for Goldman Sachs, Verizon, Abbott Labs and Others Today's Research Daily features new research reports on 16 major stocks, including Abbott (NYSE: ABT - Free Report ), Goldman Sachs (NYSE: GS - Free Report ), Verizon (NYSE: VZ - Free Report ) and Union Pacific (NYSE: UNP - Free Report ). Get the full Report on ABT - FREE Get the full Report on GS - FREE Get the full Report on VZ - FREE Get the full Report on UNP - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. | Stocks recently featured in the blog include Abbott (NYSE: ABT - Free Report ), Goldman Sachs (NYSE: GS - Free Report ), Verizon (NYSE: VZ - Free Report ) and Union Pacific (NYSE: UNP - Free Report ). Here are highlights from Friday's Analyst Blog: Top Research Reports for Goldman Sachs, Verizon, Abbott Labs and Others Today's Research Daily features new research reports on 16 major stocks, including Abbott (NYSE: ABT - Free Report ), Goldman Sachs (NYSE: GS - Free Report ), Verizon (NYSE: VZ - Free Report ) and Union Pacific (NYSE: UNP - Free Report ). Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report GOLDMAN SACHS (GS): Free Stock Analysis Report VERIZON COMM (VZ): Free Stock Analysis Report UNION PAC CORP (UNP): Free Stock Analysis Report To read this article on Zacks.com click here. | Here are highlights from Friday's Analyst Blog: Top Research Reports for Goldman Sachs, Verizon, Abbott Labs and Others Today's Research Daily features new research reports on 16 major stocks, including Abbott (NYSE: ABT - Free Report ), Goldman Sachs (NYSE: GS - Free Report ), Verizon (NYSE: VZ - Free Report ) and Union Pacific (NYSE: UNP - Free Report ). Get the full Report on ABT - FREE Get the full Report on GS - FREE Get the full Report on VZ - FREE Get the full Report on UNP - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report GOLDMAN SACHS (GS): Free Stock Analysis Report VERIZON COMM (VZ): Free Stock Analysis Report UNION PAC CORP (UNP): Free Stock Analysis Report To read this article on Zacks.com click here. | Stocks recently featured in the blog include Abbott (NYSE: ABT - Free Report ), Goldman Sachs (NYSE: GS - Free Report ), Verizon (NYSE: VZ - Free Report ) and Union Pacific (NYSE: UNP - Free Report ). Here are highlights from Friday's Analyst Blog: Top Research Reports for Goldman Sachs, Verizon, Abbott Labs and Others Today's Research Daily features new research reports on 16 major stocks, including Abbott (NYSE: ABT - Free Report ), Goldman Sachs (NYSE: GS - Free Report ), Verizon (NYSE: VZ - Free Report ) and Union Pacific (NYSE: UNP - Free Report ). Get the full Report on ABT - FREE Get the full Report on GS - FREE Get the full Report on VZ - FREE Get the full Report on UNP - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. |
33748.0 | 2016-10-24 00:00:00 UTC | Drug Stocks Q3 Earnings Roster for Oct 25: MRK, LLY & More | ABT | https://www.nasdaq.com/articles/drug-stocks-q3-earnings-roster-for-oct-25%3A-mrk-lly-more-2016-10-24 | nan | nan | The third-quarter earnings season has picked up pace with 116 S&P 500 members (as of Oct 21), accounting for 23.2% of the index's total market capitalization, having reported results, according to the Earnings Preview report.
While total earnings for these 116 index members were up 3.3% from the year-ago quarter, revenues were up 1.8% year over year. The beat ratio was 80.2% for earnings and 62.9% for revenues.
Notably, the third quarter is on track to be the first quarter to show positive earnings growth after five consecutive quarters of earnings decline for the S&P 500 index. The picture is expected to steadily improve hereafter.
In the healthcare sector, Johnson & JohnsonJNJ was the first major company to report this season. Third-quarter results were strong with the company beating on all fronts and raising the lower end of the earnings outlook for the year. J&J's Pharma segment continued to perform well despite challenges like generic competition for a few products, potential biosimilar competition and lower HCV revenues. Abbott LaboratoriesABT , which also reported last week, beat the Zacks Consensus Estimate for earnings while delivering in-line earnings.
Four more companies from the healthcare sector are set to report their third-quarter results on Oct 25. Let's see how things are shaping up for their respective announcements.
Merck & Co., Inc. MRK
Merck posted a positive surprise of 1.09% in the last reported quarter. The company surpassed estimates in all the past four quarters, resulting in an average positive surprise of 3.37%.
The company has an Earnings ESP of 0.00% and a Zacks Rank #2 (Buy). The Zacks Consensus Estimate for the quarter is pegged at 98 cents.
MERCK & CO INC Price and EPS Surprise
MERCK & CO INC Price and EPS Surprise | MERCK & CO INC Quote
Merck's new products, especially Keytruda (cancer) and Zepatier (HCV) have been doing well with the trend expected to continue. However, the company will continue to face headwinds in the form of genericization as well as heightened competition. (Read More: Can Merck Keep the Earnings Streak Alive in Q3? ).
Eli Lilly and Company LLY
Last quarter, Lilly delivered a positive earnings surprise of 1.18%. The company surpassed estimates in three of the trailing four quarters, with an average positive surprise of 4.31%.
LILLY ELI & CO Price and EPS Surprise
LILLY ELI & CO Price and EPS Surprise | LILLY ELI & CO Quote
The Zacks Consensus Estimate for the quarter is pegged at 96 cents per share. The company has an Earnings ESP of 0.00% and a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here .
New products like Trulicity and Cyramza as well as strong performance by the company's older products like Trajenta, Cialis, Forteo, Humalog Strattera and Erbitux drove significant top-line growth in the second quarter of 2016. Also, the animal health business and the diabetes franchise did reasonably well in the quarter. We expect the trend to continue in the third quarter as well. However, sales of Alimta, Cymbalta and Zyprexa are likely to decline further. (Read More: Can Eli Lilly Pull a Surprise this Earnings Season? ).
Novartis AG NVS
In the last reported quarter, Novartis recorded a positive earnings surprise of 3.39%. Overall, Novartis posted an average negative earnings surprise of 2.38% in the four trailing quarters.
NOVARTIS AG-ADR Price and EPS Surprise
NOVARTIS AG-ADR Price and EPS Surprise | NOVARTIS AG-ADR Quote
The Swiss drugmaker has an Earnings ESP of +2.54% and a Zacks Rank #3. The Zacks Consensus Estimate for the quarter is pegged at $1.18 per share.
Innovative Medicines is expected to continue being impacted by generic competition due to the genericization of Gleevec/Glivec in the U.S. The company's ophthalmologic division, Alcon, continues to face challenges due to a slowdown in cataract equipment placements and weak sales of intraocular lenses. Going forward, we expect these factors to dampen sales at the segment. On the other hand, Novartis' generic arm, Sandoz, in its efforts to strengthen the biosimilars portfolio and pipeline, should offset weakness in Alcon. (Read More: Novartis Q3 Earnings: Stock to Beat Estimates Again? ).
Vertex Pharmaceuticals Incorporated VRTX
Vertex's track record is mixed with the company delivering positive surprises in three of the last four quarters and missing the expectation in one. The average earnings surprise over the last four quarters is a negative 63.54%. In the last reported quarter, Vertex recorded a positive earnings surprise of 50.0%.
VERTEX PHARM Price and EPS Surprise
VERTEX PHARM Price and EPS Surprise | VERTEX PHARM Quote
The company has an Earnings ESP of -66.67% and a Zacks Rank #5. The Zacks Consensus Estimate for the quarter is pegged at a loss of 6 cents per share.
Kalydeco's revenues should continue growing reflecting the continued increase in the number of patients initiating treatment with Kalydeco globally. However, Orkambi sales growth has been slower than expected. (Read More: Vertex Q3 Earnings: What's in Store for the Stock? )
Looking for Ideas with Even Greater Upside?
Today's investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more. Click here for a peek at this private information >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
LILLY ELI & CO (LLY): Free Stock Analysis Report
NOVARTIS AG-ADR (NVS): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
MERCK & CO INC (MRK): Free Stock Analysis Report
VERTEX PHARM (VRTX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT , which also reported last week, beat the Zacks Consensus Estimate for earnings while delivering in-line earnings. Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report To read this article on Zacks.com click here. Third-quarter results were strong with the company beating on all fronts and raising the lower end of the earnings outlook for the year. | Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT , which also reported last week, beat the Zacks Consensus Estimate for earnings while delivering in-line earnings. LILLY ELI & CO Price and EPS Surprise LILLY ELI & CO Price and EPS Surprise | LILLY ELI & CO Quote The Zacks Consensus Estimate for the quarter is pegged at 96 cents per share. | Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT , which also reported last week, beat the Zacks Consensus Estimate for earnings while delivering in-line earnings. LILLY ELI & CO Price and EPS Surprise LILLY ELI & CO Price and EPS Surprise | LILLY ELI & CO Quote The Zacks Consensus Estimate for the quarter is pegged at 96 cents per share. | Abbott LaboratoriesABT , which also reported last week, beat the Zacks Consensus Estimate for earnings while delivering in-line earnings. Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report To read this article on Zacks.com click here. J&J's Pharma segment continued to perform well despite challenges like generic competition for a few products, potential biosimilar competition and lower HCV revenues. |
33749.0 | 2016-10-20 00:00:00 UTC | Dark Cloud And Silver Linings: Abbott Q3'16 Earnings | ABT | https://www.nasdaq.com/articles/dark-cloud-and-silver-linings-abbott-q316-earnings-2016-10-20 | nan | nan | Abbott Labs ( ABT ) reported its Q3'16 earnings on October 19th. The results for the quarter are in some ways a prologue for the next few quarters. The company reported weakness in nutrition business, Abbott's largest segment. Going forward we expect growth in the segment to remain muted in coming quarters as well. However, Established Pharmaceuticals, Diagnostics and Medical Devices segments continued to post decent growth. The trends in these segments are likely to continue. We expect the company to grow at a low to mid-single digit rate, on account of the existing portfolio of products, over the next couple of quarters.
Our price estimate of $47.50 for Abbott is under update
What To Expect Going Forward?
Over the next quarter and in fiscal 2017 we expect Abbott to report weak performance in nutrition business, due to the weaker performance of its pediatric nutrition business. The company appears to be losing market share in China to local label bands. Another, reason is the shift in sales channel to online which Abbott failed to realize sooner. If the company loses 0.5% market share annually over the next 5 years, it could imply close to 15% downside to our current price estimate. However, we expect that Abbott will be able to stabilize its position over the next fiscal year. Although China is a big market for Abbott accounting for close to 10% of nutrition segment's revenue, the company's business is diversified geographically. This will help it stabilize challenges in China.
Furthermore, we expect Abbott to post strong performance in diagnostic business on account of new innovative products such as Alinity and i-stat. The segment reported over 5% operational growth for Q3 on year-over-year basis.
Also, diabetes care segment posted growth of over 12% year over year for Q3 on a constant currency basis, on account of the performance of FreeStyle Libre in European market. The company recently got FDA approval for a pro-version in the U.S. and expects the approval for consumer version by early 2017. Once approved in the U.S., the device has the potential to become a strong franchise for Abbott. Furthermore, going into Q4 we expect the vascular segment to post mid-single digit growth which would be led by MitraClip, Absorb and Supera.
We expect the branded pharma business to continue to post strong results. The company is in leading position in growth oriented emerging markets. The division makes up for over 20% to our estimate of Abbott's valuation.
Brief Summary of Q3 Results
Revenue and adjusted (non-GAAP) EPS growth were on the expected lines. The company reported quarterly sales of $5.3 billion, implying a growth of 4% year over year on operational basis (excluding currency effect). Non-GAAP EPS for the quarter were $0.59, GAAP EPS was negative $0.22 mainly due to the re-valuation of its in equity position in Mylan. Adjusted operating margins improved by 150 basis points year on year on account of lower SG&A expense. Furthermore, the company announced the sale of its medical optics business to Johnson & Johnson for over $4.3 billion in cash (Read: Making Sense Of Abbott's Sale Of Its Optics Business ). Also, the management said that St. Jude's acquisition is on track to close but the outcome of there Alere acquisition is still uncertain.
We care deeply about your inputs, and want to ensure our content is increasingly more useful to you. Please let us know what/why you liked or disliked in this article, and importantly alternative analyses you want to see. Drop us a line atcontent@trefis.com
See the links below for more information and analysis about Abbott:
Leverage to be challenge challenge for Abbott once the deal is done, Part-1
Leverage to be challenge challenge for Abbott once the deal is done, Part-2
Why is Abbott acquiring St. Jude?
Abbott's Catch 22 With Alere
Making Sense Of Abbott's Sale Of Its Optics Business
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ( ABT ) reported its Q3'16 earnings on October 19th. We expect the company to grow at a low to mid-single digit rate, on account of the existing portfolio of products, over the next couple of quarters. Although China is a big market for Abbott accounting for close to 10% of nutrition segment's revenue, the company's business is diversified geographically. | Abbott Labs ( ABT ) reported its Q3'16 earnings on October 19th. The company reported quarterly sales of $5.3 billion, implying a growth of 4% year over year on operational basis (excluding currency effect). Furthermore, the company announced the sale of its medical optics business to Johnson & Johnson for over $4.3 billion in cash (Read: Making Sense Of Abbott's Sale Of Its Optics Business ). | Abbott Labs ( ABT ) reported its Q3'16 earnings on October 19th. Over the next quarter and in fiscal 2017 we expect Abbott to report weak performance in nutrition business, due to the weaker performance of its pediatric nutrition business. Drop us a line atcontent@trefis.com See the links below for more information and analysis about Abbott: Leverage to be challenge challenge for Abbott once the deal is done, Part-1 Leverage to be challenge challenge for Abbott once the deal is done, Part-2 Why is Abbott acquiring St. Jude? | Abbott Labs ( ABT ) reported its Q3'16 earnings on October 19th. However, we expect that Abbott will be able to stabilize its position over the next fiscal year. Although China is a big market for Abbott accounting for close to 10% of nutrition segment's revenue, the company's business is diversified geographically. |
33750.0 | 2016-10-19 00:00:00 UTC | Q3 Earnings Continue, Housing and Permits Mixed | ABT | https://www.nasdaq.com/articles/q3-earnings-continue-housing-and-permits-mixed-2016-10-19 | nan | nan | Wednesday, October 19, 2016
Before the bell halfway through the week, we saw results for September Housing Starts and Permits come in, with mixed results. Seasonally adjusted, annualized housing starts of 1.047 million was the lowest tally in a year and a half, down 9% from the previous month. However, Building Permits - a forward indicator of future housing starts - rose 6.3% to 1.22 million.
We also have a plethora of new Q3 earnings data:
Morgan Stanley MS far surpassed expectations with 81 cents per share (64 cents was the estimate) on $8.9 billion in revenues (as compared to $8.24 billion expected). It's the fourth straight beat for Morgan Stanley on the bottom line, on record sales in Wealth Management as well as stronger Trading revenues, as we saw with Goldman Sachs' stellar results yesterday.
Morgan's earnings shot up 2.3x the year-ago results of 34 cents per share. Stocks for the investment major are up more than 1% in the pre-market.
U.S. Bancorp USB also reported its Q3 earnings this morning, meeting the 84 cents per share expected while topping revenue estimates of $5.34 billion to $5.39 billion, up more than 4 1/2% year over year.
Suburban Chicago-based Abbott Labs ABT beat Q3 earnings estimates by a penny to 58 cents per share, an 8% gain year over year, while bringing sales in-line with $5.3 billion for the quarter.
Halliburton HAL results were mixed, swinging to a profit of 1 cent per share when -$0.07 was expected for the quarter, though $3.84 billion in sales missed the $3.9 billion in the Zacks Consensus Estimate. Even still HAL shares are up more than 1% in early trading; the company is up nearly 40% year to date.
Finally, Seagate Technology STX missed estimates on both top and bottom lines for its Q3. Earnings of 22 cents per share were well below the 38 cents expected, on revenues of $2.595 billion which narrowly missed the $2.603 billion the Zacks consensus had anticipated. Shares are down 1.5% ahead of the opening bell.
Mark Vickery
Senior Editor
Click here to follow this author>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
SEAGATE TECH (STX): Free Stock Analysis Report
US BANCORP (USB): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
MORGAN STANLEY (MS): Free Stock Analysis Report
HALLIBURTON CO (HAL): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Suburban Chicago-based Abbott Labs ABT beat Q3 earnings estimates by a penny to 58 cents per share, an 8% gain year over year, while bringing sales in-line with $5.3 billion for the quarter. Click to get this free report SEAGATE TECH (STX): Free Stock Analysis Report US BANCORP (USB): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MORGAN STANLEY (MS): Free Stock Analysis Report HALLIBURTON CO (HAL): Free Stock Analysis Report To read this article on Zacks.com click here. Seasonally adjusted, annualized housing starts of 1.047 million was the lowest tally in a year and a half, down 9% from the previous month. | Suburban Chicago-based Abbott Labs ABT beat Q3 earnings estimates by a penny to 58 cents per share, an 8% gain year over year, while bringing sales in-line with $5.3 billion for the quarter. Click to get this free report SEAGATE TECH (STX): Free Stock Analysis Report US BANCORP (USB): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MORGAN STANLEY (MS): Free Stock Analysis Report HALLIBURTON CO (HAL): Free Stock Analysis Report To read this article on Zacks.com click here. We also have a plethora of new Q3 earnings data: Morgan Stanley MS far surpassed expectations with 81 cents per share (64 cents was the estimate) on $8.9 billion in revenues (as compared to $8.24 billion expected). | Click to get this free report SEAGATE TECH (STX): Free Stock Analysis Report US BANCORP (USB): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MORGAN STANLEY (MS): Free Stock Analysis Report HALLIBURTON CO (HAL): Free Stock Analysis Report To read this article on Zacks.com click here. Suburban Chicago-based Abbott Labs ABT beat Q3 earnings estimates by a penny to 58 cents per share, an 8% gain year over year, while bringing sales in-line with $5.3 billion for the quarter. We also have a plethora of new Q3 earnings data: Morgan Stanley MS far surpassed expectations with 81 cents per share (64 cents was the estimate) on $8.9 billion in revenues (as compared to $8.24 billion expected). | Suburban Chicago-based Abbott Labs ABT beat Q3 earnings estimates by a penny to 58 cents per share, an 8% gain year over year, while bringing sales in-line with $5.3 billion for the quarter. Click to get this free report SEAGATE TECH (STX): Free Stock Analysis Report US BANCORP (USB): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MORGAN STANLEY (MS): Free Stock Analysis Report HALLIBURTON CO (HAL): Free Stock Analysis Report To read this article on Zacks.com click here. Wednesday, October 19, 2016 Before the bell halfway through the week, we saw results for September Housing Starts and Permits come in, with mixed results. |
33751.0 | 2016-10-19 00:00:00 UTC | Abbott Labs (ABT) Beats on Q3 Earnings, Narrows 2016 View | ABT | https://www.nasdaq.com/articles/abbott-labs-abt-beats-on-q3-earnings-narrows-2016-view-2016-10-19 | nan | nan | Abbott LaboratoriesABT reported third-quarter 2016 earnings of 59 cents per share, higher than both the Zacks Consensus Estimate of 58 cents and the year-ago figure of 54 cents.
FindTheCompany | Graphiq
Quarterly sales came in at $5.3 billion, up 2.9% year over year on a reported basis, and in line with the Zacks Consensus Estimate. The top line was, however, impacted by unfavorable foreign exchange movement of 1.1%.
Quarter in Detail
Abbott Labs operates through four segments - Established Pharmaceuticals Division (EPD), Medical Devices, Nutrition and Diagnostics.
EPD sales were up 5.3% to $1.01 billion, including a negative impact of 3.7% due to currency fluctuations. Sales in key emerging markets increased 7% on a reported basis driven by solid growth in India as well as strong demand in several countries of Latin America due to commercial initiatives and locally relevant portfolio expansion.
The Medical Devices business generated sales of $1.3 billion, up 6.4% year over year. Vascular product sales were up 5.2% on the back of double-digit growth in MitraClip. Diabetes Care sales increased 11.5% driven by continued consumer uptake of FreeStyle Libre. Sales of Medical Optics were up 4.4% backed by continued market uptake of cataract products in the premium intraocular lens segment. During the quarter, Abbott received FDA approval for Tecnis Symfony intraocular lenses.
Nutrition sales were decreased 2% year over year to $1.8 billion. Pediatric Nutrition sales decreased 4% on a reported basis. Adult Nutrition sales increased 1.4% on an operational basis led by a strong performance of Ensure.
Diagnostics sales increased 5% year over year to $1.2 billion. Core Laboratory sales and Point-of-Care Diagnostics sales were each up 5.6%. Molecular Diagnostics sales were down 0.8% as growth in the infectious disease testing business was partially offset by the planned scale-down of the genetics business.
2016 Outlook
Abbott Labs has raised the mid-point and narrowed its guidance for earnings. The company now expects earnings in the range of to $2.19 - $2.21 per share. The current Zacks Consensus Estimate stands at $2.20.
ABBOTT LABS Price
ABBOTT LABS Price | ABBOTT LABS Quote
Our Take
Abbott Labs' third-quarter results were better than expected due to strong performance of the EPD and Medical Devices segments. Going ahead, the FDA approval of Absorb, the only fully dissolving heart stent, and Tecnis Symfony intraocular lenses for the treatment of cataracts should fuel the company's topline.
The company also stands to benefit from its upcoming acquisition of St. Jude Medical Inc. STJ , which will offer it an industry leading pipeline across cardiovascular, neuromodulation, diabetes and vision care. Abbott Labs entered into a definitive agreement to acquire St. Jude Medical, Inc. for $25 billion in Apr 2016. The transaction is expected to close in the fourth quarter of 2016.
Recently, the companies have agreed to sell certain products to Terumo Corporation in an all-cash transaction of approximately $1.12 billion. The products include St. Jude Medical's Angio-Seal and Femoseal vascular closure products, and Abbott's Vado Steerable Sheath. Abbott will, however, retain its vascular closure products.
Moreover, the sale of Abbott Medical Optics to Johnson & Johnson JNJ will help Abbott reshaping its portfolio in order to focus on gaining leadership positions in cardiovascular devices and expanding diagnostics.
Abbott Labs currently carries a Zacks Rank #4 (Sell).
A Stock to Consider
A better-ranked stock in the health care sector is Incyte Corporation INCY with a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Incyte's earnings estimates for 2016 and 2017 were up a respective 22.2% and 6.6% over the last 60 days. The company has beaten earnings estimates thrice in the last four quarters, with an average surprise of 335.16%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
ST JUDE MEDICAL (STJ): Free Stock Analysis Report
INCYTE CORP (INCY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT reported third-quarter 2016 earnings of 59 cents per share, higher than both the Zacks Consensus Estimate of 58 cents and the year-ago figure of 54 cents. Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report INCYTE CORP (INCY): Free Stock Analysis Report To read this article on Zacks.com click here. Sales in key emerging markets increased 7% on a reported basis driven by solid growth in India as well as strong demand in several countries of Latin America due to commercial initiatives and locally relevant portfolio expansion. | Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report INCYTE CORP (INCY): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT reported third-quarter 2016 earnings of 59 cents per share, higher than both the Zacks Consensus Estimate of 58 cents and the year-ago figure of 54 cents. During the quarter, Abbott received FDA approval for Tecnis Symfony intraocular lenses. | Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report INCYTE CORP (INCY): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT reported third-quarter 2016 earnings of 59 cents per share, higher than both the Zacks Consensus Estimate of 58 cents and the year-ago figure of 54 cents. FindTheCompany | Graphiq Quarterly sales came in at $5.3 billion, up 2.9% year over year on a reported basis, and in line with the Zacks Consensus Estimate. | Abbott LaboratoriesABT reported third-quarter 2016 earnings of 59 cents per share, higher than both the Zacks Consensus Estimate of 58 cents and the year-ago figure of 54 cents. Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report INCYTE CORP (INCY): Free Stock Analysis Report To read this article on Zacks.com click here. FindTheCompany | Graphiq Quarterly sales came in at $5.3 billion, up 2.9% year over year on a reported basis, and in line with the Zacks Consensus Estimate. |
33752.0 | 2016-10-19 00:00:00 UTC | Wednesday Sector Laggards: Healthcare, Utilities | ABT | https://www.nasdaq.com/articles/wednesday-sector-laggards-healthcare-utilities-2016-10-19 | nan | nan | Looking at the sectors faring worst as of midday Wednesday, shares of Healthcare companies are underperforming other sectors, showing a 0.2% loss. Within that group, Intuitive Surgical Inc (Symbol: ISRG) and Abbott Laboratories (Symbol: ABT) are two large stocks that are lagging, showing a loss of 4.3% and 2.5%, respectively. Among healthcare ETFs , one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is down 0.1% on the day, and down 1.53% year-to-date. Intuitive Surgical Inc, meanwhile, is up 26.44% year-to-date, and Abbott Laboratories, is down 8.34% year-to-date. Combined, ISRG and ABT make up approximately 2.9% of the underlying holdings of XLV.
The next worst performing sector is the Utilities sector, not showing much of a gain. Among large Utilities stocks, American Water Works Co, Inc. (Symbol: AWK) and Public Service Enterprise Group Inc (Symbol: PEG) are the most notable, showing a loss of 1.0% and 0.9%, respectively. One ETF closely tracking Utilities stocks is the Utilities Select Sector SPDR ETF ( XLU ), which is down 0.1% in midday trading, and up 14.50% on a year-to-date basis. American Water Works Co, Inc., meanwhile, is up 21.84% year-to-date, and Public Service Enterprise Group Inc is up 10.31% year-to-date. Combined, AWK and PEG make up approximately 5.5% of the underlying holdings of XLU.
Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom:
Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Wednesday. As you can see, seven sectors are up on the day, while one sector is down.
10 ETFs With Stocks That Insiders Are Buying »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Combined, ISRG and ABT make up approximately 2.9% of the underlying holdings of XLV. Within that group, Intuitive Surgical Inc (Symbol: ISRG) and Abbott Laboratories (Symbol: ABT) are two large stocks that are lagging, showing a loss of 4.3% and 2.5%, respectively. Combined, AWK and PEG make up approximately 5.5% of the underlying holdings of XLU. | Within that group, Intuitive Surgical Inc (Symbol: ISRG) and Abbott Laboratories (Symbol: ABT) are two large stocks that are lagging, showing a loss of 4.3% and 2.5%, respectively. Combined, ISRG and ABT make up approximately 2.9% of the underlying holdings of XLV. Among large Utilities stocks, American Water Works Co, Inc. (Symbol: AWK) and Public Service Enterprise Group Inc (Symbol: PEG) are the most notable, showing a loss of 1.0% and 0.9%, respectively. | Within that group, Intuitive Surgical Inc (Symbol: ISRG) and Abbott Laboratories (Symbol: ABT) are two large stocks that are lagging, showing a loss of 4.3% and 2.5%, respectively. Combined, ISRG and ABT make up approximately 2.9% of the underlying holdings of XLV. Among healthcare ETFs , one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is down 0.1% on the day, and down 1.53% year-to-date. | Within that group, Intuitive Surgical Inc (Symbol: ISRG) and Abbott Laboratories (Symbol: ABT) are two large stocks that are lagging, showing a loss of 4.3% and 2.5%, respectively. Combined, ISRG and ABT make up approximately 2.9% of the underlying holdings of XLV. Looking at the sectors faring worst as of midday Wednesday, shares of Healthcare companies are underperforming other sectors, showing a 0.2% loss. |
33753.0 | 2016-10-19 00:00:00 UTC | Abbott Labs (ABT) Beats on Earnings & Sales in Q3 | ABT | https://www.nasdaq.com/articles/abbott-labs-abt-beats-on-earnings-sales-in-q3-2016-10-19 | nan | nan | Abbott LaboratoriesABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market.
Abbott Labs reports its diversified business in four segments - namely Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition.
The company has reshaped its portfolio through strategic acquisitions/divestitures in recent times. It has also been taking strategic steps to expand its footprint in the growing geographies and investing in R&D, which has resulted in numerous new product launches across its businesses.
In Feb 2015, Abbott completed the sale of its branded generics pharmaceuticals business in developed markets. Realignment of the EPD division through acquisitions in Latin America and Russia, along with business divestitures in developed markets, has positioned the company well for the coming quarters. However, unfavorable movement in foreign currency rates is affecting the top line adversely.
Abbott Labs has an impressive track record as the company beat estimates in the last four trailing quarters with an average positive earnings surprise of 3.11%.
ABBOTT LABS Price and EPS Surprise
ABBOTT LABS Price and EPS Surprise | ABBOTT LABS Quote
Currently, Abbott Labs has a Zacks Rank #4 (Sell), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Our consensus called for EPS of 58 cents per share, while the company reported EPS of 59 cents (from continuing operations excluding one-time items).
Revenue: Abbott Labs posted revenues of $5.3 billion, in line with our expectations.
Key Stats: The recent launches of FreeStyle Libre and MitraClip have boosted the performance. Foreign currency exchange rate movements negatively impacted sales by 1.1%. The company expects 2016 earnings per share in the range of $2.19 per share to $2.21 per share (excluding specified items).
Check back later for our full write up on this Abbott Labs earnings report later!
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs reports its diversified business in four segments - namely Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. ABBOTT LABS Price and EPS Surprise ABBOTT LABS Price and EPS Surprise | ABBOTT LABS Quote Currently, Abbott Labs has a Zacks Rank #4 (Sell), but that could definitely change following the company's earnings report which was just released. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. ABBOTT LABS Price and EPS Surprise ABBOTT LABS Price and EPS Surprise | ABBOTT LABS Quote Currently, Abbott Labs has a Zacks Rank #4 (Sell), but that could definitely change following the company's earnings report which was just released. | Abbott LaboratoriesABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. In Feb 2015, Abbott completed the sale of its branded generics pharmaceuticals business in developed markets. |
33754.0 | 2016-10-19 00:00:00 UTC | Earnings Reaction History: Abbott Laboratories, 44.4% Follow-Through Indicator, 2.5% Sensitive | ABT | https://www.nasdaq.com/articles/earnings-reaction-history-abbott-laboratories-444-follow-through-indicator-25-sensitive | nan | nan | Expected Earnings Release: 10/19/2016, Premarket
Avg. Extended-Hours Dollar Volume: $601,876
Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect light trading in the issue immediately following its quarterly earnings announcement. Historical earnings event related premarket and after-hours trading activity in ABT indicates that the price change in the extended hours is likely to be of limited value in forecasting additional price movement by the following regular session close.
Last 12 Qtrs Positive Only Price Reactions
Percent of time added to extended-hours gains: 37.5%
Average next regular session additional gain: 2.4%
Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 37.5% of the time (3 events) the stock posted additional gains in the following regular session by an average of 2.4%.
Last 12 Qtrs Negative Only Price Reactions
Percent of time added to extended-hours losses: 100%
Average next regular session additional loss: 4.4%
Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 100.0% of the time (1 event) the stock dropped further, adding to the extended-hours losses by an average of 4.4% by the following regular session close.
Data provided by the MT Pro service at MTNewswires.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 37.5% Average next regular session additional gain: 2.4% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 37.5% of the time (3 events) the stock posted additional gains in the following regular session by an average of 2.4%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 100% Average next regular session additional loss: 4.4% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 100.0% of the time (1 event) the stock dropped further, adding to the extended-hours losses by an average of 4.4% by the following regular session close. Extended-Hours Dollar Volume: $601,876 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 37.5% Average next regular session additional gain: 2.4% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 37.5% of the time (3 events) the stock posted additional gains in the following regular session by an average of 2.4%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 100% Average next regular session additional loss: 4.4% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 100.0% of the time (1 event) the stock dropped further, adding to the extended-hours losses by an average of 4.4% by the following regular session close. Extended-Hours Dollar Volume: $601,876 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 37.5% Average next regular session additional gain: 2.4% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 37.5% of the time (3 events) the stock posted additional gains in the following regular session by an average of 2.4%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 100% Average next regular session additional loss: 4.4% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 100.0% of the time (1 event) the stock dropped further, adding to the extended-hours losses by an average of 4.4% by the following regular session close. Extended-Hours Dollar Volume: $601,876 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Extended-Hours Dollar Volume: $601,876 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 37.5% Average next regular session additional gain: 2.4% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 37.5% of the time (3 events) the stock posted additional gains in the following regular session by an average of 2.4%. Historical earnings event related premarket and after-hours trading activity in ABT indicates that the price change in the extended hours is likely to be of limited value in forecasting additional price movement by the following regular session close. |
33755.0 | 2016-10-18 00:00:00 UTC | Pharma Boosts Johnson & Johnson Despite Falling Consumer Sales | ABT | https://www.nasdaq.com/articles/pharma-boosts-johnson-johnson-despite-falling-consumer-sales-2016-10-18 | nan | nan | Image source: Getty Images.
It surprises many investors to discover that the consumer products division of Johnson & Johnson (NYSE: JNJ) isn't its most important business segment. Indeed, recently, consumer products have been the laggard for the healthcare conglomerate, and strength in the pharmaceutical business has been the key driver of overall growth for J&J. Coming into Tuesday's third-quarter financial report, J&J investors fully expected that those trends would continue, creating modest sales growth that would translate into bottom-line success. Johnson & Johnson's results were even stronger than anticipated, giving shareholders comfort that the healthcare giant is still moving forward. Let's take a closer look at Johnson & Johnson's latest results and what lies ahead for the company.
J&J rides the pharma train higher
Johnson & Johnson's third-quarter financials continued to build positive momentum for the healthcare conglomerate. Revenue climbed 4.3% to $17.82 billion, accelerating from last quarter's growth pace and topping the consensus forecast among investors. Adjusted net income rose 12% to $4.68 billion, and that produced adjusted earnings of $1.68 per share, beating what those following the stock had expected by $0.03 per share.
As we've seen in several past quarters, the strength of Johnson & Johnson's overall business was concentrated in the pharmaceutical division. Pharma sales jumped 9% to $8.4 billion, rapidly approaching the 50% mark in terms of its total contribution to J&J's top line. Gains for medical devices were much smaller, rising 1.1% from year-ago levels, and the consumer division actually lost ground on the sales front with a 1.6% decline.
One reason for the weakness in consumer sales was the strong U.S. dollar, which hit the division more strongly than the other two segments and reversed what would have been a slight 0.1% gain in currency-neutral revenue. Interestingly, both pharma and medical devices reported small boosts to sales from currency impacts. Domestic growth continued to be the biggest influence on Johnson & Johnson's sales, picking up 6.7% compared to a 1.5% rise for international revenue.
Looking more closely at Johnson & Johnson's product lines, the company said that Listerine oral care and Aveeno skin care products were among the biggest positive contributors on the consumer front, although lower inventory levels in the U.S. held back growth. In pharma, new products like cancer-fighters Imbruvica and Darzalex showed strong growth, and existing treatments like psoriasis and arthritis drug Stelara and anti-inflammatories Simponi and Remicade also helped J&J grow. For the medical products segment, electrophysiology cardiovascular products, endocutters for advanced surgery, and Acuvue contact lenses in vision care were strong contributors to growth.
Can Johnson & Johnson keep growing?
CEO Alex Gorsky concentrated on the impact that pharma had on the company and its role in future success. "With a number of regulatory approvals, several new drug application submissions, and new breakthrough therapy designations from the FDA," Gorsky said, "we are increasingly confident in our pipeline expectation of filing 10 new pharmaceutical products between 2015 and 2019, each with revenue potential over $1 billion."
Reflecting on its success, Johnson & Johnson also made some upward adjustments to its guidance for the year. The healthcare giant kept its sales projections stable at between $71.5 billion to $72.2 billion. However, it boosted the lower end of its previous earnings range by $0.05 per share, making its new guidance between $6.68 and $6.73 per share.
One thing that could change pharma's dominance at the company is J&J's recent purchase of Abbott Medical Optics . Johnson & Johnson paid Abbott Laboratories (NYSE: ABT) $4.325 billion in cash for the division, and investors expect the acquisition to boost earnings modestly within the first year after the deal closes. Given how well Acuvue has done for the medical device division at J&J, investors hope that the purchase will further leverage the power of that brand.
Investors didn't respond very much to Johnson & Johnson's results, with the stock trading on either side of unchanged in pre-market trading after the announcement. In the long run, though, it's important that J&J continue to emphasize not only that its pharmaceutical division still has room to grow but also that it isn't neglecting the potential of its other businesses.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
Dan Caplinger has no position in any stocks mentioned. The Motley Fool recommends Johnson and Johnson. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Johnson & Johnson paid Abbott Laboratories (NYSE: ABT) $4.325 billion in cash for the division, and investors expect the acquisition to boost earnings modestly within the first year after the deal closes. Coming into Tuesday's third-quarter financial report, J&J investors fully expected that those trends would continue, creating modest sales growth that would translate into bottom-line success. In pharma, new products like cancer-fighters Imbruvica and Darzalex showed strong growth, and existing treatments like psoriasis and arthritis drug Stelara and anti-inflammatories Simponi and Remicade also helped J&J grow. | Johnson & Johnson paid Abbott Laboratories (NYSE: ABT) $4.325 billion in cash for the division, and investors expect the acquisition to boost earnings modestly within the first year after the deal closes. It surprises many investors to discover that the consumer products division of Johnson & Johnson (NYSE: JNJ) isn't its most important business segment. J&J rides the pharma train higher Johnson & Johnson's third-quarter financials continued to build positive momentum for the healthcare conglomerate. | Johnson & Johnson paid Abbott Laboratories (NYSE: ABT) $4.325 billion in cash for the division, and investors expect the acquisition to boost earnings modestly within the first year after the deal closes. It surprises many investors to discover that the consumer products division of Johnson & Johnson (NYSE: JNJ) isn't its most important business segment. Looking more closely at Johnson & Johnson's product lines, the company said that Listerine oral care and Aveeno skin care products were among the biggest positive contributors on the consumer front, although lower inventory levels in the U.S. held back growth. | Johnson & Johnson paid Abbott Laboratories (NYSE: ABT) $4.325 billion in cash for the division, and investors expect the acquisition to boost earnings modestly within the first year after the deal closes. It surprises many investors to discover that the consumer products division of Johnson & Johnson (NYSE: JNJ) isn't its most important business segment. Can Johnson & Johnson keep growing? |
33756.0 | 2016-10-18 00:00:00 UTC | Without Drugs, Johnson & Johnson Has Nothing (JNJ) | ABT | https://www.nasdaq.com/articles/without-drugs-johnson-johnson-has-nothing-jnj-2016-10-18 | nan | nan | InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips
Johnson & Johnson (NYSE: JNJ ) shareholders are waking up with a shrug today. JNJ stock is slightly off after the thinnest of earnings beats, with the save coming from the company's pharmaceutical business.
Source: Dawn Via Flickr
For the quarter ended in September, JNJ earned $4.68 billion, or $1.68 per share, on revenues of $17.82 billion. The consensus estimate had been for earnings of $1.65 per share, with a "whisper number" of $1.66. Analysts expected $17.74 billion in revenues.
Moreover, Johnson & Johnson maintained sales guidance for full-year 2016 of $71.5 billion to $72.2 billion, though it increased its adjusted earnings guidance for full-year 2016 to $6.68 to $6.73 per share.
Johnson & Johnson stock, however, was unfazed. Analysts had become accustomed to JNJ beating earnings estimates, and this upside surprise was the smallest since last December.
Though it is twice the company's newly raised dividend of 80 cents per share.
Humira in Its Sights
In its earnings release, Johnson & Johnson acknowledged that pharmaceutical products are the star of its show, with sales up 9.2% over a year ago. Cancer drugs and medicines heavily advertised on TV - such as Xarelto, an anti-coagulant whose ads starred the late Arnold Palmer, and Stelara, an immunosuppressant currently advertised for treatment of psoriasis, but recently approved for treatment of Crohn's Disease - helped the cause.
7 Stocks to Buy That Will Grow by Double Digits
The FDA approval on Crohn's disease is likely to hike the ad budget for Stelara. It will now compete more directly with Humira from AbbVie Inc (NYSE: ABBV ), which generated $14 billion in sales in 2015 as a treatment for Crohn's and rheumatoid arthritis.
Johnson & Johnson also has another rheumatoid arthritis drug, sirukumab, going through the regulatory process.
In addition to being heavily advertised, drugs to cure autoimmune diseases like Crohn's, psoriasis and rheumatoid arthritis continue to be a key focus of research . So a business risk is that they will be replaced by better drugs before their patents expire.
Thus immunosuppressant drugs such as Humira, Stelara and Otezla from Celgene Corporation (NASDAQ: CELG ) are in heavy ad rotation to generate sales quickly, despite the fact that since the drugs can be approved for treatment of several conditions, there is considerable market confusion. The conditions they treat are often more implied than stated, since it's possible they could be used to treatment other conditions that consumers may see as unrelated.
This confusion demonstrates another risk for these drugs: the possibility that a new Clinton Administration may push either to instill greater price competition or controls on advertising to lower costs.
Without Drugs, JNJ Stock Offers No Growth
Outside the pharmaceutical business, JNJ stock is a slow-growth or no-growth prospect. Its popular consumer brands - products like baby powder and shampoo - of $3.3 billion were down 1.6% against the prior year, and sales of its medical devices, $6.6 billion, increased just 1.1%.
The purchase of Abbott Medical Optics from Abbott Laboratories (NYSE: ABT ), for $4.325 billion, completed during the quarter, will help device sales going forward. That company recently launched a balloon dilation treatment for expanding the eustachion tube that runs between the ear and the mouth.
JNJ stock advanced over 15% in price so far this year, despite the fact that most analysts have it rated only as a hold , due to its single-digit growth.
This is the kind of company that investors can buy and hold if they don't care to read stories like this one.
Dana Blankenhornis a financial journalist who dabbles in fiction, his latest beingThe Reluctant Detective Travels in Time . Write him at danablankenhorn@gmail.comor follow him on Twitter at @danablankenhorn .As of this writing, he did not hold a position in any of the aforementioned securities.
More From InvestorPlace
Netflix, Inc. (NFLX) Earnings Silence the Doubters
Home Depot Inc (HD) Stock Is Threatening to Fail You
10 Stocks That Every Investor Should Own
The post Without Drugs, Johnson & Johnson Has Nothing (JNJ) appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The purchase of Abbott Medical Optics from Abbott Laboratories (NYSE: ABT ), for $4.325 billion, completed during the quarter, will help device sales going forward. 7 Stocks to Buy That Will Grow by Double Digits The FDA approval on Crohn's disease is likely to hike the ad budget for Stelara. In addition to being heavily advertised, drugs to cure autoimmune diseases like Crohn's, psoriasis and rheumatoid arthritis continue to be a key focus of research . | The purchase of Abbott Medical Optics from Abbott Laboratories (NYSE: ABT ), for $4.325 billion, completed during the quarter, will help device sales going forward. Moreover, Johnson & Johnson maintained sales guidance for full-year 2016 of $71.5 billion to $72.2 billion, though it increased its adjusted earnings guidance for full-year 2016 to $6.68 to $6.73 per share. Cancer drugs and medicines heavily advertised on TV - such as Xarelto, an anti-coagulant whose ads starred the late Arnold Palmer, and Stelara, an immunosuppressant currently advertised for treatment of psoriasis, but recently approved for treatment of Crohn's Disease - helped the cause. | The purchase of Abbott Medical Optics from Abbott Laboratories (NYSE: ABT ), for $4.325 billion, completed during the quarter, will help device sales going forward. InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips Johnson & Johnson (NYSE: JNJ ) shareholders are waking up with a shrug today. Moreover, Johnson & Johnson maintained sales guidance for full-year 2016 of $71.5 billion to $72.2 billion, though it increased its adjusted earnings guidance for full-year 2016 to $6.68 to $6.73 per share. | The purchase of Abbott Medical Optics from Abbott Laboratories (NYSE: ABT ), for $4.325 billion, completed during the quarter, will help device sales going forward. Cancer drugs and medicines heavily advertised on TV - such as Xarelto, an anti-coagulant whose ads starred the late Arnold Palmer, and Stelara, an immunosuppressant currently advertised for treatment of psoriasis, but recently approved for treatment of Crohn's Disease - helped the cause. Thus immunosuppressant drugs such as Humira, Stelara and Otezla from Celgene Corporation (NASDAQ: CELG ) are in heavy ad rotation to generate sales quickly, despite the fact that since the drugs can be approved for treatment of several conditions, there is considerable market confusion. |
33757.0 | 2016-10-18 00:00:00 UTC | 3 Companies with Perfect Earnings Records | ABT | https://www.nasdaq.com/articles/3-companies-perfect-earnings-records-2016-10-18 | nan | nan | Earnings season is now in full swing.
This week's best earnings charts include companies who have perfect earnings surprise track records.
Despite what you might think, it's not easy for companies to beat every quarter for years on end. It takes more than just finessing the guidance to do it. Only a couple dozen companies are able to do it quarter after quarter.
Here are three doing it this week:
1. US Bancorp (USB) keeps beating but the shares have stalled.
2. Abbott Labs (ABT) is in the out-of-favor drug sector. It's also in the midst of several big acquisitions that have investors nervous.
3. Citrix Systems (CTXS) has a perfect earnings record but the chart isn't so great. It just goes to show you that the earnings beat isn't the entire story.
All three of these companies should be on your short list if you're trading the earnings report.
What else should you know about these earnings charts? Tune into the short video to find out.
Want to Know More about Abbott Labs Upcoming Earnings?
Eric Dutram digs into Abbott's fundamentals in this 2-minute earnings preview.
The Best & Worst of Zacks
Today you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. From 1988 through 2015 this list has averaged a stellar gain of +26% per year. Plus, you may download 220 Zacks Rank #5 "Strong Sells." Even though this list holds many stocks that seem to be solid, it has historically performed 11X worse than the market. See these critical buys and sells free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
US BANCORP (USB): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
CITRIX SYS INC (CTXS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs (ABT) is in the out-of-favor drug sector. Click to get this free report US BANCORP (USB): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report CITRIX SYS INC (CTXS): Free Stock Analysis Report To read this article on Zacks.com click here. Citrix Systems (CTXS) has a perfect earnings record but the chart isn't so great. | Click to get this free report US BANCORP (USB): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report CITRIX SYS INC (CTXS): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs (ABT) is in the out-of-favor drug sector. The Best & Worst of Zacks Today you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. | Click to get this free report US BANCORP (USB): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report CITRIX SYS INC (CTXS): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs (ABT) is in the out-of-favor drug sector. This week's best earnings charts include companies who have perfect earnings surprise track records. | Abbott Labs (ABT) is in the out-of-favor drug sector. Click to get this free report US BANCORP (USB): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report CITRIX SYS INC (CTXS): Free Stock Analysis Report To read this article on Zacks.com click here. Despite what you might think, it's not easy for companies to beat every quarter for years on end. |
33758.0 | 2016-10-18 00:00:00 UTC | Pre-Market Earnings Report for October 19, 2016 : USB, RAI, MS, ABT, ASML, HAL, BBT, CP, STJ, APH, MTB, NTRS | ABT | https://www.nasdaq.com/articles/pre-market-earnings-report-october-19-2016-usb-rai-ms-abt-asml-hal-bbt-cp-stj-aph-mtb-ntrs | nan | nan | The following companies are expected to report earnings prior to market open on 10/19/2016. Visit our Earnings Calendar for a full list of expected earnings releases.
U.S. Bancorp ( USB ) is reporting for the quarter ending September 30, 2016. The bank company's consensus earnings per share forecast from the 13 analysts that follow the stock is $0.84. This value represents a 3.70% increase compared to the same quarter last year. In the past year USB has met analyst expectations twice and beat the expectations the other two quarters. Zacks Investment Research reports that the 2016 Price to Earnings ratio for USB is 13.19 vs. an industry ratio of 13.10, implying that they will have a higher earnings growth than their competitors in the same industry.
Reynolds American Inc ( RAI ) is reporting for the quarter ending September 30, 2016. The tobacco company's consensus earnings per share forecast from the 7 analysts that follow the stock is $0.64. This value represents a 16.36% increase compared to the same quarter last year. Zacks Investment Research reports that the 2016 Price to Earnings ratio for RAI is 20.37 vs. an industry ratio of 16.50, implying that they will have a higher earnings growth than their competitors in the same industry.
Morgan Stanley ( MS ) is reporting for the quarter ending September 30, 2016. The investment bankers company's consensus earnings per share forecast from the 7 analysts that follow the stock is $0.64. This value represents a 88.24% increase compared to the same quarter last year. MS missed the consensus earnings per share in the 3rd calendar quarter of 2015 by -46.87%. Zacks Investment Research reports that the 2016 Price to Earnings ratio for MS is 12.72 vs. an industry ratio of 7.10, implying that they will have a higher earnings growth than their competitors in the same industry.
Abbott Laboratories ( ABT ) is reporting for the quarter ending September 30, 2016. The large cap pharmaceutical company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.58. This value represents a 7.41% increase compared to the same quarter last year. In the past year ABT has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 3.77%. Zacks Investment Research reports that the 2016 Price to Earnings ratio for ABT is 18.45 vs. an industry ratio of 17.00, implying that they will have a higher earnings growth than their competitors in the same industry.
ASML Holding N.V. ( ASML ) is reporting for the quarter ending September 30, 2016. The capital goods company's consensus earnings per share forecast from the 5 analysts that follow the stock is $1.07. This value represents a 28.92% increase compared to the same quarter last year. In the past year ASML has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2016 Price to Earnings ratio for ASML is 27.79 vs. an industry ratio of 14.70, implying that they will have a higher earnings growth than their competitors in the same industry.
Halliburton Company ( HAL ) is reporting for the quarter ending September 30, 2016. The oil (field services) company's consensus earnings per share forecast from the 18 analysts that follow the stock is $-0.07. This value represents a 122.58% decrease compared to the same quarter last year. In the past year HAL has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 26.32%. Zacks Investment Research reports that the 2016 Price to Earnings ratio for HAL is -272.47 vs. an industry ratio of -7.80.
BB&T Corporation ( BBT ) is reporting for the quarter ending September 30, 2016. The bank company's consensus earnings per share forecast from the 15 analysts that follow the stock is $0.70. This value represents a 9.37% increase compared to the same quarter last year. Zacks Investment Research reports that the 2016 Price to Earnings ratio for BBT is 13.46 vs. an industry ratio of 13.10, implying that they will have a higher earnings growth than their competitors in the same industry.
Canadian Pacific Railway Limited ( CP ) is reporting for the quarter ending September 30, 2016. The transportation (rail) company's consensus earnings per share forecast from the 10 analysts that follow the stock is $2.12. This value represents a 2.91% increase compared to the same quarter last year. CP missed the consensus earnings per share in the 1st calendar quarter of 2016 by -0.55%. Zacks Investment Research reports that the 2016 Price to Earnings ratio for CP is 18.63 vs. an industry ratio of 17.90, implying that they will have a higher earnings growth than their competitors in the same industry.
St. Jude Medical, Inc. ( STJ ) is reporting for the quarter ending September 30, 2016. The medical products company's consensus earnings per share forecast from the 18 analysts that follow the stock is $1.01. This value represents a 4.12% increase compared to the same quarter last year. In the past year STJ has met analyst expectations twice and beat the expectations the other two quarters. Zacks Investment Research reports that the 2016 Price to Earnings ratio for STJ is 19.13 vs. an industry ratio of 15.20, implying that they will have a higher earnings growth than their competitors in the same industry.
Amphenol Corporation ( APH ) is reporting for the quarter ending September 30, 2016. The electrical connectors company's consensus earnings per share forecast from the 5 analysts that follow the stock is $0.68. This value represents a 4.62% increase compared to the same quarter last year. In the past year APH has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2016 Price to Earnings ratio for APH is 23.97 vs. an industry ratio of 11.60, implying that they will have a higher earnings growth than their competitors in the same industry.
M&T Bank Corporation ( MTB ) is reporting for the quarter ending September 30, 2016. The bank company's consensus earnings per share forecast from the 12 analysts that follow the stock is $2.04. This value represents a 5.70% increase compared to the same quarter last year. Zacks Investment Research reports that the 2016 Price to Earnings ratio for MTB is 14.34 vs. an industry ratio of 13.10, implying that they will have a higher earnings growth than their competitors in the same industry.
Northern Trust Corporation ( NTRS ) is reporting for the quarter ending September 30, 2016. The bank company's consensus earnings per share forecast from the 8 analysts that follow the stock is $1.08. This value represents a 12.50% increase compared to the same quarter last year. NTRS missed the consensus earnings per share in the 3rd calendar quarter of 2015 by -1.03%. Zacks Investment Research reports that the 2016 Price to Earnings ratio for NTRS is 16.61 vs. an industry ratio of 13.10, implying that they will have a higher earnings growth than their competitors in the same industry.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is reporting for the quarter ending September 30, 2016. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2016 Price to Earnings ratio for ABT is 18.45 vs. an industry ratio of 17.00, implying that they will have a higher earnings growth than their competitors in the same industry. | Abbott Laboratories ( ABT ) is reporting for the quarter ending September 30, 2016. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2016 Price to Earnings ratio for ABT is 18.45 vs. an industry ratio of 17.00, implying that they will have a higher earnings growth than their competitors in the same industry. | Zacks Investment Research reports that the 2016 Price to Earnings ratio for ABT is 18.45 vs. an industry ratio of 17.00, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories ( ABT ) is reporting for the quarter ending September 30, 2016. In the past year ABT has beat the expectations every quarter. | In the past year ABT has beat the expectations every quarter. Abbott Laboratories ( ABT ) is reporting for the quarter ending September 30, 2016. Zacks Investment Research reports that the 2016 Price to Earnings ratio for ABT is 18.45 vs. an industry ratio of 17.00, implying that they will have a higher earnings growth than their competitors in the same industry. |
33759.0 | 2016-10-18 00:00:00 UTC | Your Two Minute Earnings Preview for Abbott Labs (ABT) Stock | ABT | https://www.nasdaq.com/articles/your-two-minute-earnings-preview-abbott-labs-abt-stock-2016-10-18 | nan | nan | Today's short video takes a closer look at Abbott Labs (ABT) stock ahead of their earnings report. The company has seen extremely choppy trading as of late, and it will be up to this coming release to right the ship.
Fortunately for ABT investors, the stock has a great track record in earnings season which includes beats stretching back to 2013. The company also has a 'B' for its VGM score, so fundamentals are pretty strong for this stock as well.
However, investors should note that earnings estimate revisions have come in pretty weak as of late, pushing the stock down into 'sell' territory. Add in a bottom 20% industry rank, and this could be a name to stay away from this earnings season, at least until we see some better numbers on the earnings estimate and Zacks Rank fronts.
ABBOTT LABS Price, Consensus and EPS Surprise
ABBOTT LABS Price, Consensus and EPS Surprise | ABBOTT LABS Quote
Abbott Labs reports on October 19 th before the bell, and we are looking for earnings of $0.58/share. Make sure to watch the video for a quick guide to ABT heading into the report, but if you want to learn more about trading in earnings season, check out our podcast below:
The Best & Worst of Zacks
Today you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. From 1988 through 2015 this list has averaged a stellar gain of +26% per year. Plus, you may download 220 Zacks Rank #5 "Strong Sells." Even though this list holds many stocks that seem to be solid, it has historically performed 11X worse than the market. See these critical buys and sells free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Today's short video takes a closer look at Abbott Labs (ABT) stock ahead of their earnings report. Fortunately for ABT investors, the stock has a great track record in earnings season which includes beats stretching back to 2013. Make sure to watch the video for a quick guide to ABT heading into the report, but if you want to learn more about trading in earnings season, check out our podcast below: The Best & Worst of Zacks Today you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Today's short video takes a closer look at Abbott Labs (ABT) stock ahead of their earnings report. Fortunately for ABT investors, the stock has a great track record in earnings season which includes beats stretching back to 2013. | Make sure to watch the video for a quick guide to ABT heading into the report, but if you want to learn more about trading in earnings season, check out our podcast below: The Best & Worst of Zacks Today you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Today's short video takes a closer look at Abbott Labs (ABT) stock ahead of their earnings report. | Make sure to watch the video for a quick guide to ABT heading into the report, but if you want to learn more about trading in earnings season, check out our podcast below: The Best & Worst of Zacks Today you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. Today's short video takes a closer look at Abbott Labs (ABT) stock ahead of their earnings report. Fortunately for ABT investors, the stock has a great track record in earnings season which includes beats stretching back to 2013. |
33760.0 | 2016-10-14 00:00:00 UTC | Health Care Sector Update for 10/14/2016: NHTC, EGLT, JNJ, PFE, ABT, MRK, AMGN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-10142016-nhtc-eglt-jnj-pfe-abt-mrk-amgn-2016-10-14 | nan | nan | Top Health-care stocks:
JNJ: flat
PFE: +0.4%
ABT: flat
MRK: +1.6%
AMGN: flat
Health care shares were mostly unchanged in pre-market trade Friday.
In health care stocks news, Egalet ( EGLT ) shares fell 5.9% after the specialty pharmaceutical company said that the U.S. Food and Drug Administration will not meet the previously announced Oct. 14 prescription drug user fee act (PDUFA) date for Arymo ER.
And, Natural Health Trends ( NHTC ) said late Thursday that it estimates total revenue for the quarter ended September 30 to be $70.7 million, a 12% decrease compared to $80.8 million in the year-ago period. No analyst estimates were available for comparison.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat AMGN: flat Health care shares were mostly unchanged in pre-market trade Friday. In health care stocks news, Egalet ( EGLT ) shares fell 5.9% after the specialty pharmaceutical company said that the U.S. Food and Drug Administration will not meet the previously announced Oct. 14 prescription drug user fee act (PDUFA) date for Arymo ER. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ABT: flat AMGN: flat Health care shares were mostly unchanged in pre-market trade Friday. | ABT: flat AMGN: flat Health care shares were mostly unchanged in pre-market trade Friday. In health care stocks news, Egalet ( EGLT ) shares fell 5.9% after the specialty pharmaceutical company said that the U.S. Food and Drug Administration will not meet the previously announced Oct. 14 prescription drug user fee act (PDUFA) date for Arymo ER. | ABT: flat AMGN: flat Health care shares were mostly unchanged in pre-market trade Friday. And, Natural Health Trends ( NHTC ) said late Thursday that it estimates total revenue for the quarter ended September 30 to be $70.7 million, a 12% decrease compared to $80.8 million in the year-ago period. |
33761.0 | 2016-10-14 00:00:00 UTC | 3 Figures That Matter Most When Johnson & Johnson Reports Its 3rd-Quarter Results | ABT | https://www.nasdaq.com/articles/3-figures-matter-most-when-johnson-johnson-reports-its-3rd-quarter-results-2016-10-14 | nan | nan | Image source: Getty Images.
Did you blink? If you did, you probably missed the kickoff to earnings season for the third quarter. Although earnings season never officially ends, the vast majority of S&P 500 companies report their results within a matter of six weeks each quarter, which is traditionally understood by Wall Street to be "earnings season."
In the healthcare sector, conglomerate Johnson & Johnson (NYSE: JNJ) , the largest publicly traded company in healthcare, has the pleasure of leading things off each quarter.
Slated to report its Q3 results before the opening bell on Tuesday, Oct. 18, Johnson & Johnson is projected by Wall Street to earn $1.65 per share on $17.7 billion in sales. For reference, J&J has surpassed Wall Street's profit projections in every quarter over the past three years. Though the past is no guarantee of the future, history suggests an earnings beat is likely.
However, when all is said and done, Wall Street and investors are unlikely to be laser-focused on the headline figures. They're going to be more interested, and for good reason, in how J&J achieved its numbers. When J&J releases its Q3 figures and conducts its conference call with Wall Street analysts, here are three figures you'd be wise to pay close attention to.
1. Pharmaceuticals growth rate
Johnson & Johnson may be made up of three operating segments (pharmaceuticals, medical devices, and consumer health), but it's the company's pharmaceuticals unit that packs the biggest punch.
Image source: Getty Images.
Consumer health products are mostly inelastic, leading to strong pricing power. However, growth in consumer health products is usually in the low to mid single digits, and margins tend to be tight. A similar tale can be told of medical devices, which are often the victim of tough competition that weighs on device prices and margins. Pharmaceuticals, on the other hand, can regularly have margins in the neighborhood of 70%, if not higher. Inherent advantages in the U.S. healthcare system also allow Johnson & Johnson to increase the price of its branded and specialty therapies at a rate far above that of inflation. Long story short, growth in pharmaceuticals is extremely important for J&J.
Last year Johnson & Johnson outlined a plan to file for new drug approvals for 10 potential blockbusters by 2019. This follows bringing 14 novel therapies to market between 2009 and mid-2014, and having half of those generate $1 billion or more in annual sales, the definition of a blockbuster drug. Wall Street and investors will be looking to see if J&J can continue delivering operating sales growth of around 9% or more (as it's done through the first half of 2016) in Q3. Growth in type 2 diabetes drug Invokana, anti-inflammatory Stelara, and cancer drugs Imbruvica and Darzalex should help, but only time will tell if J&J can keep pace with its recent growth trends in pharmaceuticals.
2. Medical-devices growth rate
Second, Wall Street and investors should be mighty interested to see how well J&J's medical-devices segment performed.
As mentioned above, growth in this unit has been subpar in recent years by J&J's standards -- the company is one of the largest device makers in the world. Part of the blame can be attributed to weaker growth in the U.S. and Europe; part can be ascribed to increased competition; and part is probably due (in the U.S.) to the implementation of the Affordable Care Act. The ACA, or Obamacare, as it's more commonly known, created an uncertain expense environment following its rollout, which in turn caused some hospitals to reduce their spending and prompted patients to wait on nonurgent procedures.
Image source: Getty Images.
But during the past few years J&J has been able to realign its medical-device business. It's jettisoned underperforming subsidiaries, such as Cordis, which it sold to Cardinal Health for nearly $2 billion, and Ortho-Clinical Diagnostics, which was divested to the Carlyle Group for roughly $4 billion. It's also been simultaneously emphasizing higher-growth device segments, such as trauma, as well as hip and knee replacements.
More recently, J&J announced the acquisition of Abbott Laboratories '(NYSE: ABT) eye-surgery-equipment unit, Abbott Medical Optics, for $4.33 billion. The deal perfectly complements J&J's established Acuvue contact lens brand and expands its ophthalmologic surgical-equipment offerings, while, most importantly, providing immediate profit accretion to the company's bottom line. Abbott didn't fare too badly either, netting a $1.5 billion gain since its 2009 purchase of its Medical Optics unit, and divesting a noncore asset based on two upcoming mergers that'll realign its business focus.
In short, Wall Street is probably expecting medical-device growth that excludes divestitures and acquisitions of better than 2.5% in the U.S. (J&J reported 1.9% U.S. device sales growth in Q2 2016 sans acquisitions and divestitures), and perhaps up to 5% operating sales growth worldwide. Can J&J deliver? We'll find out next week.
3. Remicade sales forecast
There is no shortage of important medications to pay attention to when J&J reports its Q3 results. A few (Imbruvica, Stelara, Invokana) were mentioned above. But if there's one therapy that should jump to the top of the list, it's anti-inflammatory Remicade, which is used to treat rheumatoid arthritis, plaque psoriasis, ulcerative colitis, Crohn's disease, and a few other ailments.
Image source: Johnson & Johnson.
Remicade is a big deal for J&J. Through the first six months of the year, Remicade sales have tallied $3.56 billion worldwide, a 10.5% increase from the prior-year period on a currency-neutral basis. Remicade is J&J's best-selling drug, and it's accounted for 21% of its pharmaceutical-product sales in the first half of the year.
However, Remicade's sales trajectory could soon be altered. In August, J&J lost its final court battle to block the entrance of biosimilar versions of Remicade. South Korean biopharma Celltrion and Pfizer (NYSE: PFE) , Celltrion's licensing partner, are ready and raring to launch their copycat drug, known as Inflectra, following an April approval from the Food and Drug Administration. Biosimilar drugs are expected to price anywhere from 10% to 50% below the cost of brand-name drugs, but with no precedence of a U.S. launch, no one is exactly sure what to expect. Thus, we may learn a lot about the growing biosimilar market and how branded therapies will react to biosimilar competition by listening closely to what J&J has to say about Remicade's Q3 sales and its future sales forecast in the company's press release and during its conference call.
Tuesday, Oct. 18, is the big day, so circle it on your calendars.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen nameTMFUltraLong, and check him out on Twitter, where he goes by the handle@TMFUltraLong.
The Motley Fool recommends Johnson and Johnson. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | More recently, J&J announced the acquisition of Abbott Laboratories '(NYSE: ABT) eye-surgery-equipment unit, Abbott Medical Optics, for $4.33 billion. The ACA, or Obamacare, as it's more commonly known, created an uncertain expense environment following its rollout, which in turn caused some hospitals to reduce their spending and prompted patients to wait on nonurgent procedures. The deal perfectly complements J&J's established Acuvue contact lens brand and expands its ophthalmologic surgical-equipment offerings, while, most importantly, providing immediate profit accretion to the company's bottom line. | More recently, J&J announced the acquisition of Abbott Laboratories '(NYSE: ABT) eye-surgery-equipment unit, Abbott Medical Optics, for $4.33 billion. Slated to report its Q3 results before the opening bell on Tuesday, Oct. 18, Johnson & Johnson is projected by Wall Street to earn $1.65 per share on $17.7 billion in sales. Pharmaceuticals growth rate Johnson & Johnson may be made up of three operating segments (pharmaceuticals, medical devices, and consumer health), but it's the company's pharmaceuticals unit that packs the biggest punch. | More recently, J&J announced the acquisition of Abbott Laboratories '(NYSE: ABT) eye-surgery-equipment unit, Abbott Medical Optics, for $4.33 billion. Slated to report its Q3 results before the opening bell on Tuesday, Oct. 18, Johnson & Johnson is projected by Wall Street to earn $1.65 per share on $17.7 billion in sales. Pharmaceuticals growth rate Johnson & Johnson may be made up of three operating segments (pharmaceuticals, medical devices, and consumer health), but it's the company's pharmaceuticals unit that packs the biggest punch. | More recently, J&J announced the acquisition of Abbott Laboratories '(NYSE: ABT) eye-surgery-equipment unit, Abbott Medical Optics, for $4.33 billion. Pharmaceuticals growth rate Johnson & Johnson may be made up of three operating segments (pharmaceuticals, medical devices, and consumer health), but it's the company's pharmaceuticals unit that packs the biggest punch. As mentioned above, growth in this unit has been subpar in recent years by J&J's standards -- the company is one of the largest device makers in the world. |
33762.0 | 2016-10-13 00:00:00 UTC | Health Care Sector Update for 10/13/2016: FLKS, TGTX, JNJ, PFE, ABT, MRK, AMGN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-10132016-flks-tgtx-jnj-pfe-abt-mrk-amgn-2016-10-13 | nan | nan | Top Health-care stocks:
JNJ: flat
PFE: +1.3%
ABT: flat
MRK: +0.5%
AMGN: -1%
Health care shares were mostly mixed in pre-market trade Thursday.
In health care stocks news, TG Therapeutics ( TGTX ) was down 15.2% after company said it has filed with the U.S. Food and Drug Administration to make changes to its phase 3 trial of TG-1101 in leukemia. The company said the proposed changes to the trial may accelerate its approval timeline. The trial examines TG-1101, or ublituximab, in combination with ibrutinib versus ibrutinib alone in patients with previously-treated high-risk chronic lymphocytic leukemia. The amended protocol eliminates a proposed part 2 portion so the sole primary endpoint will be overall response rate, not overall response rate and progression free survival. Target enrollment has been reduced to approximately 120 patients from 330. At the new study size, the study is 90% powered to show a statistically significant improvement in ORR, with the minimal detectable difference of 20%, the company said.
And, Flex Pharma ( FLKS ) was down 17% after the company said an exploratory study of FLX-787, a topical treatment being evaluated for nocturnal leg cramps, did not demonstrate a statistically significant reduction on the endpoints of muscle cramp frequency or cramp-free nights. The company said concerns have been identified that potentially impact data interpretation at one of the sites and the U.S. Food and Drug Administration has recommended a parallel study design due to the potential for confounding clinical results. The company also said has determined cramp frequency could be an acceptable primary efficacy endpoint in its study.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat In health care stocks news, TG Therapeutics ( TGTX ) was down 15.2% after company said it has filed with the U.S. Food and Drug Administration to make changes to its phase 3 trial of TG-1101 in leukemia. And, Flex Pharma ( FLKS ) was down 17% after the company said an exploratory study of FLX-787, a topical treatment being evaluated for nocturnal leg cramps, did not demonstrate a statistically significant reduction on the endpoints of muscle cramp frequency or cramp-free nights. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ABT: flat The amended protocol eliminates a proposed part 2 portion so the sole primary endpoint will be overall response rate, not overall response rate and progression free survival. | ABT: flat In health care stocks news, TG Therapeutics ( TGTX ) was down 15.2% after company said it has filed with the U.S. Food and Drug Administration to make changes to its phase 3 trial of TG-1101 in leukemia. And, Flex Pharma ( FLKS ) was down 17% after the company said an exploratory study of FLX-787, a topical treatment being evaluated for nocturnal leg cramps, did not demonstrate a statistically significant reduction on the endpoints of muscle cramp frequency or cramp-free nights. | ABT: flat Top Health-care stocks: JNJ: flat In health care stocks news, TG Therapeutics ( TGTX ) was down 15.2% after company said it has filed with the U.S. Food and Drug Administration to make changes to its phase 3 trial of TG-1101 in leukemia. |
33763.0 | 2016-10-13 00:00:00 UTC | J&J (JNJ) Likely to Beat Earnings Estimates in Q3 Again | ABT | https://www.nasdaq.com/articles/jj-jnj-likely-to-beat-earnings-estimates-in-q3-again-2016-10-13 | nan | nan | Johnson & JohnsonJNJ , the bellwether of healthcare companies, is scheduled to report third-quarter 2016 results on Oct 18, before the opening bell. Last quarter, the company reported a positive earnings surprise of 4.19%.
J&J has consistently surpassed earnings expectations. The company's earnings beat expectations in each of the last four quarters, with an average positive surprise of 2.88%. Will J&J be able to beat estimates this time as well?
Let's see how things are shaping up for this announcement.
Why a Likely Positive Surprise?
For the third quarter of 2016, our proven model shows that J&J is again likely to beat earnings estimates because it has the right combination of two key ingredients.
Positive Zacks ESP:Earnings ESP , which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is +4.88%. This is a meaningful and leading indicator of a likely positive earnings surprise for the shares.
Zacks Rank #3 (Hold): Note that stocks with Zacks Ranks #1 (Strong Buy), #2 (Buy) and #3 have a significantly higher chance of beating earnings.
However, we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
The combination of J&J's Zacks Rank #3 and +4.88% ESP makes us reasonably confident of an earnings beat this season.
JOHNSON & JOHNS Price and EPS Surprise
JOHNSON & JOHNS Price and EPS Surprise | JOHNSON & JOHNS Quote
Will the Pharma Segment Continue to Drive Results?
J&J's Pharmaceutical segment has been performing well and should continue the same this quarter as well on the back of strong sales of new products as well as core growth products. Robust market growth and increased share should boost sales of Simponi and Stelara. Imbruvica should benefit from increased patient uptake. New cancer treatment, Darzalex, has been off to an encouraging start in the U.S. It gained EU approval in May 2016, which should further add to the drug's sales.
Xarelto and Invokana/Invokamet should keep up their performance thanks to growth in prescription share. Invega Sustenna should also benefit due to strong sales.
However, Olysio sales will keep declining due to increased competition while Invega continues to face a decline in sales due to generic competition.
J&J continues to assume no biosimilar competition for Procrit or Remicade in the U.S. even though the FDA approved a Remicade biosimilar (Inflectra) earlier this April. The company also does not expect generic competition for Zytiga, Risperdal Consta, and Invega Sustenna this year.
The Medical Device business will continue to be affected by softglobal marketconditions and pricing challenges. The company is working on driving growth in this segment through new product launches and by transforming its commercial models.
Meanwhile, the Consumer business is slowly recovering from the impact of the manufacturing issues that had affected this segment.
The company has been quite active on the deal making front. In Sep 2016, J&J announced its intention to acquire Abbott Laboratories' ABT Abbott Medical Optics for $4.325 billion in cash. With this proposed acquisition, J&J is looking to strengthen its eye care segment. The acquisition is slated to close in the first quarter of 2017.
In Jul 2016, J&J acquired privately held company Vogue International in a deal worth $3.3 billion in cash. The acquisition is expected to strengthen its position in hair care and contribute to the profitability of the company's Consumer business.
J&J's share buyback program (worth up to $10 billion) should boost the bottom line. Currency movement and operations in Venezuela will remain headwinds.
Stocks That Warrant a Look
J&J is not the only company looking up this earnings season. Here are a couple of health care stocks that you may want to consider as our model shows that they too have the right combination of elements to post an earnings beat this quarter.
Amgen Inc. AMGN is expected to report third-quarter results on Oct 26. It has an Earnings ESP of +1.79% and a Zacks Rank #3. You can see the complete list of today's Zacks #1 Rank stocks here .
Bristol-Myers Squibb Company BMY has an Earnings ESP of +7.81% and a Zacks Rank #3. It is scheduled to report third-quarter results on Oct 27.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BRISTOL-MYERS (BMY): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
AMGEN INC (AMGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In Sep 2016, J&J announced its intention to acquire Abbott Laboratories' ABT Abbott Medical Optics for $4.325 billion in cash. Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Johnson & JohnsonJNJ , the bellwether of healthcare companies, is scheduled to report third-quarter 2016 results on Oct 18, before the opening bell. | Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. In Sep 2016, J&J announced its intention to acquire Abbott Laboratories' ABT Abbott Medical Optics for $4.325 billion in cash. JOHNSON & JOHNS Price and EPS Surprise JOHNSON & JOHNS Price and EPS Surprise | JOHNSON & JOHNS Quote Will the Pharma Segment Continue to Drive Results? | Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. In Sep 2016, J&J announced its intention to acquire Abbott Laboratories' ABT Abbott Medical Optics for $4.325 billion in cash. Zacks Rank #3 (Hold): Note that stocks with Zacks Ranks #1 (Strong Buy), #2 (Buy) and #3 have a significantly higher chance of beating earnings. | In Sep 2016, J&J announced its intention to acquire Abbott Laboratories' ABT Abbott Medical Optics for $4.325 billion in cash. Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Last quarter, the company reported a positive earnings surprise of 4.19%. |
33764.0 | 2016-10-13 00:00:00 UTC | Celgene/Agios Ink Deals with Abbott to Identify IDH Mutations | ABT | https://www.nasdaq.com/articles/celgene-agios-ink-deals-with-abbott-to-identify-idh-mutations-2016-10-13 | nan | nan | Celgene CorporationCELG and Agios Pharmaceuticals, Inc. AGIO announced that they have entered into collaboration agreements with Abbott Laboratories ABT to develop and commercialize diagnostic tests to identify isocitrate dehydrogenase (IDH) mutations in patients with acute myeloid leukemia (AML).
The companies will use Abbott's m2000 RealTi m e System, a polymerase chain reaction (PCR) instrument that helps automate the PCR process to analyze results and simplify the complex and manual steps related to molecular diagnostics.
Celgene is developing an IDH2 inhibitor, enasidenib, for the treatment of patients with relapsed or refractory AML who have an IDH2 mutation. Currently, enasidenib is in a phase III study, IDHENTIFY, which is comparing the candidate with conventional therapy in older patients.
CELGENE CORP Price
CELGENE CORP Price | CELGENE CORP Quote
Agios is developing an IDH1 inhibitor, AG-120, for the treatment of patients with relapsed or refractory AML who have an IDH1 mutation.
We remind investors that Celgene had inked a discovery and development collaboration, and a license agreement with Agios focused on targeting cancer metabolism in Apr 2010. In May 2016, the collaboration agreement was amended, whereby Agios acquired full global development and commercialization rights to AG-120. Previously, Agios has held only the U.S. rights to AG-120.
AGIOS PHARMACT Price
AGIOS PHARMACT Price | AGIOS PHARMACT Quote
According to information provided by the company, IDH1 and IDH2 mutations occur in approximately 20% of all AML patients.
Celgene currently carries a Zacks Rank #3 (Hold), while Agios is a Zacks Rank #4 (Sell) stock.
A Stock to Consider
Geron Corporation GERN is a better-ranked stock in the health care sector, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
The company has posted a positive earnings surprise in each of the four trailing quarters, bringing the average beat to 20.78%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
GERON CORP (GERN): Free Stock Analysis Report
CELGENE CORP (CELG): Free Stock Analysis Report
AGIOS PHARMACT (AGIO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Celgene CorporationCELG and Agios Pharmaceuticals, Inc. AGIO announced that they have entered into collaboration agreements with Abbott Laboratories ABT to develop and commercialize diagnostic tests to identify isocitrate dehydrogenase (IDH) mutations in patients with acute myeloid leukemia (AML). Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report GERON CORP (GERN): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report AGIOS PHARMACT (AGIO): Free Stock Analysis Report To read this article on Zacks.com click here. Currently, enasidenib is in a phase III study, IDHENTIFY, which is comparing the candidate with conventional therapy in older patients. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report GERON CORP (GERN): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report AGIOS PHARMACT (AGIO): Free Stock Analysis Report To read this article on Zacks.com click here. Celgene CorporationCELG and Agios Pharmaceuticals, Inc. AGIO announced that they have entered into collaboration agreements with Abbott Laboratories ABT to develop and commercialize diagnostic tests to identify isocitrate dehydrogenase (IDH) mutations in patients with acute myeloid leukemia (AML). CELGENE CORP Price CELGENE CORP Price | CELGENE CORP Quote Agios is developing an IDH1 inhibitor, AG-120, for the treatment of patients with relapsed or refractory AML who have an IDH1 mutation. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report GERON CORP (GERN): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report AGIOS PHARMACT (AGIO): Free Stock Analysis Report To read this article on Zacks.com click here. Celgene CorporationCELG and Agios Pharmaceuticals, Inc. AGIO announced that they have entered into collaboration agreements with Abbott Laboratories ABT to develop and commercialize diagnostic tests to identify isocitrate dehydrogenase (IDH) mutations in patients with acute myeloid leukemia (AML). CELGENE CORP Price CELGENE CORP Price | CELGENE CORP Quote Agios is developing an IDH1 inhibitor, AG-120, for the treatment of patients with relapsed or refractory AML who have an IDH1 mutation. | Celgene CorporationCELG and Agios Pharmaceuticals, Inc. AGIO announced that they have entered into collaboration agreements with Abbott Laboratories ABT to develop and commercialize diagnostic tests to identify isocitrate dehydrogenase (IDH) mutations in patients with acute myeloid leukemia (AML). Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report GERON CORP (GERN): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report AGIOS PHARMACT (AGIO): Free Stock Analysis Report To read this article on Zacks.com click here. Celgene is developing an IDH2 inhibitor, enasidenib, for the treatment of patients with relapsed or refractory AML who have an IDH2 mutation. |
33765.0 | 2016-10-12 00:00:00 UTC | Can Johnson & Johnson Keep Growing Healthier? | ABT | https://www.nasdaq.com/articles/can-johnson-johnson-keep-growing-healthier-2016-10-12 | nan | nan | Image source: Johnson & Johnson.
Most people know healthcare giant Johnson & Johnson (NYSE: JNJ) because of the over-the-counter brands that they have in their medicine cabinets. Yet even though Tylenol, Band-Aid, and other consumer products help drive brand awareness, Johnson & Johnson has a much larger role in the pharmaceutical and medical devices markets, and the drug business in particular has been the biggest growth driver in recent years.
As investors prepare for Tuesday's third-quarter financial report from Johnson & Johnson, they want to see whether the company can keep producing the growth in revenue and earnings that they've come to expect. Let's take an early look at what's been happening at Johnson & Johnson and whether it can build up more positive momentum going forward.
Stats on Johnson & Johnson
Data source: Yahoo! Finance.
What's ahead for Johnson & Johnson earnings?
In recent months, investors have been more excited about the prospects for better earnings from Johnson & Johnson, boosting their full-year 2016 and 2017 projections by $0.08 to $0.10 per share. Yet the stock hasn't done anything for shareholders lately, falling 4% since July.
Johnson & Johnson's second-quarter results created modest enthusiasm about the healthcare conglomerate's future prospects. The company boosted its sales by nearly 4% from the year-ago quarter, and adjusted earnings also managed to climb modestly and satisfy investors who were bracing for a flat performance from J&J. Currency pressures continued to weigh on the international business, but strength in the U.S. helped to offset those downward impacts, and the pharmaceutical division remained the key driver of growth for Johnson & Johnson. The company also boosted its sales and earnings guidance for 2016, citing hopes that significant clinical milestones in its pipeline of candidate drugs could help push results upward even further in the long run.
How J&J sees better times ahead
New products are an important driver of growth for Johnson & Johnson, and the company has high hopes for some of its more recent offerings. The research that J&J is doing to come up with oncology treatments has been highly successful, with sales rising at a 25% to 30% year-over-year rate during the first half of 2016. Further candidate drugs within the pipeline also take aim squarely at cancer, and with a mix of treatments that serve large populations more effectively than competing drugs as well as those serving small populations for which previous treatments have been unavailable, Johnson & Johnson expects oncology to keep gaining in importance.
At the same time, Johnson & Johnson is trying to serve the growing market for those with diabetes. The company's OneTouch Via insulin delivery device should see its launch within the next 12 months, and it caters to the demand among diabetics to have a discreet way of getting the insulin they need without the hassle of injections. Without competition for the moment, J&J has an ability to make the most of the first-mover opportunity.
More broadly, one thing that Johnson & Johnson is always looking to do is to focus its business on the areas with the highest potential for strengthening its leadership position in the industry. That involves both selling off slower-growth businesses and looking for strategic acquisitions that can bulk up its competitive position in emerging growth industries. For instance, in September, J&J bought the Abbott Medical Optics eye-surgery equipment unit of Abbott Laboratories (NYSE: ABT) , paying $4.3 billion to strengthen its overall medical device lineup. At the same time, with the unit's eye drop and solutions business adding to its Lasik and cataract procedure equipment, Johnson & Johnson will be able to integrate the purchase with its Acuvue contact lens business to strengthen exposure to a market expected to grow at a solid 5% annual pace over the next four to five years. The move shows that even if J&J has been more conservative in sizing its acquisitions than some of its pharma peers, it still makes moves that take it in the right direction.
In the Johnson & Johnson earnings report, investors will want to keep a close eye not only on whether the pharmaceutical business continues to take the lead in producing growth but also on the contributions that the medical device and consumer segments are able to make to its overall success. In order to make dramatic gains, Johnson & Johnson will need all of its major businesses pulling their weight to produce the growth that investors really want to see from the company going forward.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
Dan Caplinger has no position in any stocks mentioned. The Motley Fool recommends Johnson and Johnson. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | For instance, in September, J&J bought the Abbott Medical Optics eye-surgery equipment unit of Abbott Laboratories (NYSE: ABT) , paying $4.3 billion to strengthen its overall medical device lineup. The company boosted its sales by nearly 4% from the year-ago quarter, and adjusted earnings also managed to climb modestly and satisfy investors who were bracing for a flat performance from J&J. The company also boosted its sales and earnings guidance for 2016, citing hopes that significant clinical milestones in its pipeline of candidate drugs could help push results upward even further in the long run. | For instance, in September, J&J bought the Abbott Medical Optics eye-surgery equipment unit of Abbott Laboratories (NYSE: ABT) , paying $4.3 billion to strengthen its overall medical device lineup. How J&J sees better times ahead New products are an important driver of growth for Johnson & Johnson, and the company has high hopes for some of its more recent offerings. Further candidate drugs within the pipeline also take aim squarely at cancer, and with a mix of treatments that serve large populations more effectively than competing drugs as well as those serving small populations for which previous treatments have been unavailable, Johnson & Johnson expects oncology to keep gaining in importance. | For instance, in September, J&J bought the Abbott Medical Optics eye-surgery equipment unit of Abbott Laboratories (NYSE: ABT) , paying $4.3 billion to strengthen its overall medical device lineup. As investors prepare for Tuesday's third-quarter financial report from Johnson & Johnson, they want to see whether the company can keep producing the growth in revenue and earnings that they've come to expect. In the Johnson & Johnson earnings report, investors will want to keep a close eye not only on whether the pharmaceutical business continues to take the lead in producing growth but also on the contributions that the medical device and consumer segments are able to make to its overall success. | For instance, in September, J&J bought the Abbott Medical Optics eye-surgery equipment unit of Abbott Laboratories (NYSE: ABT) , paying $4.3 billion to strengthen its overall medical device lineup. At the same time, Johnson & Johnson is trying to serve the growing market for those with diabetes. In the Johnson & Johnson earnings report, investors will want to keep a close eye not only on whether the pharmaceutical business continues to take the lead in producing growth but also on the contributions that the medical device and consumer segments are able to make to its overall success. |
33766.0 | 2016-10-11 00:00:00 UTC | iShares U.S. Medical Devices ETF Experiences Big Inflow | ABT | https://www.nasdaq.com/articles/ishares-us-medical-devices-etf-experiences-big-inflow-2016-10-11 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $50.8 million dollar inflow -- that's a 3.6% increase week over week in outstanding units (from 9,800,000 to 10,150,000). Among the largest underlying components of IHI, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is off about 2.5%, Abbott Laboratories (Symbol: ABT) is off about 4.4%, and Danaher Corp (Symbol: DHR) is lower by about 1.9%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average:
Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $146.9108 as the 52 week high point - that compares with a last trade of $143.50. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IHI, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is off about 2.5%, Abbott Laboratories (Symbol: ABT) is off about 4.4%, and Danaher Corp (Symbol: DHR) is lower by about 1.9%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $146.9108 as the 52 week high point - that compares with a last trade of $143.50. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IHI, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is off about 2.5%, Abbott Laboratories (Symbol: ABT) is off about 4.4%, and Danaher Corp (Symbol: DHR) is lower by about 1.9%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $146.9108 as the 52 week high point - that compares with a last trade of $143.50. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IHI, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is off about 2.5%, Abbott Laboratories (Symbol: ABT) is off about 4.4%, and Danaher Corp (Symbol: DHR) is lower by about 1.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $50.8 million dollar inflow -- that's a 3.6% increase week over week in outstanding units (from 9,800,000 to 10,150,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $146.9108 as the 52 week high point - that compares with a last trade of $143.50. | Among the largest underlying components of IHI, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is off about 2.5%, Abbott Laboratories (Symbol: ABT) is off about 4.4%, and Danaher Corp (Symbol: DHR) is lower by about 1.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $50.8 million dollar inflow -- that's a 3.6% increase week over week in outstanding units (from 9,800,000 to 10,150,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $146.9108 as the 52 week high point - that compares with a last trade of $143.50. |
33767.0 | 2016-10-11 00:00:00 UTC | Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for October 12, 2016 | ABT | https://www.nasdaq.com/articles/abbott-laboratories-abt-ex-dividend-date-scheduled-october-12-2016-2016-10-11 | nan | nan | Abbott Laboratories ( ABT ) will begin trading ex-dividend on October 12, 2016. A cash dividend payment of $0.26 per share is scheduled to be paid on November 15, 2016. Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 4th quarter that ABT has paid the same dividend. At the current stock price of $43.5, the dividend yield is 2.39%.
The previous trading day's last sale of ABT was $43.5, representing a -6.21% decrease from the 52 week high of $46.38 and a 20.83% increase over the 52 week low of $36.
ABT is a part of the Health Care sector, which includes companies such as Johnson & Johnson ( JNJ ) and Pfizer, Inc. ( PFE ). ABT's current earnings per share, an indicator of a company's profitability, is $1.51. Zacks Investment Research reports ABT's forecasted earnings growth in 2016 as 2.29%, compared to an industry average of 5%.
For more information on the declaration, record and payment dates, visit the ABT Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to ABT through an Exchange Traded Fund [ETF]?
The following ETF(s) have ABT as a top-10 holding:
PowerShares Dynamic Pharmaceuticals ( PJP )
PowerShares Russell Top 200 Pure Value Portfolio ( PXLV ).
The top-performing ETF of this group is PXLV with an increase of 8.88% over the last 100 days. PJP has the highest percent weighting of ABT at 4.22%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports ABT's forecasted earnings growth in 2016 as 2.29%, compared to an industry average of 5%. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. | ABT's current earnings per share, an indicator of a company's profitability, is $1.51. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott Laboratories ( ABT ) will begin trading ex-dividend on October 12, 2016. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. The following ETF(s) have ABT as a top-10 holding: PowerShares Dynamic Pharmaceuticals ( PJP ) PowerShares Russell Top 200 Pure Value Portfolio ( PXLV ). | ABT's current earnings per share, an indicator of a company's profitability, is $1.51. Abbott Laboratories ( ABT ) will begin trading ex-dividend on October 12, 2016. Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. |
33768.0 | 2016-10-11 00:00:00 UTC | Pre-Market Most Active for Oct 11, 2016 : AAPL, STJ, ABT, TWTR, MT, ILMN, TVIX, BCS, ABX, SUPN, SQQQ, QQQ | ABT | https://www.nasdaq.com/articles/pre-market-most-active-oct-11-2016-aapl-stj-abt-twtr-mt-ilmn-tvix-bcs-abx-supn-sqqq-qqq | nan | nan | The NASDAQ 100 Pre-Market Indicator is up 3.98 to 4,897.75. The total Pre-Market volume is currently 6,466,895 shares traded.
The following are the most active stocks for the pre-market session :
Apple Inc. ( AAPL ) is +2.13 at $118.18, with 1,863,628 shares traded. As reported by Zacks, the current mean recommendation for AAPL is in the "buy range".
St. Jude Medical, Inc. ( STJ ) is -2.54 at $78.74, with 1,404,196 shares traded. STJ's current last sale is 95.15% of the target price of $82.75.
Abbott Laboratories ( ABT ) is -0.15 at $43.35, with 948,800 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range".
Twitter, Inc. ( TWTR ) is +0.4 at $17.96, with 608,472 shares traded. TWTR's current last sale is 112.25% of the target price of $16.
ArcelorMittal ( MT ) is -0.02 at $6.40, with 546,094 shares traded. As reported by Zacks, the current mean recommendation for MT is in the "buy range".
Illumina, Inc. ( ILMN ) is -49.01 at $135.84, with 267,705 shares traded.ILMN is scheduled to provide an earnings report on 10/18/2016, for the fiscal quarter ending Sep2016. The consensus earnings per share forecast is 0.91 per share, which represents a 80 percent increase over the EPS one Year Ago
VelocityShares Daily 2x VIX Short Term ETN ( TVIX ) is +0.25 at $16.81, with 240,002 shares traded., following a 52-week high recorded in prior regular session.
Barclays PLC ( BCS ) is -0.04 at $8.49, with 222,164 shares traded. BCS's current last sale is 86.19% of the target price of $9.85.
Barrick Gold Corporation ( ABX ) is -0.13 at $15.45, with 199,983 shares traded. ABX's current last sale is 75.37% of the target price of $20.5.
Supernus Pharmaceuticals, Inc. ( SUPN ) is +1.63 at $26.32, with 119,410 shares traded. As reported by Zacks, the current mean recommendation for SUPN is in the "buy range".
ProShares UltraPro Short QQQ ( SQQQ ) is +0.04 at $13.21, with 107,459 shares traded., following a 52-week high recorded in prior regular session.
PowerShares QQQ Trust, Series 1 ( QQQ ) is -0.07 at $119.15, with 106,202 shares traded. This represents a 25.63% increase from its 52 Week Low.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is -0.15 at $43.35, with 948,800 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range". The following are the most active stocks for the pre-market session : Apple Inc. ( AAPL ) is +2.13 at $118.18, with 1,863,628 shares traded. | Abbott Laboratories ( ABT ) is -0.15 at $43.35, with 948,800 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range". The consensus earnings per share forecast is 0.91 per share, which represents a 80 percent increase over the EPS one Year Ago VelocityShares Daily 2x VIX Short Term ETN ( TVIX ) is +0.25 at $16.81, with 240,002 shares traded., following a 52-week high recorded in prior regular session. | Abbott Laboratories ( ABT ) is -0.15 at $43.35, with 948,800 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range". The total Pre-Market volume is currently 6,466,895 shares traded. | As reported by Zacks, the current mean recommendation for ABT is in the "buy range". Abbott Laboratories ( ABT ) is -0.15 at $43.35, with 948,800 shares traded. The NASDAQ 100 Pre-Market Indicator is up 3.98 to 4,897.75. |
33769.0 | 2016-10-10 00:00:00 UTC | Ex-Dividend Reminder: Abbott Laboratories, PerkinElmer and Mid-America Apartment Communities | ABT | https://www.nasdaq.com/articles/ex-dividend-reminder-abbott-laboratories-perkinelmer-and-mid-america-apartment-communities | nan | nan | Looking at the universe of stocks we cover at Dividend Channel , on 10/12/16, Abbott Laboratories (Symbol: ABT), PerkinElmer, Inc. (Symbol: PKI), and Mid-America Apartment Communities Inc (Symbol: MAA) will all trade ex-dividend for their respective upcoming dividends. Abbott Laboratories will pay its quarterly dividend of $0.26 on 11/15/16, PerkinElmer, Inc. will pay its quarterly dividend of $0.07 on 11/10/16, and Mid-America Apartment Communities Inc will pay its quarterly dividend of $0.82 on 10/31/16. As a percentage of ABT's recent stock price of $43.24, this dividend works out to approximately 0.60%, so look for shares of Abbott Laboratories to trade 0.60% lower - all else being equal - when ABT shares open for trading on 10/12/16. Similarly, investors should look for PKI to open 0.12% lower in price and for MAA to open 0.95% lower, all else being equal.
Below are dividend history charts for ABT, PKI, and MAA, showing historical dividends prior to the most recent ones declared.
Abbott Laboratories (Symbol: ABT) :
PerkinElmer, Inc. (Symbol: PKI) :
Mid-America Apartment Communities Inc (Symbol: MAA) :
In general, dividends are not always predictable, following the ups and downs of company profits over time. Therefore, a good first due diligence step in forming an expectation of annual yield going forward, is looking at the history above, for a sense of stability over time. This can help in judging whether the most recent dividends from these companies are likely to continue. If they do continue, the current estimated yields on annualized basis would be 2.41% for Abbott Laboratories, 0.50% for PerkinElmer, Inc., and 3.79% for Mid-America Apartment Communities Inc.
In Monday trading, Abbott Laboratories shares are currently up about 0.6%, PerkinElmer, Inc. shares are up about 0.6%, and Mid-America Apartment Communities Inc shares are up about 0.7% on the day.
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | As a percentage of ABT's recent stock price of $43.24, this dividend works out to approximately 0.60%, so look for shares of Abbott Laboratories to trade 0.60% lower - all else being equal - when ABT shares open for trading on 10/12/16. Looking at the universe of stocks we cover at Dividend Channel , on 10/12/16, Abbott Laboratories (Symbol: ABT), PerkinElmer, Inc. (Symbol: PKI), and Mid-America Apartment Communities Inc (Symbol: MAA) will all trade ex-dividend for their respective upcoming dividends. Below are dividend history charts for ABT, PKI, and MAA, showing historical dividends prior to the most recent ones declared. | Looking at the universe of stocks we cover at Dividend Channel , on 10/12/16, Abbott Laboratories (Symbol: ABT), PerkinElmer, Inc. (Symbol: PKI), and Mid-America Apartment Communities Inc (Symbol: MAA) will all trade ex-dividend for their respective upcoming dividends. Abbott Laboratories (Symbol: ABT) : PerkinElmer, Inc. (Symbol: PKI) : Mid-America Apartment Communities Inc (Symbol: MAA) : In general, dividends are not always predictable, following the ups and downs of company profits over time. As a percentage of ABT's recent stock price of $43.24, this dividend works out to approximately 0.60%, so look for shares of Abbott Laboratories to trade 0.60% lower - all else being equal - when ABT shares open for trading on 10/12/16. | Looking at the universe of stocks we cover at Dividend Channel , on 10/12/16, Abbott Laboratories (Symbol: ABT), PerkinElmer, Inc. (Symbol: PKI), and Mid-America Apartment Communities Inc (Symbol: MAA) will all trade ex-dividend for their respective upcoming dividends. Abbott Laboratories (Symbol: ABT) : PerkinElmer, Inc. (Symbol: PKI) : Mid-America Apartment Communities Inc (Symbol: MAA) : In general, dividends are not always predictable, following the ups and downs of company profits over time. As a percentage of ABT's recent stock price of $43.24, this dividend works out to approximately 0.60%, so look for shares of Abbott Laboratories to trade 0.60% lower - all else being equal - when ABT shares open for trading on 10/12/16. | Looking at the universe of stocks we cover at Dividend Channel , on 10/12/16, Abbott Laboratories (Symbol: ABT), PerkinElmer, Inc. (Symbol: PKI), and Mid-America Apartment Communities Inc (Symbol: MAA) will all trade ex-dividend for their respective upcoming dividends. As a percentage of ABT's recent stock price of $43.24, this dividend works out to approximately 0.60%, so look for shares of Abbott Laboratories to trade 0.60% lower - all else being equal - when ABT shares open for trading on 10/12/16. Below are dividend history charts for ABT, PKI, and MAA, showing historical dividends prior to the most recent ones declared. |
33770.0 | 2016-10-07 00:00:00 UTC | Did Pfizer's No-Split Decision Cost Investors a Lot of Money? | ABT | https://www.nasdaq.com/articles/did-pfizers-no-split-decision-cost-investors-lot-money-2016-10-07 | nan | nan | PFE data by YCharts .
But this isn't the best comparison. I'd instead look at a similar choice faced by Abbott Labs (NYSE: ABT) . Back in 2011, Abbott announced plans to separate into two companies -- one focused on branded prescription drugs and the other focused on products including medical devices and generic drugs. Abbott CEO Miles White promoted the split as a move that would stir investor interest and create more value for shareholders.
White was right on target. On Jan. 2, 2013, AbbVie (NYSE: ABBV) opened its doors as a new publicly traded company. The biotech's products included blockbuster drug Humira and a strong pipeline. Here's how shares of AbbVie and Abbott have performed since then:
ABT data by YCharts .
Could Pfizer have achieved these kind of results with a PfiVie spin-off? Maybe not. After all, Pfizer doesn't have a drug that matches the superstar status of Humira. However, the company's innovative health segment includes blockbuster drug Lyrica IH, which posted an impressive 19% year-over-year growth rate in the first half of 2016. Several other drugs are rising stars, with Ibrance and Xeljanz leading the way.
Acquisitions are also bolstering Pfizer's innovative health lineup. The buyout of Anacor Pharmaceuticals in June added promising atopic dermatitis drug crisaborole. Pfizer's recently completed acquisition of Medivation gives it prostate cancer drug Xtandi.
Meanwhile, Pfizer's essential health unit includes plenty of drugs with declining sales like Lipitor and Zoloft. Last year's acquisition of Hospira added injectable drugs and biosimilars, which give the essential health business segment a pathway to growth.
The right call?
Pfizer says that it can drive value more effectively for shareholders by remaining intact. By operating two units within the same corporate umbrella, Pfizer is "already accessing many of the potential benefits of a split -- sharper focus, increased accountability, and a greater sense of urgency," says CEO Ian Read.
I don't doubt that Read is correct. However, I wonder if the company might have underappreciated the psychological boost a split could have had in the investor community. Pfizer has been something of a "blah" stock for a while now. I'm just not sure that's going to change significantly without a major splash like a split could have provided.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
Keith Speights has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | I'd instead look at a similar choice faced by Abbott Labs (NYSE: ABT) . Here's how shares of AbbVie and Abbott have performed since then: ABT data by YCharts . However, the company's innovative health segment includes blockbuster drug Lyrica IH, which posted an impressive 19% year-over-year growth rate in the first half of 2016. | I'd instead look at a similar choice faced by Abbott Labs (NYSE: ABT) . Here's how shares of AbbVie and Abbott have performed since then: ABT data by YCharts . The biotech's products included blockbuster drug Humira and a strong pipeline. | I'd instead look at a similar choice faced by Abbott Labs (NYSE: ABT) . Here's how shares of AbbVie and Abbott have performed since then: ABT data by YCharts . Back in 2011, Abbott announced plans to separate into two companies -- one focused on branded prescription drugs and the other focused on products including medical devices and generic drugs. | Here's how shares of AbbVie and Abbott have performed since then: ABT data by YCharts . I'd instead look at a similar choice faced by Abbott Labs (NYSE: ABT) . Abbott CEO Miles White promoted the split as a move that would stir investor interest and create more value for shareholders. |
33771.0 | 2016-10-03 00:00:00 UTC | Endo International Reports Positive Phase II Data on Xiaflex | ABT | https://www.nasdaq.com/articles/endo-international-reports-positive-phase-ii-data-on-xiaflex-2016-10-03 | nan | nan | Endo International plc'sENDP subsidiary Endo Pharmaceuticals Inc. announced positive data from a phase II trial which evaluated the safety and efficacy of Xiaflex (collagenase clostridium histolyticum) injection for the treatment of palmar Dupuytren's disease nodules.
Endo International added Xiaflex to its portfolio after the acquisition of Auxilium Pharma in Jan 2015.
The randomized, double-blind, placebo-controlled, dose-ranging study was conducted in 75 adult participants with Dupuytren's disease and at least 1 nodule. The participants received a single injection of CCH 0.40 mg or 0.60 mg. The majority of participants were satisfied with their treatment.
Meanwhile, 88.9% in 0.40 mg CCH group and 83.3% in the 0.60 mg CCH group were "very satisfied" or "quite satisfied" at week 8, compared to placebo. CCH was well tolerated during the study with only one adverse event reported as severe. However, no discontinuation was reported from the study because of an adverse event.
Meanwhile, Xiaflex is also being evaluated in a phase II study for the treatment of adhesive capsulitis.
We note that Xiaflex is currently approved in the U.S., EU, Canada and Australia for the treatment of Dupuytren's contracture (DC) in adult patients with a palpable cord, and approved in U.S. for Peyronie's disease (PD) in adult men with a palpable plaque and penile curvature deformity of at least 30 degrees at the start of therapy. Xiaflex enjoys Orphan drug status for both the indications in the U.S. and is the only FDA-approved treatment of adult patients with DC with a palpable cord.
Xiaflex recorded revenues of $86.4 million in the first six months of 2016, registering an increase of 27.2% compared to the first six months of 2015.
Moreover, additional studies on Xiaflex are expected to be initiated for other indications, such as plantar fibromatosis and lateral hip fat, later in 2016.
ENDO INTL PLC Price
ENDO INTL PLC Price | ENDO INTL PLC Quote
Zacks Rank & Key Picks
AbbVie Inc. currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in health care sector include Anika Therapeutics Inc ANIK , ANI Pharmaceuticals, Inc. ANIP and Abbott Laboratories ABT .
Anika Therapeutics - a Zacks Rank #1 (Strong Buy) stock - has seen its earnings estimates for 2016 and 2017 rise 9.4% and 11.5%, respectively, over the last 60 days. The company recorded a positive earnings surprise in each of the last four quarters, with an average beat of 42.19%. Its share price jumped 25.6% year to date.
ANI Pharmaceuticals witnessed an increase of 9.5% and 4.7% in its earnings estimates for 2016 and 2017, respectively, in the last 60 days. It has beaten earnings estimates twice in the last four quarters, reaching the average to 46.85%. The company's stock has rallied 50.6% year to date. The company also sports a Zacks Rank #1. You can see the complete list of today's Zacks #1 Rank stocks here .
Abbott Laboratories carries a Zacks Rank #2 (Buy). The earnings estimates for 2016 and 2017 almost remained unchanged over the past 60 days. The company recorded a positive earnings surprise in each of the last four quarters, with an average beat of 3.11%. Share price of the company has risen marginally on a year-to-date basis.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
ANIKA THERAPEUT (ANIK): Free Stock Analysis Report
ENDO INTL PLC (ENDP): Free Stock Analysis Report
ANI PHARMACEUT (ANIP): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Better-ranked stocks in health care sector include Anika Therapeutics Inc ANIK , ANI Pharmaceuticals, Inc. ANIP and Abbott Laboratories ABT . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ENDO INTL PLC (ENDP): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Xiaflex is currently approved in the U.S., EU, Canada and Australia for the treatment of Dupuytren's contracture (DC) in adult patients with a palpable cord, and approved in U.S. for Peyronie's disease (PD) in adult men with a palpable plaque and penile curvature deformity of at least 30 degrees at the start of therapy. | Better-ranked stocks in health care sector include Anika Therapeutics Inc ANIK , ANI Pharmaceuticals, Inc. ANIP and Abbott Laboratories ABT . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ENDO INTL PLC (ENDP): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. ENDO INTL PLC Price ENDO INTL PLC Price | ENDO INTL PLC Quote Zacks Rank & Key Picks AbbVie Inc. currently carries a Zacks Rank #3 (Hold). | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ENDO INTL PLC (ENDP): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Better-ranked stocks in health care sector include Anika Therapeutics Inc ANIK , ANI Pharmaceuticals, Inc. ANIP and Abbott Laboratories ABT . Endo International plc'sENDP subsidiary Endo Pharmaceuticals Inc. announced positive data from a phase II trial which evaluated the safety and efficacy of Xiaflex (collagenase clostridium histolyticum) injection for the treatment of palmar Dupuytren's disease nodules. | Better-ranked stocks in health care sector include Anika Therapeutics Inc ANIK , ANI Pharmaceuticals, Inc. ANIP and Abbott Laboratories ABT . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ENDO INTL PLC (ENDP): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Anika Therapeutics - a Zacks Rank #1 (Strong Buy) stock - has seen its earnings estimates for 2016 and 2017 rise 9.4% and 11.5%, respectively, over the last 60 days. |
33772.0 | 2016-10-03 00:00:00 UTC | J&J's Psoriasis Drug Shows Superior Efficacy Over Humira | ABT | https://www.nasdaq.com/articles/jjs-psoriasis-drug-shows-superior-efficacy-over-humira-2016-10-03 | nan | nan | Johnson & JohnsonJNJ subsidiary, Janssen Therapeutics announced that data presented from a phase III trial showed superior efficacy of its pipeline candidate guselkumab, over AbbVie Inc.'s ABBV drug Humira in the treatment of moderate-to-severe plaque psoriasis.
Data from the VOYAGE 1 trial (n=837) showed that significantly higher proportions of patients with moderate-to-severe plaque psoriasis treated with guselkumab achieved high rates of skin clearance compared to those receiving placebo. 73% of the patients receiving guselkumab achieved near complete skin clearance versus 2.9% on placebo.
The active comparator arm of the VOYAGE trial evaluated guselkumab versus top-selling medicine Humira. The study demonstrated the statistically significant efficacy of guselkumab compared to Humira after week 16 which was maintained through 48 weeks of treatment. Almost 50% of patients treated with Humira achieved near complete skin clearance versus 73% for guselkumab.
JOHNSON & JOHNS Price
JOHNSON & JOHNS Price | JOHNSON & JOHNS Quote
Humira is also approved for the treatment of rheumatoid arthritis and other autoimmune conditions.
The data was presented at the European Academy of Dermatology and Venereology (EADV) Congress in Austria.
Guselkumab, an anti-IL-23 human monoclonal antibody, is being evaluated in three pivotal phase III studies - VOYAGE 1, VOYAGE 2 and NAVIGATE - for moderate-to-severe plaque psoriasis. A phase II trial evaluating guselkumab in moderate-to-severely active psoriatic arthritis is also ongoing.
J&J carries a Zacks Rank #3 (Hold). Stocks worth considering in the large-cap healthcare sector are Eli Lilly and Co. LLY and Abbott Laboratories ABT .
Eli Lilly has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Eli Lilly has delivered an average four quarter positive earnings surprise of 4.31%. Its earnings estimate for 2016 has risen by 0.3% while that for 2017 has risen more than 2% over the last 90 days.
Abbott, also enjoying a Zacks Rank #2, has delivered positive earnings surprises for the past four straight quarters, with an average surprise of 3.11%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
LILLY ELI & CO (LLY): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks worth considering in the large-cap healthcare sector are Eli Lilly and Co. LLY and Abbott Laboratories ABT . Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Johnson & JohnsonJNJ subsidiary, Janssen Therapeutics announced that data presented from a phase III trial showed superior efficacy of its pipeline candidate guselkumab, over AbbVie Inc.'s ABBV drug Humira in the treatment of moderate-to-severe plaque psoriasis. | Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks worth considering in the large-cap healthcare sector are Eli Lilly and Co. LLY and Abbott Laboratories ABT . Data from the VOYAGE 1 trial (n=837) showed that significantly higher proportions of patients with moderate-to-severe plaque psoriasis treated with guselkumab achieved high rates of skin clearance compared to those receiving placebo. | Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks worth considering in the large-cap healthcare sector are Eli Lilly and Co. LLY and Abbott Laboratories ABT . Johnson & JohnsonJNJ subsidiary, Janssen Therapeutics announced that data presented from a phase III trial showed superior efficacy of its pipeline candidate guselkumab, over AbbVie Inc.'s ABBV drug Humira in the treatment of moderate-to-severe plaque psoriasis. | Stocks worth considering in the large-cap healthcare sector are Eli Lilly and Co. LLY and Abbott Laboratories ABT . Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Johnson & JohnsonJNJ subsidiary, Janssen Therapeutics announced that data presented from a phase III trial showed superior efficacy of its pipeline candidate guselkumab, over AbbVie Inc.'s ABBV drug Humira in the treatment of moderate-to-severe plaque psoriasis. |
33773.0 | 2016-09-30 00:00:00 UTC | Boston Scientific to Buy EndoChoice, Boost Endoscopy Line | ABT | https://www.nasdaq.com/articles/boston-scientific-to-buy-endochoice-boost-endoscopy-line-2016-09-30 | nan | nan | In an effort to boost its endoscopy business, medical device major, Boston ScientificBSX recently entered into a definitive agreement to acquire EndoChoice Holdings, Inc. GI . The deal has been inked at a total equity value of approximately $210 million.
Boston Scientific will launch a tender offer for all outstanding shares of EndoChoice at a cash price of $8.00 per share. The transaction is expected to close in the fourth quarter of 2016, subject to certain closing conditions.
Atlanta, GA-based EndoChoice works on platform technologies, including endoscopic imaging systems, devices and infection control products and pathology services for specialists, which are helpful in treating various gastrointestinal conditions, including colon cancer. The company's products and services include single-use devices, such as resection and retrieval devices, needles, graspers and infection control kits. It also caters to pathology services and imaging technologies.
According to Boston Scientific, post the completion of this acquisition, EndoChoice's vast portfolio will be integrated with its Endoscopy division. This will therefore enable the company to provide better comprehensive gastroenterology solutions. This should also expand Boston Scientific's foothold in the new categories within the endoscopy market.
Financial Benefits
The inclusion of EndoChoice that generated revenues of $75 million over the last fiscal year, is expected to be breakeven to Boston Scientific's adjusted earnings per share in 2017 and accretive thereafter.
We note that Boston Scietific continues to perform well in its Endoscopy business. The company's single-use SpyGlass DS visualization system, the AXIOS stent for drainage of pancreatic fluid and next-generation hemostasis clip - the Resolution 360 were the key factors that drove sales growth in this business division in the last reported second quarter.
Management was particularly upbeat about the high-single-digit growth in this business' U.S. franchise, while overseas too, the unit delivered strong double-digit growth. Management was further encouraged to note consistent strong growth in the core Endo business, on the back of this business' innovative portfolio and broad-based global expansion initiatives.
Going ahead, management is determined to continue to innovate in endoscopic ultrasound and other exciting therapeutic categories including pulmonary and oncology to further enhance the company's global leadership in endoscopy. We believe the latest acquisition, post closure, will further boost the company's growing Endoscopy business worldwide.
Two other stocks that warrant a look in the gastrointestinal market are Medtronic plc MDT and Abbott Laboratories ABT .
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
MEDTRONIC (MDT): Free Stock Analysis Report
ENDOCHOICE HLDG (GI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Two other stocks that warrant a look in the gastrointestinal market are Medtronic plc MDT and Abbott Laboratories ABT . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report BOSTON SCIENTIF (BSX): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report ENDOCHOICE HLDG (GI): Free Stock Analysis Report To read this article on Zacks.com click here. In an effort to boost its endoscopy business, medical device major, Boston ScientificBSX recently entered into a definitive agreement to acquire EndoChoice Holdings, Inc. GI . | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report BOSTON SCIENTIF (BSX): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report ENDOCHOICE HLDG (GI): Free Stock Analysis Report To read this article on Zacks.com click here. Two other stocks that warrant a look in the gastrointestinal market are Medtronic plc MDT and Abbott Laboratories ABT . Atlanta, GA-based EndoChoice works on platform technologies, including endoscopic imaging systems, devices and infection control products and pathology services for specialists, which are helpful in treating various gastrointestinal conditions, including colon cancer. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report BOSTON SCIENTIF (BSX): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report ENDOCHOICE HLDG (GI): Free Stock Analysis Report To read this article on Zacks.com click here. Two other stocks that warrant a look in the gastrointestinal market are Medtronic plc MDT and Abbott Laboratories ABT . Atlanta, GA-based EndoChoice works on platform technologies, including endoscopic imaging systems, devices and infection control products and pathology services for specialists, which are helpful in treating various gastrointestinal conditions, including colon cancer. | Two other stocks that warrant a look in the gastrointestinal market are Medtronic plc MDT and Abbott Laboratories ABT . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report BOSTON SCIENTIF (BSX): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report ENDOCHOICE HLDG (GI): Free Stock Analysis Report To read this article on Zacks.com click here. Atlanta, GA-based EndoChoice works on platform technologies, including endoscopic imaging systems, devices and infection control products and pathology services for specialists, which are helpful in treating various gastrointestinal conditions, including colon cancer. |
33774.0 | 2016-09-30 00:00:00 UTC | Health Care Sector Update for 09/30/2016: JNJ, PFE, ABT, MRK, AMGN, AUPH, THLD | ABT | https://www.nasdaq.com/articles/health-care-sector-update-09302016-jnj-pfe-abt-mrk-amgn-auph-thld-2016-09-30 | nan | nan | Top Health-care stocks:
JNJ: +0.5%
PFE: +0.2%
ABT: flat
MRK: +1.7%
AMGN: flat
Health care shares were mostly higher in pre-market trade Friday.
In health care stocks news, Aurinia Pharmaceuticals ( AUPH ) was up 14% after it said late Thursday voclosporin achieved the primary endpoint of complete remission at 24 weeks as well as pre-specified secondary endpoints in its phase 2b AURA-LV study for Lupus Nephritis. The study is ongoing to its 48-week endpoint, when similar and additional secondary analysis will be conducted and presented early next year.
And, Threshold Pharmaceuticals ( THLD ) tumbled 57.6% after company said its two phase 2 proof-of-concept clinical trials of tarloxotinib didn't meet the activity thresholds required to move forward, despite more promising results seen in preclinical translational studies. The company said that, as a result, it will not make any further investment in this program, and instead will focus resources on the evofosfamide program as well as an earlier-stage anticancer candidate, TH-3424. For evofosfamide, the company said it plans to demonstrate the potential therapeutic value of adding evofosfamide to immune checkpoint inhibition, to continue to pursue discussions with Japanese regulatory authorities regarding potential registration pathways for evofosfamide, and to advance TH-3424 through IND-enabling toxicology studies with the goal of reaching the clinic in 2017.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat AMGN: flat Health care shares were mostly higher in pre-market trade Friday. In health care stocks news, Aurinia Pharmaceuticals ( AUPH ) was up 14% after it said late Thursday voclosporin achieved the primary endpoint of complete remission at 24 weeks as well as pre-specified secondary endpoints in its phase 2b AURA-LV study for Lupus Nephritis. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ABT: flat AMGN: flat Health care shares were mostly higher in pre-market trade Friday. | ABT: flat In health care stocks news, Aurinia Pharmaceuticals ( AUPH ) was up 14% after it said late Thursday voclosporin achieved the primary endpoint of complete remission at 24 weeks as well as pre-specified secondary endpoints in its phase 2b AURA-LV study for Lupus Nephritis. And, Threshold Pharmaceuticals ( THLD ) tumbled 57.6% after company said its two phase 2 proof-of-concept clinical trials of tarloxotinib didn't meet the activity thresholds required to move forward, despite more promising results seen in preclinical translational studies. | ABT: flat Top Health-care stocks: AMGN: flat Health care shares were mostly higher in pre-market trade Friday. |
33775.0 | 2016-09-29 00:00:00 UTC | Noteworthy ETF Inflows: IHI, TMO, ABT, DHR | ABT | https://www.nasdaq.com/articles/noteworthy-etf-inflows-ihi-tmo-abt-dhr-2016-09-29 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $58.2 million dollar inflow -- that's a 4.2% increase week over week in outstanding units (from 9,450,000 to 9,850,000). Among the largest underlying components of IHI, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is off about 0.2%, Abbott Laboratories (Symbol: ABT) is off about 0.5%, and Danaher Corp (Symbol: DHR) is lower by about 0.3%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average:
Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $146.48 as the 52 week high point - that compares with a last trade of $144.65. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IHI, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is off about 0.2%, Abbott Laboratories (Symbol: ABT) is off about 0.5%, and Danaher Corp (Symbol: DHR) is lower by about 0.3%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $146.48 as the 52 week high point - that compares with a last trade of $144.65. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IHI, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is off about 0.2%, Abbott Laboratories (Symbol: ABT) is off about 0.5%, and Danaher Corp (Symbol: DHR) is lower by about 0.3%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $146.48 as the 52 week high point - that compares with a last trade of $144.65. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IHI, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is off about 0.2%, Abbott Laboratories (Symbol: ABT) is off about 0.5%, and Danaher Corp (Symbol: DHR) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $58.2 million dollar inflow -- that's a 4.2% increase week over week in outstanding units (from 9,450,000 to 9,850,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $146.48 as the 52 week high point - that compares with a last trade of $144.65. | Among the largest underlying components of IHI, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is off about 0.2%, Abbott Laboratories (Symbol: ABT) is off about 0.5%, and Danaher Corp (Symbol: DHR) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $58.2 million dollar inflow -- that's a 4.2% increase week over week in outstanding units (from 9,450,000 to 9,850,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $146.48 as the 52 week high point - that compares with a last trade of $144.65. |
33776.0 | 2016-09-29 00:00:00 UTC | 7 Healthcare Stocks in Focus on World Heart Day | ABT | https://www.nasdaq.com/articles/7-healthcare-stocks-focus-world-heart-day-2016-09-29 | nan | nan | Every year on Sep 29, World Heart Day is observed to raise awareness about cardiovascular (CV) diseases including heart disease and stroke. The focus is on creating heart-healthy environments that will help reduce cardiovascular risk be it at work or at home.
According to the World Heart Federation, CV diseases are the most common cause of death across the world with more than 17 million people dying annually. This figure is expected to cross 23 million by 2030. Some of the factors contributing to these numbers include uncontrolled hypertension, high cholesterol levels, obesity, smoking, diabetes and a sedentary lifestyle.
According to information provided by the Centers for Disease Control and Prevention (CDC), more than 610,000 people die of heart disease in the U.S. every year and about 735,000 Americans have a heart attack.
Given these statistics, it is not surprising that several healthcare companies devote a significant amount of R&D dollars on developing treatments and devices for cardiovascular and other diseases that increase the risk of heart issues. And it is not just healthcare companies that are involved in the fitness segment - as people are becoming more conscious about their health, tech companies are coming out with fitness trackers that help keep track of heart rates, calories burned and sleep patterns.
This World Heart Day, let's take a look at some well-positioned stocks in this segment of the market.
Abbott Park, IL- based Abbott LaboratoriesABT has a strong presence in the cardiovascular disease device market. According to information provided by the company, in the U.S. alone, more than 40% of adults are expected to have one or more types of CV diseases by 2030. This Zacks Rank #2 (Buy) stock has several CV devices in its portfolio and recently gained FDA approval for its Absorb bioresorbable heart stent, making it the only fully dissolving stent in the U.S. for the treatment of coronary artery disease, which affects 15 million people in the U.S. and remains a leading cause of death worldwide.
Moreover, Abbott's upcoming acquisition of St. Jude Medical, which has a strong position in heart failure devices, atrial fibrillation and cardiac rhythm management, will complement Abbott's strength in coronary intervention and transcatheter mitral repair. Once the acquisition goes through, the combined company expects to compete in nearly every area of the large and high-growth cardiovascular device markets with an aggregate market opportunity of $30 billion.
ABBOTT LABS Price and Consensus
ABBOTT LABS Price and Consensus | ABBOTT LABS Quote
Marlborough, MA-based Boston Scientific CorporationBSX also has a strong position in the heart disease device market - the company's offerings in this segment include coronary stents, balloon catheters, rotational atherectomy systems, guide wires, guide catheters, embolic protection devices, crossing and re-entry devices for the treatment of chronically occluded coronary vessels, diagnostic catheters used in percutaneous transluminal coronary angioplasty procedures, and intravascular ultrasound (IVUS) imaging systems. Boston Scientific is a Zacks Rank #3 (Hold) stock.
BOSTON SCIENTIF Price and Consensus
BOSTON SCIENTIF Price and Consensus | BOSTON SCIENTIF Quote
Irvine, CA-based Edwards Lifesciences Corp.EW holds a leading position in patient-focused innovations for structural heart disease and critical care monitoring. The company's products like annuloplasty rings, catheters and heart valves enable the treatment of patients with cardiovascular disease. The company is focused on developing transformational structural heart therapies and estimates that the global transcatheter aortic valve replacement (TAVR) opportunity could cross $5 billion in 2021. This Zacks Rank #2 stock is a leader in the approximately $1.8 billion global surgical heart valve segment. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
EDWARDS LIFESCI Price and Consensus
EDWARDS LIFESCI Price and Consensus | EDWARDS LIFESCI Quote
Moving away from medical device companies, here is a look at some pharma and biotech stocks that are working on developing treatments for cardiovascular diseases as well as diseases like hypertension, cholesterol and diabetes that increase the risk of heart problems.
One such company is biotech giant Amgen Inc.AMGN - cardiovascular disease is one of the key focus areas for this Thousand Oaks, CA-based company. Two approved products within this segment include Repatha (a PCSK9 inhibitor for treating high cholesterol) and chronic heart failure treatment Corlanor. Meanwhile, Amgen's cardiovascular disease pipeline includes omecamtiv mecarbil (heart failure) and AMG 899 (a CETP inhibitor for the treatment of dyslipidemia). Amgen is a Zacks Rank #3 stock.
AMGEN INC Price and Consensus
AMGEN INC Price and Consensus | AMGEN INC Quote
Swiss company, Novartis AGNVS is also involved in the heart failure segment - the Zacks Rank #3 stock has an approved drug in the form of Entresto for the treatment of heart failure with reduced ejection fraction. According to a report from the American Heart Association, heart failure affects nearly 6 million Americans of whom 50% have the reduced ejection fraction form. More than 300,000 deaths due to this life-threatening condition are reported every year in the U.S.
Novartis recently announced that it will be conducting more than 40 studies on Entresto over a five-year period to generate additional data on the drug and to increase understanding of heart failure.
NOVARTIS AG-ADR Price and Consensus
NOVARTIS AG-ADR Price and Consensus | NOVARTIS AG-ADR Quote
While there are several companies like Merck, Novo Nordisk and Sanofi in the diabetes market, Indianapolis, IN-based Zacks Rank #2 stock Eli Lilly and CompanyLLY looks well positioned in this market. Approved products include Trulicity, Jardiance, Humalog, Basaglar and Trajenta. Lilly has quite a few diabetes treatments in development as well. According to information provided by the American Heart Association, adults with diabetes are two to four times more likely to have heart disease or a stroke than adults without diabetes.
LILLY ELI & CO Price and Consensus
LILLY ELI & CO Price and Consensus | LILLY ELI & CO Quote
New York-based Pfizer Inc.PFE also has quite a few compounds in its cardiovascular and metabolic diseases pipeline. These include bococizumab (a PCSK9 inhibitor for hyperlipidemia) and ertugliflozin (type II diabetes) as well as some mid- and early-stage candidates for acute coronary syndrome, type II diabetes and hyperlipidemia. The Zacks Rank #3 stock entered an agreement earlier this year with The California Institute for Biomedical Research for the development of antibody-based therapeutic agents for the treatment of heart failure. Pfizer is no stranger to this market considering one of its highest-selling drugs was cholesterol treatment Lipitor before it went generic.
PFIZER INC Price and Consensus
PFIZER INC Price and Consensus | PFIZER INC Quote
Looking for Ideas with Even Greater Upside?
Today's investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more. Click here for a peek at this private information >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PFIZER INC (PFE): Free Stock Analysis Report
LILLY ELI & CO (LLY): Free Stock Analysis Report
NOVARTIS AG-ADR (NVS): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
EDWARDS LIFESCI (EW): Free Stock Analysis Report
AMGEN INC (AMGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Park, IL- based Abbott LaboratoriesABT has a strong presence in the cardiovascular disease device market. Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BOSTON SCIENTIF (BSX): Free Stock Analysis Report EDWARDS LIFESCI (EW): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Given these statistics, it is not surprising that several healthcare companies devote a significant amount of R&D dollars on developing treatments and devices for cardiovascular and other diseases that increase the risk of heart issues. | Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BOSTON SCIENTIF (BSX): Free Stock Analysis Report EDWARDS LIFESCI (EW): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Park, IL- based Abbott LaboratoriesABT has a strong presence in the cardiovascular disease device market. BOSTON SCIENTIF Price and Consensus BOSTON SCIENTIF Price and Consensus | BOSTON SCIENTIF Quote Irvine, CA-based Edwards Lifesciences Corp.EW holds a leading position in patient-focused innovations for structural heart disease and critical care monitoring. | Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BOSTON SCIENTIF (BSX): Free Stock Analysis Report EDWARDS LIFESCI (EW): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Park, IL- based Abbott LaboratoriesABT has a strong presence in the cardiovascular disease device market. ABBOTT LABS Price and Consensus ABBOTT LABS Price and Consensus | ABBOTT LABS Quote Marlborough, MA-based Boston Scientific CorporationBSX also has a strong position in the heart disease device market - the company's offerings in this segment include coronary stents, balloon catheters, rotational atherectomy systems, guide wires, guide catheters, embolic protection devices, crossing and re-entry devices for the treatment of chronically occluded coronary vessels, diagnostic catheters used in percutaneous transluminal coronary angioplasty procedures, and intravascular ultrasound (IVUS) imaging systems. | Abbott Park, IL- based Abbott LaboratoriesABT has a strong presence in the cardiovascular disease device market. Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BOSTON SCIENTIF (BSX): Free Stock Analysis Report EDWARDS LIFESCI (EW): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Two approved products within this segment include Repatha (a PCSK9 inhibitor for treating high cholesterol) and chronic heart failure treatment Corlanor. |
33777.0 | 2016-09-28 00:00:00 UTC | Pain Therapeutics (PTIE) Down on CRL for Chronic Pain Drug | ABT | https://www.nasdaq.com/articles/pain-therapeutics-ptie-down-crl-chronic-pain-drug-2016-09-28 | nan | nan | Pain Therapeutics Inc. 's PTIE shares plunged 51.3% after the company announced that the FDA has issued a complete response letter (CRL) for the new drug application (NDA) for its lead candidate Remoxy ER (oxycodone capsules). The company was looking to get Remoxy approved for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, for which alternative treatment options are inadequate. Overall, the company's shares have declined 56.4%.
The FDA said that Remoxy cannot be approved in its present form. In the CRL, the agency has asked the company to conduct additional studies that are required to gain approval for Remoxy, with label claims on three routes of abuse (injection, inhalation and snorting).
The company had also sought for a label claim against abuse by chewing. In its CRL, the FDA asked company to submit a revised label proposal for the claim.
However, the company confirmed that the FDA did not bring up any safety, efficacy, manufacturing, stability, bioequivalence or any other issue that were raised in the previous CRL. We remind investors that this is the third time that the FDA has issued a CRL for Remoxy.
Pain Therapeutics said that it is currently evaluating the CRL and intends to hold further discussions with the regulatory body. The company said that the additional actions requisitioned by the FDA in the CRL may take approximately a year to conduct and cost the company about $5 million.
The CRL is a huge setback for the company as it is highly dependent on Remoxy for growth and has no approved product in its portfolio. A positive response from the agency would have enabled the company to launch its first drug.
PAIN THERAPEUT Price
PAIN THERAPEUT Price | PAIN THERAPEUT Quote
Zacks Rank & Key Picks
Pain Therapeutics currently carries a Zacks Rank #2 (Buy). Some other favorably placed stocks in health care sector include Anika Therapeutics Inc ANIK , ANI Pharmaceuticals, Inc. ANIP and Abbott Laboratories ABT . All the three stocks sport a a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Anika Therapeutics' earnings estimates for 2016 and 2017 were up a respective 12.6% and 14% over the last 60 days. The company has recorded a positive earnings surprise in each of the last four quarters with an average beat of 42.19%. Its share price has jumped 22% year to date.
ANI Pharmaceuticals witnessed an increase of 9.5% and 4.7% in its earnings estimates for 2016 and 2017, respectively, in the last 60 days. It has beaten earnings estimates twice in the last four quarters, bringing the average positive surprise to 46.85%. The company's share price has surged 54.8% year to date.
Corcept Therapeutics' earnings estimates for 2016 and 2017 were up 25% and 12.5%, respectively, over the past 60 days. Share price of the company have soared 40.5% year to date.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
ANIKA THERAPEUT (ANIK): Free Stock Analysis Report
PAIN THERAPEUT (PTIE): Free Stock Analysis Report
ANI PHARMACEUT (ANIP): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some other favorably placed stocks in health care sector include Anika Therapeutics Inc ANIK , ANI Pharmaceuticals, Inc. ANIP and Abbott Laboratories ABT . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report PAIN THERAPEUT (PTIE): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Pain Therapeutics Inc. 's PTIE shares plunged 51.3% after the company announced that the FDA has issued a complete response letter (CRL) for the new drug application (NDA) for its lead candidate Remoxy ER (oxycodone capsules). | Some other favorably placed stocks in health care sector include Anika Therapeutics Inc ANIK , ANI Pharmaceuticals, Inc. ANIP and Abbott Laboratories ABT . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report PAIN THERAPEUT (PTIE): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. PAIN THERAPEUT Price PAIN THERAPEUT Price | PAIN THERAPEUT Quote Zacks Rank & Key Picks Pain Therapeutics currently carries a Zacks Rank #2 (Buy). | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report PAIN THERAPEUT (PTIE): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Some other favorably placed stocks in health care sector include Anika Therapeutics Inc ANIK , ANI Pharmaceuticals, Inc. ANIP and Abbott Laboratories ABT . Pain Therapeutics Inc. 's PTIE shares plunged 51.3% after the company announced that the FDA has issued a complete response letter (CRL) for the new drug application (NDA) for its lead candidate Remoxy ER (oxycodone capsules). | Some other favorably placed stocks in health care sector include Anika Therapeutics Inc ANIK , ANI Pharmaceuticals, Inc. ANIP and Abbott Laboratories ABT . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report PAIN THERAPEUT (PTIE): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. In the CRL, the agency has asked the company to conduct additional studies that are required to gain approval for Remoxy, with label claims on three routes of abuse (injection, inhalation and snorting). |
33778.0 | 2016-09-28 00:00:00 UTC | Better Buy: Johnson & Johnson vs. AbbVie | ABT | https://www.nasdaq.com/articles/better-buy-johnson-johnson-vs-abbvie-2016-09-28 | nan | nan | Image source: Getty Images.
Keeping the world healthy takes a huge amount of effort, and many of the largest companies on the planet have made it their mission to make people healthier and make money in the process. Two leaders in the industry are Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) , and both have done a good job of generating profits for investors. AbbVie is slightly more focused on the pharmaceutical side of healthcare while Johnson & Johnson has a broader set of products that encompasses over-the-counter products as well as a highly specialized medical device business. Yet after strong stock performance from both, curious investors want to know which makes more sense to add to portfolios now. Let's compare Johnson & Johnson and AbbVie on a number of metrics to see which looks more attractive right now.
Valuation and stock performance
Both Johnson & Johnson and AbbVie have seen their stocks rise over the past year. But J&J has climbed much faster, jumping by more than a third since last September. That compares to a quite respectable but still inferior 21% gain for AbbVie over the same 12-month time period.
When looking at valuations, the fact that Johnson & Johnson has climbed more quickly than AbbVie shows up in their relative price tags. Focusing on earnings over the past year, Johnson & Johnson trades at a trailing earnings multiple of 22. That compares to less than 19 for AbbVie, making the smaller company the more attractive. A similar result happens when you incorporate future earnings expectations into the picture. J&J's forward multiple is 16.5, which is just three-quarters of its trailing earnings multiple. But AbbVie carries a forward multiple of just over 11. Based solely on valuation, AbbVie gets the nod over Johnson & Johnson based on these simple measures.
Dividends
For dividend investors, both Johnson & Johnson and AbbVie have good track records and are attractive to income investors. AbbVie has the better yield right now, weighing in at 3.5% dividend yield. Johnson & Johnson pays a 2.7% yield. Interestingly, both companies have payout ratios in the neighborhood of 60%, indicating that AbbVie has the stronger earnings power to back up its higher dividend yield. That's consistent with expectations for higher earnings in the near future.
Both companies have also made sizable dividend increases. AbbVie paid a nearly 12% increase in its dividend in early 2016, and Johnson & Johnson gave investors a 7% raise. By doing so, Johnson & Johnson lengthened its streak of consecutive dividend increases to 54 straight years. AbbVie has only been around for a few years, but former parent Abbott Labs (NYSE: ABT) had a similar 43-year streak of dividend increases if you adjust for the AbbVie spinoff. In terms of dividend growth, both AbbVie and Johnson & Johnson have strong credibility in sharing their successes with shareholders. The two companies are quite close to each other, with AbbVie getting the nod for a slightly higher yield even with J&J's lengthier streak of annual boosts.
Growth prospects and risk
Johnson & Johnson and AbbVie have worked hard to find success in what has become an increasingly cutthroat industry. For Johnson & Johnson, the pharmaceutical division has emerged as the high-growth producer, doubling the growth rate of the entire company. Several blockbuster drugs have allowed J&J to offset the threat of patent cliffs on the pharma business' overall revenue. For the most part, Johnson & Johnson has looked to develop its business internally, avoiding the high-profile acquisitions that some of its rivals have pursued. Steady growth prospects give J&J the blue-chip reputation it has earned from countless investors. Yet some worry about the downward pressure that the medical device business has had on the company overall, holding back the faster-growing pharma division.
On the other hand, AbbVie has had to prove that it has a future beyond its best-known blockbuster. For years, AbbVie's success has centered on Humira, the anti-inflammatory treatment that has driven the bulk of its sales. AbbVie's main patents on Humira are slated to start expiring toward the end of this year, and thus far, efforts to find a replacement for potential lost revenue from the drug have been mixed at best. AbbVie spent $21 billion to acquire Pharmacyclics and its 50% share of profits from cancer treatment Imbruvica, with J&J owning the other half. Despite its purer-play status, AbbVie has a lot more uncertainty than Johnson & Johnson, justifying its cheaper valuation.
Overall, Johnson & Johnson and AbbVie offer different propositions to investors. Johnson & Johnson's longer dividend history, more secure pipeline, and diversification make it a good blue-chip choice for investors. AbbVie is less expensive but carries risks, and the company will have to overcome those risks in order to prove that its stock was indeed a true bargain at current levels.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
Dan Caplinger has no position in any stocks mentioned. The Motley Fool recommends Johnson and Johnson. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie has only been around for a few years, but former parent Abbott Labs (NYSE: ABT) had a similar 43-year streak of dividend increases if you adjust for the AbbVie spinoff. Interestingly, both companies have payout ratios in the neighborhood of 60%, indicating that AbbVie has the stronger earnings power to back up its higher dividend yield. Yet some worry about the downward pressure that the medical device business has had on the company overall, holding back the faster-growing pharma division. | AbbVie has only been around for a few years, but former parent Abbott Labs (NYSE: ABT) had a similar 43-year streak of dividend increases if you adjust for the AbbVie spinoff. Valuation and stock performance Both Johnson & Johnson and AbbVie have seen their stocks rise over the past year. Focusing on earnings over the past year, Johnson & Johnson trades at a trailing earnings multiple of 22. | AbbVie has only been around for a few years, but former parent Abbott Labs (NYSE: ABT) had a similar 43-year streak of dividend increases if you adjust for the AbbVie spinoff. Valuation and stock performance Both Johnson & Johnson and AbbVie have seen their stocks rise over the past year. Dividends For dividend investors, both Johnson & Johnson and AbbVie have good track records and are attractive to income investors. | AbbVie has only been around for a few years, but former parent Abbott Labs (NYSE: ABT) had a similar 43-year streak of dividend increases if you adjust for the AbbVie spinoff. Valuation and stock performance Both Johnson & Johnson and AbbVie have seen their stocks rise over the past year. Focusing on earnings over the past year, Johnson & Johnson trades at a trailing earnings multiple of 22. |
33779.0 | 2016-09-26 00:00:00 UTC | AbbVie (ABBV) HCV Combination Drug Positive in Phase IIIb | ABT | https://www.nasdaq.com/articles/abbvie-abbv-hcv-combination-drug-positive-in-phase-iiib-2016-09-26 | nan | nan | AbbVie Inc.ABBV announced positive results from the phase IIIb study, Garnet, on a combination of its hepatitis drugs Viekirax (ombitasvir/paritaprevir/ritonavir tablets) and Exviera (dasabuvir tablets) for the treatment of patients with chronic hepatitis C virus (HCV) infection without liver cirrhosis.
Garnet is a phase IIIb, multicenter, open-label, single-arm study. It was designed to investigate the safety and efficacy of a combination of Viekirax and Exviera without ribavirin. The study enrolled 166 patients across 20 sites in the world, with 163 patients suffering from a GT1b chronic HCV infection without cirrhosis. The study met its primary endpoint with 98% of patients achieving a sustained virologic response at 12 weeks after treatment. In fact, the study showed high response rates within just eight weeks of treatment with the combination medicine.
The data were presented at the 2016 EASL Special Conference, New Perspectives in Hepatitis C Virus Infection in Paris, France.
Adverse events reported in the study were mostly mild, with one patient discontinuing treatment.
AbbVie's leading HCV treatment, Viekira Pak, an all-oral, short-course, interferon-free therapy, with or without ribavirin, was approved by the FDA in Dec 2014. In Jan 2015, a combination of Viekirax and Exviera was approved in Europe for the treatment of genotype 1 (GT1) chronic HCV infection. Viekirax is also approved in Europe for the treatment of chronic HCV genotype 4 (GT4) infections.
Genotype 1 is the most prevalent of the six major HCV genotypes. Around 160 million people worldwide are infected with HCV, with genotype 1 accounting for approximately 51.8% of the total HCV infected patients. The approval, thus, gave the company access to a huge potential patient population.
ABBVIE INC Price
ABBVIE INC Price | ABBVIE INC Quote
Zacks Rank & Key Picks
AbbVie currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in health care sector include Anika Therapeutics Inc ANIK , ANI Pharmaceuticals, Inc. ANIP and Abbott Laboratories ABT .
Anika Therapeutics' earnings estimates for 2016 and 2017 were up a respective 12.6% and 14% over the last 60 days. The company has recorded a positive earnings surprise in each of the last four quarters with an average beat of 42.19%. Its share price has jumped 23.2% year to date. Anika Therapeutics currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
ANI Pharmaceuticals has a Zacks Rank #1 as well. The company witnessed an increase of 9.5% and 4.7% in its earnings estimates for 2016 and 2017, respectively, in the last 60 days. It has beaten earnings estimates twice in the last four quarters, bringing the average positive surprise to 46.85%. The company's share price has surged 51.2% year to date.
Abbott Laboratories carries a Zacks Rank #2 (Buy). Over the past 60 days, the company's earnings estimates for 2016 and 2017 were mostly unchanged. It has delivered a positive earnings surprise in all of the four quarters, resulting in an average beat of 3.11%. Share price of the company have dipped 1.7% year to date.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
ANIKA THERAPEUT (ANIK): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
ANI PHARMACEUT (ANIP): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in health care sector include Anika Therapeutics Inc ANIK , ANI Pharmaceuticals, Inc. ANIP and Abbott Laboratories ABT . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie's leading HCV treatment, Viekira Pak, an all-oral, short-course, interferon-free therapy, with or without ribavirin, was approved by the FDA in Dec 2014. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in health care sector include Anika Therapeutics Inc ANIK , ANI Pharmaceuticals, Inc. ANIP and Abbott Laboratories ABT . AbbVie Inc.ABBV announced positive results from the phase IIIb study, Garnet, on a combination of its hepatitis drugs Viekirax (ombitasvir/paritaprevir/ritonavir tablets) and Exviera (dasabuvir tablets) for the treatment of patients with chronic hepatitis C virus (HCV) infection without liver cirrhosis. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in health care sector include Anika Therapeutics Inc ANIK , ANI Pharmaceuticals, Inc. ANIP and Abbott Laboratories ABT . AbbVie Inc.ABBV announced positive results from the phase IIIb study, Garnet, on a combination of its hepatitis drugs Viekirax (ombitasvir/paritaprevir/ritonavir tablets) and Exviera (dasabuvir tablets) for the treatment of patients with chronic hepatitis C virus (HCV) infection without liver cirrhosis. | Some better-ranked stocks in health care sector include Anika Therapeutics Inc ANIK , ANI Pharmaceuticals, Inc. ANIP and Abbott Laboratories ABT . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV announced positive results from the phase IIIb study, Garnet, on a combination of its hepatitis drugs Viekirax (ombitasvir/paritaprevir/ritonavir tablets) and Exviera (dasabuvir tablets) for the treatment of patients with chronic hepatitis C virus (HCV) infection without liver cirrhosis. |
33780.0 | 2016-09-26 00:00:00 UTC | J&J's Recent Move: A Visionary Acquisition Or An Optical Illusion? | ABT | https://www.nasdaq.com/articles/jjs-recent-move-visionary-acquisition-or-optical-illusion-2016-09-26 | nan | nan | Johnson & Johnson ( JNJ ) has agreed to acquire Abbott's Medical Optics (AMO) business in an all cash deal valued at $4.3 billion. We previously looked at what this divestiture means for Abbott ( ABT ) (Read: Making Sense Of Abbott's Sale ). As far as J&J is concerned we consider the transaction to be good strategic move for its existing Vision Care division. We believe that there is enough potential in this segment which the company can tap into with a larger product portfolio.
Our price estimate for Johnson & Johnson is $118, which is roughly where it now trades.
The Deal Makes Strategic Sense
After the restructuring and certain divestitures in its medical device segment, it was widely speculated that the J&J may be planning to exit this segment completely. But the management has made it clear in conference calls over the last few quarters that it continues to focus on this business. The company plans small tuck-in acquisitions and is re-assessing its go-to-market strategy. The acquisition of Abbott's Optice business is a step in this direction.
The total world wide vision-care market is estimated at $68 billion and is expected to grow at roughly 5% per year. Furthermore, the market penetration of products in the eye health business very low. For instance, the penetration in the contact lens segment is estimated at around 18%. The ageing population in the developed markets and rising income in the emerging countries will further fuel the growth of eye-care segment globally. Given the size and low market penetration, there exists sizable market opportunity for future growth.
J&J's main product in the eye care segment is the Acuve brand of contact lenses. With this acquisition, the company will be able to broaden its portfolio in the vision-care by adding products in cataract surgery, laser refractive surgery (LASIK) and consumer eye health products such as over-the-counter drops. Furthermore, overall J&J has been aligning its medical-devices portfolio towards surgical devices. Abbott Medical Optical's significant presence in cataract and LASIK surgery reinforces this. The consumer eye health products that the acquisition will bring in fits well with J&J's existing consumer oriented product in vision-care.
The company would be able to use its own expansive and Abbott's acquired business' supply chain to faster increase penetration.
The Acquisition Would Not Have Much Financial Impact
J&J will pay $4.3 billion to Abbott in cash. Given the company's solid cash position, with nearly $40 billion in cash and equivalents, the transaction should not be a cause of worry. Furthermore, cash is low yield asset and it appears to be a good move by the company to invest in businesses which have growth potential.
J&J's vision-care business generated $2.6 billion in FY'15 while Abbott Medical Optical generated $1.1 billion in the same period. On pro-forma basis the the division will make up for about 5% of the total revenue. The management expects only incremental accretion to EPS once the deal is closed. But, with such a large untapped market the division would add significant value in long-term.
Have more questions about Johnson & Johnson? See the links below.
Drugs, Devices, Consumer: What's Johnson & Johnson's Revenue and Earnings breakdown?
How Increased Focus On Pharmaceuticals In The Last 5 Years Has Helped J&J?
By How Much Can J&J's Revenue And EBITDA Grow Over The Next 3 Years?
What Percentage Of Its Revenue Could J&J Lose Solely Due To Patent Losses Over The Next 5 Years?
If Remicade Biosimilar Hits The U.S. Market In 2017, Does J&J Face Any Meaningful EPS Decline?
Considering Recent Divestitures, Should J&J Trim Its Medical Devices Segment Further?
Despite The Revenue Fall, J&J's Business Has A Silver Lining
Three Things To Watch Out For J&J This Year
Here Is Why J&J Could See Growth As It Reports Its Q1 2016 Results
Why We Are Slightly Bullish On J&J?
Notes:
1) The purpose of these analyses is to help readers focus on a few important things. We hope such lean communication sparks thinking, and encourages readers to comment and ask questions on the comment section, or email content@trefis.com
2) Figures mentioned are approximate values to help our readers remember the key concepts more intuitively. For precise figures, please refer to our complete analysis for Johnson & Johnson
See More at Trefis |View Interactive Institutional Research(Powered by Trefis)
Get Trefis Technology
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We previously looked at what this divestiture means for Abbott ( ABT ) (Read: Making Sense Of Abbott's Sale ). The ageing population in the developed markets and rising income in the emerging countries will further fuel the growth of eye-care segment globally. Furthermore, cash is low yield asset and it appears to be a good move by the company to invest in businesses which have growth potential. | We previously looked at what this divestiture means for Abbott ( ABT ) (Read: Making Sense Of Abbott's Sale ). Johnson & Johnson ( JNJ ) has agreed to acquire Abbott's Medical Optics (AMO) business in an all cash deal valued at $4.3 billion. With this acquisition, the company will be able to broaden its portfolio in the vision-care by adding products in cataract surgery, laser refractive surgery (LASIK) and consumer eye health products such as over-the-counter drops. | We previously looked at what this divestiture means for Abbott ( ABT ) (Read: Making Sense Of Abbott's Sale ). Johnson & Johnson ( JNJ ) has agreed to acquire Abbott's Medical Optics (AMO) business in an all cash deal valued at $4.3 billion. With this acquisition, the company will be able to broaden its portfolio in the vision-care by adding products in cataract surgery, laser refractive surgery (LASIK) and consumer eye health products such as over-the-counter drops. | We previously looked at what this divestiture means for Abbott ( ABT ) (Read: Making Sense Of Abbott's Sale ). Johnson & Johnson ( JNJ ) has agreed to acquire Abbott's Medical Optics (AMO) business in an all cash deal valued at $4.3 billion. Furthermore, the market penetration of products in the eye health business very low. |
33781.0 | 2016-09-22 00:00:00 UTC | 3 Top Dividend Stocks for Your Roth IRA | ABT | https://www.nasdaq.com/articles/3-top-dividend-stocks-your-roth-ira-2016-09-22 | nan | nan | Years of testing and experience have proven that dividend investing is one of the surest paths to financial independence. Although it isn't as sexy as investing in the next Silicon Valley start-up, the constant compounding that reinvesting your dividends creates can work miracles over time.
When it comes time to stash your dividend payers in a retirement account, I highly suggest considering a Roth IRA. That's because you've already paid taxes on the money, and all future dividends, reinvestments, and disbursements are completely tax-free. That's a big deal if you are a dedicated, buy-to-hold income investor.
With that in mind, here is why I think you should consider buying shares of conglomerate 3M (NYSE: MMM) , soda and snack-maker Pepsi (NYSE: PEP) , and pharma giant AbbVie (NYSE: ABBV) .
A history of dividend payments and increases
To make the list of official Dividend Aristocrats, a company needs to have:
Made dividend payments for at least 100 consecutive quarters (25 years)
Increased said payment at least once per year.
All three of the stocks on this list qualify on those metrics.
Data source: Dividendinvestor.com *Shows current growth rate since spin-out
You might be looking at AbbVie and wonder why it's included if it only has two years of dividend history. That's because the company was spun out of Abbot Labs -- a parent company that has increased its dividend for over 25 consecutive years.
The real key to focus on here is the rate at which these dividends have been growing. Imagine buying shares of 3M today. You get $4.44 per share, or a 2.5% dividend yield -- not bad, but nothing to write home about. However, if the dividend continues increasing by the same amount (14%) over the next decade, the yield on your original investment will be a whopping $16.46 per share -- or 9.1% -- per year.
If we do the same calculations with Pepsi and AbbVie, we get a dividend yield in 10 years of 6% and 27.9%. More than likely, AbbVie's growth will temper, but that doesn't change the fact that these have the potential to be massive returns on your original investment.
Enough free cash flow to make it happen
The most important metric for dividend investors to watch is the payout ratio from free cash flow (FCF). FCF is what the company brings in via operations during a year, minus any capital expenditures. It is from FCF that dividends are paid, so the lower the ratio, the better.
Create column charts
Data source: Yahoo! Finance
Over the past 12 months, none of these companies has come anywhere close to the "danger zone" of using over 90% of FCF to pay its dividend.
The bottom line, however, is that all three of these companies could continue paying their dividend in tough economic times, and will likely continue their increases if the macro economy can avoid a meltdown.
Wide moats
A "moat" is another way of saying that a company has a sustainable competitive advantage. Without moats, a company's products would become commoditized -- that's good for consumers, but generally not so good for investors.
3M is an industrial conglomerate with many irons in the fire. Your office likely has glue, tape, or Post-it notes from 3M. But the company also has operations in healthcare, manufacturing, electronics, and transportation. The company's brand names, economies of scale, and its cash stash of over $1.8 billion provide a substantial moat.
Pepsi, on the other hand, relies almost solely on the power of its brands for a moat. Those brands -- which include the namesake soda, Gatorade, Mountain Dew, Lays, Doritos, Fritos, Quaker Oats, and more -- are very powerful. They help Pepsi enjoy better margins than rivals, as the company can count on customers paying a few cents more for each of these products.
AbbVie, on the other hand, is in a bit more precarious position. As a pharmaceutical company, it relies on patents to protect its moat. Those patents, however, expire -- and when they do, sales can fall off a cliff. Humira has been one of its best sellers over the years, but investors need to make sure the company is still piling money back into research and development to ensure a pipeline of future blockbuster drugs. The company's $8 billion in cash also gives it options for acquiring up-and-coming drug compounds.
When you add these three characteristics together -- a history of dividend growth, low payout ratios from FCF, and wide moats -- you have a recipe for long-term investing success. Throw those dividends in a Roth IRA, and you're looking at tax-free growth that can help you retire very comfortably.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
Brian Stoffel has no position in any stocks mentioned. The Motley Fool owns shares of and recommends PepsiCo. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Although it isn't as sexy as investing in the next Silicon Valley start-up, the constant compounding that reinvesting your dividends creates can work miracles over time. Humira has been one of its best sellers over the years, but investors need to make sure the company is still piling money back into research and development to ensure a pipeline of future blockbuster drugs. When you add these three characteristics together -- a history of dividend growth, low payout ratios from FCF, and wide moats -- you have a recipe for long-term investing success. | With that in mind, here is why I think you should consider buying shares of conglomerate 3M (NYSE: MMM) , soda and snack-maker Pepsi (NYSE: PEP) , and pharma giant AbbVie (NYSE: ABBV) . Enough free cash flow to make it happen The most important metric for dividend investors to watch is the payout ratio from free cash flow (FCF). When you add these three characteristics together -- a history of dividend growth, low payout ratios from FCF, and wide moats -- you have a recipe for long-term investing success. | A history of dividend payments and increases To make the list of official Dividend Aristocrats, a company needs to have: Made dividend payments for at least 100 consecutive quarters (25 years) Increased said payment at least once per year. That's because the company was spun out of Abbot Labs -- a parent company that has increased its dividend for over 25 consecutive years. Enough free cash flow to make it happen The most important metric for dividend investors to watch is the payout ratio from free cash flow (FCF). | Data source: Dividendinvestor.com *Shows current growth rate since spin-out You might be looking at AbbVie and wonder why it's included if it only has two years of dividend history. However, if the dividend continues increasing by the same amount (14%) over the next decade, the yield on your original investment will be a whopping $16.46 per share -- or 9.1% -- per year. If we do the same calculations with Pepsi and AbbVie, we get a dividend yield in 10 years of 6% and 27.9%. |
33782.0 | 2016-09-21 00:00:00 UTC | Bristol-Myers Opdivo's Regulatory Application Validated in EU | ABT | https://www.nasdaq.com/articles/bristol-myers-opdivos-regulatory-application-validated-in-eu-2016-09-21 | nan | nan | Bristol-Myers Squibb CompanyBMY announced that its type II variation application for Opdivo has been validated by the European Medicines Agency (EMA). The company is looking to expand Opdivo's label to include the treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after a failure of prior platinum-containing therapy. The validation marks the initiation of the EMA's centralized review process.
The application primarily included data from an open-label, single-arm phase II study, CheckMate -275. The company plans to present data from the study at the European Society for Medical Oncology Congress.
We are encouraged by the validation of the regulatory application for Opdivo in the EU. Per the company's press release, bladder cancer is the fifth-most commonly diagnosed cancer in Europe, accounting for an estimated 151,000 new cases per year and resulting in 52,000 deaths annually. UC urothelial carcinoma is the most common type of bladder cancer, which accounts for roughly 90% of the cases.
Meanwhile, the company is also working on expanding the drug's label. Opdivo is currently under priority review in the U.S. for the treatment of patients with previously treated recurrent or metastatic squamous cell carcinoma of the head and neck. A response from the FDA is expected by Nov 11, 2016. The product is also under review in the EU for the same indication.
Note that Opdivo has recorded worldwide sales of $1.5 billion in the first half of 2016. A label expansion in additional indications would give the product access to a higher patient population and increase the commercial potential of the drug significantly.
BRISTOL-MYERS Price
BRISTOL-MYERS Price | BRISTOL-MYERS Quote
Zacks Rank & Key Picks
Bristol-Myers currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in health care sector include ANI Pharmaceuticals, Inc. ANIP , Cambrex Corporation CBM and Abbott Laboratories ABT . While both ANI Pharmaceuticals and Cambrex sport a Zacks Rank #1 (Strong Buy), Abbott carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BRISTOL-MYERS (BMY): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
CAMBREX CORP (CBM): Free Stock Analysis Report
ANI PHARMACEUT (ANIP): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in health care sector include ANI Pharmaceuticals, Inc. ANIP , Cambrex Corporation CBM and Abbott Laboratories ABT . Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report CAMBREX CORP (CBM): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. The company is looking to expand Opdivo's label to include the treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after a failure of prior platinum-containing therapy. | Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report CAMBREX CORP (CBM): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in health care sector include ANI Pharmaceuticals, Inc. ANIP , Cambrex Corporation CBM and Abbott Laboratories ABT . BRISTOL-MYERS Price BRISTOL-MYERS Price | BRISTOL-MYERS Quote Zacks Rank & Key Picks Bristol-Myers currently carries a Zacks Rank #3 (Hold). | Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report CAMBREX CORP (CBM): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in health care sector include ANI Pharmaceuticals, Inc. ANIP , Cambrex Corporation CBM and Abbott Laboratories ABT . The company is looking to expand Opdivo's label to include the treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after a failure of prior platinum-containing therapy. | Some better-ranked stocks in health care sector include ANI Pharmaceuticals, Inc. ANIP , Cambrex Corporation CBM and Abbott Laboratories ABT . Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report CAMBREX CORP (CBM): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Bristol-Myers Squibb CompanyBMY announced that its type II variation application for Opdivo has been validated by the European Medicines Agency (EMA). |
33783.0 | 2016-09-21 00:00:00 UTC | The Zacks Analyst Blog Highlights: Abbott Labs, Comcast, Goldman Sachs, Microsoft and Philip Morris | ABT | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-abbott-labs-comcast-goldman-sachs-microsoft-and-philip | nan | nan | For Immediate Release
Chicago, IL - September 21, 2016 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Abbott Labs ( ABT ), Comcast ( CMCSA ), Goldman Sachs ( GS ), Microsoft ( MSFT ) and Philip Morris ( PM ).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .
Here are highlights from Tuesday's Analyst Blog:
Top Research Reports for Goldman Sachs, Comcast, Abbott Labs
Today's Research Daily features new research reports on 16 major stocks, including Abbott Labs ( ABT ), Comcast ( CMCSA ) and Goldman Sachs ( GS ).
Shares of Buy ranked Abbott have been under pressure lately, in sympathy with the broader pharma group on political uncertainty about pricing issues (the stock is down more than 6% year-to-date). But the Zacks analyst likes the manner in which the pharma major has been reshaping its portfolio through strategic acquisitions/divestitures. In order to focus on strengths - cardiovascular devices and diagnostics - Abbott has inked a deal to divest its vision care business to J&J. Moreover, the Alere acquisition should boost the diagnostics business, while the St. Jude Medical buyout will complement its cardiovascular devices division and strengthen its long-term growth potential (You can read the full research report on Abbott here>> )
Goldman Sachs shares have come back a bit in recent weeks, but remain in negative territory for the year on persistent macro headwinds for the space as a whole. These issues notwithstanding, the Zacks analyst likes this Buy-ranked stock for its well-diversified business model and industry leading investment banking franchise. The company is also seeking to capitalize on new growth opportunities through several strategic investments including its digital consumer lending platform. Venturing into the ETF market will act as a tailwind, while regulatory approval for its 2016 capital plan demonstrates its financial strength. (You can read the full research report on Goldman Sachs here>> )
Comcast 's continued momentum (the stock is up 16% year-to-date) reflects the strength in its Cable business and significant improvement in the NBC Universal segment. Also, Comcast is investing heavily in its theme park business. The company has forayed into the over-the-top video delivery market with the launch of its Internet TV service "Stream". Comcast's incorporation of Netflix services into its X1 platform is aimed at checking customer churn and providing viewers with more streaming options and flexibility at breakthrough prices. (You can read the full research report on Comcast here >> )
Other noteworthy reports we are featuring today include Microsoft ( MSFT ) and Philip Morris ( PM ).
Today's Long-Term Buys & Sells
Today you can gain access to the best long-term trades unearthed by Zacks Research. These moves have double and triple-digit profit potential and are rarely available to the public. Starting now, you can look inside our stocks under $10, home run and value stock portfolios, plus more. Want a peek at this private information? Click here >>
You can find all of today's stock research reports here>>
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today .
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros .
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
COMCAST CORP A (CMCSA): Free Stock Analysis Report
GOLDMAN SACHS (GS): Free Stock Analysis Report
MICROSOFT CORP (MSFT): Free Stock Analysis Report
PHILIP MORRIS (PM): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include Abbott Labs ( ABT ), Comcast ( CMCSA ), Goldman Sachs ( GS ), Microsoft ( MSFT ) and Philip Morris ( PM ). Here are highlights from Tuesday's Analyst Blog: Top Research Reports for Goldman Sachs, Comcast, Abbott Labs Today's Research Daily features new research reports on 16 major stocks, including Abbott Labs ( ABT ), Comcast ( CMCSA ) and Goldman Sachs ( GS ). Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report COMCAST CORP A (CMCSA): Free Stock Analysis Report GOLDMAN SACHS (GS): Free Stock Analysis Report MICROSOFT CORP (MSFT): Free Stock Analysis Report PHILIP MORRIS (PM): Free Stock Analysis Report To read this article on Zacks.com click here. | Stocks recently featured in the blog include Abbott Labs ( ABT ), Comcast ( CMCSA ), Goldman Sachs ( GS ), Microsoft ( MSFT ) and Philip Morris ( PM ). Here are highlights from Tuesday's Analyst Blog: Top Research Reports for Goldman Sachs, Comcast, Abbott Labs Today's Research Daily features new research reports on 16 major stocks, including Abbott Labs ( ABT ), Comcast ( CMCSA ) and Goldman Sachs ( GS ). Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report COMCAST CORP A (CMCSA): Free Stock Analysis Report GOLDMAN SACHS (GS): Free Stock Analysis Report MICROSOFT CORP (MSFT): Free Stock Analysis Report PHILIP MORRIS (PM): Free Stock Analysis Report To read this article on Zacks.com click here. | Here are highlights from Tuesday's Analyst Blog: Top Research Reports for Goldman Sachs, Comcast, Abbott Labs Today's Research Daily features new research reports on 16 major stocks, including Abbott Labs ( ABT ), Comcast ( CMCSA ) and Goldman Sachs ( GS ). Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report COMCAST CORP A (CMCSA): Free Stock Analysis Report GOLDMAN SACHS (GS): Free Stock Analysis Report MICROSOFT CORP (MSFT): Free Stock Analysis Report PHILIP MORRIS (PM): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include Abbott Labs ( ABT ), Comcast ( CMCSA ), Goldman Sachs ( GS ), Microsoft ( MSFT ) and Philip Morris ( PM ). | Stocks recently featured in the blog include Abbott Labs ( ABT ), Comcast ( CMCSA ), Goldman Sachs ( GS ), Microsoft ( MSFT ) and Philip Morris ( PM ). Here are highlights from Tuesday's Analyst Blog: Top Research Reports for Goldman Sachs, Comcast, Abbott Labs Today's Research Daily features new research reports on 16 major stocks, including Abbott Labs ( ABT ), Comcast ( CMCSA ) and Goldman Sachs ( GS ). Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report COMCAST CORP A (CMCSA): Free Stock Analysis Report GOLDMAN SACHS (GS): Free Stock Analysis Report MICROSOFT CORP (MSFT): Free Stock Analysis Report PHILIP MORRIS (PM): Free Stock Analysis Report To read this article on Zacks.com click here. |
33784.0 | 2016-09-21 00:00:00 UTC | Why Did Abbott’s Stock Plummet Recently? | ABT | https://www.nasdaq.com/articles/why-did-abbotts-stock-plummet-recently-2016-09-21 | nan | nan | Over the last one month, Abbott 's ( ABT ) stock has declined more than 10%. The market has been relatively benign during this period, with the mean daily return totalling 1.8% for NYSE index, -2% for S&P 500 and -1.8% for DJIA. We believe that the change in price reflects concerns regarding risk on account of upcoming deals with St. Jude and Alere. If these deals go through Abbott's financial leverage will significantly increase. However, we believe the fundamentals of the company are strong given its diversified business and geographic presence. Abbott is a strong player in cardio-vascular devices segment. St. Jude's acquisition would position Abbott in a leadership position in this market.
Our price estimate of $47.50 for Abbott is 14% above the current market price
Impending Deals Spooking The Market
Abbott is set to acquire St. Jude Medical (subject to regulatory approvals) in a deal valued at about $25 billion. Further, the deal with Alere has gone to court and recently the two companies have agreed on mediation. It is being speculated that Abbott is dragging its feet and wants to back-out. The primary concern is that if both the deals go through, Abbott's leverage will increase significantly which will imply higher risk. This would get reflected in the cost of capital of the company. Debt is cheaper than equity. But as leverage increase investors, creditors require higher returns to compensate for increased risk due to higher debt burden. The table below estimates the change in cost of equity in case the two deals go through:
The higher cost of equity reflects increased risk as debt increases. We have used CAPM for calculation of cost of equity and, have assumed risk free rate of 1.71% and market risk premium of about 4.86%.
Debt May Get Costly
There is speculation of the possibility of Federal Reserve increasing its target funds rate by the end of this year. If it happens, it will signal the end of an era of cheap liquidity. Furthermore, the credit rating agencies have expressed concern on the prospective deals with St. Jude and Alere and, have kept Abbott on negative watch-list. A rating downgrade in combination with a hike in interest rate would make debt costlier for Abbott. Also, as the rate hike becomes a reality, there would be a shift in investments from equities to debt instruments. In such a scenario, the equities that are being perceived riskier tend to see greater outflow.
Why We Are Not Changing Our Forecast?
We believe the fundamentals of Abbott are strong. The company has diversified sources revenue. The deal with St. Jude would bolster Abbott's position in cardio-vascular segment. Abbott continues to launch strong innovative products in cardio segment, a recent example being bioresorbable stent Absorb. With acquisition of St. Jude Medical it will have a complete portfolio of products in this segment and position the company in the leadership position in a $30 billion market. Furthermore, there is no certainty that the Alere acquisition will close. The recent price decline is more of a short-term phenomenon.
See the links below for more information and analysis about Abbott:
Why is Abbott acquiring St. Jude?
What's Abbott's Fundamental Value Based On Expected 2016 Results?
What is Abbott's Revenue And Gross Profit Breakdown?
How Has Abbott's Revenue Mix Changed In The Last 5 Years?
Notes:
1) If you like or have any questions about our analysis, please write us back at content@trefis.com.The purpose of these analyses is to help you focus only on a few important things.
2) Figures mentioned are approximate values to help our readers remember the key concepts more intuitively. For precise figures, please refer to our complete analysis for Abbott Laboratories
See More at Trefis |View Interactive Institutional Research(Powered by Trefis)
Get Trefis Technology
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Over the last one month, Abbott 's ( ABT ) stock has declined more than 10%. Debt May Get Costly There is speculation of the possibility of Federal Reserve increasing its target funds rate by the end of this year. Furthermore, the credit rating agencies have expressed concern on the prospective deals with St. Jude and Alere and, have kept Abbott on negative watch-list. | Over the last one month, Abbott 's ( ABT ) stock has declined more than 10%. Our price estimate of $47.50 for Abbott is 14% above the current market price Impending Deals Spooking The Market Abbott is set to acquire St. Jude Medical (subject to regulatory approvals) in a deal valued at about $25 billion. The table below estimates the change in cost of equity in case the two deals go through: The higher cost of equity reflects increased risk as debt increases. | Over the last one month, Abbott 's ( ABT ) stock has declined more than 10%. Our price estimate of $47.50 for Abbott is 14% above the current market price Impending Deals Spooking The Market Abbott is set to acquire St. Jude Medical (subject to regulatory approvals) in a deal valued at about $25 billion. The table below estimates the change in cost of equity in case the two deals go through: The higher cost of equity reflects increased risk as debt increases. | Over the last one month, Abbott 's ( ABT ) stock has declined more than 10%. We believe that the change in price reflects concerns regarding risk on account of upcoming deals with St. Jude and Alere. The table below estimates the change in cost of equity in case the two deals go through: The higher cost of equity reflects increased risk as debt increases. |
33785.0 | 2016-09-19 00:00:00 UTC | Notable ETF Outflow Detected - IHI, ABT, TMO, SYK | ABT | https://www.nasdaq.com/articles/notable-etf-outflow-detected-ihi-abt-tmo-syk-2016-09-19 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $71.4 million dollar outflow -- that's a 5.0% decrease week over week (from 10,000,000 to 9,500,000). Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.9%, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.3%, and Stryker Corp. (Symbol: SYK) is up by about 0.7%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average:
Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $145.75 as the 52 week high point - that compares with a last trade of $143.67. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.9%, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.3%, and Stryker Corp. (Symbol: SYK) is up by about 0.7%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $145.75 as the 52 week high point - that compares with a last trade of $143.67. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.9%, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.3%, and Stryker Corp. (Symbol: SYK) is up by about 0.7%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $145.75 as the 52 week high point - that compares with a last trade of $143.67. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.9%, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.3%, and Stryker Corp. (Symbol: SYK) is up by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $71.4 million dollar outflow -- that's a 5.0% decrease week over week (from 10,000,000 to 9,500,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $145.75 as the 52 week high point - that compares with a last trade of $143.67. | Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.9%, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.3%, and Stryker Corp. (Symbol: SYK) is up by about 0.7%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $145.75 as the 52 week high point - that compares with a last trade of $143.67. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
33786.0 | 2016-09-19 00:00:00 UTC | J&J (JNJ) to Buy Abbott's Vision Care Unit for $4.3 Billion | ABT | https://www.nasdaq.com/articles/jj-jnj-to-buy-abbotts-vision-care-unit-for-%244.3-billion-2016-09-19 | nan | nan | Johnson & JohnsonJNJ entered into a definitive agreement with Abbott Laboratories ABT under which it will acquire Abbott's vision care business, Abbott Medical Optics (AMO) for $4.325 billion in cash.
Abbott Medical Optics' ophthalmic products cover three areas - cataract surgery, laser refractive surgery and consumer eye health (contact solution, eye drops, etc.) - which should be a strategic addition to J&J's Acuvue contact lens business. Abbott Medical Optics reported sales of $1.1 billion for 2015.
Apart from broadening J&J's vision care business, the buyout will introduce the health care giant to the fast growing cataract surgery market, with the addition of AMO's world-class intraocular lenses used in cataract surgery.
JOHNSON & JOHNS Price
JOHNSON & JOHNS Price | JOHNSON & JOHNS Quote
According to the National Eye Institute, more than half of the U.S. population have cataract or have had cataract surgery by the age of 80. Moreover, in 2016, it has been estimated that nearly one in four cataract surgeries will be performed on people aged less than 65 years.
The transaction is expected to close in the first quarter of 2017, subject to shareholder approval. Abbott Medical Optics will be part of J&J's Medical Devices segment. The deal is expected to be immediately accretive to J&J's adjusted earnings after the close. The deal will not impact Abbott's earnings target for 2017.
We believe that the AMO divesture makes sense for Abbott, as it has lately been making strategic acquisitions in the cardiovascular devices and diagnostics segment. In April this year, it entered into a definitive agreement to acquire St. Jude Medical Inc. STJ , a premier medical device company with a leading position in heart failure devices, atrial fibrillation and cardiac rhythm management for $25 billion. St. Jude Medical buyout will complement its cardiovascular devices business and strengthen its long-term growth potential.
The $5.8 billion acquisition of Alere, Inc. ALR announced in Jan 2016 should bolster the diagnostics business significantly. While the St Jude's deal is expected to close in the fourth quarter, the Alere deal has run into trouble.
In April, Abbott had requested to call off the deal. In August, Alere filed a lawsuit against Abbott in the Delaware Chancery Court to force Abbott to complete the acquisition.
ABBOTT LABS Price
ABBOTT LABS Price | ABBOTT LABS Quote
While J&J carries a Zacks Rank #2 (Buy), Abbott has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
In a separate press release, J&J announced that its subsidiary, Janssen, has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for a label expansion of its plaque psoriasis drug Stelara. The CHMP has recommended marketing authorization for Stelara in the EU for the treatment of adult patients with moderate-to-severely active Crohn's disease. The drug is also under review in the U.S. for the same indication.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
ST JUDE MEDICAL (STJ): Free Stock Analysis Report
ALERE INC (ALR): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Johnson & JohnsonJNJ entered into a definitive agreement with Abbott Laboratories ABT under which it will acquire Abbott's vision care business, Abbott Medical Optics (AMO) for $4.325 billion in cash. Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report ALERE INC (ALR): Free Stock Analysis Report To read this article on Zacks.com click here. St. Jude Medical buyout will complement its cardiovascular devices business and strengthen its long-term growth potential. | Johnson & JohnsonJNJ entered into a definitive agreement with Abbott Laboratories ABT under which it will acquire Abbott's vision care business, Abbott Medical Optics (AMO) for $4.325 billion in cash. Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report ALERE INC (ALR): Free Stock Analysis Report To read this article on Zacks.com click here. JOHNSON & JOHNS Price JOHNSON & JOHNS Price | JOHNSON & JOHNS Quote According to the National Eye Institute, more than half of the U.S. population have cataract or have had cataract surgery by the age of 80. | Johnson & JohnsonJNJ entered into a definitive agreement with Abbott Laboratories ABT under which it will acquire Abbott's vision care business, Abbott Medical Optics (AMO) for $4.325 billion in cash. Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report ALERE INC (ALR): Free Stock Analysis Report To read this article on Zacks.com click here. ABBOTT LABS Price ABBOTT LABS Price | ABBOTT LABS Quote While J&J carries a Zacks Rank #2 (Buy), Abbott has a Zacks Rank #3 (Hold). | Johnson & JohnsonJNJ entered into a definitive agreement with Abbott Laboratories ABT under which it will acquire Abbott's vision care business, Abbott Medical Optics (AMO) for $4.325 billion in cash. Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report ALERE INC (ALR): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Medical Optics will be part of J&J's Medical Devices segment. |
33787.0 | 2016-09-16 00:00:00 UTC | The 3 Best Long-Term Dividend Stocks to Buy Now | ABT | https://www.nasdaq.com/articles/3-best-long-term-dividend-stocks-buy-now-2016-09-16 | nan | nan | Few dispute that dividend growth investing is back en vogue, but not everyone seems to know exactly why dividend investing is one of the most well-documented ways to beat the market when deftly executed.
So, why does dividend growth investing garner so much respect among seasoned investors?
Perhaps it seems obvious, but dividend growth investing is beloved because it flat-out works -- especially when dividends are reinvested to buy additional shares. As just one of the many examples, a study from asset manager BlackRock found that a selected basket of dividend growth stocks outperformed an equally weighted basket of all stocks by roughly 30% from 1979 through 2004.
Especially when combined with a strategy to reinvest all dividend payments to buy more shares, the results can be truly astounding, while requiring little additional time. Here's a quick snapshot of a few of what I see as the best long-term dividend stocks on the market today.
Data sources: Google Finance and Dividend.com.
What makes these long-term dividend stocks so special?
For starters, each has an enviable track record of growing their dividend payments each year. If our strategy is to beat the market by buying great dividend growth stocks and reinvesting their proceeds, these seem like relatively safe bets based on the multidecade history of annual dividend increases alone. However, the sectors in which the above names operate -- consumer staples and healthcare -- also provide a stable foundation for continued success for many years to come.
Johnson & Johnson
The aging Baby Boomer population should serve as a long-term tailwind for the entire healthcare sector, and Johnson & Johnson 's(NYSE: JNJ) formidable competitive position within the industry makes it a fantastic option for long-term dividend investors.
All three of J&J's core business segments -- consumer, medical devices, and pharmaceutical -- are all relatively stable, producing consistent revenues and profits from which it can fund its dividend. The pharmaceutical segment continues to act as the straw that stirs J&J's financial drink, accounting for the greatest percentage of the company's sales and profits. It is also the fastest-growing segment in Johnson & Johnson's business, increasing nearly 9% in the company's most recent quarter versus a 0.8% increase in medical devices and a 1.8% decline in consumer sales.
Segment-specific vicissitudes aside, Johnson & Johnson remains a hugely profitable enterprise by virtually any metric. Its 56% dividend payout ratio seems sustainable for a business of its size, profitability, and capex requirements. Trading at around 22 times its past-12-months' earnings values, the company's stock is below that of the overall market, which also doesn't seem particularly out of line for a company of its quality and maturity. At the end of the day, Johnson & Johnson remains a fantastic option for investors looking to fund their retirements through long-term dividend investing.
Abbott Labs
Much like Johnson & Johnson above, Abbott Labs '(NYSE: ABT) place as a diversified healthcare products company makes it a dividend dynamo capable of standing the test of time. After spinning out its biotech business into the publicly traded AbbVie in 2013, Abbott Labs appears focused and ready to seize the considerable opportunities provided by its market. In the company's most recently reported quarter, three of Abbot Labs' four reporting segments produced sales growth in the mid to high single digits, and its nutrition segment -- the long "disappointment" in the report -- still saw sales rise 4.3%.
Like many large U.S. multinationals, the outsized strength of the U.S. dollar has served as a moderate headwind to Abbott's results, though the company remains quite profitable all the same. Furthermore, analysts see Abbott Labs producing double-digit profit growth in each of the next two full fiscal years, making its valuation discount relative to its peers seem likely to disappear if the company continues to execute.
Also like Johnson & Johnson, Abbott Labs' streak of 43 consecutive annual dividend increases make it a fairly safe bet that its continued dividend growth will proceed for years to come. With a 2.5% current dividend yield and hugely favorable demographics to underpin its long-term growth, Abbott Labs also seems like a fantastic option for dividend investors today.
Procter & Gamble
Though I could easily continue to sing the praises of the other healthcare name on the list above -- Medtronic -- I'll instead make the case for consumer staples powerhouse Procter & Gamble (NYSE: PG) as a slam-dunk long-term dividend growth play. To see what makes P&G such a fantastic business, it helps to understand what has led its stock price to slightly underperform the market over the last two years.
The company behind such well-known everyday brands including Tide, Bounty, Pampers, and many more has been hammered by negative foreign exchange impacts in recent quarters. Procter & Gamble has also faced increased competition from a host in insurgent products that have adroitly leveraged the lower barriers to entry provided by technology; Dollar Shave Club's challenge to Gillette is perhaps the most obvious example, though others abound. For whatever reason, P&G's management had been slow to respond, though the company's more recent plan to reduce costs and reinvest in brand growth has been warmly received by analysts, which brings me to my overarching point in this investing thesis: P&G's ability to endure.
As the largest consumer goods company in the world with leading market share across the bulk of its product segments, P&G's fortress-like competitive position should give it the ability to withstand and adapt to whatever changes will inevitably come its way. The company is an institution, one that consistently produces robust profits come rain, snow, sleet, or shine. Some years will be better than others, but its leading brands and distribution virtually guarantee consumers will continue to use Procter & Gamble's products for generations to come.
The same holds true with P&G's cash dividends. Case in point: Procter & Gamble's amazing history of dividend growth dates back to the Eisenhower administration. Especially given its current 3% dividend, Procter & Gamble remains arguably the best dividend stock on the market for long-term payout growth.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early, in-the-know investors! To be one of them, just click here .
Andrew Tonner has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Johnson and Johnson. The Motley Fool owns shares of Medtronic. The Motley Fool recommends Kimberly-Clark and Procter and Gamble. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs Much like Johnson & Johnson above, Abbott Labs '(NYSE: ABT) place as a diversified healthcare products company makes it a dividend dynamo capable of standing the test of time. Procter & Gamble has also faced increased competition from a host in insurgent products that have adroitly leveraged the lower barriers to entry provided by technology; Dollar Shave Club's challenge to Gillette is perhaps the most obvious example, though others abound. For whatever reason, P&G's management had been slow to respond, though the company's more recent plan to reduce costs and reinvest in brand growth has been warmly received by analysts, which brings me to my overarching point in this investing thesis: P&G's ability to endure. | Abbott Labs Much like Johnson & Johnson above, Abbott Labs '(NYSE: ABT) place as a diversified healthcare products company makes it a dividend dynamo capable of standing the test of time. Johnson & Johnson The aging Baby Boomer population should serve as a long-term tailwind for the entire healthcare sector, and Johnson & Johnson 's(NYSE: JNJ) formidable competitive position within the industry makes it a fantastic option for long-term dividend investors. Also like Johnson & Johnson, Abbott Labs' streak of 43 consecutive annual dividend increases make it a fairly safe bet that its continued dividend growth will proceed for years to come. | Abbott Labs Much like Johnson & Johnson above, Abbott Labs '(NYSE: ABT) place as a diversified healthcare products company makes it a dividend dynamo capable of standing the test of time. Johnson & Johnson The aging Baby Boomer population should serve as a long-term tailwind for the entire healthcare sector, and Johnson & Johnson 's(NYSE: JNJ) formidable competitive position within the industry makes it a fantastic option for long-term dividend investors. Also like Johnson & Johnson, Abbott Labs' streak of 43 consecutive annual dividend increases make it a fairly safe bet that its continued dividend growth will proceed for years to come. | Abbott Labs Much like Johnson & Johnson above, Abbott Labs '(NYSE: ABT) place as a diversified healthcare products company makes it a dividend dynamo capable of standing the test of time. It is also the fastest-growing segment in Johnson & Johnson's business, increasing nearly 9% in the company's most recent quarter versus a 0.8% increase in medical devices and a 1.8% decline in consumer sales. At the end of the day, Johnson & Johnson remains a fantastic option for investors looking to fund their retirements through long-term dividend investing. |
33788.0 | 2016-09-15 00:00:00 UTC | Daily Dividend Report: INTC, ABT, KR, HST, LHO | ABT | https://www.nasdaq.com/articles/daily-dividend-report-intc-abt-kr-hst-lho-2016-09-15 | nan | nan | Intel has declared a quarterly dividend of 26 cents per share on the company's common stock. The dividend will be payable on Dec. 1, 2016, to stockholders of record on Nov. 7, 2016.
Abbott declared a quarterly common dividend of 26 cents per share. The cash dividend is payable Nov. 15, 2016, to shareholders of record at the close of business on Oct. 14, 2016.
Kroger ( KR ) declared a quarterly dividend of 12 cents per share to be paid on December 1, 2016, to shareholders of record as of the close of business on November 15, 2016.
Host Hotels & Resorts ( HST ) authorized a regular quarterly cash dividend of $0.20 per share on the Company's common stock. The dividend is payable on October 17, 2016, to stockholders of record on September 30, 2016.
LaSalle Hotel Properties ( LHO ) declared a quarterly dividend of $0.45 per common share of beneficial interest for the quarter ending September 30, 2016. The third quarter dividend will be paid on October 17, 2016 to common shareholders of record on September 30, 2016.
VIDEO: Daily Dividend Report: INTC, ABT, KR, HST, LHO
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | VIDEO: Daily Dividend Report: INTC, ABT, KR, HST, LHO The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Intel has declared a quarterly dividend of 26 cents per share on the company's common stock. Kroger ( KR ) declared a quarterly dividend of 12 cents per share to be paid on December 1, 2016, to shareholders of record as of the close of business on November 15, 2016. | VIDEO: Daily Dividend Report: INTC, ABT, KR, HST, LHO The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Kroger ( KR ) declared a quarterly dividend of 12 cents per share to be paid on December 1, 2016, to shareholders of record as of the close of business on November 15, 2016. Host Hotels & Resorts ( HST ) authorized a regular quarterly cash dividend of $0.20 per share on the Company's common stock. | VIDEO: Daily Dividend Report: INTC, ABT, KR, HST, LHO The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Kroger ( KR ) declared a quarterly dividend of 12 cents per share to be paid on December 1, 2016, to shareholders of record as of the close of business on November 15, 2016. LaSalle Hotel Properties ( LHO ) declared a quarterly dividend of $0.45 per common share of beneficial interest for the quarter ending September 30, 2016. | VIDEO: Daily Dividend Report: INTC, ABT, KR, HST, LHO The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Intel has declared a quarterly dividend of 26 cents per share on the company's common stock. The cash dividend is payable Nov. 15, 2016, to shareholders of record at the close of business on Oct. 14, 2016. |
33789.0 | 2016-09-11 00:00:00 UTC | 3 Great Dividend Stocks in the Bargain Bin for Retirees | ABT | https://www.nasdaq.com/articles/3-great-dividend-stocks-bargain-bin-retirees-2016-09-11 | nan | nan | Image source: Getty Images.
If you're looking for a long-term winner as a retiree, it's hard to beat a stock that not only pays growing dividends, but whose shares are in the bargain bin because of short-term disappointments. Even the highest-quality companies suffer setbacks, which can present a golden opportunity to buy beaten-down shares and watch them rebound. In addition, with the stock having taken a hit, your investment dollars buy more shares, meaning a juicier yield and a bigger income stream for decades -- perhaps even the rest of your life.
Remember that no stock is without risk, and there are no guarantees. But if you have some patience and don't mind a little risk, these three companies have a long history of solid performance and could make great choices for a retirement portfolio.
Bristol-Myers Squibb: management flubbed it, but the stock will be back
Blame Bristol-Myers Squibb (NYSE: BMY) for being overly ambitious. The Big Pharma company motored to a 17-year high in July, only to take a sharp plunge in August. The stock is now down about 25%, meaning Bristol-Myers' dividend yield is a more attractive 2.7%. At the pre-plunge price, shares were yielding only 2%.
But what caused the drop? Chalk it up to an unexpected clinical trial failure for the company's PD-L1 inhibitor, Opdivo, the world's best-selling cancer drug. In a first-line non-small-cell lung cancer (NSCLC) trial, Opdivo failed to outperform conventional chemotherapy. Since Merck & Co. 's PD-L1 inhibitor, Keytruda, succeeded in a somewhat similar trial, Opdivo's failure shocked the market. In fact, the biotech twittersphere went nuts. "The failure is a MAJOR SURPRISE -- possibly the biggest clinical surprise of my career," wrote Mark Schoenbaum of research firm Evercore ISI.
Actually, it wasn't so much a surprise as an overreach. What the headlines missed was that the trials were designed differently. Bristol-Myers' trial included a broad group of patients, while Merck played it safe by including only patients whose tumors expressed a lot of PD-L1, making them more likely to benefit from PD-L1-inhibiting drugs.
Short-term, management's decision really hurt this stock, but the market appears to have punished Bristol-Myers enough. And it should be remembered that Opdivo has been outselling Keytruda 2-to-1, thanks in part to a management team that's often gone for the wider market approval in its clinical trials. For instance, in second-line NSCLC treatment, Opdivo is approved for all patients, while Keytruda is approved only for those with high PD-L1 levels.
Bristol-Myers will have another shot at the first-line NSCLC market with a late-stage study testing Opdivo and another drug called Yervoy. Results are expected by January 2018.
Meanwhile, this company's growth engine is firing on all cylinders , with last quarter showing 17% growth in revenue to $4.9 billion, compared with the year-ago quarter. U.S. revenues increased an eye-popping 46% to $2.7 billion, as compared with a year ago. Looking forward, the company's top-line forecast is to grow by double digits for the rest of 2016 and by high single digits heading into 2017 and beyond.
At the end of last quarter, Bristol-Meyers had $7.9 billion in cash and marketable securities, giving it financial flexibility. In short, the August sell-off put this pharma in the sweet spot to generate a solid income stream while investors wait for it to recover.
Image source: Getty Images.
CVS Health Corporation: a prescription for success
CVS Health Corporation 's(NYSE: CVS) 1.8% dividend may not seem like much at first, but CVS offers great dividend growth. The company has raised its dividend for 13 straight years. In fact, management raised the dividend 21% just last year and has boosted it 750% over the past 10 years. In addition, the company's payout ratio is still a low 33%, meaning there's plenty of room to keep raising the dividend.
Companies that are able to aggressively grow their dividends usually do so because earnings are accelerating. In the second quarter, CVS's adjusted EPS increased 8.3% year over year. Combining all of its sales data, net revenues were up 17.6% to a record $43.7 billion last quarter, compared with the year-ago quarter.
While most people think of CVS as a drugstore operator, it's also the country's second-largest pharmacy benefit manager (PBM), with more than 80 million members. The larger you are in the PBM business, the better deals you can negotiate on drug prices, which clearly is important, with drug pricing a growing concern in the U.S.
In terms of its retail pharmacy business, revenue increased $2.8 billion to $20 billion, or 16% year-over-year, in the most recent quarter, thanks to the addition of long-term care pharmacy operations from its acquisition of Omnicare, Inc, as well as the addition of clinics and pharmacies from its deal with Target Corporation . Add in the company's 1,100 Minute Clinic urgent-care facilities, with plans to open another 400 in the next few years, and this stock looks poised for fast growth in the coming decades.
Despite turning in solid financial results in the first and second quarters of 2016, CVS has seen its stock declined 6% since the beginning of the year. Add it all up, and this currently lagging stock could be just what the doctor ordered to revitalize your retirement portfolio.
Image source: Getty Images.
Abbott Labs: Grace Groner shows the way
If you're looking for a great stock that's paid increasing dividends decade after decade, look no further than Abbott Labs (NYSE: ABT) . Having spun off its biotech department back in 2013 into AbbVie , the parent company has paid increasing dividends for an amazing 44 years. The global healthcare products company now offers a shareholder payout of 2.5%, after raising its dividend 7% in the past year.
Abbott's stock price has dropped about 6% over the past 12 months, but the long-term trajectory of this company is not only intact but also likely to be reignited by recent acquisitions. In fact, last quarter's results were a standout , with every single segment delivering mid- to high-single-digit operational growth. Point-of-care diagnostics saw an 11.5% jump, emerging-market pharmaceuticals grew 15.9%, and vascular medical devices grew 8.9%. In addition, with its $25 billion acquisition of St. Jude Medical , which should close before the end of the year, investors should see continued growth far into the future.
One story any retiree can appreciate is that of Grace Groner, who was a secretary at Abbott Labs 80 years ago. Groner bought three shares of Abbott Laboratories in 1935 for $60 each. She held on to the stock and reinvested her dividends in more shares, while Abbott split dozens of times and grew into a healthcare behemoth.
By 2010, she owned more than 100,000 shares valued at $7 million.
I can't tell you where this company will be in another 80 years, but taking into account its highly diversified revenue stream -- which is a stabilizing factor for any company -- as well as its rich and stable history and an above-average dividend yield, it's a good option for retirement investors.
Buy on the dip and let it rip
One of my favorite rules of thumb for successful stock investing is to buy greatness on sale. All three of these companies offer the kind of growth potential, safety, and expanding dividends that create long-term champs. And best of all, they're in the bargain bin.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
Cheryl Swanson owns shares of CVS Health. The Motley Fool recommends CVS Health. The Motley Fool owns shares of and recommends Twitter. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs: Grace Groner shows the way If you're looking for a great stock that's paid increasing dividends decade after decade, look no further than Abbott Labs (NYSE: ABT) . In addition, with the stock having taken a hit, your investment dollars buy more shares, meaning a juicier yield and a bigger income stream for decades -- perhaps even the rest of your life. But if you have some patience and don't mind a little risk, these three companies have a long history of solid performance and could make great choices for a retirement portfolio. | Abbott Labs: Grace Groner shows the way If you're looking for a great stock that's paid increasing dividends decade after decade, look no further than Abbott Labs (NYSE: ABT) . Chalk it up to an unexpected clinical trial failure for the company's PD-L1 inhibitor, Opdivo, the world's best-selling cancer drug. CVS Health Corporation: a prescription for success CVS Health Corporation 's(NYSE: CVS) 1.8% dividend may not seem like much at first, but CVS offers great dividend growth. | Abbott Labs: Grace Groner shows the way If you're looking for a great stock that's paid increasing dividends decade after decade, look no further than Abbott Labs (NYSE: ABT) . CVS Health Corporation: a prescription for success CVS Health Corporation 's(NYSE: CVS) 1.8% dividend may not seem like much at first, but CVS offers great dividend growth. I can't tell you where this company will be in another 80 years, but taking into account its highly diversified revenue stream -- which is a stabilizing factor for any company -- as well as its rich and stable history and an above-average dividend yield, it's a good option for retirement investors. | Abbott Labs: Grace Groner shows the way If you're looking for a great stock that's paid increasing dividends decade after decade, look no further than Abbott Labs (NYSE: ABT) . But if you have some patience and don't mind a little risk, these three companies have a long history of solid performance and could make great choices for a retirement portfolio. Meanwhile, this company's growth engine is firing on all cylinders , with last quarter showing 17% growth in revenue to $4.9 billion, compared with the year-ago quarter. |
33790.0 | 2016-09-09 00:00:00 UTC | Notable ETF Outflow Detected - XLV, ABBV, TMO, ABT | ABT | https://www.nasdaq.com/articles/notable-etf-outflow-detected-xlv-abbv-tmo-abt-2016-09-09 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $124.1 million dollar outflow -- that's a 1.0% decrease week over week (from 176,265,324 to 174,565,324). Among the largest underlying components of XLV, in trading today AbbVie Inc. (Symbol: ABBV) is off about 0.5%, Thermo Fisher Scientific Inc (Symbol: TMO) is off about 3%, and Abbott Laboratories (Symbol: ABT) is lower by about 1.1%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average:
Looking at the chart above, XLV's low point in its 52 week range is $62.68 per share, with $76.00 as the 52 week high point - that compares with a last trade of $72.30. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XLV, in trading today AbbVie Inc. (Symbol: ABBV) is off about 0.5%, Thermo Fisher Scientific Inc (Symbol: TMO) is off about 3%, and Abbott Laboratories (Symbol: ABT) is lower by about 1.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $124.1 million dollar outflow -- that's a 1.0% decrease week over week (from 176,265,324 to 174,565,324). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XLV, in trading today AbbVie Inc. (Symbol: ABBV) is off about 0.5%, Thermo Fisher Scientific Inc (Symbol: TMO) is off about 3%, and Abbott Laboratories (Symbol: ABT) is lower by about 1.1%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $62.68 per share, with $76.00 as the 52 week high point - that compares with a last trade of $72.30. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of XLV, in trading today AbbVie Inc. (Symbol: ABBV) is off about 0.5%, Thermo Fisher Scientific Inc (Symbol: TMO) is off about 3%, and Abbott Laboratories (Symbol: ABT) is lower by about 1.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $124.1 million dollar outflow -- that's a 1.0% decrease week over week (from 176,265,324 to 174,565,324). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $62.68 per share, with $76.00 as the 52 week high point - that compares with a last trade of $72.30. | Among the largest underlying components of XLV, in trading today AbbVie Inc. (Symbol: ABBV) is off about 0.5%, Thermo Fisher Scientific Inc (Symbol: TMO) is off about 3%, and Abbott Laboratories (Symbol: ABT) is lower by about 1.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $124.1 million dollar outflow -- that's a 1.0% decrease week over week (from 176,265,324 to 174,565,324). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $62.68 per share, with $76.00 as the 52 week high point - that compares with a last trade of $72.30. |
33791.0 | 2016-09-08 00:00:00 UTC | Health Care Sector Update for 09/08/2016: BLRX, APRI, JNJ, PFE, ABT, MRK, AMGN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-09082016-blrx-apri-jnj-pfe-abt-mrk-amgn-2016-09-08 | nan | nan | Top Health-care stocks:
JNJ: +0.3%
PFE: flat
ABT: flat
MRK: flat
AMGN: flat
Health care shares were mostly unchanged in pre-market trade Thursday.
In health care stocks news, Apricus Biosciences ( APRI ) was up 18.8% after it said that Argentina has granted its partner, Ferring Pharmaceuticals, market approval for Vitaros, a topical cream for the treatment of erectile dysfunction. Apricus said Argentina is the twenty-fourth country in which the product has been approved. It is not approved in the U.S.
And, drug development company BioLineRx ( BLRX ) was up 6.2% after the company said data on its BL-8040 in combination with Cytarabine in relapsed or refractory acute myeloid leukemia show it to be well tolerated at all doses tested. The trial data also suggest long durability of the remissions achieved. "The results from this study clearly confirm the anti-leukemic activity of BL-8040 and reinforce our interest in the AML space," said Philip Serlin, chief financial officer of BioLineRx.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | PFE: flat ABT: flat MRK: flat AMGN: flat Health care shares were mostly unchanged in pre-market trade Thursday. In health care stocks news, Apricus Biosciences ( APRI ) was up 18.8% after it said that Argentina has granted its partner, Ferring Pharmaceuticals, market approval for Vitaros, a topical cream for the treatment of erectile dysfunction. It is not approved in the U.S. And, drug development company BioLineRx ( BLRX ) was up 6.2% after the company said data on its BL-8040 in combination with Cytarabine in relapsed or refractory acute myeloid leukemia show it to be well tolerated at all doses tested. | PFE: flat ABT: flat MRK: flat AMGN: flat Health care shares were mostly unchanged in pre-market trade Thursday. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | PFE: flat ABT: flat MRK: flat AMGN: flat Health care shares were mostly unchanged in pre-market trade Thursday. In health care stocks news, Apricus Biosciences ( APRI ) was up 18.8% after it said that Argentina has granted its partner, Ferring Pharmaceuticals, market approval for Vitaros, a topical cream for the treatment of erectile dysfunction. It is not approved in the U.S. And, drug development company BioLineRx ( BLRX ) was up 6.2% after the company said data on its BL-8040 in combination with Cytarabine in relapsed or refractory acute myeloid leukemia show it to be well tolerated at all doses tested. | PFE: flat ABT: flat MRK: flat AMGN: flat Health care shares were mostly unchanged in pre-market trade Thursday. Top Health-care stocks: In health care stocks news, Apricus Biosciences ( APRI ) was up 18.8% after it said that Argentina has granted its partner, Ferring Pharmaceuticals, market approval for Vitaros, a topical cream for the treatment of erectile dysfunction. |
33792.0 | 2016-09-02 00:00:00 UTC | 3 Stocks to Add to Your Social Security Benefits | ABT | https://www.nasdaq.com/articles/3-stocks-add-your-social-security-benefits-2016-09-02 | nan | nan | Social Security is a very important program: it provides over half of all retirement income for 53% of married couples. And yet, it's often nowhere near enough to replace the income that retirees had when they were working.
Consider a household that had one working member that averaged $50,000 per year in his/her career. If both regular and spousal benefits are collected starting at age 62 (the most popular age to retire), they would amount to just under $19,000 per year. While that's not chump change, it is a 60% cut in income.
That's why keeping your nest egg invested in retirement is so important. Today, I'm offering up Dividend Aristocrats that investors would do well to consider. These are stocks that have increased their dividend payout for 20 consecutive years. Why is that such an important trait?
Look at how the group, as a whole, fared between 2005 and 2014.
Create line charts
If you put $10,000 in an S&P 500 fund, you would have finished the decade with about $21,000. But an investment in dividend aristocrats would have left you with much more, about $27,300! Typically, the greatest assets of holding these stocks is 1. the compounding effect of reinvested dividends, and 2. downside protection offered by the dividend in market swoons (in 2008, the Aristocrats outperformed the market by over 15 percentage points).
AbbVie has a big dividend, and tons of room for growth
In an effort to offer some diversification, each stock comes from a different sector. From the pharmaceutical sector, we have AbbVie (NYSE: ABBV) , which was created when the company was spun out of Abbott Labs (NYSE: ABT) .
AbbVie's most important drugs include Humira (rheumatoid arthritis), Imbruica (leukemia), and Viekira Pak (hepatitis C). While all three are patent protected, the more critical factor in the company's long-term success is the fact that it has $8 billion in cash on hand and spent over $4 billion on research and development last year to keep its pipeline churning out important drugs.
The stock offers a sizable 3.5% yield. While that's nice, retirees should get even more excited about the fact that the payout has grown by 23% per year since the spinout, and AbbVie only used 48% of its free cash flow on dividends over the past 12 months.
Colgate-Palmolive dominates many cleaning and bathroom cabinets
One of the great things about investing in consumer staples is that power of brands. Unlike technology companies, which can be disrupted by new products in the blink of an eye, consumer staples are unlikely to change so quickly.
Colgate-Palmolive (NYSE: CL) owns some of the most powerful brands out there, including its namesake toothpaste and dish soap brands, Speed Stick deodorant, Irish Spring, and Hill's pet food. Because shoppers are familiar with -- and trust -- these products, Colgate has the pricing power to slowly inch prices up. That extra cash drops directly to the company's bottom line.
Right now, Colgate offers a 2.1% dividend yield. It has shown modest growth over the past five years, averaging an 8% bump per year. But perhaps most important, its dividend is very safe, as only 58% of free cash flow was used to pay the dividend last year.
Shares of AT&T will give you a big yield
Finally, we have a stalwart of the telecom industry. AT&T (NYSE: T) owns some of the most valuable communications properties in the world. It merged with DIRECTV last year. According to Statista, AT&T holds a 32% market share for wireless domestic subscribers, and it provides broadband connection for over 15 million U.S. subscribers.
While AT&T offers the biggest yield out of these three companies (4.7%), it also has the smallest prospects for dividend growth. That's because 66% of free cash flow is used to pay its dividend, and over the past five years, dividend hikes have averaged only 2%.
It's important for AT&T to keep cash on hand in case the economy sours. The capital expenditures to maintain AT&T's network aren't cheap, and the company has over $130 billion in long-term debt. That's not unusual for telecoms, but it speaks to the fact that investors need to accept that the payout won't grow substantially in the years to come.
With Treasuries yielding less than they ever have, many retirees are looking for added sources of income. Dividend Aristocrats provide just that. Buying a basket of dividend stocks that include these three will likely help supplement your income in retirement.
The $15,834 Social Security bonus most retirees completely overlook
If you're like most Americans, you're a few years (or more) behind on your retirement savings. But a handful of little-known "Social Security secrets" could help ensure a boost in your retirement income. For example: one easy trick could pay you as much as $15,834 more... each year! Once you learn how to maximize your Social Security benefits, we think you could retire confidently with the peace of mind we're all after. Simply click here to discover how to learn more about these strategies.
Brian Stoffel has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | From the pharmaceutical sector, we have AbbVie (NYSE: ABBV) , which was created when the company was spun out of Abbott Labs (NYSE: ABT) . AbbVie's most important drugs include Humira (rheumatoid arthritis), Imbruica (leukemia), and Viekira Pak (hepatitis C). While that's nice, retirees should get even more excited about the fact that the payout has grown by 23% per year since the spinout, and AbbVie only used 48% of its free cash flow on dividends over the past 12 months. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. From the pharmaceutical sector, we have AbbVie (NYSE: ABBV) , which was created when the company was spun out of Abbott Labs (NYSE: ABT) . That's because 66% of free cash flow is used to pay its dividend, and over the past five years, dividend hikes have averaged only 2%. | From the pharmaceutical sector, we have AbbVie (NYSE: ABBV) , which was created when the company was spun out of Abbott Labs (NYSE: ABT) . Typically, the greatest assets of holding these stocks is 1. the compounding effect of reinvested dividends, and 2. downside protection offered by the dividend in market swoons (in 2008, the Aristocrats outperformed the market by over 15 percentage points). But perhaps most important, its dividend is very safe, as only 58% of free cash flow was used to pay the dividend last year. | From the pharmaceutical sector, we have AbbVie (NYSE: ABBV) , which was created when the company was spun out of Abbott Labs (NYSE: ABT) . The stock offers a sizable 3.5% yield. Right now, Colgate offers a 2.1% dividend yield. |
33793.0 | 2016-09-02 00:00:00 UTC | Health Care Sector Update for 09/02/2016: ALR,ATEC,GMED,ELTP | ABT | https://www.nasdaq.com/articles/health-care-sector-update-09022016-alratecgmedeltp-2016-09-02 | nan | nan | Top Health Care Stocks
JNJ +0.09%
PFE +0.17%
MRK -0.52%
ABT +0.05%
AMGN -0.34%
Health care stocks were trading on the plus side today, with the NYSE Health Care Index climbing about 0.4% although shares of health care companies in the S&P 500 were up just 0.1% as a group this afternoon.
In company news, Alere ( ALR ) was hanging on to moderate gains this afternoon following reports a state judge in Delaware will fast-track the diagnostics company's lawsuit accusing would-be merger partner Abbott Laboratories ( ABT ) of slow-walking its proposed $5.8 billion buyout offer for Alere.
The judge didn't rule on a request to start a trial later this month and instead ordered the companies to first try resolving the dispute in mediation, according to a Bloomberg report.
Alere and Abbott announced a deal on Feb. 1 but Abbott tried to scuttle the transaction less than two months later after the U.S. Department of Justice began separate probes into Alere's overseas sales practices and its Medicare, Medicaid and Tricare patient billing records. Abbott also contends Alere may have misrepresented certain covenants, warranties and other conditions in the merger documents. Alere filed suit last week seeking to force Abbott into following through on the buyout proposal.
ALR shares were up nearly 2% at $39.09 apiece in late trade, easing from a prior run to $39.24 a share. ABT shares were lower just before today's close, sinking about 0.5% to $42.10 each after earlier falling to a session low of $41.89 a share.
In other sector news,
(+) ATEC, Completes previously announced sale of its international operations and distribution channel to Globus Medical ( GMED ) and announces new capital structure)
(-) ELTP, FDA warns the company's operating procedures don't adequately address how to monitor and reverse adverse drug experiences following recent inspection of manufacturing facility.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In company news, Alere ( ALR ) was hanging on to moderate gains this afternoon following reports a state judge in Delaware will fast-track the diagnostics company's lawsuit accusing would-be merger partner Abbott Laboratories ( ABT ) of slow-walking its proposed $5.8 billion buyout offer for Alere. ABT shares were lower just before today's close, sinking about 0.5% to $42.10 each after earlier falling to a session low of $41.89 a share. The judge didn't rule on a request to start a trial later this month and instead ordered the companies to first try resolving the dispute in mediation, according to a Bloomberg report. | In company news, Alere ( ALR ) was hanging on to moderate gains this afternoon following reports a state judge in Delaware will fast-track the diagnostics company's lawsuit accusing would-be merger partner Abbott Laboratories ( ABT ) of slow-walking its proposed $5.8 billion buyout offer for Alere. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ABT shares were lower just before today's close, sinking about 0.5% to $42.10 each after earlier falling to a session low of $41.89 a share. | In company news, Alere ( ALR ) was hanging on to moderate gains this afternoon following reports a state judge in Delaware will fast-track the diagnostics company's lawsuit accusing would-be merger partner Abbott Laboratories ( ABT ) of slow-walking its proposed $5.8 billion buyout offer for Alere. ABT shares were lower just before today's close, sinking about 0.5% to $42.10 each after earlier falling to a session low of $41.89 a share. Health care stocks were trading on the plus side today, with the NYSE Health Care Index climbing about 0.4% although shares of health care companies in the S&P 500 were up just 0.1% as a group this afternoon. | In company news, Alere ( ALR ) was hanging on to moderate gains this afternoon following reports a state judge in Delaware will fast-track the diagnostics company's lawsuit accusing would-be merger partner Abbott Laboratories ( ABT ) of slow-walking its proposed $5.8 billion buyout offer for Alere. ABT shares were lower just before today's close, sinking about 0.5% to $42.10 each after earlier falling to a session low of $41.89 a share. Health care stocks were trading on the plus side today, with the NYSE Health Care Index climbing about 0.4% although shares of health care companies in the S&P 500 were up just 0.1% as a group this afternoon. |
33794.0 | 2016-08-30 00:00:00 UTC | Health Care Sector Update for 08/30/2016: PTLA, RIGL, JNJ, PFE, ABT, MRK, AMGN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-08302016-ptla-rigl-jnj-pfe-abt-mrk-amgn-2016-08-30 | nan | nan | Top Health-care stocks:
JNJ: flat
PFE: flat
ABT: -1.1%
MRK: flat
AMGN: flat
Health care shares were mostly unchanged in pre-market trade Tuesday.
In health care stocks news, Rigel Pharmaceuticals ( RIGL ) was up 5.3% as the company said it has met the primary endpoint in a phase 3 study of a treatment for adult chronic/persistent immune thrombocytopenia, a disease in which the immune system attacks and destroys the body's own blood platelets. The study showed that 18% of patients receiving fostamatinib achieved a stable platelet response compared to none receiving a placebo control. Results from the second phase 3 study are expected in October or November. The most frequent adverse events were gastrointestinal-related, the company said, and the safety profile of the product was consistent with prior clinical experience.
And, Portola Pharmaceuticals ( PTLA ) was up 2.3% after it reported interim results of a phase 3b/4 study of AndexXa, a drug to reduce bleeding. Portola said its drug reduced acute major bleeding, and sustained the anti-bleeding action when followed by a 120-minute infusion. The interim results were presented orally at the European Society of Cardiology 2016 Congress in Rome, and were published simultaneously online in The New England Journal of Medicine.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The most frequent adverse events were gastrointestinal-related, the company said, and the safety profile of the product was consistent with prior clinical experience. And, Portola Pharmaceuticals ( PTLA ) was up 2.3% after it reported interim results of a phase 3b/4 study of AndexXa, a drug to reduce bleeding. The interim results were presented orally at the European Society of Cardiology 2016 Congress in Rome, and were published simultaneously online in The New England Journal of Medicine. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And, Portola Pharmaceuticals ( PTLA ) was up 2.3% after it reported interim results of a phase 3b/4 study of AndexXa, a drug to reduce bleeding. | MRK: flat AMGN: flat Health care shares were mostly unchanged in pre-market trade Tuesday. In health care stocks news, Rigel Pharmaceuticals ( RIGL ) was up 5.3% as the company said it has met the primary endpoint in a phase 3 study of a treatment for adult chronic/persistent immune thrombocytopenia, a disease in which the immune system attacks and destroys the body's own blood platelets. And, Portola Pharmaceuticals ( PTLA ) was up 2.3% after it reported interim results of a phase 3b/4 study of AndexXa, a drug to reduce bleeding. | Top Health-care stocks: JNJ: flat PFE: flat MRK: flat AMGN: flat Health care shares were mostly unchanged in pre-market trade Tuesday. And, Portola Pharmaceuticals ( PTLA ) was up 2.3% after it reported interim results of a phase 3b/4 study of AndexXa, a drug to reduce bleeding. |
33795.0 | 2016-08-29 00:00:00 UTC | 7 Safe Dividend Stocks That Beat Bear Markets | ABT | https://www.nasdaq.com/articles/7-safe-dividend-stocks-that-beat-bear-markets-2016-08-29 | nan | nan | InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips
In the midst of the second-longest bull market ever recorded, many conservative dividend investors are feeling increasingly anxious. The S&P 500's forward P/E ratio of 17.1 sits approximately 20% above its 10-year average.
To make matters even more uncomfortable for income investors, lower-for-longer interest rates have made safe haven companies such as utilities and consumer staples even more expensive relative to history.
No one knows where the market will go from here, but the following companies all have strong Dividend Safety Scores and performed well during the last recession.
These companies are safe income bets for buy-and-hold investors and dependable sources of retirement income .
While it's hard to make a compelling valuation case for some of the stocks on this list, I believe they will still outperform again in the event of an economic downturn. If nothing else, they are high quality companies to keep on your watch list .
7 Best Dividend Stocks You Haven't Heard Of
In addition to the stocks below, investors can use the free Recession Performance Analyzer tool to research how their holdings performed during the last recession.
Safe Dividend Stocks That Beat Bear Markets: Procter & Gamble Co ( PG )
Sector: Consumer Staples
Industry: Soap & Cleaning Preparations
Dividend Safety Score: 99
Forward P/E Ratio: 22.3x
Dividend Yield: 3.1%
Procter & Gamble Co ( PG ) is one of the largest consumer packaged goods companies in the world. With products sold in more than 180 countries, PG's brand portfolio includes some of the most well-known names in the beauty, grooming, health care, family care, baby and feminine care segments. Twenty-one brands within PG's massive portfolio generate in excess of $1 billion annually, and 11 brands generate more than $500 million.
Of the ten product categories encompassing its 65 brands, PG leads in seven of them and ranks second in the remaining three. The company's net sales for 2015 totaled $70.7 billion, and free cash flow came in at 102%. Historically, PG stock has remained a safe dividend stock, even throughout the most recent U.S. recession.
Although shares were down 14% in 2008, PG stock still outperformed the broader index by 23%. Further, despite a 3% decline in sales during the financial crisis, management upheld the company's trend of increasing dividends , boosting the per-share payout from $1.36 in 2007 to $1.55 in 2008. Currently, PG's dividend sits at $2.68 per share, up 1.9% from 2015, representing a 3.07% yield and a 72% payout ratio.
As the company's brands have grown in popularity and operations have expanded across the globe, PG has enjoyed consistent and predictable positive free cash flow, regardless of bear markets and economic conditions around the world. This positive free cash flow has allowed management to faithfully increase PG stocks' dividend every year for over five decades running.
Read More: P&G - Organic Growth Ahead? Maybe…
Safe Dividend Stocks That Beat Bear Markets: Verizon Communications Inc. (VZ)
Sector: Telecommunications I
Industry: Wireless Services
Dividend Safety Score: 86
Forward P/E Ratio: 13.4x
Dividend Yield: 4.3%
Verizon Communications Inc. ( VZ ) is currently the largest telecom company in the United States, operating in multiple segments including business and residential wired telephone services, broadband internet access, and wireless telephone services. Currently, VZ claims more than 5.5 million Fios Internet customers, owns approximately 200 data centers in 24 countries and counts 99% of Fortune 1,000 companies as customers. However, the real bread and butter for VZ is its 108 million wireless customers, which account for nearly 90% of the company's net profit.
Controlling the largest wireless network in the U.S. has helped management maintain consistent dividend payouts, as well as growth. VZ is a dividend achiever that has bumped its per-share dividend payout every year since 2004, with the latest increase of 2.3% bringing the annual total to $2.26 per share of VZ stock. This represents a yield of 4.3% and a payout ratio of 64%, which is in line with the company's historical averages and why VZ is considered one of the more appealing, safe dividend stocks .
Even during our country's most recent bear market, VZ stock was down only 18% in 2008, yet sales grew by 4% and management again increased the dividend. Despite the company's massive debt load of more than $100 billion, free cash flow has remained consistent and kept dividends on the rise.
Considering that VZ's wireless network stretches across the country, with its LTE network covering more than 2.4 million square miles, and the fact that the company ranks No. 1 in speed, data, and reliability tests, the chance of a newcomer to the wireless arena taking away market share is virtually nonexistent.
The 7 Best Cheap Dividend Stocks to Buy Now
Additionally, the exponential increase in mobile device usage and the ever-increasing need for Internet data give the company a solid foundation upon which VZ stock - and dividends - will continue to grow. It's no wonder why Verizon is part of Warren Buffett's portfolio of dividend stocks.
Read More: Verizon - A High Yield Stock Owned by Warren Buffett
Safe Dividend Stocks That Beat Bear Markets: Consolidated Edison, Inc. (ED)
Sector: Utilities
Industry: Electric Power
Dividend Safety Score: 97
Forward P/E Ratio: 19.2x
Dividend Yield: 3.5%
Consolidated Edison, Inc. ( ED ) is not only one of the oldest utility companies in the U.S., it's also one of the largest investor-owned holding companies. It owns competitive energy businesses, most notably Consolidated Edison Company of New York, Inc. and Orange and Rockland Utilities, Inc., among others. Those companies beneath the umbrella of Con Edison operate in a variety of energy-producing arenas including electricity and natural gas, which Con Edison then sells to retail and wholesale customers. Additionally, Con Edison facilitates the development and operation of renewable energy projects in Massachusetts and California.
Traditionally, energy companies have been a mainstay in conservative, income-producing portfolios, and Con Edison is no exception. Regardless of the national economy, people will always need electricity and other types of fuel, and their position at the top of the priority list makes utility and energy companies some of the safest, most predictable stocks for dividend investors looking to supplement retirement income.
This recession-resistant status is further evidenced by the fact that Con Edison's sales only declined by 4% during the financial crisis, and management still had the resources to increase the ED stock dividend. Con Edison has one of the most impressive, consistent track records of any dividend-paying stock on the market; the company has increased its per-share dividend payout every year for the past 41 consecutive years. The most recent increase was 3.1%, raising the ED stock dividend to its current level of $2.68 per share and representing a yield of 3.5% and a payout ratio of 68%.
It's highly unlikely that the company will stop paying dividends any time in the foreseeable future, and with such a stellar track record, Con Edison's divided is the epitome of stability in an otherwise volatile financial market, putting ED stock near the top of the list of safe dividend stocks.
Read More: Consolidated Edison Provides Safe Retirement Income
Safe Dividend Stocks That Beat Bear Markets: Realty Income Corp (O)
Sector: Real Estate
Industry: Retail
Dividend Safety Score: 86
Forward P/E Ratio: 23.7x
Dividend Yield: 3.6%
Realty Income Corp ( O ) is a real estate investment trust, or REIT, whose primary business involves the acquisition and purchase of commercial properties, and the subsequent leasing of those properties to commercial tenants. Realty Income Corp currently has a portfolio of 4,646 properties in 49 states and Puerto Rico and assets valued at nearly $13 billion.
With nearly 250 commercial tenants generating annual revenue in excess of $1 billion, Realty Income Corp has cultivated the resources necessary to maintain the ideals of the company's founders - "to use the rent collected from commercial properties held under long-term leases to support monthly dividends to shareholders." This presents a good opportunity for dividend investors because, regardless of the state of the economy, commercial leases must still get paid. And, in the event a lease is terminated, a hefty lump-sum penalty fee is often tied to such contract violations. Realty Income Corp's resistance to a bear market and economic volatility was clear during America's financial crisis when the company's sales dropped by a mere 1% and O stock declined by just 8% in 2008.
Valuing REITs is not the same as valuing more traditional stocks since the company's primary real estate assets do not typically depreciate in value and instead appreciate. However, a depreciation figure is still calculated and appears on balance sheets, which distorts the true health of the operation and may elicit concern from the non-initiated. Instead, REITs are often evaluated based on the level of funds from operations, which is similar in nature to the cash flow from operations figures for other non-REIT securities. As of July 27, Realty Income Corp expected to generate FFO in excess of $720 million, or $2.85-$2.90 per share.
Since its 1994 IPO, Realty Income Corp has paid 533 consecutive monthly dividends and has increased those dividends for 75 consecutive quarters. Although O stock doesn't have an impressively large dividend - currently 20 cents per share - payouts are made monthly, rather than quarterly. The annualized dividend for Realty Income Corp is $2.42 per share, which represents a yield of 3.6% and a payout ratio of 83%.
9 Dividend Stocks to Buy With Both Fists
Retirement investors looking for monthly income, as opposed to the traditional quarterly payouts, might do well to consider Realty Income Corp stock. Learn more about investing in monthly dividend stocks here .
Read More: Realty Income - A Premium Monthly Dividend Stock
Safe Dividend Stocks That Beat Bear Markets: Johnson & Johnson (JNJ)
Sector: Medical
Industry: Pharma
Dividend Safety Score: 99
Forward P/E Ratio: 17.8x
Dividend Yield: 2.7%
Johnson & Johnson ( JNJ ) is perhaps one of the most well-known consumer household brand names in the United States. JNJ is actually a holding company in the business of manufacturing, developing, and selling personal care and healthcare products such as toiletries and over-the-counter pharmaceuticals. Beneath the JNJ umbrella, more than 250 businesses operate in 60 different countries and generate sales in excess of $70 billion. Of the 100+ drugs marketed by JNJ, 11 generate revenue of more than $1 billion annually. Additionally, JNJ is one of only two industrial companies in the U.S. to maintain its AAA credit rating with both Moody's and Standard & Poor's.
With advantages similar to Procter & Gamble, as described above, JNJ operates in a market that is relatively resistant to periods of economic volatility. Regardless of the state of the economy, people will still buy personal care products and medications. During America's most recent recession, sales declined by only 3%, and JNJ stock was down only 8% in 2008. Further supporting JNJ during such times of economic distress is its Medical Devices division, which markets and sells medication and other supplies directly to hospitals and related facilities. Such wholesale customers are much less likely than individual consumers to reduce or eliminate purchases of JNJ goods.
Since 1963, JNJ has paid a consistent quarterly dividend and management has issued an increase every single year. With a 53-year track record, the JNJ dividend is another shining example of stability and predictability, which is why JNJ is an extremely safe dividend stock for buy-and-hold investors . Currently, the annual dividend is $3.20 per share of JNJ stock, an increase of nearly 8.5% over last year's $2.95 per-share payout, and representing a yield of 2.67% and a payout ratio of 56%.
JNJ operations generate annual free cash flow approaching $16 billion, with 70% of JNJ's sales coming from products that hold the No. 1 or No. 2global marketshare spot. So, the JNJ stock dividend doesn't appear to be at risk and is definitely worth considering as a prime contender in any long-term retirement or income portfolio.
Read More: Johnson & Johnson - Predictable Income Growth for Retirees
Safe Dividend Stocks That Beat Bear Markets: Abbott Laboratories (ABT)
Sector: Medical
Industry: Pharma
Dividend Safety Score: 92
Forward P/E Ratio: 20.1x
Dividend Yield: 2.4%
Abbott Laboratories ( ABT ) is a Chicago-based healthcare company that manufactures, develops, and sells generic pharmaceutical products in more than 130 countries. Operating primarily in the diagnostic, nutritional, and vascular product categories, Abbott's products include nutritional supplements for both children and adults, diagnostic testing kits for hospitals and laboratories, and a range of heart-related medical devices. Interestingly, about 50% of the company's sales are direct-to-consumer, "making Abbott one of the most consumer-facing healthcare companies in the world," and 70% of ABT's revenue originates in foreign markets.
With Abbott's growing global presence, and key position in developing middle-class emerging market economies, the company's major business segments remain poised to capitalize on expanding healthcare capabilities in those regions. This tactic has clearly worked well for ABT stock, with share prices up more than 80% over the past decade, even considering the stock's -2% return in 2008. A further testament to the effectiveness of the company's strategy is the fact that sales actually increased 4% during the recent recession in the U.S.
ABT stock is attractive to dividend investors because of its impressive 43-year track record of increasing annual payouts. Currently, ABT pays a quarterly dividend of 26 cents per share, or $1.04 per year, which is an increase of 8.3% over last year's $0.96 payout, and represents a yield of 2.35% and a payout ratio of 68%.
With a yield that's higher than the average dividend-paying stock in the S&P 500, and management's history of increased payouts, ABT stock is one to consider for retirement portfolios. Further, if analyst expectations prove correct regarding Abbott's projected annual earnings growth of 10% over the next five years, ABT shareholders could likely receive even larger payouts in the foreseeable future.
Either way, even if analysts are wrong and Abbott doesn't increase earnings by 10% or more, the stability of the company's dividend remains solid thanks to the sheer number of people in the world who will be entering an age bracket where increased medical attention - and spending - will become necessary to maintain quality of life.
7 Dividend Stocks That Really Crank Out the Cash
This, together with management's global growth strategy and track record of consistently boosting dividends, makes ABT a top contender on the list of safe dividend stocks.
Read More: Abbott - A Quality Dividend Aristocrat
Safe Dividend Stocks That Beat Bear Markets: General Mills, Inc. (GIS)
Sector: Consumer Staples I
ndustry: Food
Dividend Safety Score: 98
Forward P/E Ratio: 23.2x
Dividend Yield: 2.7%
General Mills, Inc. ( GIS ) manufactures and sells a wide variety of consumer foods through various brands both nationally and globally. Some of the most common household names including Betty Crocker, Cheerios, Haagen-Dazs, and Pillsbury are among the General Mills family, and Gold Medal flour - which was the company's first international flagship product back in 1880 - is still the most popular flour sold in the U.S.
GIS focuses the majority of its efforts on the five food-related product categories that generate more than 75% of the company's global net sales: cereal, snacks, yogurt, convenience meals, and ice cream. With annual revenue that has surpassed $17 billion, stemming from consistently-increasing global product sales in more than 100 countries, GIS has earned a reputation as a stable, recession-resistant stock. Over the past decade, GIS stock has increased more than 165%, and in 2008 - when the rest of the United States was struggling to survive the country's worst financial crisis since the Great Depression - GIS was actually up more than 9% and sales activity increased 7%. Regardless of the state of the economy, people still need to eat.
Additionally, GIS has one of the longest-running uninterrupted dividend payout track records on Wall Street, with payments stretching back more than 117 years. The company's growth model has intentionally been built around the slow pace of the packaged food industry, so GIS stock isn't likely to skyrocket, but it's not likely to tank, either. The most recent dividend increase was 4% and became effective on June 29, bumping the quarterly payout to 48 cents per share, or $1.92 per year, which represents a yield of 2.7% and a payout ratio of 66%.
GIS may not be a glamorous stock in a headlining industry, but that's exactly why it's attractive to retirement investors - on Wall Street, "exciting" usually means "volatile," and that's never a good thing for long-term dividend stability.
Read More: General Mills - A High Quality Dividend Stock
It's never a bad idea to measure up your dividend portfolio to make sure it is still aligned with your risk tolerance and investment objectives while markets are still healthy.
The companies reviewed above aren't necessarily cheap, but they have some of the sturdiest fundamentals a conservative investor can find.
Investors concerned most with safe income and capital preservation should keep them in mind.
The post 7 Safe Dividend Stocks That Beat Bear Markets appeared first on Simply Safe Dividends .
The post 7 Safe Dividend Stocks That Beat Bear Markets appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Read More: Johnson & Johnson - Predictable Income Growth for Retirees Safe Dividend Stocks That Beat Bear Markets: Abbott Laboratories (ABT) Sector: Medical Industry: Pharma Dividend Safety Score: 92 Forward P/E Ratio: 20.1x Dividend Yield: 2.4% Abbott Laboratories ( ABT ) is a Chicago-based healthcare company that manufactures, develops, and sells generic pharmaceutical products in more than 130 countries. Interestingly, about 50% of the company's sales are direct-to-consumer, "making Abbott one of the most consumer-facing healthcare companies in the world," and 70% of ABT's revenue originates in foreign markets. This tactic has clearly worked well for ABT stock, with share prices up more than 80% over the past decade, even considering the stock's -2% return in 2008. | Read More: Johnson & Johnson - Predictable Income Growth for Retirees Safe Dividend Stocks That Beat Bear Markets: Abbott Laboratories (ABT) Sector: Medical Industry: Pharma Dividend Safety Score: 92 Forward P/E Ratio: 20.1x Dividend Yield: 2.4% Abbott Laboratories ( ABT ) is a Chicago-based healthcare company that manufactures, develops, and sells generic pharmaceutical products in more than 130 countries. Interestingly, about 50% of the company's sales are direct-to-consumer, "making Abbott one of the most consumer-facing healthcare companies in the world," and 70% of ABT's revenue originates in foreign markets. This tactic has clearly worked well for ABT stock, with share prices up more than 80% over the past decade, even considering the stock's -2% return in 2008. | Read More: Johnson & Johnson - Predictable Income Growth for Retirees Safe Dividend Stocks That Beat Bear Markets: Abbott Laboratories (ABT) Sector: Medical Industry: Pharma Dividend Safety Score: 92 Forward P/E Ratio: 20.1x Dividend Yield: 2.4% Abbott Laboratories ( ABT ) is a Chicago-based healthcare company that manufactures, develops, and sells generic pharmaceutical products in more than 130 countries. Interestingly, about 50% of the company's sales are direct-to-consumer, "making Abbott one of the most consumer-facing healthcare companies in the world," and 70% of ABT's revenue originates in foreign markets. This tactic has clearly worked well for ABT stock, with share prices up more than 80% over the past decade, even considering the stock's -2% return in 2008. | Read More: Johnson & Johnson - Predictable Income Growth for Retirees Safe Dividend Stocks That Beat Bear Markets: Abbott Laboratories (ABT) Sector: Medical Industry: Pharma Dividend Safety Score: 92 Forward P/E Ratio: 20.1x Dividend Yield: 2.4% Abbott Laboratories ( ABT ) is a Chicago-based healthcare company that manufactures, develops, and sells generic pharmaceutical products in more than 130 countries. Interestingly, about 50% of the company's sales are direct-to-consumer, "making Abbott one of the most consumer-facing healthcare companies in the world," and 70% of ABT's revenue originates in foreign markets. This tactic has clearly worked well for ABT stock, with share prices up more than 80% over the past decade, even considering the stock's -2% return in 2008. |
33796.0 | 2016-08-29 00:00:00 UTC | Abbott Labs Sued by Alere over Pending $5.8B Acquisition | ABT | https://www.nasdaq.com/articles/abbott-labs-sued-by-alere-over-pending-%245.8b-acquisition-2016-08-29 | nan | nan | Abbott Laboratories ' ABT agreement to acquire Alere Inc. ALR came into the spotlight after Alere announced that it has sued Abbott Labs in an attempt to close the pending takeover worth $5.8 billion.
Alere filed a complaint against Abbott Labs in the Delaware Chancery Court, seeking to force Abbott Labs to take all the necessary actions to obtain anti-trust approvals and fulfill its obligations under the terms of the merger agreement.
A redacted version of the complaint is expected to be disclosed next week.
ABBOTT LABS Price
ABBOTT LABS Price | ABBOTT LABS Quote
Note that in Jan 2016, Abbott Labs entered into a definitive agreement to acquire Alere. As per terms of the agreement, Abbott Labs would pay $56 per common share in cash to Alere shareholders upon the completion of the transaction. Also, the company would assume/refinance Alere's net debt of $2.6 billion.
However, eventually, Abbott Labs became reluctant to complete the deal and had even requested to call it off in Apr 2016. The company informed Alere that it has serious concerns regarding the accuracy of various representations, warranties and covenants made by Alere in their merger agreement. It had also agreed upon paying the legal costs in the range of $30-$50 million in respect to Alere's transaction expenses, which was rejected by the latter.
We expect investors to focus on further updates regarding the Alere acquisition from Abbott Labs.
Abbott Labs currently has a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector include Actelion Ltd. ALIOF and ANI Pharmaceuticals, Inc. ANIP . Both the stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
ALERE INC (ALR): Free Stock Analysis Report
ACTELION LTD (ALIOF): Free Stock Analysis Report
ANI PHARMACEUT (ANIP): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ' ABT agreement to acquire Alere Inc. ALR came into the spotlight after Alere announced that it has sued Abbott Labs in an attempt to close the pending takeover worth $5.8 billion. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALERE INC (ALR): Free Stock Analysis Report ACTELION LTD (ALIOF): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. As per terms of the agreement, Abbott Labs would pay $56 per common share in cash to Alere shareholders upon the completion of the transaction. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALERE INC (ALR): Free Stock Analysis Report ACTELION LTD (ALIOF): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ' ABT agreement to acquire Alere Inc. ALR came into the spotlight after Alere announced that it has sued Abbott Labs in an attempt to close the pending takeover worth $5.8 billion. ABBOTT LABS Price ABBOTT LABS Price | ABBOTT LABS Quote Note that in Jan 2016, Abbott Labs entered into a definitive agreement to acquire Alere. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALERE INC (ALR): Free Stock Analysis Report ACTELION LTD (ALIOF): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ' ABT agreement to acquire Alere Inc. ALR came into the spotlight after Alere announced that it has sued Abbott Labs in an attempt to close the pending takeover worth $5.8 billion. Alere filed a complaint against Abbott Labs in the Delaware Chancery Court, seeking to force Abbott Labs to take all the necessary actions to obtain anti-trust approvals and fulfill its obligations under the terms of the merger agreement. | Abbott Laboratories ' ABT agreement to acquire Alere Inc. ALR came into the spotlight after Alere announced that it has sued Abbott Labs in an attempt to close the pending takeover worth $5.8 billion. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALERE INC (ALR): Free Stock Analysis Report ACTELION LTD (ALIOF): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. ABBOTT LABS Price ABBOTT LABS Price | ABBOTT LABS Quote Note that in Jan 2016, Abbott Labs entered into a definitive agreement to acquire Alere. |
33797.0 | 2016-08-29 00:00:00 UTC | Health Care Sector Update for 08/29/2016: MYL, TNXP, JNJ, PFE, ABT, MRK, AMGN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-08292016-myl-tnxp-jnj-pfe-abt-mrk-amgn-2016-08-29 | nan | nan | Top Health-care stocks:
JNJ: flat
PFE: flat
ABT: flat
MRK: flat
AMGN: flat
Health care shares were unchanged in pre-market trade Monday.
In health care stocks news, Tonix Pharmaceuticals Holding ( TNXP ) was up 13% after the company said it received final meeting minutes from an end-of-phase 2/pre-phase 3 meeting with the U.S. Food and Drug Administration that confirm the FDA's acceptance of proposed phase 3 studies and the planned new drug application data package for a post-traumatic stress disorder treatment. The company said the minutes indicated that positive results from two phase 3 efficacy and safety studies and long-term safety exposure studies would support the registration of TNX-102 for the treatment of PTSD. Tonix expects that the first phase 3 study will be in military-related PTSD patients and the second phase 3 study will be in predominantly civilian PTSD patients. The first study is expected to be launched in Q1 2017 with the second to follow later in the year.
And, Mylan ( MYL ) was up 2% after it said its U.S. subsidiary will launch a generic to EpiPen auto-injector for the emergency treatment of allergic reactions. The generic will have a list price of $300 per two-pack carton, which represents a discount of more than 50% to the Mylan list price. The company expects to launch sales of both 0.15 mg and 0.30 mg strengths within several weeks, pending completion of labeling revisions.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health-care stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Health care shares were unchanged in pre-market trade Monday. In health care stocks news, Tonix Pharmaceuticals Holding ( TNXP ) was up 13% after the company said it received final meeting minutes from an end-of-phase 2/pre-phase 3 meeting with the U.S. Food and Drug Administration that confirm the FDA's acceptance of proposed phase 3 studies and the planned new drug application data package for a post-traumatic stress disorder treatment. The company said the minutes indicated that positive results from two phase 3 efficacy and safety studies and long-term safety exposure studies would support the registration of TNX-102 for the treatment of PTSD. | Top Health-care stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Health care shares were unchanged in pre-market trade Monday. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health-care stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Health care shares were unchanged in pre-market trade Monday. In health care stocks news, Tonix Pharmaceuticals Holding ( TNXP ) was up 13% after the company said it received final meeting minutes from an end-of-phase 2/pre-phase 3 meeting with the U.S. Food and Drug Administration that confirm the FDA's acceptance of proposed phase 3 studies and the planned new drug application data package for a post-traumatic stress disorder treatment. The company said the minutes indicated that positive results from two phase 3 efficacy and safety studies and long-term safety exposure studies would support the registration of TNX-102 for the treatment of PTSD. | Top Health-care stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Health care shares were unchanged in pre-market trade Monday. The company said the minutes indicated that positive results from two phase 3 efficacy and safety studies and long-term safety exposure studies would support the registration of TNX-102 for the treatment of PTSD. The first study is expected to be launched in Q1 2017 with the second to follow later in the year. |
33798.0 | 2016-08-26 00:00:00 UTC | Health Care Sector Update for 08/26/2016: ALR,ABT,TGTX,ACOR | ABT | https://www.nasdaq.com/articles/health-care-sector-update-08262016-alrabttgtxacor-2016-08-26 | nan | nan | Top Health Care Stocks
JNJ +0.46%
PFE +0.17%
MRK +0.47%
ABT +0.85%
AMGN +1.05%
Health care stocks remained mixed late Friday, with the NYSE Health Care Index climbing late to its break-even mark while shares of health care companies in the S&P 500 were ahead over 0.4% as a group.
In company news, Alere ( ALR ) was lower in late trade after the diagnostics products company Friday said it plans to release a redacted version of its complaint against Abbott Laboratories ( ABT ) in a bid to to convince the larger rival to follow through with a proposed $5.8 billion buyout proposal.
The suit, filed yesterday in Delaware Chancery Court, also would protect the interests of Alere shareholders and enforce its rights under the merger agreement, the company said today.
Abbott late last month agreed to buy Alere but soon tried to scuttle the deal as a federal probe into alleged Medicare and Medicaid billing improprieties expanded to also include the company's sales practices in Africa, Asia and Latin America. At one point this month Abbott offered Alere up to $50 million to walk away from the transaction. The offer was rejected.
ALR shares were down nearly 3% at $39.59 apiece, earlier sinking to a session low of $38.80 a share. ABT shares also turned higher again in late trade, rising about 0.5% to $43.06 each.
In other sector news,
(+) TGTX, Confirms Orphan Drug Designation for TG-1101 for the treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder.
(-) ACOR, Confirms Orphan Drug designation for its BTT1023 for the treatment of primary sclerosing cholangitis.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In company news, Alere ( ALR ) was lower in late trade after the diagnostics products company Friday said it plans to release a redacted version of its complaint against Abbott Laboratories ( ABT ) in a bid to to convince the larger rival to follow through with a proposed $5.8 billion buyout proposal. ABT shares also turned higher again in late trade, rising about 0.5% to $43.06 each. The suit, filed yesterday in Delaware Chancery Court, also would protect the interests of Alere shareholders and enforce its rights under the merger agreement, the company said today. | In company news, Alere ( ALR ) was lower in late trade after the diagnostics products company Friday said it plans to release a redacted version of its complaint against Abbott Laboratories ( ABT ) in a bid to to convince the larger rival to follow through with a proposed $5.8 billion buyout proposal. ABT shares also turned higher again in late trade, rising about 0.5% to $43.06 each. Health care stocks remained mixed late Friday, with the NYSE Health Care Index climbing late to its break-even mark while shares of health care companies in the S&P 500 were ahead over 0.4% as a group. | In company news, Alere ( ALR ) was lower in late trade after the diagnostics products company Friday said it plans to release a redacted version of its complaint against Abbott Laboratories ( ABT ) in a bid to to convince the larger rival to follow through with a proposed $5.8 billion buyout proposal. ABT shares also turned higher again in late trade, rising about 0.5% to $43.06 each. Health care stocks remained mixed late Friday, with the NYSE Health Care Index climbing late to its break-even mark while shares of health care companies in the S&P 500 were ahead over 0.4% as a group. | ABT shares also turned higher again in late trade, rising about 0.5% to $43.06 each. In company news, Alere ( ALR ) was lower in late trade after the diagnostics products company Friday said it plans to release a redacted version of its complaint against Abbott Laboratories ( ABT ) in a bid to to convince the larger rival to follow through with a proposed $5.8 billion buyout proposal. Top Health Care Stocks |
33799.0 | 2016-08-25 00:00:00 UTC | Analysts Anticipate 12% Gains Ahead For RYH | ABT | https://www.nasdaq.com/articles/analysts-anticipate-12-gains-ahead-ryh-2016-08-25 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Guggenheim S&P 500 Equal Weight Health Care ETF (Symbol: RYH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $176.39 per unit.
With RYH trading at a recent price near $156.86 per unit, that means that analysts see 12.45% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of RYH's underlying holdings with notable upside to their analyst target prices are HCA Holdings Inc (Symbol: HCA), Biogen Inc (Symbol: BIIB), and Abbott Laboratories (Symbol: ABT). Although HCA has traded at a recent price of $74.02/share, the average analyst target is 24.29% higher at $92.00/share. Similarly, BIIB has 13.52% upside from the recent share price of $309.33 if the average analyst target price of $351.14/share is reached, and analysts on average are expecting ABT to reach a target price of $48.82/share, which is 13.08% above the recent price of $43.17. Below is a twelve month price history chart comparing the stock performance of HCA, BIIB, and ABT:
Combined, HCA, BIIB, and ABT represent 5.59% of the Guggenheim S&P 500 Equal Weight Health Care ETF. Below is a summary table of the current analyst target prices discussed above:
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is a twelve month price history chart comparing the stock performance of HCA, BIIB, and ABT: Combined, HCA, BIIB, and ABT represent 5.59% of the Guggenheim S&P 500 Equal Weight Health Care ETF. Three of RYH's underlying holdings with notable upside to their analyst target prices are HCA Holdings Inc (Symbol: HCA), Biogen Inc (Symbol: BIIB), and Abbott Laboratories (Symbol: ABT). Similarly, BIIB has 13.52% upside from the recent share price of $309.33 if the average analyst target price of $351.14/share is reached, and analysts on average are expecting ABT to reach a target price of $48.82/share, which is 13.08% above the recent price of $43.17. | Three of RYH's underlying holdings with notable upside to their analyst target prices are HCA Holdings Inc (Symbol: HCA), Biogen Inc (Symbol: BIIB), and Abbott Laboratories (Symbol: ABT). Below is a twelve month price history chart comparing the stock performance of HCA, BIIB, and ABT: Combined, HCA, BIIB, and ABT represent 5.59% of the Guggenheim S&P 500 Equal Weight Health Care ETF. Similarly, BIIB has 13.52% upside from the recent share price of $309.33 if the average analyst target price of $351.14/share is reached, and analysts on average are expecting ABT to reach a target price of $48.82/share, which is 13.08% above the recent price of $43.17. | Similarly, BIIB has 13.52% upside from the recent share price of $309.33 if the average analyst target price of $351.14/share is reached, and analysts on average are expecting ABT to reach a target price of $48.82/share, which is 13.08% above the recent price of $43.17. Three of RYH's underlying holdings with notable upside to their analyst target prices are HCA Holdings Inc (Symbol: HCA), Biogen Inc (Symbol: BIIB), and Abbott Laboratories (Symbol: ABT). Below is a twelve month price history chart comparing the stock performance of HCA, BIIB, and ABT: Combined, HCA, BIIB, and ABT represent 5.59% of the Guggenheim S&P 500 Equal Weight Health Care ETF. | Below is a twelve month price history chart comparing the stock performance of HCA, BIIB, and ABT: Combined, HCA, BIIB, and ABT represent 5.59% of the Guggenheim S&P 500 Equal Weight Health Care ETF. Three of RYH's underlying holdings with notable upside to their analyst target prices are HCA Holdings Inc (Symbol: HCA), Biogen Inc (Symbol: BIIB), and Abbott Laboratories (Symbol: ABT). Similarly, BIIB has 13.52% upside from the recent share price of $309.33 if the average analyst target price of $351.14/share is reached, and analysts on average are expecting ABT to reach a target price of $48.82/share, which is 13.08% above the recent price of $43.17. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.